

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>University Engagement</u>				
<u>University Engagement</u>				
Greasley, Philip A	3048106964	\$20,000.	\$0.	\$20,000.
KY Council on Postsecondary Education Lumina-UK Andragogy Workshop				
University Engagement	Totals:	\$20,000.	\$0.	\$20,000.
	University Engagement Totals:	\$20,000.	\$0.	\$20,000.
<u>Commercialization & Economic Development</u>				
<u>Commercialization & Economic Development</u>				
Harvey, Dean E	3048105999	\$142,880.	\$0.	\$142,880.
Economic Development Administration Driving High-Wage Job and Wealth Creation Throughout Kentucky				
Commercialization & Economic Development	Totals:	\$142,880.	\$0.	\$142,880.
<u>Business Development</u>				
Powell, Patrick S	3048105956	\$175,000.	\$0.	\$175,000.
KY Science and Technology Co Inc KSTC ICC Project				
Business Development	Totals:	\$175,000.	\$0.	\$175,000.
<u>Small Business Development Center</u>				
Naugle, Lottie Becky	3048105989	\$13,500.	\$0.	\$13,500.
Commerce Lexington Inc KY Small Business Development Center Lease				
Naugle, Lottie Becky	3048106648	\$1,398,078.	\$0.	\$1,398,078.
Small Business Administration Kentucky Small Business Development Center				
Naugle, Lottie Becky	3048106648	\$0.	\$40,358.	\$40,358.
Small Business Administration Kentucky Small Business Development Center				
Small Business Development Center	Totals:	\$1,411,578.	\$40,358.	\$1,451,936.
	Commercialization & Economic Development Totals:	\$1,729,458.	\$40,358.	\$1,769,816.
<u>Research</u>				
<u>VP for Research</u>				
Tracy, James W		\$6,428,471.	\$0.	\$6,428,471.
National Center for Research Resources ARRA: Core Rederivation and Barrier Renovation				
Tracy, James W	3048103738	\$0.	\$2,321.	\$2,321.
KY Department of Environmental Protection Supplemental Environmental Project Compliance Assistance Tools and Services				
Tracy, James W	3048103738	\$0.	\$1,822.	\$1,822.
KY Department of Environmental Protection Supplemental Environmental Project Compliance Assistance Tools and Services				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Research</u>				
<u>VP for Research</u>				
Tracy, James W	3048103738	\$0.	\$1,544.	\$1,544.
KY Department of Environmental Protection Supplemental Environmental Project Compliance Assistance Tools and Services				
VP for Research	Totals:	\$6,428,471.	\$5,687.	\$6,434,158.
<u>KY Geological Survey</u>				
Andrews, William M	3048105826	\$208,267.	\$0.	\$208,267.
US Geological Survey Quaternary and Surficial Geologic Mapping for Geotechnical and Geophysical Applications in Kentucky				
Lynch, Michael J	3048105991	\$15,000.	\$0.	\$15,000.
KY Board of Registration for Professional Geologists Communications Specialist Liaison for the Kentucky Board of Registration for Professional Geologists				
Nuttall, Brandon C	3046954900	\$0.	\$111,866.	\$111,866.
Illinois State Geological Survey Assessment of Geological Carbon Sequestration Options in the Illinois Basin-Phase II				
Nuttall, Brandon C	3046954900	\$0.	\$191,308.	\$191,308.
Illinois State Geological Survey Assessment of Geological Carbon Sequestration Options in the Illinois Basin-Phase II				
Weisenfluh, Gerald A	3048106068	\$87,047.	\$0.	\$87,047.
KY Energy and Environment Cabinet Producing Web-based Coal Industry Maps for Kentucky				
Weisenfluh, Gerald A	3048106071	\$15,195.	\$0.	\$15,195.
US Geological Survey National Catalog Metadata Submissions for Kentucky Sites				
Weisenfluh, Gerald A	3048106414	\$50,000.	\$0.	\$50,000.
KY Transportation Cabinet Analysis of Geologic Context of Transportation Maintenance Costs				
KY Geological Survey	Totals:	\$375,509.	\$303,174.	\$678,683.
<u>Appalachian Center</u>				
Billings, Dwight B	3048105617	\$0.	\$58,308.	\$58,308.
National Science Foundation Fellowship for Fitzgerald: The Messy Politics of Clean Coal, Contested Energy Alternatives in the Appalachian Coalfields				
Appalachian Center	Totals:	\$0.	\$58,308.	\$58,308.
<u>Interdisc Human Development Institute</u>				
Cinnamond, Karen E	3048105801	\$0.	-\$40,271.	-\$40,271.
KY Department of Vocational Rehabilitation UK Migrant Program 09-10				
Compton, Jonathan F	3048105234	\$0.	\$16,690.	\$16,690.
KY Department of Education UK Post Secondary Transition				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Research</u>				
<u>Interdisc Human Development Institute</u>				
Compton, Jonathan F	3048106415	\$364,281.	\$0.	\$364,281.
KY Department of Education Post Secondary Transition FY 10				
Farley, Joanne	3048105379	\$0.	\$45,000.	\$45,000.
University of Tennessee Tennessee State Improvement Grant				
Hall, Meada G	3048105965	\$109,827.	\$0.	\$109,827.
KY Department of Education Community Based Work Transition				
Hall, Meada G	3048105966	\$157,762.	\$0.	\$157,762.
KY Department of Vocational Rehabilitation Community Based Work Transition Program 09-10				
Harrison, Mary Elizabeth Mille	3048105900	\$193,336.	\$0.	\$193,336.
KY Council on Developmental Disabilities KY's Postsecondary Inclusion Project (PIP)				
Harrison, Mary Elizabeth Mille	3048105967	\$121,946.	\$0.	\$121,946.
KY Department of Education Paraeducators of Kentucky				
Harrison, Ron N	3048105801	\$263,211.	\$0.	\$263,211.
KY Department of Vocational Rehabilitation UK Migrant Program 09-10				
Harrison, Ron N	3048105866	\$3,159,439.	\$0.	\$3,159,439.
Department for Mental Health Mental Retardation Service Supports for Community Living FY10				
Kearns, Jacqueline	3046846000	\$0.	\$507,765.	\$507,765.
Pearson Educational Measurement ILSSA NJ				
Kearns, Jacqueline	3048104002	\$0.	\$1,499,997.	\$1,499,997.
Department of Education GSEG Consortia: Priority B, AA-AAS Validity Evaluation				
Kearns, Jacqueline	3048104344	\$0.	\$78,451.	\$78,451.
KY Department of Education Low Incidence Instructional Strategies				
Kearns, Jacqueline	3048104454	\$0.	\$39,999.	\$39,999.
University of Minnesota Multi-State General Supervision Enhancement Grant Consortium				
Kearns, Jacqueline	3048105845	\$0.	\$446,648.	\$446,648.
KY Department of Education KY Alternate Assessment				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Research</u>				
<u>Interdisc Human Development Institute</u>				
Kearns, Jacqueline	3048107004	\$68,148.	\$0.	\$68,148.
KY Department of Education UK SPDG Low Incidence Instructional Strategies Initiative				
Kleinert, Harold L	3048105814	\$528,000.	\$0.	\$528,000.
Administration for Children and Families University Center for Excellence in Developmental Disabilities				
Lewis, Preston O	3048084500	\$0.	\$49,438.	\$49,438.
University of Oregon National Center for the Study for the Study of Supported Text in Electronic Learning Environments				
Lewis, Preston O	3048106925	\$46,009.	\$0.	\$46,009.
University of Oregon Center on Accessible and Supported Electronic Text to Improve Mathematics Achievements for Students with Disabilities				
Lewis, Richard J	3048106788	\$0.	\$240,622.	\$240,622.
Department of Education Mid-South Regional Resource Center				
Lewis, Richard J	3048106788	\$1,300,000.	\$0.	\$1,300,000.
Department of Education Mid-South Regional Resource Center				
Rous, Beth	3048104410	\$0.	\$30,000.	\$30,000.
University of North Carolina Early Childhood Personnel Center				
Rous, Beth	3048104410	\$0.	\$21,264.	\$21,264.
University of North Carolina Early Childhood Personnel Center				
Rous, Beth	3048105008	\$0.	\$2,500.	\$2,500.
KY Department for Public Health UK First Steps Transition Activities				
Rous, Beth	3048105789	\$375,000.	\$0.	\$375,000.
KY Health Services Cabinet Training Into Practice Project Services FY10/Z915				
Rous, Beth	3048105853	\$231,000.	\$0.	\$231,000.
KY Department of Education KY Data Systems (KEDS) FY10				
Rous, Beth	3048105855	\$75,000.	\$0.	\$75,000.
KY Department of Education KY Early Childhood Transition Project FY10				
Rous, Beth	3048106059	\$150,059.	\$0.	\$150,059.
KY Department for Public Health KY Early Childhood Data System - First Step				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Research</u>				
<u>Interdisc Human Development Institute</u>				
Rous, Beth	3048106065	\$2,670,570.	\$0.	\$2,670,570.
KY Cabinet for Health and Family Services IHDI Child Care Quality Enhancement Initiative FY 09-10				
Rous, Beth	3048106517	\$58,014.	\$0.	\$58,014.
KY Department for Public Health UK First Steps KEIS				
Rous, Beth	3048106681	\$38,000.	\$0.	\$38,000.
KY Department of Education State Personnel Grant Development Grant				
Sheppard-Jones, Kathleen A	3046935400	\$0.	\$86,385.	\$86,385.
Department of Education Ky. Resident Training Program in Rehabilitation Technology				
Sheppard-Jones, Kathleen A	3048105788	\$974,728.	\$0.	\$974,728.
KY Cabinet for Health and Family Services Human Development Services - Home Modifications				
Sheppard-Jones, Kathleen A	3048105813	\$240,291.	\$0.	\$240,291.
Department for Mental Health Mental Retardation Service Belonging in the Community FY10				
Sheppard-Jones, Kathleen A	3048105852	\$28,988.	\$0.	\$28,988.
KY Department for the Blind Client Satisfaction Survey FY 10				
Sheppard-Jones, Kathleen A	3048105975	\$416,218.	\$0.	\$416,218.
KY Department of Vocational Rehabilitation Consumer Satisfaction Survey 09-10				
Sheppard-Jones, Kathleen A	3048106521	\$81,281.	\$0.	\$81,281.
KY Cabinet for Health and Family Services HART Supported Living				
Tyree, Milton S	3048106835	\$30,629.	\$0.	\$30,629.
Lifeskills Inc The Roles Initiative				
Wickham, Donna R	3048105747	\$0.	\$19,086.	\$19,086.
Virgin Islands Department of Education ILSSA Virgin Islands				
Wickham, Donna R	3048105845	\$257,500.	\$0.	\$257,500.
KY Department of Education KY Alternate Assessment				
Interdisc Human Development Institute	Totals:	\$11,939,237.	\$3,043,574.	\$14,982,811.
<u>Computational Sciences</u>				
Connolly, John W	3046901800	\$0.	\$17,213.	\$17,213.
National Science Foundation Building Kentucky's New Economy with EPSCoR				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Research				
Computational Sciences				
Connolly, John W	3048104850	\$0.	\$1,000,000.	\$1,000,000.
KY Council on Postsecondary Education State EPSCoR: Transforming Kentucky's New Economy				
Connolly, John W	3048105113	\$0.	\$2,492,000.	\$2,492,000.
National Science Foundation NSF/EPSCoR: Transforming Kentucky's New Economy with EPSCoR				
Connolly, John W	3048105250	\$0.	\$255,477.	\$255,477.
National Science Foundation Collaborative Research: CRIF: CRF: Extensible Cyberenvironments for Empirical and Semiempirical Hamiltonian Parameter Optimization and Dissemination				
Connolly, John W	3048105250	\$0.	\$131,306.	\$131,306.
National Science Foundation Collaborative Research: CRIF: CRF: Extensible Cyberenvironments for Empirical and Semiempirical Hamiltonian Parameter Optimization and Dissemination				
Kucera, Barbara A	3048106314	\$3,000,000.	\$0.	\$3,000,000.
National Science Foundation ARRA: Collaborative Research: Cyberinfrastructure for a Virtual Observatory and Ecological Informatics System (VOEIS)				
Kucera, Barbara A	3048106314	\$0.	\$-87,336.	\$-87,336.
National Science Foundation ARRA: Collaborative Research: Cyberinfrastructure for a Virtual Observatory and Ecological Informatics System (VOEIS)				
Kucera, Barbara A	3048106314	\$0.	\$-88,037.	\$-88,037.
National Science Foundation ARRA: Collaborative Research: Cyberinfrastructure for a Virtual Observatory and Ecological Informatics System (VOEIS)				
Kucera, Barbara A	3048106314	\$0.	\$-2,824,627.	\$-2,824,627.
National Science Foundation ARRA: Collaborative Research: Cyberinfrastructure for a Virtual Observatory and Ecological Informatics System (VOEIS)				
Kucera, Barbara A	3048106819	\$3,000,000.	\$0.	\$3,000,000.
National Science Foundation ARRA: Collaborative Research: Cyberinfrastructure for a Virtual Observatory and Ecological Informatics System (VOEIS)				
Menon, Madhusudan K	3046385700	\$0.	\$118,000.	\$118,000.
Department of Energy Magnetism in Low-Dimensional Carbon Materials				
Menon, Madhusudan K	3046385700	\$0.	\$118,000.	\$118,000.
Department of Energy Magnetism in Low-Dimensional Carbon Materials				
Computational Sciences	Totals:	\$6,000,000.	\$1,131,996.	\$7,131,996.

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Research</u>				
<u>KY Water Resources Institute</u>				
Ormsbee, Lindell E	3046989200	\$0.	\$92,335.	\$92,335.
US Geological Survey State Water Research Institute Program				
Ormsbee, Lindell E	3048106102	\$95,795.	\$0.	\$95,795.
KY River Authority 09-10 Watershed Management Services				
KY Water Resources Institute	Totals:	\$95,795.	\$92,335.	\$188,130.
<u>Ctr for Applied Energy Research</u>				
Andrews, Rodney	3048104956	\$0.	\$1,325,875.	\$1,325,875.
Department of Energy Coal Fuel Alliance (CFA): Design and Construction of Early Lead Mini Fischer-Tropsch Refinery at the University of Kentucky Center for Applied Energy Research				
Andrews, Rodney	3048105200	\$0.	\$895,749.	\$895,749.
KY Office of Energy Policy Development of an Algae-Based System for CO2 Mitigation from Coal-Fired Power Plants				
Andrews, Rodney	3048105615	\$0.	\$-107,868.	\$-107,868.
Department of Energy Kentucky Research Consortium for Energy and Environment				
Andrews, Rodney	3048105615	\$0.	\$-39,747.	\$-39,747.
Department of Energy Kentucky Research Consortium for Energy and Environment				
Andrews, Rodney	3048105615	\$0.	\$179,937.	\$179,937.
Department of Energy Kentucky Research Consortium for Energy and Environment				
Andrews, Rodney	3048105615	\$0.	\$35,769.	\$35,769.
Department of Energy Kentucky Research Consortium for Energy and Environment				
Andrews, Rodney	3048105885	\$100,000.	\$0.	\$100,000.
KY Energy and Environment Cabinet CAER Regional Representatives				
Andrews, Rodney	3048106076	\$1,984,322.	\$0.	\$1,984,322.
National Science Foundation ARRA: EFRI-HyBI: Lignin Deconstruction for the Production of Liquid Fuels				
Andrews, Rodney	3048106849	\$11,832,685.	\$0.	\$11,832,685.
National Institute of Standards & Technology ARRA:Expansion of The University of Kentucky Center for Applied Energy Research Laboratory Facilities				
Andrews, Rodney	3048106913	\$165,735.	\$0.	\$165,735.
KY Energy and Environment Cabinet EEC Matching: Design and Construction of Coal/Biomass-to-Liquids (CBTL) Process Development Unit (PDU) at the University of Kentucky				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Research</u>				
<u>Ctr for Applied Energy Research</u>				
Crocker, Mark	3046947300	\$0.	\$96,253.	\$96,253.
Department of Energy Investigation of Aging Mechanisms in Lean NOx Traps				
Crocker, Mark	3048106749	\$70,500.	\$0.	\$70,500.
University of Houston Development of Optimal Catalyst Designs and Operating Strategies for Lean NOx Reduction in Coupled LNT-SCR Systems				
Crocker, Mark	3048106749	\$0.	\$301,687.	\$301,687.
University of Houston Development of Optimal Catalyst Designs and Operating Strategies for Lean NOx Reduction in Coupled LNT-SCR Systems				
Crocker, Mark	3048106828	\$124,409.	\$0.	\$124,409.
Sapphire Energy Inc Upgrading of algae oil to hydrocarbon fuels via catalytic decarboxylation				
Davis, Burtron H	3048083500	\$0.	\$200,000.	\$200,000.
National Aeronautics and Space Administration Basic Studies for the Production and Upgrading of Fischer-Tropsch Synthesis Products to Fuels				
Davis, Burtron H	3048083500	\$0.	\$219,853.	\$219,853.
National Aeronautics and Space Administration Basic Studies for the Production and Upgrading of Fischer-Tropsch Synthesis Products to Fuels				
Davis, Burtron H	3048106596	\$111,285.	\$0.	\$111,285.
Texas A&M University Kinetics of Slurry Phase Fischer-Tropsch Synthesis on a Cobalt Catalyst				
Hampson, Steven K	3048105839	\$348,983.	\$0.	\$348,983.
KY Department for Public Health UK Paducah Gaseous Diffusion Plant-AIP				
Hampson, Steven K	3048106057	\$94,201.	\$0.	\$94,201.
KY Cabinet for Health and Family Services UK Maxey Flats				
Hiett, John K	3048105754	\$0.	\$1,529.	\$1,529.
KY Department for Natural Resources Mine Mapping Program				
Hiett, John K	3048105754	\$220,687.	\$0.	\$220,687.
KY Department for Natural Resources Mine Mapping Program				
Hower, James C	3048099600	\$0.	\$22,500.	\$22,500.
US Geological Survey Vitrinite maximum reflectance and maceral studeis in support of USGS coal research.				
Lipka, Steve	3048104401	\$0.	\$150,000.	\$150,000.
US Office of Naval Research High Energy Density Carbons for Electrochemical Capacitors				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Research</u>				
<u>Ctr for Applied Energy Research</u>				
Lipka, Steve	3048106587	\$25,000.	\$0.	\$25,000.
NEI Corporation A Low Cost Utility-Scale Battery with a New Chemistry				
Liu, Kunlei		\$200,000.	\$0.	\$200,000.
Illinois Clean Coal Institute The Impact of Elements in Illinois Coal on Post-Combustion CO2 Capture Performance				
Liu, Kunlei	3048105493	\$0.	\$250,000.	\$250,000.
Multiple Industry Sponsors Carbon Management Research Group				
Liu, Kunlei	3048105493	\$0.	\$400,000.	\$400,000.
Multiple Industry Sponsors Carbon Management Research Group				
Liu, Kunlei	3048105493	\$0.	\$200,000.	\$200,000.
Multiple Industry Sponsors Carbon Management Research Group				
Liu, Kunlei	3048105493	\$0.	\$200,000.	\$200,000.
Multiple Industry Sponsors Carbon Management Research Group				
Liu, Kunlei	3048105595	\$0.	\$1,000,000.	\$1,000,000.
KY Office of Energy Policy Carbon Management Research Group				
Medina, Shiela	3048106670	\$149,596.	\$0.	\$149,596.
Kentucky Highlands Investment Corporation High Efficiency Manufactured Home Communities				
Morton, Samuel	3048106417	\$7,500.	\$0.	\$7,500.
Florida A&M University Enzymatic and Multiphase Solution Processing of Lignocellulosic Biomass				
Robl, Thomas L	3048106047	\$913,985.	\$0.	\$913,985.
Department of Energy Coal-Derived Low Energy Materials for Sustainable Construction				
Robl, Thomas L	3048106791	\$114,248.	\$0.	\$114,248.
KY Energy and Environment Cabinet Coal-Derived Low Energy Materials for Sustainable Construction				
Weisenberger, Matthew	3048107000	\$52,104.	\$0.	\$52,104.
Materials Sciences Corp Thermal Management for Integration into Existing Systems				
Ctr for Applied Energy Research	Totals:	\$16,515,240.	\$5,331,537.	\$21,846,777.

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Research</u>				
<u>Magnetic Resonance Imaging System Cntr</u>				
Smith, Charles D	3048106085	\$1,412,730.	\$0.	\$1,412,730.
Health Resources and Services Administration UK 3T MRI Upgrade and Space Renovation				
Magnetic Resonance Imaging System Cntr	Totals:	\$1,412,730.	\$0.	\$1,412,730.
	Research Totals:	\$42,766,982.	\$9,966,611.	\$52,733,593.
<u>Dentistry</u>				
<u>Dentistry Research & Graduate Studies</u>				
Ebersole, Jeffrey L	3048106011	\$350,500.	\$0.	\$350,500.
KY Cabinet for Health and Family Services Support for Dental Public Health Activities				
Ebersole, Jeffrey L	3048106622	\$1,451,533.	\$0.	\$1,451,533.
National Center for Research Resources ARRA Supplement: An Intervention Trial for Effects of Oral Health Improvement of Adverse Maternal-Fetal Outcomes of Gestational Diabetes				
Ebersole, Jeffrey L	3048106697	\$0.	\$3,104.	\$3,104.
National Center for Research Resources Center for the Biologic Basis of Oral/Systemic Disease (CBBOSD)				
Ebersole, Jeffrey L	3048106697	\$1,861,884.	\$0.	\$1,861,884.
National Center for Research Resources Center for the Biologic Basis of Oral/Systemic Disease (CBBOSD)				
Novak, Michael J	3048106611	\$941,490.	\$0.	\$941,490.
Health Resources and Services Administration Rural Health Outreach Special Initiative				
Oz, Helieh	3048105728	\$111,375.	\$0.	\$111,375.
National Institute of Dental Research ARRA: A Novel Murine Model of Chronic Inflammatory Periodontitis				
Dentistry Research & Graduate Studies	Totals:	\$4,716,782.	\$3,104.	\$4,719,886.
<u>Oral Health Science</u>				
De Leeuw, Rinskje	3046972300	\$0.	\$135,000.	\$135,000.
National Institute of Dental Research Central Pain Processing in Chronic Face Pain: fMRI Study				
Lin, Yi-Ling	3048106705	\$111,375.	\$0.	\$111,375.
National Institute of Dental Research Is Mitf the Missing Puzzle Linking NFATc1 to Osteoclastogenesis				
Raybould, Ted P	3048106553	\$74,979.	\$0.	\$74,979.
Health Resources and Services Administration Dental Reimbursement Program				
Raybould, Ted P	3048106595	\$290,966.	\$0.	\$290,966.
Health Resources and Services Administration Residency Training in General and Pediatric Dentistry: Advocacy and Care Disparities				
Oral Health Science	Totals:	\$477,320.	\$135,000.	\$612,320.

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Dentistry</u>				
<u>Oral Health Practice</u>				
Miller, Craig S	3048106776	\$62,763.	\$0.	\$62,763.
Four Tigers LLC Delivery of Polyphenols in Gum for Treatment of Gingivitis				
Miller, Craig S	3048106814	\$266,075.	\$0.	\$266,075.
Rice University Development of Lab on a Chip System for Saliva-Based Diagnostics				
Morford, Lorri A	3048107015	\$10,000.	\$0.	\$10,000.
American Association of Women Dentists Procter and Gamble Research Scholarship				
Oral Health Practice	Totals:	\$338,838.	\$0.	\$338,838.
	Dentistry Totals:	\$5,532,940.	\$138,104.	\$5,671,044.
<u>Nursing</u>				
<u>Nursing</u>				
Ashford, Kristin Beth	3048106117	\$0.	\$1,698.	\$1,698.
KY Cabinet for Health and Family Services Tobacco Prevention and Cessation Programs - GIFTS				
Ashford, Kristin Beth	3048106117	\$21,224.	\$0.	\$21,224.
KY Cabinet for Health and Family Services Tobacco Prevention and Cessation Programs - GIFTS				
Brockopp, Dorothy Y	3048105993	\$15,000.	\$0.	\$15,000.
American Cancer Society Fellowship for Celestine Gochett: Breast Cancer Survivorship: Factors Related to Psychological Well-Being				
Chung, Misook L	3048106785	\$75,000.	\$0.	\$75,000.
American Heart Association Sodium Watcher Program for Adults with Heart Failure				
Hahn, Ellen J	3048093000	\$0.	\$61,980.	\$61,980.
National Heart Lung and Blood Institute An Intervention for Promoting Smoke-free Policy in Rural Kentucky				
Hahn, Ellen J	3048104094	\$0.	\$50,000.	\$50,000.
Foundation for a Healthy KY UK Tobacco Policy Research Program - Kentucky Center for Smoke-Free Policy				
Hahn, Ellen J	3048105485	\$0.	\$5,205.	\$5,205.
KY Youth Advocates Rural Media Tobacco Prevention Project				
Hahn, Ellen J	3048105869	\$135,000.	\$0.	\$135,000.
KY Health Services Cabinet Community Partnerships for Tobacco Use Cessation and Prevention				
Hahn, Ellen J	3048105912	\$41,364.	\$0.	\$41,364.
KY Department for Public Health Indoor Radon Project				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Nursing</u>				
<u>Nursing</u>				
Hahn, Ellen J	3048106070	\$276,884.	\$0.	\$276,884.
National Heart Lung and Blood Institute ARRA: An Intervention for Promoting Smoke-free Policy in Rural Kentucky - Administrative Supplement				
Hatcher, Jennifer	3048104914	\$0.	\$135,321.	\$135,321.
National Cancer Institute Promoting Mammography in African American Women Visiting the Emergency Department				
Howard, Patricia B	3048105798	\$73,820.	\$0.	\$73,820.
Health Resources and Services Administration Advanced Education Nursing Traineeships				
Kirschling, Jane	3048106114	\$1,883,970.	\$0.	\$1,883,970.
Health Resources and Services Administration Health Care and Other Facilities: Nursing Building Student Space Fit-up				
Moser, Debra K	3048060900	\$0.	\$151,482.	\$151,482.
University of California San Francisco Improving Self Care Behaviors and Outcomes in Rural Patients with Heart Failure				
Moser, Debra K	3048104719	\$0.	\$45,000.	\$45,000.
American Heart Association Great Rivers Affiliate Fellowship/Jia-Rong Wu: Effect of a Medication Taking Behavior Feedback, Theory-Based Intervention on Outcomes in Patients with Heart Failure				
Moser, Debra K	3048106061	\$231,756.	\$0.	\$231,756.
National Institute for Nursing Research Center for Biobehavioral Research in Self-Management of Cardiopulmonary Disease				
Moser, Debra K	3048106305	\$15,610.	\$0.	\$15,610.
Mayo Clinic Heart Failure in the Community				
Moser, Debra K	3048106577	\$988,431.	\$0.	\$988,431.
National Institute for Nursing Research ARRA: Biobehavioral Cardiovascular Health Promotion Intervention in a State Prison System				
Moser, Debra K	3048106671	\$3,300.	\$0.	\$3,300.
Indiana University Psychosocial and Behavioral Factors, Physical Symptoms, and Heart Failure Outcomes				
Prevost, Suzanne	3048106646	\$116,315.	\$0.	\$116,315.
Vanderbilt University Bridging the Gap to Quality Cared: The ISAT Initiative for Nursing Faculty				
Prevost, Suzanne	3048106831	\$35,000.	\$0.	\$35,000.
University of California San Francisco Robert Wood Johnson Executive Nurse Fellows Program				
Prevost, Suzanne	3048106921	\$90,112.	\$0.	\$90,112.
Vanderbilt University Crafting the Ultimate Faculty Simulation Experience				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Nursing</u>				
<u>Nursing</u>				
Reed, Deborah B	3048104034	\$0.	\$352,037.	\$352,037.
National Institute of Occupational Safety and Health Refinement and Enhancement of Agricultural Safety Curricula for Children (REACCH)				
Salt, Elizabeth Garrison	3048105773	\$7,000.	\$0.	\$7,000.
American College of Rheumatology Decision Making Processes Related to Treatment in Women with Rheumatoid Arthritis				
Nursing	Totals:	\$4,009,786.	\$802,723.	\$4,812,509.
	Nursing Totals:	\$4,009,786.	\$802,723.	\$4,812,509.
<u>Medicine</u>				
<u>Area Health Educ Ctr</u>				
Norton, James C	3048105916	\$0.	\$-34,000.	\$-34,000.
KY Health Services Cabinet FY10 SAAA UK Area Health Education Centers				
Norton, James C	3048105916	\$0.	\$-6,700.	\$-6,700.
KY Health Services Cabinet FY10 SAAA UK Area Health Education Centers				
Norton, James C	3048105916	\$868,737.	\$0.	\$868,737.
KY Health Services Cabinet FY10 SAAA UK Area Health Education Centers				
Norton, James C	3048106508	\$278,808.	\$0.	\$278,808.
University of Louisville Model State Supported AHEC				
Norton, James C	3048106687	\$198,737.	\$0.	\$198,737.
KY Department for Public Health FY10 SAAA UK Area Health Education Centers				
Norton, James C	3048106807	\$15,000.	\$0.	\$15,000.
KY Department for Public Health FY10 UK AHEC Hispanic Foundation				
Area Health Educ Ctr	Totals:	\$1,361,282.	\$-40,700.	\$1,320,582.
<u>Kentucky Telecare</u>				
Sprang, Robert R	3048105556	\$0.	\$-1,956.	\$-1,956.
AT&T Foundation ADHD parent Training using Telemedicine				
Kentucky Telecare	Totals:	\$0.	\$-1,956.	\$-1,956.
<u>Spinal Cord & Brain Injury Res Ctr</u>				
Geddes, James W	3048104347	\$0.	\$99,089.	\$99,089.
KY Spinal Cord and Head Injury Research Trust Inhibition of ERK 1/2 Signaling Following Spinal Cord Injury				
Geddes, James W	3048104350	\$0.	\$99,971.	\$99,971.
KY Spinal Cord and Head Injury Research Trust Implications of High Neuronal Cyclophilin D Levels for Spinal Cord Injury				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
<u>Spinal Cord & Brain Injury Res Ctr</u>				
Geddes, James W	3048105797	\$0.	\$303,452.	\$303,452.
National Institute of Neurological Disorders & Stroke Calpain as a Therapeutic Target for TBI (P01)				
Geddes, James W	3048105998	\$73,894.	\$0.	\$73,894.
National Institute of Neurological Disorders & Stroke ARRA: Calpain as a Therapeutic Target for TBI (PO1)				
Geddes, James W	3048106042	\$324,844.	\$0.	\$324,844.
National Institute of Neurological Disorders & Stroke Cyclophilin D as a Therapeutic Target following Traumatic Brain Injury				
Geddes, James W	3048106124	\$82,849.	\$0.	\$82,849.
National Institute of Neurological Disorders & Stroke ARRA: Calpain as a Therapeutic Target for TBI(PO1)				
Hall, Edward D	3048081200	\$0.	\$99,221.	\$99,221.
KY Spinal Cord and Head Injury Research Trust Antioxidant/Calpain Inhibitor Combination Strategy in Acute SCI				
Hall, Edward D	3048081200	\$0.	\$3,110.	\$3,110.
KY Spinal Cord and Head Injury Research Trust Antioxidant/Calpain Inhibitor Combination Strategy in Acute SCI				
Hall, Edward D	3048106565	\$270,753.	\$0.	\$270,753.
National Institute on Drug Abuse Therapeutic Strategies for Neurodegeneration Training Grant				
Hall, Edward D	3048106566	\$29,198.	\$0.	\$29,198.
National Institute of Neurological Disorders & Stroke Fellowship Vaishnav: Therapeutic Strategies for Spinal Cord Injury				
Hall, Edward D	3048106947	\$99,899.	\$0.	\$99,899.
KY Spinal Cord and Head Injury Research Trust Dual Mechanism Inhibition of Lipid Peroxidation in Acute Sci				
Lifshitz, Jonathan	3048104351	\$0.	\$99,893.	\$99,893.
KY Spinal Cord and Head Injury Research Trust Somatosensory Circuit Disruption and Rehabilitation after Diffuse Brain Injury				
Lifshitz, Jonathan	3048106935	\$321,152.	\$0.	\$321,152.
National Institute of Neurological Disorders & Stroke Neural Circuit disruption by diffuse brain injury: basis for morbidity & therapy				
Onifer, Stephen	3048106946	\$99,000.	\$0.	\$99,000.
KY Spinal Cord and Head Injury Research Trust Promoting Primary Afferent Collateral Sprouting and Rehabilitation in Improve Forepaw Function after Cervical Spinal Cord Injury				
Rabchevsky, Alexander G	3048105500	\$0.	\$99,616.	\$99,616.
KY Spinal Cord and Head Injury Research Trust Effects of acety-l-carnitine treatment on mitochondrial function, tissue sparing and hind limb locomotor recovery following contusion spinal cord injury				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Spinal Cord & Brain Injury Res Ctr</u>				
Saatman, Kathryn	3048081300	\$0.	\$98,010.	\$98,010.
KY Spinal Cord and Head Injury Research Trust Calpatatin in brain contusion and axonal injury: a novel therapeutic approach				
Saatman, Kathryn	3048104348	\$0.	\$98,855.	\$98,855.
KY Spinal Cord and Head Injury Research Trust Neuroprotective Efficacy of Regionally Targeted IGF-1 Overexpression for Traumatic Brain Injury				
Saatman, Kathryn	3048106945	\$99,821.	\$0.	\$99,821.
KY Spinal Cord and Head Injury Research Trust Role for kinase activation in transport impairment after traumatic axonal injury				
Snow, Diane M	3048104905	\$0.	\$326,000.	\$326,000.
National Institute of Neurological Disorders & Stroke Designer PGs for CNS Injury				
Spinal Cord & Brain Injury Res Ctr	Totals:	\$1,401,410.	\$1,327,217.	\$2,728,627.
<u>Graduate Center for Toxicology</u>				
Li, Guo-Min	3046998900	\$0.	\$227,246.	\$227,246.
National Cancer Institute Mechnism of PCNA-Dependant 5' -3' Mismatch Excisiion				
Orren, David K	3048106048	\$240,260.	\$0.	\$240,260.
National Institute on Aging Telomeric Dysfunction and the Premature Aging and Cancer-Prone Disease Werner Syndrome				
Shi, Xianglin	3048054000	\$0.	\$22,725.	\$22,725.
National Cancer Institute Mechanisms of As-induced Carcinogenesis				
Shi, Xianglin	3048054000	\$0.	\$204,522.	\$204,522.
National Cancer Institute Mechanisms of As-induced Carcinogenesis				
Shi, Xianglin	3048083200	\$0.	\$27,835.	\$27,835.
National Cancer Institute Oxidative Stress in Cr(VI)-Induced Carcinogenesis				
Shi, Xianglin	3048083200	\$0.	\$250,515.	\$250,515.
National Cancer Institute Oxidative Stress in Cr(VI)-Induced Carcinogenesis				
Shi, Xianglin	3048089500	\$0.	\$331,091.	\$331,091.
National Institute of Environmental Health Sciences Apple Peel Extract Protects UV-induced Carcinogenesis				
Shi, Xianglin	3048104536	\$0.	\$326,329.	\$326,329.
National Institute of Environmental Health Sciences Reactive Oxygen Species in Ni(II) Carcinogenesis				
Shi, Xianglin	3048106756	\$663,511.	\$0.	\$663,511.
National Cancer Institute ARRA: Mechanisms of As-Induced Carcinogenesis				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Graduate Center for Toxicology</u>				
St Clair, Daret K	3048105006	\$0.	\$372,364.	\$372,364.
National Cancer Institute Redox Regulation of Tumor Suppression by MnSOD				
St Clair, Daret K	3048105194	\$0.	\$270,000.	\$270,000.
National Cancer Institute MnSOD in Chemotherapeutic-Induced Cardiac Injury				
VORE, MARY	3048104322	\$0.	\$297,190.	\$297,190.
National Institute of Child Health and Human Develop Hepatic Drug Elimination in Pregnancy				
VORE, MARY	3048104322	\$0.	\$29,719.	\$29,719.
National Institute of Child Health and Human Develop Hepatic Drug Elimination in Pregnancy				
VORE, MARY	3048104322	\$0.	\$33,021.	\$33,021.
National Institute of Child Health and Human Develop Hepatic Drug Elimination in Pregnancy				
VORE, MARY	3048104352	\$0.	\$30,744.	\$30,744.
National Institute of Environmental Health Sciences Summer Educational Experience for Research in Toxicology				
VORE, MARY	3048105232	\$0.	\$270,000.	\$270,000.
National Cancer Institute The Role of MRP1 in Protection of Cardiac Injury				
VORE, MARY	3048105964	\$194,916.	\$0.	\$194,916.
National Institute of Environmental Health Sciences NRSA T32: Molecular Mechanisms of Toxicity Training Grant				
Yang, Hsin-Sheng	3048105499	\$0.	\$10,988.	\$10,988.
National Cancer Institute The Role of Pcd4 in Colorectal Tumor Progression				
Yang, Hsin-Sheng	3048105499	\$0.	\$30,399.	\$30,399.
National Cancer Institute The Role of Pcd4 in Colorectal Tumor Progression				
Yang, Hsin-Sheng	3048105499	\$0.	\$273,589.	\$273,589.
National Cancer Institute The Role of Pcd4 in Colorectal Tumor Progression				
Graduate Center for Toxicology	Totals:	\$1,098,687.	\$3,008,277.	\$4,106,964.
<u>McDowell Cancer Network</u>				
Armstrong, Debra K	3048106634	\$14,500.	\$0.	\$14,500.
KY Breast Cancer Trust and Research Fund Horses and Hope				
Armstrong, Debra K	3048106653	\$28,144.	\$0.	\$28,144.
KY Department for Public Health Kentucky Cancer Demostration Project				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
McDowell Cancer Network				
Arnold, Susanne M	3048106556	\$188,100.	\$0.	\$188,100.
Health Resources and Services Administration Completion of the Marty Driesler Lung Cancer Study: Early Detection of Lung Cancer in a High Risk Population				
Arnold, Susanne M	3048106954	\$2.	\$0.	\$2.
Arno Therapeutics Inc A Phase 1 Study of DB-67(7-T-Butyldimethylsilyl 1-10-Hydroxy in Adult Patients with): MULTI -06 (formerly 3048065800)				
D'Orazio, John A	3048104922	\$0.	\$164,813.	\$164,813.
National Cancer Institute Coleus forskohlii extract: melanization and UV protection by a natural product				
D'Orazio, John A	3048106119	\$112,794.	\$0.	\$112,794.
National Cancer Institute ARRA: Coleus forskohlii extract: melanization and UV protection by a natural product				
Durbin, Eric B	3048106122	\$4,500.	\$0.	\$4,500.
KY Department for Public Health KCR Data Matching Project				
Evers, Bernard Mark	3046572100	\$0.	\$1,804,400.	\$1,804,400.
KY Lung Cancer Research Fund Kentucky Lung Cancer Research Program				
Evers, Bernard Mark	3048105880	\$500,000.	\$0.	\$500,000.
National Cancer Institute UK SPORE in Gastrointestinal Cancer				
Evers, Bernard Mark	3048105891	\$56,542.	\$0.	\$56,542.
AM Biotechnologies Inc SBIR: New Reagents for the synthesis of Nuclease-resistant siRNA				
Evers, Bernard Mark	3048105986	\$0.	\$111,792.	\$111,792.
National Institute on Aging Surgical Studies of Aging and the Gut				
Evers, Bernard Mark	3048105986	\$164,185.	\$0.	\$164,185.
National Institute on Aging Surgical Studies of Aging and the Gut				
Evers, Bernard Mark	3048106018	\$148,500.	\$0.	\$148,500.
University of Texas Medical Branch at Galveston Studies in Gastrointestinal Endocrinology				
Evers, Bernard Mark	3048106313	\$0.	\$-5,459.	\$-5,459.
National Institute Diabetes & Digestive & Kidney Surgical Studies of Functional Gene Expression				
Evers, Bernard Mark	3048106313	\$329,733.	\$0.	\$329,733.
National Institute Diabetes & Digestive & Kidney Surgical Studies of Functional Gene Expression				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>McDowell Cancer Network</u>				
Evers, Bernard Mark	3048106411	\$348,475.	\$0.	\$348,475.
National Institute on Aging Surgical Studies of Ontogeny, Aging and the Gut				
Evers, Bernard Mark	3048106691	\$715,228.	\$0.	\$715,228.
National Cancer Institute ARRA: Supporting New Faculty Recruitment Through Biomedical Research Core Centers (P30)				
Fleischman, Roger A		\$2.	\$0.	\$2.
Eli Lilly and Company A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin				
Fleming, Steven T	3048104059	\$0.	\$26,666.	\$26,666.
Center for Disease Control and Prevention Breast and Prostate Cancer Patterns of Care in Kentucky				
Gao, Tianyan	3048105914	\$0.	\$-40,316.	\$-40,316.
National Cancer Institute The Role of PHLPP in Colon Cancer				
Gao, Tianyan	3048105914	\$283,403.	\$0.	\$283,403.
National Cancer Institute The Role of PHLPP in Colon Cancer				
Gao, Tianyan	3048106717	\$0.	\$107,597.	\$107,597.
American Cancer Society Molecular Mechanisms of PHLPP-Mediated Regulation in Colon Cancer				
Gao, Tianyan	3048106717	\$90,000.	\$0.	\$90,000.
American Cancer Society Molecular Mechanisms of PHLPP-Mediated Regulation in Colon Cancer				
Hayslip, John		\$2.	\$0.	\$2.
Celgene Azacitidine with Rituximab, Vincristine, and Cyclophosphamide in Refractory Follicular Lymphoma: A Phase I Trial				
Hayslip, John		\$2.	\$0.	\$2.
Cephalon Inc Frontline Treatment with Bendamustine in Combination with Rituximab in Adults Age 65 or older with Chronic Lymphocytic Leukemia-A Phase II Study				
Hayslip, John	3048106938	\$2.	\$0.	\$2.
Cephalon Inc An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Predmison (R-CVP)				
Hayslip, John	3048107002	\$2.	\$0.	\$2.
Celgene A Phase 2, Open-label Trial to Evaluate the Efficacy and Safety of MGCD0103 Administered in Combination with Azacitidine (Vidaza) to Subjects with Relapsed or Refractory Hodgkins or non-Hodgkins Lymphoma and to Evaluate the Pharmacokinetics				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
McDowell Cancer Network				
Hopenhayn, Claudia	3048104897	\$0.	\$33,000.	\$33,000.
Battelle Memorial Institute Monitoring the Impact of a Prophylactic HPV Vaccine on HPV types in Cervical Cancer using Tissues for Kentucky Cancer Registry				
Howard, Dianna S	3048106953	\$2.	\$0.	\$2.
Pfizer Inc A Prospective, Randomized Trial Comparing the Efficacy of Anidulafungin and Vori: BMT-303 (Formerly 3048104472)				
Howard, Dianna S	3048107008	\$2.	\$0.	\$2.
ViroPharma Inc A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Prophylactic use of Maribavir for the Prevention of Cytomeglaovirus Disease in Recipients of Allogeneic Stem Cell Transplants				
Jia, Jianhang	3048105857	\$0.	-\$68,517.	-\$68,517.
National Institute of General Medical Sciences The Regulation of Smoothened in Hedgehog Signaling				
Jia, Jianhang	3048105857	\$358,092.	\$0.	\$358,092.
National Institute of General Medical Sciences The Regulation of Smoothened in Hedgehog Signaling				
Jia, Jianhang	3048106426	\$77,000.	\$0.	\$77,000.
American Heart Association The Regulation of Hedgehog Signaling by Smoothened and Its Binding Partners				
Liu, Chunming	3048105898	\$279,349.	\$0.	\$279,349.
National Institute Diabetes & Digestive & Kidney GKLF/Beta-Catenin Crosstalk in the Intestine				
Liu, Chunming	3048105898	\$0.	-\$24,671.	-\$24,671.
National Institute Diabetes & Digestive & Kidney GKLF/Beta-Catenin Crosstalk in the Intestine				
Liu, Chunming	3048106405	\$10,974.	\$0.	\$10,974.
University of Texas Medical Branch at Galveston ARRA: Targeting COX-2 Expressing Myofibroblasts in Colorectal Cancer (CRC)				
Massarweh, Suleiman A.	3048107009	\$2.	\$0.	\$2.
Bayer Pharmaceuticals A Phase II Study of Adding the Multikinase Inhibitor Sorafenib (Nexavar) to Existing Endocrine Therapy in Patient with Advanced Breast Cancer				
Mullett, Timothy	3048105584	\$0.	-\$2.	-\$2.
Proacta Inc A Randomized Phase II, Multi-Center, Open-Label, Trial of PR104 and Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer				
Mullett, Timothy	3048106967	\$2.	\$0.	\$2.
AMGen A Randomized, Double-blind, Placebo-controlled study to evaluate the long-term safety and efficacy of Darbepoetin alfa administered at 500 ug once every 3 weeks in anemic subjects with advanced NSCLC receiving multi-cy				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
McDowell Cancer Network				
O'Connor, Kathleen L	3048105702	\$0.	\$-2,282.	\$-2,282.
National Cancer Institute Ingegrin Contributions to Pancreatic Cancer				
O'Connor, Kathleen L	3048106408	\$0.	\$43,673.	\$43,673.
National Cancer Institute Novel Mechanisms of Carcinoma Cell Migration				
O'Connor, Kathleen L	3048106408	\$225,153.	\$0.	\$225,153.
National Cancer Institute Novel Mechanisms of Carcinoma Cell Migration				
Rinehart, John J	3048106951	\$2.	\$0.	\$2.
Schering Plough Co An Open-Label, Two Part Study to Determine the Safety, Tolerability, and Activity: GU-58 (Formerly 3048104488)				
Rinehart, John J	3048106952	\$2.	\$0.	\$2.
Pfizer Inc A Randomized Phase II Study of the Efficacy and Safety of Sunitinib Malate Sched: GU-55 (Formerly 3048097700)				
Tucker, Thomas C	3046921300	\$0.	\$403,973.	\$403,973.
National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program Expansion				
Tucker, Thomas C	3046921300	\$0.	\$98,700.	\$98,700.
National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program Expansion				
Tucker, Thomas C	3046921300	\$0.	\$900,000.	\$900,000.
National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program Expansion				
Tucker, Thomas C	3048105016	\$0.	\$33,759.	\$33,759.
Macro International Co Surveillance Pilot Project for Precancerous Lesions Among Cancer Registries in Monitoring the Impact of HPV				
Tucker, Thomas C	3048106690	\$1,140,056.	\$0.	\$1,140,056.
Center for Disease Control and Prevention National Cancer Prevention and Control Program				
Tucker, Thomas C	3048106941	\$89,454.	\$0.	\$89,454.
Battelle Memorial Institute Pre-Invasive Cervical Cancer Project				
Wyatt, Stephen W	3046859900	\$0.	\$24,160.	\$24,160.
National Cancer Institute Cancer Information Services				
Wyatt, Stephen W	3046859900	\$0.	\$329,370.	\$329,370.
National Cancer Institute Cancer Information Services				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>McDowell Cancer Network</u>				
Wyatt, Stephen W	3046859900	\$0.	\$185,840.	\$185,840.
National Cancer Institute Cancer Information Services				
Zhou, Binhua P.	3048105904	\$0.	\$156,630.	\$156,630.
National Cancer Institute Regulation of Snail in Breast Cancer Progression and Metastasis				
Zhou, Binhua P.	3048105904	\$125,520.	\$0.	\$125,520.
National Cancer Institute Regulation of Snail in Breast Cancer Progression and Metastasis				
Zhou, Binhua P.	3048106503	\$100,000.	\$0.	\$100,000.
Mary Kay Ash Charitable Foundation Dissecting the Dysregulation of Epithelial-Mesenchymal Transition at Breast Cancer Metastasis				
McDowell Cancer Network	Totals:	\$5,389,726.	\$4,283,126.	\$9,672,852.
<u>Sanders-Brown Center on Aging</u>				
Blonder, Lee X	3048011400	\$0.	\$355,629.	\$355,629.
National Institute of Mental Health Neuroimaging Studies of Depression in Parkinson's Disease				
Head, Elizabeth	3048105504	\$0.	\$703,198.	\$703,198.
National Institute on Aging Beta-Amyloid Immunization in a Canine Model of Aging				
Head, Elizabeth	3048105552	\$0.	\$126,225.	\$126,225.
National Institute on Aging The Effect of Antioxidants and Behavioral Enrichment on Gene Expression in Aged C.				
Head, Elizabeth	3048106406	\$201,192.	\$0.	\$201,192.
Akeso Health Sciences LLC SBIR: Medical Food Cocktail for Alzheimer's Disease				
Head, Elizabeth	3048106593	\$499,305.	\$0.	\$499,305.
National Institute on Aging Aging of Frontal Structure and Function in Down Syndrome and Dementia				
Jicha, Gregory A	3048103788	\$0.	\$8,694.	\$8,694.
University of California San Diego MultiCenter Trial to Evaluate Home-Based Assessment Methods for Alzheimer's Disease Prevention Research in People over 75 Years Old				
Jicha, Gregory A	3048103788	\$0.	\$1,594.	\$1,594.
University of California San Diego MultiCenter Trial to Evaluate Home-Based Assessment Methods for Alzheimer's Disease Prevention Research in People over 75 Years Old				
Jicha, Gregory A	3048103788	\$0.	\$2,694.	\$2,694.
University of California San Diego MultiCenter Trial to Evaluate Home-Based Assessment Methods for Alzheimer's Disease Prevention Research in People over 75 Years Old				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
<u>Sanders-Brown Center on Aging</u>				
Jicha, Gregory A	3048104560	\$0.	\$42,647.	\$42,647.
University of California San Diego A Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study Evaluating the Efficacy and Safety of 18 Months Treatment with PF-04494700 in Participants with Mild-to-Moderate AD (RAGE)				
Jicha, Gregory A	3048104560	\$0.	\$19,767.	\$19,767.
University of California San Diego A Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study Evaluating the Efficacy and Safety of 18 Months Treatment with PF-04494700 in Participants with Mild-to-Moderate AD (RAGE)				
Jicha, Gregory A	3048104818	\$0.	\$8,470.	\$8,470.
Elan Pharmaceuticals PLC A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolopoprotien E4 epsilon4 NON-Carriers				
Jicha, Gregory A	3048104818	\$0.	\$8,964.	\$8,964.
Elan Pharmaceuticals PLC A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolopoprotien E4 epsilon4 NON-Carriers				
Jicha, Gregory A	3048104818	\$0.	\$37,164.	\$37,164.
Elan Pharmaceuticals PLC A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolopoprotien E4 epsilon4 NON-Carriers				
Jicha, Gregory A	3048104818	\$0.	\$8,447.	\$8,447.
Elan Pharmaceuticals PLC A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolopoprotien E4 epsilon4 NON-Carriers				
Jicha, Gregory A	3048104818	\$0.	\$8,560.	\$8,560.
Elan Pharmaceuticals PLC A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolopoprotien E4 epsilon4 NON-Carriers				
Jicha, Gregory A	3048104818	\$0.	\$16,749.	\$16,749.
Elan Pharmaceuticals PLC A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolopoprotien E4 epsilon4 NON-Carriers				
Jicha, Gregory A	3048104818	\$0.	\$38,532.	\$38,532.
Elan Pharmaceuticals PLC A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolopoprotien E4 epsilon4 NON-Carriers				
Jicha, Gregory A	3048104818	\$0.	\$8,044.	\$8,044.
Elan Pharmaceuticals PLC A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolopoprotien E4 epsilon4 NON-Carriers				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
<u>Sanders-Brown Center on Aging</u>				
Jicha, Gregory A	3048104819	\$0.	\$1,465.	\$1,465.
Elan Pharmaceuticals PLC A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolopoprotien E4 epsilon4 Carriers				
Jicha, Gregory A	3048104819	\$0.	\$-22,338.	\$-22,338.
Elan Pharmaceuticals PLC A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolopoprotien E4 epsilon4 Carriers				
Jicha, Gregory A	3048104819	\$0.	\$15,272.	\$15,272.
Elan Pharmaceuticals PLC A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolopoprotien E4 epsilon4 Carriers				
Jicha, Gregory A	3048104819	\$0.	\$22,338.	\$22,338.
Elan Pharmaceuticals PLC A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolopoprotien E4 epsilon4 Carriers				
Jicha, Gregory A	3048104819	\$0.	\$22,338.	\$22,338.
Elan Pharmaceuticals PLC A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolopoprotien E4 epsilon4 Carriers				
Jicha, Gregory A	3048104819	\$0.	\$5,777.	\$5,777.
Elan Pharmaceuticals PLC A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolopoprotien E4 epsilon4 Carriers				
Jicha, Gregory A	3048104819	\$0.	\$2,520.	\$2,520.
Elan Pharmaceuticals PLC A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolopoprotien E4 epsilon4 Carriers				
Jicha, Gregory A	3048104819	\$0.	\$1,465.	\$1,465.
Elan Pharmaceuticals PLC A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolopoprotien E4 epsilon4 Carriers				
Jicha, Gregory A	3048104819	\$0.	\$2,930.	\$2,930.
Elan Pharmaceuticals PLC A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolopoprotien E4 epsilon4 Carriers				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Sanders-Brown Center on Aging</u>				
Jicha, Gregory A	3048104819	\$0.	\$14,191.	\$14,191.
Elan Pharmaceuticals PLC A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolipoprotein E4 epsilon4 Carriers				
Jicha, Gregory A	3048105559	\$0.	\$9,998.	\$9,998.
University of California San Diego Study of the Safety and Effectiveness of Immune Globulin Intravenous (IGIV) for the Treatment of Mild to Moderate Alzheimer Disease				
Jicha, Gregory A	3048105559	\$0.	\$13,756.	\$13,756.
University of California San Diego Study of the Safety and Effectiveness of Immune Globulin Intravenous (IGIV) for the Treatment of Mild to Moderate Alzheimer Disease				
Jicha, Gregory A	3048105559	\$0.	\$9,625.	\$9,625.
University of California San Diego Study of the Safety and Effectiveness of Immune Globulin Intravenous (IGIV) for the Treatment of Mild to Moderate Alzheimer Disease				
Jicha, Gregory A	3048105559	\$0.	\$-3,750.	\$-3,750.
University of California San Diego Study of the Safety and Effectiveness of Immune Globulin Intravenous (IGIV) for the Treatment of Mild to Moderate Alzheimer Disease				
Jicha, Gregory A	3048105847	\$0.	\$4,498.	\$4,498.
Medivation Inc CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve Month Safety and Efficacy Study Evaluating Dimebon in Patients with Mild-to-Moderate Alzheimer's Disease on Donepezil				
Jicha, Gregory A	3048105847	\$2.	\$0.	\$2.
Medivation Inc CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve Month Safety and Efficacy Study Evaluating Dimebon in Patients with Mild-to-Moderate Alzheimer's Disease on Donepezil				
Jicha, Gregory A	3048105847	\$0.	\$11,152.	\$11,152.
Medivation Inc CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve Month Safety and Efficacy Study Evaluating Dimebon in Patients with Mild-to-Moderate Alzheimer's Disease on Donepezil				
Jicha, Gregory A	3048105847	\$0.	\$24,912.	\$24,912.
Medivation Inc CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve Month Safety and Efficacy Study Evaluating Dimebon in Patients with Mild-to-Moderate Alzheimer's Disease on Donepezil				
Jicha, Gregory A	3048105884	\$2.	\$0.	\$2.
Premier Research International LLC A Randomized Controlled Trial to Assess the Efficacy of a Medical Food in Patients with Mild to Moderate Alzheimer's Disease using Alzheimer's Disease Medication				
Jicha, Gregory A	3048105884	\$0.	\$4,097.	\$4,097.
Premier Research International LLC A Randomized Controlled Trial to Assess the Efficacy of a Medical Food in Patients with Mild to Moderate Alzheimer's Disease using Alzheimer's Disease Medication				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Sanders-Brown Center on Aging</u>				
Jicha, Gregory A	3048105884	\$0.	\$769.	\$769.
Premier Research International LLC A Randomized Controlled Trial to Assess the Efficacy of a Medical Food in Patients with Mild to Moderate Alzheimer's Disease using Alzheimer's Disease Medication				
LeVine, Harry	3048104659	\$0.	\$53,478.	\$53,478.
Emory University Alzheimer's Disease: Modeling Pathologic Strain-like Variants of Multimeric a-Beta				
LeVine, Harry	3048105784	\$250,000.	\$0.	\$250,000.
Coins for Alzheimers Research Trust Molecular Basis of PIB in the AD Brain: Inducing the AD Phenotype in Neuronal Culture and TgAPP/PS1				
Lovell, Mark	3048105024	\$0.	\$155,656.	\$155,656.
National Institute on Aging Aberrant Protein Complexes as Biomarkers of Alzheimer's Disease				
Markesbery, William	3048105745	\$1,274,260.	\$0.	\$1,274,260.
National Institute on Aging Alzheimer's Disease Center Core				
Markesbery, William	3048105745	\$0.	\$10,338.	\$10,338.
National Institute on Aging Alzheimer's Disease Center Core				
Markesbery, William	3048106072	\$241,715.	\$0.	\$241,715.
National Institute on Aging ARRA Administrative Supplement: Alzheimer's Disease Core Center				
Markesbery, William	3048106315	\$25,000.	\$0.	\$25,000.
University of Washington National Alzheimer's Coordinating Center (NACC) - Year 11				
Markesbery, William	3048106315	\$0.	\$1,450.	\$1,450.
University of Washington National Alzheimer's Coordinating Center (NACC) - Year 11				
Markesbery, William	3048106315	\$0.	\$-1,450.	\$-1,450.
University of Washington National Alzheimer's Coordinating Center (NACC) - Year 11				
Nelson, Peter	3046980700	\$0.	\$176,729.	\$176,729.
National Institute of Neurological Disorders & Stroke Alpha-Synuclein MRNA is a Putative MicroRNA Target				
Nelson, Peter	3048105044	\$0.	\$50,000.	\$50,000.
Alzheimers Association New Investigators Research Grant Program: Mechanism and therapeutic significance of an AD-relevant microRNA pathway				
Norris, Christopher M	3048043000	\$0.	\$257,206.	\$257,206.
National Institute on Aging Calcineurin and Inflammatory Signaling Processes in Aging and AD				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Sanders-Brown Center on Aging</u>				
Scheff, Stephen W	3048105031	\$0.	\$101,640.	\$101,640.
University of Pittsburgh Neurobiology of Mild Cognitive Impairment in the Elderly				
Scheff, Stephen W	3048105377	\$0.	\$99,402.	\$99,402.
KY Spinal Cord and Head Injury Research Trust Hyperglycemia and Traumatic Brain Injury				
Scheff, Stephen W	3048106589	\$222,750.	\$0.	\$222,750.
National Institute of Neurological Disorders & Stroke ARRA: Pyncnogenol and Traumatic Brain Injury				
Telling, Glenn	3046905000	\$0.	\$98,213.	\$98,213.
National Institute of Neurological Disorders & Stroke Transgenetic Studies of Prion Disease in Cervids				
Telling, Glenn	3046905000	\$0.	\$317,923.	\$317,923.
National Institute of Neurological Disorders & Stroke Transgenetic Studies of Prion Disease in Cervids				
Telling, Glenn	3048105664	\$0.	\$247,312.	\$247,312.
University of Texas Health Science Center at Houston Pathogenesis, Transmission and Detection of Zoonotic Prion Disease				
VAN ELDIK, LINDA	3048106932	\$197,690.	\$0.	\$197,690.
American Health Assistance Foundation Attenuating Proinflammatory Cytokine Upregulation as an AD Therapeutic Strategy				
VAN ELDIK, LINDA	3048106940	\$0.	\$50,014.	\$50,014.
Alzheimers Association Proinflammatory Cytokine Overproduction: A Contributor to Pathophysiology				
VAN ELDIK, LINDA	3048106940	\$157,221.	\$0.	\$157,221.
Alzheimers Association Proinflammatory Cytokine Overproduction: A Contributor to Pathophysiology				
VAN ELDIK, LINDA	3048106962	\$371,250.	\$0.	\$371,250.
National Institute of Neurological Disorders & Stroke Modulation of CNS Proinflammatory Cytokine Production				
Sanders-Brown Center on Aging	Totals:	\$3,440,387.	\$3,154,304.	\$6,594,691.
<u>Mag Resonance Imag Sys Ctr</u>				
Smith, Charles D	3046940800	\$0.	\$10,631.	\$10,631.
University of California San Diego Alzheimer's Disease Neuroimaging Initiative				
Smith, Charles D	3046940800	\$0.	\$26,663.	\$26,663.
University of California San Diego Alzheimer's Disease Neuroimaging Initiative				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
<u>Mag Resonance Imag Sys Ctr</u>				
Smith, Charles D	3046940800	\$0.	\$4,469.	\$4,469.
University of California San Diego Alzheimer's Disease Neuroimaging Initiative				
Mag Resonance Imag Sys Ctr	Totals:	\$0.	\$41,763.	\$41,763.
<u>Rural Ky Healthcare</u>				
Allen, Larry	3048105985	\$0.	\$1,564.	\$1,564.
Health Resources and Services Administration State Office of Rural Health Grant Program				
Allen, Larry	3048105985	\$167,200.	\$0.	\$167,200.
Health Resources and Services Administration State Office of Rural Health Grant Program				
Allen, Larry	3048106080	\$30,000.	\$0.	\$30,000.
KY Cabinet for Health and Family Services Rural Cooperative Agreement				
Allen, Larry	3048106088	\$270,000.	\$0.	\$270,000.
Health Resources and Services Administration Kentucky State Loan Repayment Program				
Allen, Larry	3048106096	\$506,413.	\$0.	\$506,413.
Health Resources and Services Administration Medicare Rural Hospital Flexibility Grant Program				
Allen, Larry	3048106404	\$345,823.	\$0.	\$345,823.
Health Resources and Services Administration Small Rural Hospital Improvement Grant Program (SHIP)				
Allen, Larry	3048106608	\$105,000.	\$0.	\$105,000.
Health Resources and Services Administration ARRA: Kentucky State Loan Repayment Program (SLRP), ARRA 2009 Funding				
Casey, Baretta R	3048105140	\$0.	\$162,786.	\$162,786.
National Institute of General Medical Sciences Appalachian Kentucky Bridges to Success				
Feltner, Frances J	3048105844	\$1,999,900.	\$0.	\$1,999,900.
KY Department for Public Health Kentucky Homeplace FY10				
Rural Ky Healthcare	Totals:	\$3,424,336.	\$164,350.	\$3,588,686.
<u>Center on Drug and Alcohol Research</u>				
Havens, Jennifer Rochussen	3048104775	\$0.	\$627,278.	\$627,278.
National Institute on Drug Abuse Social Networks and HIV Risk Among Rural Drug Users				
Leukefeld, Carl G	3048105867	\$5,759,193.	\$0.	\$5,759,193.
KY Health Services Cabinet TAP and Substance Abuse and Domestic Violence Project				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Center on Drug and Alcohol Research</u>				
Lofwall, Michelle Renee	3048105475	\$0.	\$130,673.	\$130,673.
Reckitt Benckiser Pharmaceuticals Inc Evaluating the Uptake of Instruction for Office-based Opioid Addiction Practices Aimed at Decreasing and Preventing Buprenorphine Diversion and Misuse				
Shannon, Lisa	3048105484	\$0.	\$120,000.	\$120,000.
KY Administrative Office of the Courts Treatment Drug Court Service Enhancement Project - Floyd & Perry Counties				
Shannon, Lisa	3048105537	\$0.	\$50,000.	\$50,000.
Community Action Council for Lexington Fayette et Comprehensive Treatment Service for Homeless Individuals and Families				
Shannon, Lisa	3048106655	\$60,000.	\$0.	\$60,000.
KY Administrative Office of the Courts Treatment Drug Court Service Enhancement Project - Christian County				
Shannon, Lisa	3048106672	\$56,460.	\$0.	\$56,460.
Volunteers of America of Los Angeles Volunteers of America Los Angeles				
Shannon, Lisa	3048106673	\$44,800.	\$0.	\$44,800.
HOPE Center of Lexington Evaluation for the Center on Substance Abuse Treatment Men (CSAT-Men)				
Shannon, Lisa	3048106673	\$0.	\$-600.	\$-600.
HOPE Center of Lexington Evaluation for the Center on Substance Abuse Treatment Men (CSAT-Men)				
Shannon, Lisa	3048106845	\$60,000.	\$0.	\$60,000.
KY Administrative Office of the Courts Treatment Drug Court Service Enhancement Project - Knox/Laurel Counties				
Shannon, Lisa	3048106847	\$60,000.	\$0.	\$60,000.
KY Administrative Office of the Courts Treatment Drug Court Service Enhancement Project - Hardin County				
Shannon, Lisa	3048106848	\$60,000.	\$0.	\$60,000.
KY Administrative Office of the Courts Treatment Drug Court Service Enhancement Project - Hopkins County				
Tindall, Michele Staton	3048105771	\$161,273.	\$0.	\$161,273.
KY Department of Corrections Treatment Outcome Study for Prison-Based Substance Abuse Treatment Program 09-10 (CJ-KTOS)				
Walker, James R	3048104615	\$0.	\$50,000.	\$50,000.
KY River Community Care Inc Program Evaluation, Clinical Training, and Consultative Services for KRCC Staff				
Walker, James R	3048105736	\$0.	\$898.	\$898.
KY Cabinet for Health and Family Services UTC Division of Child Care - STARS Project				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Center on Drug and Alcohol Research</u>				
Walker, James R	3048105875	\$87,539.	\$0.	\$87,539.
KY Cabinet for Health and Family Services UTC Division of Child Care - STARS Project				
Walker, James R	3048105917	\$10,000.	\$0.	\$10,000.
KY Housing Corp Kentucky Housing Corporation - KTOS				
Walker, James R	3048106050	\$1,302,421.	\$0.	\$1,302,421.
Department for Mental Health Mental Retardation Service FS/OP (TAA6, TAA7, TAAU) -- Kentucky Treatment Outcome Study				
Walsh, Sharon L	3048106045	\$342,199.	\$0.	\$342,199.
National Institute on Drug Abuse ARRA: New Neural Targets for Opioid Use Disorders: Human Studies				
Webster, John Matthew	3048104821	\$0.	\$73,250.	\$73,250.
National Institute on Alcohol Abuse and Alcoholism Drugged Driving in Alcohol-restricted Rural Appalachia				
Webster, John Matthew	3048105295	\$0.	\$183,125.	\$183,125.
National Institute on Drug Abuse A Web-based Employment Intervention for Drug Court Participants				
Center on Drug and Alcohol Research	Totals:	\$8,003,885.	\$1,234,624.	\$9,238,509.
<u>Anatomy & Neurobiology</u>				
Bradley, Luke H.	3048106904	\$60,000.	\$0.	\$60,000.
Pharmaceutical Research and Manufacturers of Ameri Investigation of the antiapoptotic effects of Dopamine Neuron Stimulating Peptide-11				
Bueler, Hans Rudolf	3048105258	\$0.	\$29,507.	\$29,507.
Parkinson Schweiz Identification of Novel PINK1 Substrates Using Proteomics and Conditional PINK1 Knockout Cells				
Bueler, Hans Rudolf	3048105258	\$0.	\$4,160.	\$4,160.
Parkinson Schweiz Identification of Novel PINK1 Substrates Using Proteomics and Conditional PINK1 Knockout Cells				
Duncan, Marilyn J	3048103522	\$0.	\$294,319.	\$294,319.
National Institute on Aging Neural Mechanisms Resetting the Aged Circadian Pacemaker				
Duncan, Marilyn J	3048104274	\$0.	\$272,559.	\$272,559.
National Institute of Neurological Disorders & Stroke Multiple Circadian oscillators: Regulation of a neuroendocrine rhythm				
Duncan, Marilyn J	3048104274	\$0.	\$27,256.	\$27,256.
National Institute of Neurological Disorders & Stroke Multiple Circadian oscillators: Regulation of a neuroendocrine rhythm				
Gash, Don M	3048091000	\$0.	\$2,868.	\$2,868.
Medtronics Inc RNA-Mediated SIRNA Master Research Agreement				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Anatomy & Neurobiology</u>				
Gash, Don M	3048091000	\$0.	\$182,169.	\$182,169.
Medtronics Inc RNA-Mediated SIRNA Master Research Agreement				
Gash, Don M	3048091000	\$0.	\$420,116.	\$420,116.
Medtronics Inc RNA-Mediated SIRNA Master Research Agreement				
Gash, Don M	3048091000	\$0.	\$370.	\$370.
Medtronics Inc RNA-Mediated SIRNA Master Research Agreement				
Gerhardt, Greg A	3046967500	\$0.	\$26,093.	\$26,093.
Medical University of South Carolina Dual Hit Hypothesis of Aging Related DA Dysfunction				
Gerhardt, Greg A	3048106125	\$1,153,440.	\$0.	\$1,153,440.
National Institute of Neurological Disorders & Stroke Restoration of Dopamine Function in Parkinson's Disease				
Gerhardt, Greg A	3048106663	\$120,000.	\$0.	\$120,000.
National Science Foundation Micro-Fluidics Neurochemical Analyzer				
Gerhardt, Greg A	3048106768	\$166,914.	\$0.	\$166,914.
Wake Forest University Restorative Encoding Memory Integration Neural Device-In Vivo Testing				
Gold, Brian T	3048105251	\$0.	\$124,766.	\$124,766.
National Science Foundation The Cognitive Neuroscience of Bilingual Advantages in Executive Control				
Gold, Brian T	3048105251	\$0.	\$191,921.	\$191,921.
National Science Foundation The Cognitive Neuroscience of Bilingual Advantages in Executive Control				
Gold, Brian T	3048106564	\$304,425.	\$0.	\$304,425.
National Institute on Aging The effects of bilingualism on age-related cognitive and neurobiological declines				
Grondin, Richard C	3046956000	\$0.	\$19,621.	\$19,621.
Medtronics Inc New Neural Therapy Studies: 2005-1				
Hardy, Peter A	3048106423	\$389,919.	\$0.	\$389,919.
Codman & Shurtleff Inc Utilizing Novel Tracers to Determine the Distribution of Therapeutic Agents in vivo				
Joseph, Jane E	3048103754	\$0.	\$302,360.	\$302,360.
National Institute of Child Health and Human Develop Functional Neuroanatomy of Development Changes in Face Processing				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Anatomy & Neurobiology</u>				
Joseph, Jane E	3048105862	\$364,680.	\$0.	\$364,680.
National Institute on Drug Abuse ARRA: Exploring the neurobiological response to anti-drug media messages with fMRA				
Joseph, Jane E	3048106507	\$7,712.	\$0.	\$7,712.
National Institute of Child Health and Human Develop ARRA: Functional neuroanatomy of developmental changes in face processing				
Joseph, Jane E	3048106572	\$267,046.	\$0.	\$267,046.
National Institute of Mental Health A Comparative Developmental Connectivity Study of Face Processing				
Anatomy & Neurobiology	Totals:	\$2,834,136.	\$1,898,085.	\$4,732,221.
<u>Emergency Medicine</u>				
Humphries, Roger L		\$78,669.	\$0.	\$78,669.
University of Michigan UK NETT Clinical Hub Site: Supplement to NINDS award				
Humphries, Roger L	3048087100	\$0.	\$-2,000.	\$-2,000.
MedImmune Inc An Epidemiological Study to Evaluate the Seasonality of Respiratory Syncytial Virus-Associated Lower Respiratory TRact Infections (LRI) or Apnea in Infants in the Emergency Department				
Humphries, Roger L	3048100900	\$0.	\$194,117.	\$194,117.
National Institute of Neurological Disorders & Stroke UK NETT Clinical Site hub				
Humphries, Roger L	3048104000	\$0.	\$78,669.	\$78,669.
University of Michigan UK NETT Clinical Hub Site				
Emergency Medicine	Totals:	\$78,669.	\$270,786.	\$349,455.
<u>Behavioral Science</u>				
Andrykowski, Michael A	3048106113	\$38,329.	\$0.	\$38,329.
National Cancer Institute NRSA fellowship for Jessica Burris: Cigarette Smoking among Head and Neck Cancer Patients: A Prospective Study				
Andrykowski, Michael A	3048106942	\$23,126.	\$0.	\$23,126.
East Tennessee State University ARRA: A Population-Based Controlled Investigation of QOL and Health Behaviors Among Survivors of Cancer Diagnosed During Young Adulthood				
Fernander, Anita	3048106642	\$74,250.	\$0.	\$74,250.
National Cancer Institute The Impact of Smoke-Free Policy on Quitline Utilization and Smoking Outcomes				
Garrity, Thomas F	3048105990	\$283,901.	\$0.	\$283,901.
National Institute on Drug Abuse Research Training in Drug Abuse Behavior				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Behavioral Science</u>				
Knudsen, Hannah K	3048104382	\$0.	\$37,126.	\$37,126.
University of Georgia CTN Membership and Adoption of Innovative TX Practices				
Knudsen, Hannah K	3048106643	\$128,478.	\$0.	\$128,478.
Robert Wood Johnson Foundation Barriers to the Adoption of Pharmacotherapies in Publicly Funded Substance Abuse Treatment: Policy Barriers and Access to Physicians				
Leukefeld, Carl G	3048077800	\$0.	\$248,348.	\$248,348.
National Center for Research Resources TRY-IT Translating Reserach to Youth through Information Technology				
Leukefeld, Carl G	3048106638	\$677,275.	\$0.	\$677,275.
National Institute on Drug Abuse Central States Criminal Justice Drug Abuse Center - CJDATS				
Leukefeld, Carl G	3048106856	\$152,685.	\$0.	\$152,685.
National Development and Research Institutes Incorporat ARRA: Computer-Delivered Psychosocial Treatment for Offenders with Substance use Disorders				
Lile, Joshua	3046902300	\$0.	\$152,141.	\$152,141.
National Institute on Drug Abuse A Pharmacological Analysis of Delta 9-THC in Humans				
Lile, Joshua	3048105287	\$0.	\$366,250.	\$366,250.
National Institute on Drug Abuse GABA Drugs for Cannabis-Use Disorders: Initial Mechanistic Studies in Humans				
Rush, Craig R	3046925900	\$0.	\$306,293.	\$306,293.
National Institute on Drug Abuse Stimulant Abuse Pharmacotherapy: Novel Antipsychotics				
Rush, Craig R	3048105279	\$0.	\$366,250.	\$366,250.
National Institute on Drug Abuse GABAA Modulation as a Target for Developing Medications for Methamphetamine Abuse				
Rush, Craig R	3048105510	\$0.	\$362,588.	\$362,588.
National Institute on Drug Abuse Agonist Replacement Therapy for Methamphetamine Dependence: Human Lab Studies				
Schoenberg, Nancy E	3048104977	\$0.	\$570,775.	\$570,775.
National Center on Minority Health and Health Disparities Faith Moves Mountains: A CBPR Appalachian Wellness & Cancer Prevention Program				
Schoenberg, Nancy E	3048105145	\$0.	\$619,717.	\$619,717.
National Institute Diabetes & Digestive & Kidney An Intergenerational CBPR Intervention to Reduce Appalachian Health Disparities				
Stoops, William W	3048104631	\$0.	\$219,750.	\$219,750.
National Institute on Drug Abuse Human Lab Model of Behavioral/ Pharmacological Treatment for Cocaine Dependence				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Behavioral Science</u>				
Stoops, William W	3048105882	\$581,516.	\$0.	\$581,516.
National Institute on Drug Abuse ARRA: Neuropharmacology of Tramadol: Clinical Efficacy and Abuse Potential				
Studts, Jamie Lawrence	3048106765	\$57,141.	\$0.	\$57,141.
University of Miami School of Medicine ARRA: A Targeted Decision Aid to Improve Minority Participation in Clinical Trials				
Behavioral Science	Totals:	\$2,016,701.	\$3,249,238.	\$5,265,939.
<u>Graduate Center for Nutritional Sciences</u>				
Cassis, Lisa A	3048104794	\$0.	\$21,000.	\$21,000.
American Heart Association Great Rivers Affiliate Fellowship for Xuan Zhang: Androgen Regulation of the AT1a Receptor (AT1aR) in Angiotensin II-Induced Abdominal Aortic Aneurysms				
Cassis, Lisa A	3048104798	\$0.	\$21,000.	\$21,000.
American Heart Association Great Rivers Affiliate Fellowship for Manisha Gupte: ACE2 Expression in Adipocytes and Regulation in Obesity-Related Hypertension				
Cassis, Lisa A	3048105444	\$0.	\$384.	\$384.
National Heart Lung and Blood Institute Fellowship for Sean Thatcher: ACE2 in Hypercholesterolemia and Angiotensin II - Induced Vascular Diseases				
Cassis, Lisa A	3048106090	\$371,250.	\$0.	\$371,250.
National Heart Lung and Blood Institute Angiotensin: A Link Between Obesity and Hypertension				
Cassis, Lisa A	3048106658	\$548,391.	\$0.	\$548,391.
National Heart Lung and Blood Institute ARRA: Biomedical Research Core Centers (P30) through Fetal Programming				
Cassis, Lisa A	3048106956	\$50,474.	\$0.	\$50,474.
National Heart Lung and Blood Institute Fellowship for Sean Thatcher: ACE2 in Hypercholesterolemia and Angiotensin II-Induced Vascular Diseases				
St Clair, Daret K	3048106575	\$90,478.	\$0.	\$90,478.
National Institute Diabetes & Digestive & Kidney NRSA T32: Training Program in Oxidative Stress and Nutrition				
Wang, Shuxia	3048105920	\$293,000.	\$0.	\$293,000.
National Institute Diabetes & Digestive & Kidney Upstream Stimulatory Factor 2 Regulation of Renin in Diabetic Nephropathy				
Wang, Shuxia	3048106510	\$50,000.	\$0.	\$50,000.
American Society of Nephrology Protective Role of PKG in Renal Ischemia-Reperfusion Injury				
Graduate Center for Nutritional Sciences	Totals:	\$1,403,593.	\$42,384.	\$1,445,977.
<u>Molecular & Cellular Biochemistry</u>				
Chi, Young-In	3048104911	\$0.	\$25,000.	\$25,000.
KY Diabetes Research Trust Fund Identification of HNF and HNF4 Mediated Regulators of Insulin Secretion in Beta-Cells				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
<u>Molecular & Cellular Biochemistry</u>				
Chi, Young-In	3048105892	\$192,500.	\$0.	\$192,500.
American Diabetes Association Inc Structural Studies of HNF 1alpha and HNF 4alpha				
Chi, Young-In	3048105892	\$0.	\$-34,650.	\$-34,650.
American Diabetes Association Inc Structural Studies of HNF 1alpha and HNF 4alpha				
Creamer, Trevor P	3048105437	\$0.	\$159,567.	\$159,567.
National Science Foundation Calmodulin Mediated Disorder-to-Order Transitions: Calcineurin as a Model System				
Creamer, Trevor P	3048105437	\$0.	\$11,850.	\$11,850.
National Science Foundation Calmodulin Mediated Disorder-to-Order Transitions: Calcineurin as a Model System				
Dutch, Rebecca	3048105529	\$0.	\$294,030.	\$294,030.
National Institute of Allergy and Infectious Diseases Paramyxovirus F protein mediated membrane fusion				
Fried, Michael Gregory	3048096900	\$0.	\$27,951.	\$27,951.
Ohio State University Molecular Basis of Interchromosomal Gene Regulation				
Gentry, Matthew Shawn	3048105237	\$0.	\$74,250.	\$74,250.
National Institute of Neurological Disorders & Stroke Novel Model Systems Link Floridean Starch Metabolism to Lafora Disease				
Gentry, Matthew Shawn	3048105237	\$0.	\$192,356.	\$192,356.
National Institute of Neurological Disorders & Stroke Novel Model Systems Link Floridean Starch Metabolism to Lafora Disease				
Hersh, Louis B	3048104925	\$0.	\$79,609.	\$79,609.
Alzheimers Association A Modified Nephilysin for Gene Therapy				
Hersh, Louis B	3048105791	\$237,623.	\$0.	\$237,623.
National Institute on Drug Abuse Training in Drug Abuse Related Research				
Hersh, Louis B	3048105830	\$166,823.	\$0.	\$166,823.
National Institute on Aging ARRA: Nephilysin and Peripheral Clearance of Amyloid Peptides				
Hersh, Louis B	3048106428	\$1,785,490.	\$0.	\$1,785,490.
National Center for Research Resources Center of Biomedical Research Excellence in the Molecular Basis of Human Disease - Administrative Core				
Hersh, Louis B	3048106637	\$0.	\$-224,850.	\$-224,850.
National Center for Research Resources ARRA: Center for Biomedical Research Excellence in Molecular Basis of Human Disease - Supplemental - Viral Vector CORE				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
<u>Molecular & Cellular Biochemistry</u>				
Hersh, Louis B	3048106637	\$445,313.	\$0.	\$445,313.
National Center for Research Resources ARRA: Center for Biomedical Research Excellence in Molecular Basis of Human Disease - Supplemental - Viral Vector CORE				
McCann, Richard	3048103414	\$0.	\$10,500.	\$10,500.
American Heart Association Ohio Valley Affiliate Fellowship for Steven Smith: The Role of Talin in Cell Adhesion and Migration, and How a C-terminal Modular element Affects its Function				
Moncman, Carole	3048105265	\$0.	\$183,125.	\$183,125.
National Eye Institute Temporal and Spatial Patterns of Structural Proteins in Extraocular Muscles				
Murphy, Michael Paul	3048105946	\$24,151.	\$0.	\$24,151.
National Institute of Neurological Disorders & Stroke ARRA: Cellular Nucleic Acid Binding Protein (CNBP) in Aging and Disease - Student Summer Research Supplemental				
Ozcan, Sabire	3048103413	\$0.	\$1,750.	\$1,750.
American Heart Association Ohio Valley Affiliate Fellowship for Nathan Vanderford: Regulation of the Glucose-Dependent Expression of MafA in Pancreatic Beta Cells				
Ozcan, Sabire	3048105534	\$0.	\$-13,821.	\$-13,821.
American Diabetes Association Inc Role of Histone Deacetylation and Protein Phosphatases in Insulin Gene Expression				
Ozcan, Sabire	3048105883	\$32,332.	\$0.	\$32,332.
National Institute Diabetes & Digestive & Kidney ARRA: Histone Acetylation and Insulin Gene Expression				
Ozcan, Sabire	3048106918	\$37,680.	\$0.	\$37,680.
National Institute Diabetes & Digestive & Kidney ARRA: Administrative Supplement for Histone Acetylation and Insulin Gene Expression				
Ozcan, Sabire	3048106919	\$222,750.	\$0.	\$222,750.
National Institute Diabetes & Digestive & Kidney ARRA: Beta-Cell Transcription Factors and Insulin Gene Expression				
Shimojo, Masahito	3048106115	\$50,000.	\$0.	\$50,000.
Hereditary Disease Foundation Studies of novel REST / NRSF-Interlacing LIM domain Protein (RILP) in Huntington's Disease				
Spielmann, H Peter	3048104852	\$0.	\$311,313.	\$311,313.
National Institute of General Medical Sciences Synthetic Probes of Protein Prenylation				
Stamm, Stefan	3048105550	\$0.	\$45,000.	\$45,000.
Prader Willi Syndrome Association Role of snoRNAs in Prader-Willi Syndrome				
Stamm, Stefan	3048105877	\$267,300.	\$0.	\$267,300.
National Institute of General Medical Sciences Regulation of alternative pre-mRNA processing by small nucleolar RNA's				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
<u>Molecular & Cellular Biochemistry</u>				
Stamm, Stefan	3048106023	\$129,828.	\$0.	\$129,828.
Muscular Dystrophy Association Promotion of Exon 7 Inclusion to Treat Spinal Muscular Atrophy				
Stamm, Stefan	3048106665	\$45,000.	\$0.	\$45,000.
Foundation for Prader Willi Research Identification of Substances that Substitute the Loss of snoRNA's from the Prader-Willi critical region				
Stamm, Stefan	3048106966	\$96,525.	\$0.	\$96,525.
Shire Human Genetic Therapies Incorporated Identification and Testing of HBII-52 and HBII85 snoRNA Molecules as Potential Therapy for Prader Willi Syndrome				
Tang, Xiaoqing	3048103834	\$0.	\$2,234.	\$2,234.
National Institute Diabetes & Digestive & Kidney Role of microRNAs in insulin production and secretion in pancreatic beta-cells				
Tang, Xiaoqing	3048103834	\$0.	\$101,505.	\$101,505.
National Institute Diabetes & Digestive & Kidney Role of microRNAs in insulin production and secretion in pancreatic beta-cells				
Tang, Xiaoqing	3048105770	\$74,250.	\$0.	\$74,250.
National Institute Diabetes & Digestive & Kidney Role of miR-30d in insulin gene expression in pancreatic beta cells				
Turco, Salvatore J	3048105277	\$0.	\$289,128.	\$289,128.
Washington University Glycosylation Mutants of Leishmania				
Vander Kooi, Craig William	3048106824	\$150,000.	\$0.	\$150,000.
KY Lung Cancer Research Fund Physical Mechanisms of VEGF receptor activation and novel models of inhibition				
Waechter, Charles J	3048106669	\$112,602.	\$0.	\$112,602.
National Institute of General Medical Sciences ARRA: Regulation of Protein N-Glycosylation in the CNS				
Whiteheart, Sidney W	3048104241	\$0.	\$293,000.	\$293,000.
National Heart Lung and Blood Institute Molecular Mechanisms of Platelet Exocytosis				
Whiteheart, Sidney W	3048105772	\$43,000.	\$0.	\$43,000.
American Heart Association Great Rivers Affiliate Fellowship for Michael Chicka: Unveiling the Molecular Mechanisms Underlying Ca ²⁺ -triggered Platelet Secretion				
Zhu, Haining	3048105150	\$0.	\$183,000.	\$183,000.
National Institute on Aging Role of P62 in Protein Aggregation and Neurodegeneration in ALS				
Zhu, Haining	3048105538	\$0.	\$21,825.	\$21,825.
Brigham and Womens Hospital Fellowship for: Xiaohu Tang - Abrogating Interaction between Mutant SOD1 and Dynein: A Novel ALS Therapeutic Strategy				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
<u>Molecular & Cellular Biochemistry</u>				
Zhu, Haining	3048106645	\$233,888.	\$0.	\$233,888.
National Institute on Aging ARRA: Role of 62 in Protein Aggregation and Neurogeneration in ALS				
Molecular & Cellular Biochemistry	Totals:	\$4,347,055.	\$2,033,672.	\$6,380,727.
<u>Internal Medicine</u>				
Ain, Kenneth B	3046976500	\$0.	\$54,625.	\$54,625.
Celgene Phase II Trail of REVLIMID (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas				
Ain, Kenneth B	3048093400	\$0.	\$5,260.	\$5,260.
AstraZeneca Pharmaceuticals An international Phase II randomized double-blinded, placebo-controlled, multi-center study to assess the efficacy of ZD6474(Zactima TM) versus placebo in patients with unresectable locally advanced or metastatic medullary thyroid cancer				
Ain, Kenneth B	3048093400	\$0.	\$2,222.	\$2,222.
AstraZeneca Pharmaceuticals An international Phase II randomized double-blinded, placebo-controlled, multi-center study to assess the efficacy of ZD6474(Zactima TM) versus placebo in patients with unresectable locally advanced or metastatic medullary thyroid cancer				
Ain, Kenneth B	3048093400	\$0.	\$47,742.	\$47,742.
AstraZeneca Pharmaceuticals An international Phase II randomized double-blinded, placebo-controlled, multi-center study to assess the efficacy of ZD6474(Zactima TM) versus placebo in patients with unresectable locally advanced or metastatic medullary thyroid cancer				
Ain, Kenneth B	3048093400	\$0.	\$22,148.	\$22,148.
AstraZeneca Pharmaceuticals An international Phase II randomized double-blinded, placebo-controlled, multi-center study to assess the efficacy of ZD6474(Zactima TM) versus placebo in patients with unresectable locally advanced or metastatic medullary thyroid cancer				
Ain, Kenneth B	3048104863	\$0.	\$126,000.	\$126,000.
National Cancer Institute Transcriptional Repression of Sodium Iodide Symporter in Thyroid Carcinoma				
Angulo, Paul	3048106640	\$192,218.	\$0.	\$192,218.
National Institute Diabetes & Digestive & Kidney Prognosis of Nonalcoholic Fatty Liver Disease				
Arnold, Susanne M	3046259800	\$0.	\$6,100.	\$6,100.
Southwest Oncology Group Southwest Oncology Group Studies				
Arnold, Susanne M	3046259800	\$0.	\$10,000.	\$10,000.
Southwest Oncology Group Southwest Oncology Group Studies				
Arnold, Susanne M	3046259800	\$0.	\$-2,000.	\$-2,000.
Southwest Oncology Group Southwest Oncology Group Studies				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Arnold, Susanne M	3046259800	\$0.	\$2,000.	\$2,000.
Southwest Oncology Group Southwest Oncology Group Studies				
Arnold, Susanne M	3046259800	\$0.	\$18,200.	\$18,200.
Southwest Oncology Group Southwest Oncology Group Studies				
Arnold, Susanne M	3048065800	\$0.	\$360.	\$360.
Arno Therapeutics Inc A Phase 1 Study of DB-67 (7-t-butylidimethylsilyl-10-hydroxycamptothecin) in Adult Patients with Refractory or Metastatic Solid Malignancies				
Arnold, Susanne M	3048076600	\$0.	\$-2,000.	\$-2,000.
AstraZeneca Pharmaceuticals A Phase III, International, RANdomized, Double-BLind, Parallel-Group, Multi-Center, Study to Assess the Efficacy of ZD6474 Versus Erlotinib (TARCEVA) in Patients with Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC)				
Arnold, Susanne M	3048104326	\$0.	\$1,588.	\$1,588.
AMGen A Phase 2, Single-Arm, Open Label, Multi-Center Trial of Panitumumab Monotherapy in Patients with Platinum Refractory Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck				
Arnold, Susanne M	3048104326	\$0.	\$8,192.	\$8,192.
AMGen A Phase 2, Single-Arm, Open Label, Multi-Center Trial of Panitumumab Monotherapy in Patients with Platinum Refractory Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck				
Arsenescu, Razvan I	3048103221	\$0.	\$18,328.	\$18,328.
AstraZeneca Pharmaceuticals Role of Polymeric Immunoglobulin Receptor (pIgR) in the Pathogenesis of Crohn's Disease				
Arsenescu, Razvan I	3048104522	\$0.	\$252.	\$252.
Robarts Research Institute An observational prospective study to identify clinical, endoscopic and/or biological predictors that correlate with histopathologic findings in subjects with moderate to severe ulcerative colitis				
Booth, David C	3048012300	\$0.	\$3,150.	\$3,150.
Actelion Pharmaceuticals Ltd COMPASS 2: Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Pts. with Pulmonary Arterial Hypertension-A Multicenter, Double-Blind, RANdomized, Placebo-Controlled,.....Phase IV Study				
Booth, David C	3048105860	\$0.	\$4,498.	\$4,498.
Gilead Palo Alto Inc An Open-Label, Multi-Center Study Evaluating the Validity, Reliability, and Responsiveness of a New Women's Ischemia Symptom Questionnaire in Women with Chronic Angina Treated with Ranolazine Extended-Release Tablets				
Booth, David C	3048106500	\$0.	\$159.	\$159.
Actelion Pharmaceuticals Ltd COMPASS 2: Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Pts. with Pulmonary Arterial Hypertension-A Multicenter, Double-Blind, RANdomized, Placebo-Controlled,.....Phase IV Study				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Bruemmer, Dennis C	3048104987	\$0.	\$21,000.	\$21,000.
American Heart Association Great Rivers Affiliate Fellowship for Yue Zhao: The Regulation of Function of NOR1 in Endothelial Cells				
Bruemmer, Dennis C	3048105001	\$0.	\$25,000.	\$25,000.
KY Diabetes Research Trust Fund Telomeres in Obesity and Diabetes				
Bruemmer, Dennis C	3048105383	\$0.	\$159,975.	\$159,975.
American Diabetes Association Inc Telomere Attrition in Adipose Tissue Senescence and Insulin Resistance				
Bruemmer, Dennis C	3048105383	\$0.	\$-17,775.	\$-17,775.
American Diabetes Association Inc Telomere Attrition in Adipose Tissue Senescence and Insulin Resistance				
Bruemmer, Dennis C	3048106006	\$276,211.	\$0.	\$276,211.
National Heart Lung and Blood Institute ARRA: Role of the Nuclear Receptor Nor-1 in Atherosclerosis and Vascular Injury				
Bruemmer, Dennis C	3048106098	\$412,695.	\$0.	\$412,695.
National Heart Lung and Blood Institute ARRA: Telomerase in Inflammation and Atherosclerosis				
Campbell, Charles L.	3046979000	\$0.	\$1,800.	\$1,800.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vytarin Efficacy International Trail				
Campbell, Charles L.	3046979000	\$0.	\$600.	\$600.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vytarin Efficacy International Trail				
Campbell, Charles L.	3046979000	\$0.	\$600.	\$600.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vytarin Efficacy International Trail				
Campbell, Charles L.	3046979000	\$0.	\$6,200.	\$6,200.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vytarin Efficacy International Trail				
Campbell, Charles L.	3046979000	\$0.	\$250.	\$250.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vytarin Efficacy International Trail				
Campbell, Charles L.	3046979000	\$0.	\$2,000.	\$2,000.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vytarin Efficacy International Trail				
Campbell, Charles L.	3046979000	\$0.	\$3,950.	\$3,950.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vytarin Efficacy International Trail				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Campbell, Charles L.	3046979000	\$0.	\$3,050.	\$3,050.
Schering Plough Co IMPROVE-IT: Improved Reduction of Outcomes: Vytorin Efficacy International Trail				
Campbell, Charles L.	3048106728	\$2.	\$0.	\$2.
Duke University Solstice, a Study of Losmapimod Treatment on Inflammation and Infarct Size: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553				
Campbell, Charles L.	3048106943	\$2.	\$0.	\$2.
GlaxoSmithKline SOLID TIMI-52 The Stabilization of pLaques Using Darapladib-Thrombolysis in Myocardial Infarction 52				
Cassia, Lisa A	3048106312	\$2,032,725.	\$0.	\$2,032,725.
National Center for Research Resources COBRE: Center of Research in Obesity and Cardiovascular Disease				
Crofford, Leslie J	3046988500	\$0.	\$25,558.	\$25,558.
University of Pittsburgh Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis and				
Crofford, Leslie J	3048106859	\$334,125.	\$0.	\$334,125.
National Institute Arthritis Musculoskeletal & Skin Microsomal Prostaglandin E Synthase in Rheumatoid Arthritis				
Daugherty, Alan	3048104960	\$0.	\$45,000.	\$45,000.
American Heart Association Great Rivers Affiliate Fellowship for Venkateswaran Subramanian: Role of peroxisome proliferator activated receptor gamma in angiotensin II induced abdominal aortic aneurysm				
Daugherty, Alan	3048105369	\$0.	\$36,625.	\$36,625.
National Heart Lung and Blood Institute Sources and Effects of Angiotensin Peptides in Atherosclerosis				
Daugherty, Alan	3048105369	\$0.	\$329,625.	\$329,625.
National Heart Lung and Blood Institute Sources and Effects of Angiotensin Peptides in Atherosclerosis				
De Villiers, Willem	3046569500	\$0.	\$-600.	\$-600.
Centocor Inc A Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate and Efficacy of Infliximab in Patients with Active Ulcerative Colitis				
De Villiers, Willem	3048103698	\$0.	\$328.	\$328.
Kendle International Open Label Long Term Clinical Trial Evaluating Efficacy and Safety of Chronic Therapy with Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNF) in Patients Suffering from Crohn's Disease				
De Villiers, Willem	3048103743	\$0.	\$2,062.	\$2,062.
Bristol Myers Squibb Company Abatacept in Subject with Active Ulcerative Colitis				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Internal Medicine</u>				
De Villiers, Willem	3048103743	\$0.	\$1,069.	\$1,069.
Bristol Myers Squibb Company Abatacept in Subject with Active Ulcerative Colitis				
De Villiers, Willem	3048103743	\$0.	\$3,258.	\$3,258.
Bristol Myers Squibb Company Abatacept in Subject with Active Ulcerative Colitis				
De Villiers, Willem	3048103743	\$0.	\$9,055.	\$9,055.
Bristol Myers Squibb Company Abatacept in Subject with Active Ulcerative Colitis				
De Villiers, Willem	3048103743	\$0.	\$4,363.	\$4,363.
Bristol Myers Squibb Company Abatacept in Subject with Active Ulcerative Colitis				
De Villiers, Willem	3048103743	\$0.	\$4,738.	\$4,738.
Bristol Myers Squibb Company Abatacept in Subject with Active Ulcerative Colitis				
De Villiers, Willem	3048103743	\$0.	\$3,290.	\$3,290.
Bristol Myers Squibb Company Abatacept in Subject with Active Ulcerative Colitis				
De Villiers, Willem	3048103744	\$0.	\$3,737.	\$3,737.
Bristol Myers Squibb Company Abatacept in Subject with Active Crohn's Disease				
De Villiers, Willem	3048103744	\$0.	\$1,104.	\$1,104.
Bristol Myers Squibb Company Abatacept in Subject with Active Crohn's Disease				
De Villiers, Willem	3048103744	\$0.	\$252.	\$252.
Bristol Myers Squibb Company Abatacept in Subject with Active Crohn's Disease				
De Villiers, Willem	3048103744	\$0.	\$3,819.	\$3,819.
Bristol Myers Squibb Company Abatacept in Subject with Active Crohn's Disease				
De Villiers, Willem	3048103744	\$0.	\$1,450.	\$1,450.
Bristol Myers Squibb Company Abatacept in Subject with Active Crohn's Disease				
De Villiers, Willem	3048103744	\$0.	\$587.	\$587.
Bristol Myers Squibb Company Abatacept in Subject with Active Crohn's Disease				
De Villiers, Willem	3048103879	\$0.	\$2,998.	\$2,998.
Duke University A Phase III, multi-center, placebo-controlled, randomized, double-blind retreatment study to evaluate the safety and efficacy of PROCHYMAL IV Infusion for the reinduction of remission in subjects experiencing...moderate to severe Crohn's				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
De Villiers, Willem	3048104103	\$0.	\$5,100.	\$5,100.
Duke University A Phase III, Multi-Center, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of PROCHYMAL TM IV Infusion for the Induction of Remission in Subjects Experiencing Treatment-Refractory Moderate-to-Sever Crohn's Disease				
De Villiers, Willem	3048104103	\$0.	\$36,300.	\$36,300.
Duke University A Phase III, Multi-Center, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of PROCHYMAL TM IV Infusion for the Induction of Remission in Subjects Experiencing Treatment-Refractory Moderate-to-Sever Crohn's Disease				
De Villiers, Willem	3048104103	\$0.	\$18,000.	\$18,000.
Duke University A Phase III, Multi-Center, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of PROCHYMAL TM IV Infusion for the Induction of Remission in Subjects Experiencing Treatment-Refractory Moderate-to-Sever Crohn's Disease				
De Villiers, Willem	3048104254	\$0.	\$2,930.	\$2,930.
Quintiles Inc A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety & Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis				
De Villiers, Willem	3048104254	\$0.	\$6,399.	\$6,399.
Quintiles Inc A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety & Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis				
De Villiers, Willem	3048104254	\$0.	\$1,260.	\$1,260.
Quintiles Inc A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety & Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis				
De Villiers, Willem	3048104255	\$0.	\$4,153.	\$4,153.
Quintiles Inc A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety & Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis				
De Villiers, Willem	3048104255	\$0.	\$8,020.	\$8,020.
Quintiles Inc A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety & Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis				
De Villiers, Willem	3048104557	\$0.	\$36,364.	\$36,364.
Genentech Inc Observational Study of Biomarkers in Subjects with Inflammatory Bowel Disease (IBD) Compared with Non-IBD Control Subjects				
De Villiers, Willem	3048104557	\$0.	\$21,302.	\$21,302.
Genentech Inc Observational Study of Biomarkers in Subjects with Inflammatory Bowel Disease (IBD) Compared with Non-IBD Control Subjects				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
De Villiers, Willem	3048104557	\$0.	\$81,762.	\$81,762.
Genentech Inc Observational Study of Biomarkers in Subjects with Inflammatory Bowel Disease (IBD) Compared with Non-IBD Control Subjects				
De Villiers, Willem	3048104557	\$0.	\$22,086.	\$22,086.
Genentech Inc Observational Study of Biomarkers in Subjects with Inflammatory Bowel Disease (IBD) Compared with Non-IBD Control Subjects				
De Villiers, Willem	3048104557	\$0.	\$21,696.	\$21,696.
Genentech Inc Observational Study of Biomarkers in Subjects with Inflammatory Bowel Disease (IBD) Compared with Non-IBD Control Subjects				
De Villiers, Willem	3048105468	\$0.	\$4,380.	\$4,380.
Quintiles Inc A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter, Multiple Dose Study for the Induction and Maintenance of Clinical Response and Remission with MLN0002 in Patients with Moderate to Severe Ulcerative Colitis				
De Villiers, Willem	3048105469	\$0.	\$11,784.	\$11,784.
Quintiles Inc A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission with MLN0002 in Patients with Moderate to Severe Crohn's Disease				
De Villiers, Willem	3048105469	\$0.	\$1,050.	\$1,050.
Quintiles Inc A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission with MLN0002 in Patients with Moderate to Severe Crohn's Disease				
De Villiers, Willem	3048105649	\$0.	\$4,043.	\$4,043.
Centocor Inc Ustekinumab Therapy in Subjects with ... Crohn's Disease Previously Treated with TNF Antagonist Therapy (C0743T26)				
De Villiers, Willem	3048105649	\$0.	\$851.	\$851.
Centocor Inc Ustekinumab Therapy in Subjects with ... Crohn's Disease Previously Treated with TNF Antagonist Therapy (C0743T26)				
De Villiers, Willem	3048106410	\$2.	\$0.	\$2.
Elan Pharmaceuticals PLC Natalizumab in Fistulizing Crohn's Disease: An Observational Study				
De Villiers, Willem	3048106410	\$0.	\$18,848.	\$18,848.
Elan Pharmaceuticals PLC Natalizumab in Fistulizing Crohn's Disease: An Observational Study				
De Villiers, Willem	3048106676	\$2.	\$0.	\$2.
Elan Pharmaceuticals PLC INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring				
De Villiers, Willem	3048106676	\$0.	\$2,498.	\$2,498.
Elan Pharmaceuticals PLC INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
De Villiers, Willem	3048106989	\$2.	\$0.	\$2.
Schwarz BioSciences Inc A Non-Interventional Long-Term Post-Marketing Registry of Patients Treated with Certolizumab Pegol (Cimzia) for Crohn's Disease - C87075				
Dignan, Mark B	3048105955	\$89,684.	\$0.	\$89,684.
National Cancer Institute ARRA: Influence of Health Literacy and Cancer among Rural Patients in Rehabilitation				
Dignan, Mark B	3048106706	\$251,985.	\$0.	\$251,985.
National Cancer Institute ARRA: Appalachia Community Cancer Network				
Doherty, Dennis E	3048072200	\$0.	\$38,692.	\$38,692.
Ohio State University Long-Term Oxygen Treatment (LOTT) Trail				
Doherty, Dennis E	3048072200	\$0.	\$2,788.	\$2,788.
Ohio State University Long-Term Oxygen Treatment (LOTT) Trail				
Doherty, Dennis E	3048103685	\$0.	\$2,671.	\$2,671.
Pfizer Inc A 24 Week, randomized, Double-Blind, Placebo Controlled, Milticenter Study to Evaluate the Efficacy and Safety of 18 MCG of Tiotropium Inhalation Capsules Administered by Handihaler Once-Daily Plus PRN Albuterol (Salbutamol) VS Placebo Plus PRN Albuterol				
Doherty, Dennis E	3048103685	\$0.	\$4,939.	\$4,939.
Pfizer Inc A 24 Week, randomized, Double-Blind, Placebo Controlled, Milticenter Study to Evaluate the Efficacy and Safety of 18 MCG of Tiotropium Inhalation Capsules Administered by Handihaler Once-Daily Plus PRN Albuterol (Salbutamol) VS Placebo Plus PRN Albuterol				
Doherty, Dennis E	3048103685	\$0.	\$18,604.	\$18,604.
Pfizer Inc A 24 Week, randomized, Double-Blind, Placebo Controlled, Milticenter Study to Evaluate the Efficacy and Safety of 18 MCG of Tiotropium Inhalation Capsules Administered by Handihaler Once-Daily Plus PRN Albuterol (Salbutamol) VS Placebo Plus PRN Albuterol				
Doherty, Dennis E	3048103685	\$0.	\$4,745.	\$4,745.
Pfizer Inc A 24 Week, randomized, Double-Blind, Placebo Controlled, Milticenter Study to Evaluate the Efficacy and Safety of 18 MCG of Tiotropium Inhalation Capsules Administered by Handihaler Once-Daily Plus PRN Albuterol (Salbutamol) VS Placebo Plus PRN Albuterol				
Doherty, Dennis E	3048103685	\$0.	\$6,974.	\$6,974.
Pfizer Inc A 24 Week, randomized, Double-Blind, Placebo Controlled, Milticenter Study to Evaluate the Efficacy and Safety of 18 MCG of Tiotropium Inhalation Capsules Administered by Handihaler Once-Daily Plus PRN Albuterol (Salbutamol) VS Placebo Plus PRN Albuterol				
Doherty, Dennis E	3048104205	\$0.	\$5,318.	\$5,318.
Quintiles Inc A Randomized Placebo-Controlled Efficacy and Safety Study of 1 Year Treatment Duration With High- and Medium-Dose Inhaled Mometasone Furoate/Formoterol Combination Formulation Compared with Formoterol				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Doherty, Dennis E	3048104205	\$0.	\$45,913.	\$45,913.
Quintiles Inc A Randomized Placebo-Controlled Efficacy and Safety Study of 1 Year Treatment Duration With High- and Medium-Dose Inhaled Mometasone Furoate/Formoterol Combination Formulation Compared with Formoterol				
Doherty, Dennis E	3048104205	\$0.	\$22,991.	\$22,991.
Quintiles Inc A Randomized Placebo-Controlled Efficacy and Safety Study of 1 Year Treatment Duration With High- and Medium-Dose Inhaled Mometasone Furoate/Formoterol Combination Formulation Compared with Formoterol				
Doherty, Dennis E	3048104205	\$0.	\$2,403.	\$2,403.
Quintiles Inc A Randomized Placebo-Controlled Efficacy and Safety Study of 1 Year Treatment Duration With High- and Medium-Dose Inhaled Mometasone Furoate/Formoterol Combination Formulation Compared with Formoterol				
Doherty, Dennis E	3048104892	\$0.	\$1,953.	\$1,953.
InterMune Pharmaceuticals An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies				
Doherty, Dennis E	3048104892	\$0.	\$1,040.	\$1,040.
InterMune Pharmaceuticals An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies				
Doherty, Dennis E	3048104892	\$0.	\$315.	\$315.
InterMune Pharmaceuticals An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies				
Doherty, Dennis E	3048104892	\$0.	\$1,103.	\$1,103.
InterMune Pharmaceuticals An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies				
Doherty, Dennis E	3048105652	\$0.	\$6,300.	\$6,300.
Boehringer Ingelheim A Phase III Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution				
Doherty, Dennis E	3048105652	\$0.	\$4,998.	\$4,998.
Boehringer Ingelheim A Phase III Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution				
Doherty, Dennis E	3048107003	\$2.	\$0.	\$2.
Forest Research Institute Incorporated A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety and Tolerability of 2 Doses of Acridinium Bromide Compared with Placebo for 12 Weeks in Patients with Moderate to Severe, Stable Chronic Obst.				
Elayi, Samy Claude	3048105763	\$0.	\$1,350.	\$1,350.
University of California San Francisco Evaluating the Effectiveness of the LifeVest Defibrillator and Improving Methods for Determining the Use of Implantable Cardioverter Defibrillators (The VEST/PREDICTS Study)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Internal Medicine</u>				
Elayi, Samy Claude	3048105763	\$0.	\$3,654.	\$3,654.
University of California San Francisco Evaluating the Effectiveness of the LifeVest Defibrillator and Improving Methods for Determining the Use of Implantable Cardioverter Defibrillators (The VEST/PREDICTS Study)				
Elayi, Samy Claude	3048105763	\$0.	\$3,498.	\$3,498.
University of California San Francisco Evaluating the Effectiveness of the LifeVest Defibrillator and Improving Methods for Determining the Use of Implantable Cardioverter Defibrillators (The VEST/PREDICTS Study)				
Elayi, Samy Claude	3048105763	\$0.	\$945.	\$945.
University of California San Francisco Evaluating the Effectiveness of the LifeVest Defibrillator and Improving Methods for Determining the Use of Implantable Cardioverter Defibrillators (The VEST/PREDICTS Study)				
Fleischman, Roger A	3046806900	\$0.	\$150.	\$150.
Favrille Inc Favid-06: Phase III, Randomized, Double Blind Placebo-controlled Trial of Favid and GM-CSF versus Placebo and GM-CSF Following Rituximab in Subjects with Follicular B-Cell Non-Hodgkin's Lymphoma				
Greenberg, Richard N	3046865800	\$0.	\$252.	\$252.
Bristol Myers Squibb Company Phase IV, Multicenter Cross-Sectional Study to Evaluate the I50L Substitution among subjects Experiencing Virologic Failure on a HART regimen containing Atazanavir (ATV)				
Greenberg, Richard N	3046918500	\$0.	\$5,282.	\$5,282.
Virxsys Corporation A Phase II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Biological Activity of Repeated doses of Autologous T Cells Transduced with VRX496 in HIV-Positive Subjects				
Greenberg, Richard N	3046999700	\$0.	\$2,000.	\$2,000.
PPD Development Inc A Phase 2 (a), Dose-Blinded, Block Randomized Dose and Schedule Selection Study to Evaluate the Immunogenicity and Safety of the Recombinant Plague Vaccine rF1V in Healthy Volunteers				
Greenberg, Richard N	3046999700	\$0.	\$-8,167.	\$-8,167.
PPD Development Inc A Phase 2 (a), Dose-Blinded, Block Randomized Dose and Schedule Selection Study to Evaluate the Immunogenicity and Safety of the Recombinant Plague Vaccine rF1V in Healthy Volunteers				
Greenberg, Richard N	3048073000	\$0.	\$1,888.	\$1,888.
Bavarian Nordic A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN (IMVAMUNE) Smallpox Vaccine in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis				
Greenberg, Richard N	3048073000	\$0.	\$3,794.	\$3,794.
Bavarian Nordic A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN (IMVAMUNE) Smallpox Vaccine in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis				
Greenberg, Richard N	3048073000	\$0.	\$12,000.	\$12,000.
Bavarian Nordic A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN (IMVAMUNE) Smallpox Vaccine in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Greenberg, Richard N	3048073000	\$0.	\$907.	\$907.
Bavarian Nordic				
A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN (IMVAMUNE) Smallpox Vaccine in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis				
Greenberg, Richard N	3048103306	\$0.	\$1,209.	\$1,209.
GlaxoSmithKline				
Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FTC or Maintenance of the Initial Regimen for an Additional 48				
Greenberg, Richard N	3048103306	\$0.	\$1,200.	\$1,200.
GlaxoSmithKline				
Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FTC or Maintenance of the Initial Regimen for an Additional 48				
Greenberg, Richard N	3048103306	\$0.	\$2,419.	\$2,419.
GlaxoSmithKline				
Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FTC or Maintenance of the Initial Regimen for an Additional 48				
Greenberg, Richard N	3048103306	\$0.	\$1,209.	\$1,209.
GlaxoSmithKline				
Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FTC or Maintenance of the Initial Regimen for an Additional 48				
Greenberg, Richard N	3048103306	\$0.	\$1,209.	\$1,209.
GlaxoSmithKline				
Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FTC or Maintenance of the Initial Regimen for an Additional 48				
Greenberg, Richard N	3048104321	\$0.	\$3,521.	\$3,521.
Wyeth Pharmaceuticals Inc				
A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating the Safety, Tolerability & Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared with a 23-Valent Pneumococcal Polysaccharide Vaccine (23vPS) in Ambulatory				
Greenberg, Richard N	3048104321	\$0.	\$9,498.	\$9,498.
Wyeth Pharmaceuticals Inc				
A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating the Safety, Tolerability & Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared with a 23-Valent Pneumococcal Polysaccharide Vaccine (23vPS) in Ambulatory				
Greenberg, Richard N	3048104321	\$0.	\$10,847.	\$10,847.
Wyeth Pharmaceuticals Inc				
A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating the Safety, Tolerability & Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared with a 23-Valent Pneumococcal Polysaccharide Vaccine (23vPS) in Ambulatory				
Greenberg, Richard N	3048104321	\$0.	\$25,963.	\$25,963.
Wyeth Pharmaceuticals Inc				
A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating the Safety, Tolerability & Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared with a 23-Valent Pneumococcal Polysaccharide Vaccine (23vPS) in Ambulatory				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Greenberg, Richard N	3048104349	\$0.	\$2,490.	\$2,490.
Wyeth Pharmaceuticals Inc A Phase 3, Randomized, Active-Controlled, Modified, Double-Blind Trial to Evaluate the Safety, Tolerability and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months				
Greenberg, Richard N	3048104349	\$0.	\$7,235.	\$7,235.
Wyeth Pharmaceuticals Inc A Phase 3, Randomized, Active-Controlled, Modified, Double-Blind Trial to Evaluate the Safety, Tolerability and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months				
Greenberg, Richard N	3048104349	\$0.	\$4,076.	\$4,076.
Wyeth Pharmaceuticals Inc A Phase 3, Randomized, Active-Controlled, Modified, Double-Blind Trial to Evaluate the Safety, Tolerability and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine When Administered Over 12 Months				
Greenberg, Richard N	3048104861	\$0.	\$3,238.	\$3,238.
Pfizer Inc An International, Multi-Center, Prospective, Observational Study of the Safety of Maraviroc Used With Optimized Background Therapy in Treatment Experienced HIV 1 Infected Patients				
Greenberg, Richard N	3048104861	\$0.	\$2,077.	\$2,077.
Pfizer Inc An International, Multi-Center, Prospective, Observational Study of the Safety of Maraviroc Used With Optimized Background Therapy in Treatment Experienced HIV 1 Infected Patients				
Greenberg, Richard N	3048104861	\$0.	\$378.	\$378.
Pfizer Inc An International, Multi-Center, Prospective, Observational Study of the Safety of Maraviroc Used With Optimized Background Therapy in Treatment Experienced HIV 1 Infected Patients				
Greenberg, Richard N	3048105117	\$0.	\$1,134.	\$1,134.
Tibotec Pharmaceuticals Ltd A Phase III, Randomized, Double-Blind Trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in Combination with a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-naive HIV-1 Infected Subjects				
Greenberg, Richard N	3048105117	\$0.	\$941.	\$941.
Tibotec Pharmaceuticals Ltd A Phase III, Randomized, Double-Blind Trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in Combination with a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-naive HIV-1 Infected Subjects				
Greenberg, Richard N	3048105117	\$0.	\$655.	\$655.
Tibotec Pharmaceuticals Ltd A Phase III, Randomized, Double-Blind Trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in Combination with a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-naive HIV-1 Infected Subjects				
Greenberg, Richard N	3048105117	\$0.	\$3,397.	\$3,397.
Tibotec Pharmaceuticals Ltd A Phase III, Randomized, Double-Blind Trial of TMC278 25 mg q.d. versus efavirenz 600 mg q.d. in Combination with a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-naive HIV-1 Infected Subjects				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Greenberg, Richard N	3048105289	\$0.	\$2,840.	\$2,840.
Gilead Sciences Inc A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered with a Background Regimen in HIV-1				
Greenberg, Richard N	3048105805	\$0.	\$19,241.	\$19,241.
Bavarian Nordic A Randomized, Double-Blind, Placebo-Controlled Phase I/II Study to Evaluate the Safety and Immunogenicity of One and Two Doses of IMVAMUNE Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects				
Greenberg, Richard N	3048105805	\$0.	\$16,784.	\$16,784.
Bavarian Nordic A Randomized, Double-Blind, Placebo-Controlled Phase I/II Study to Evaluate the Safety and Immunogenicity of One and Two Doses of IMVAMUNE Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects				
Greenberg, Richard N	3048105805	\$0.	\$11,759.	\$11,759.
Bavarian Nordic A Randomized, Double-Blind, Placebo-Controlled Phase I/II Study to Evaluate the Safety and Immunogenicity of One and Two Doses of IMVAMUNE Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects				
Greenberg, Richard N	3048105805	\$0.	\$15,316.	\$15,316.
Bavarian Nordic A Randomized, Double-Blind, Placebo-Controlled Phase I/II Study to Evaluate the Safety and Immunogenicity of One and Two Doses of IMVAMUNE Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects				
Greenberg, Richard N	3048105805	\$0.	\$22,434.	\$22,434.
Bavarian Nordic A Randomized, Double-Blind, Placebo-Controlled Phase I/II Study to Evaluate the Safety and Immunogenicity of One and Two Doses of IMVAMUNE Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects				
Greenberg, Richard N	3048105805	\$0.	\$24,811.	\$24,811.
Bavarian Nordic A Randomized, Double-Blind, Placebo-Controlled Phase I/II Study to Evaluate the Safety and Immunogenicity of One and Two Doses of IMVAMUNE Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects				
Greenberg, Richard N	3048105868	\$0.	\$3,841.	\$3,841.
Novartis A Phase 3, Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety of Novartis MenACWY Conugate Vaccine when Administered with Routine Infant Vaccinations to Healthy Infants				
Greenberg, Richard N	3048105868	\$2.	\$0.	\$2.
Novartis A Phase 3, Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety of Novartis MenACWY Conugate Vaccine when Administered with Routine Infant Vaccinations to Healthy Infants				
Greenberg, Richard N	3048106600	\$0.	\$4,693.	\$4,693.
PaxVax Incorporated A Phase 1 Evaluation of the Safety and Immunogenicity of a Replication-Competent Adenovirus Serotype 4-Vectored H5N1				
Greenberg, Richard N	3048106600	\$2.	\$0.	\$2.
PaxVax Incorporated A Phase 1 Evaluation of the Safety and Immunogenicity of a Replication-Competent Adenovirus Serotype 4-Vectored H5N1				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Greenberg, Richard N	3048106600	\$0.	\$100,857.	\$100,857.
PaxVax Incorporated A Phase 1 Evaluation of the Safety and Immunogenicity of a Replication-Competent Adenovirus Serotype 4-Vectored H5N1				
Greenberg, Richard N	3048106922	\$2.	\$0.	\$2.
Wyeth Pharmaceuticals Inc A Phase 3, Open-Label Single Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13-Valent Pneumococcal Conjugate Vaccine in Human Immunodeficiency Virus Subjects 18 Years of Age or Older				
Greenberg, Richard N	3048106923	\$2.	\$0.	\$2.
Wyeth Pharmaceuticals Inc A Study to Evaluate the Persistence of the Antibody Response Elicited by 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Adults who Have Previously Been Vaccinated with With 2 Doses				
Guo, Zhenheng	3048104909	\$0.	\$25,000.	\$25,000.
KY Diabetes Research Trust Fund A Novel Mechanism by which Type 2 Diabetes Promotes Restenosis				
Guo, Zhenheng	3048105895	\$258,056.	\$0.	\$258,056.
National Heart Lung and Blood Institute ARRA: A Novel Mechanism by Which iPLA2 Links Diabetes to Cardiovascular Diseases				
Gurley, John C	3046640500	\$0.	\$250.	\$250.
Medtronics Inc Insync Registry: Insync Post Market Registry Cardiac Resynchronization Therapy				
Gurley, John C	3046640500	\$0.	\$250.	\$250.
Medtronics Inc Insync Registry: Insync Post Market Registry Cardiac Resynchronization Therapy				
Gurley, John C	3046857600	\$0.	\$315.	\$315.
Atritech Inc WATCHMEN Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation (Protect AF)				
Gurley, John C	3048034600	\$0.	\$840.	\$840.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
Gurley, John C	3048034600	\$0.	\$7,566.	\$7,566.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
Gurley, John C	3048034600	\$0.	\$50,880.	\$50,880.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
Gurley, John C	3048034600	\$0.	\$50,702.	\$50,702.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Gurley, John C	3048034600	\$0.	\$33,375.	\$33,375.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
Gurley, John C	3048034600	\$0.	\$2,974.	\$2,974.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
Gurley, John C	3048034600	\$0.	\$2,962.	\$2,962.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
Gurley, John C	3048034600	\$0.	\$3,663.	\$3,663.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
Gurley, John C	3048034600	\$0.	\$1,109.	\$1,109.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
Gurley, John C	3048034600	\$0.	\$2,197.	\$2,197.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
Gurley, John C	3048034600	\$0.	\$5,609.	\$5,609.
AGA Medical Co Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migraine and PFO Using the AMPLATZER PFO Occluder Compared to Medical Management				
Gurley, John C	3048105525	\$0.	\$1,450.	\$1,450.
AGA Medical Co Closure of Atrial Septal Defects with the Amplatzer Septal Occluder - Post Market Study II (ASD PMS II)				
Gurley, John C	3048105525	\$0.	\$1,300.	\$1,300.
AGA Medical Co Closure of Atrial Septal Defects with the Amplatzer Septal Occluder - Post Market Study II (ASD PMS II)				
Gurley, John C	3048105525	\$0.	\$500.	\$500.
AGA Medical Co Closure of Atrial Septal Defects with the Amplatzer Septal Occluder - Post Market Study II (ASD PMS II)				
Gurley, John C	3048105525	\$0.	\$600.	\$600.
AGA Medical Co Closure of Atrial Septal Defects with the Amplatzer Septal Occluder - Post Market Study II (ASD PMS II)				
Gurley, John C	3048105525	\$0.	\$750.	\$750.
AGA Medical Co Closure of Atrial Septal Defects with the Amplatzer Septal Occluder - Post Market Study II (ASD PMS II)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Hamdalla, Hussam Nader	3048104582	\$0.	\$2,000.	\$2,000.
Momenta Pharmaceuticals Inc A Randomized, Multi-Center, Open-Label, Parallel Group Feasability Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. UFH in Subjects with Stable Coronary Artery Disease Undergoing				
Hamdalla, Hussam Nader	3048104582	\$0.	\$17,100.	\$17,100.
Momenta Pharmaceuticals Inc A Randomized, Multi-Center, Open-Label, Parallel Group Feasability Study to Determine the Safety and Efficacy of the Rationally Engineered Heparin M118 vs. UFH in Subjects with Stable Coronary Artery Disease Undergoing				
Hayslip, John	3048104985	\$0.	\$-2,000.	\$-2,000.
Celgene A Phase 2, Open label trial to evaluate the Efficacy and Safety of MGCD0103 Administered in Combination with Vidaza to subjects with Relapsed or Refractory Hodgkins or non-Hodgkin Lymphoma and to evaluate different formulations of MGCD0103				
Hirschowitz, Edward A	3048100100	\$0.	\$256,375.	\$256,375.
National Cancer Institute Autoantibodies in NSCLC as Markers of Disease				
Howard, Dianna S	3048037800	\$0.	\$1,792.	\$1,792.
Genzyme Corp 06-LEUK-GZ (CLO341000405): A Phase III Randomized, Double-Blind, Controlled Study Comparing Clofarabine and Cytarabine versus Cytarabine Alone in Adult Patients>60 years old with Acute Myelogenous Leukemia (AML) who Have Relapsed or are Refractory after				
Howard, Dianna S	3048037800	\$0.	\$2,403.	\$2,403.
Genzyme Corp 06-LEUK-GZ (CLO341000405): A Phase III Randomized, Double-Blind, Controlled Study Comparing Clofarabine and Cytarabine versus Cytarabine Alone in Adult Patients>60 years old with Acute Myelogenous Leukemia (AML) who Have Relapsed or are Refractory after				
Howard, Dianna S	3048103404	\$0.	\$-2,912.	\$-2,912.
ViroPharma Inc A Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy and Safety of Prophylactic use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants				
Karounos, Dennis G	3046861000	\$0.	\$155.	\$155.
George Washington University Natural History of the Development of Type 1 Diabetes				
Karounos, Dennis G	3048105358	\$0.	\$1,695.	\$1,695.
Spherix Inc The Effects of Naturlose (Tagatose) on Glycemic Control and Safety of Naturlose Over One Year in Subjects with Type 2 Diabetes Under Diet Control and Exercise				
Karounos, Dennis G	3048105358	\$0.	\$3,785.	\$3,785.
Spherix Inc The Effects of Naturlose (Tagatose) on Glycemic Control and Safety of Naturlose Over One Year in Subjects with Type 2 Diabetes Under Diet Control and Exercise				
Karounos, Dennis G	3048105358	\$0.	\$3,590.	\$3,590.
Spherix Inc The Effects of Naturlose (Tagatose) on Glycemic Control and Safety of Naturlose Over One Year in Subjects with Type 2 Diabetes Under Diet Control and Exercise				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Karounos, Dennis G	3048105358	\$0.	\$6,995.	\$6,995.
Spherix Inc The Effects of Naturlose (Tagatose) on Glycemic Control and Safety of Naturlose Over One Year in Subjects with Type 2 Diabetes Under Diet Control and Exercise				
Karounos, Dennis G	3048105358	\$0.	\$4,800.	\$4,800.
Spherix Inc The Effects of Naturlose (Tagatose) on Glycemic Control and Safety of Naturlose Over One Year in Subjects with Type 2 Diabetes Under Diet Control and Exercise				
Karounos, Dennis G	3048105872	\$0.	\$775.	\$775.
University of South Florida TrialNet: Natural History of the Development of Type 1 Diabetes				
Karounos, Dennis G	3048105872	\$2.	\$0.	\$2.
University of South Florida TrialNet: Natural History of the Development of Type 1 Diabetes				
Karounos, Dennis G	3048105872	\$0.	\$1,598.	\$1,598.
University of South Florida TrialNet: Natural History of the Development of Type 1 Diabetes				
Karounos, Dennis G	3048105872	\$0.	\$975.	\$975.
University of South Florida TrialNet: Natural History of the Development of Type 1 Diabetes				
Karounos, Dennis G	3048105962	\$0.	\$-28,019.	\$-28,019.
American Diabetes Association Inc Mechanisms of preventing type 1 diabetes with inactive insulin				
Karounos, Dennis G	3048105962	\$98,782.	\$0.	\$98,782.
American Diabetes Association Inc Mechanisms of preventing type 1 diabetes with inactive insulin				
Karounos, Dennis G	3048106304	\$0.	\$9,353.	\$9,353.
Novo Nordisk Pharmaceuticals Inc A 52 Week Randomized, Controlled, Open Label, Multicenter, Multinational, Parallel, Treat to Target Trial Comparing Efficacy and Safety of SIBA and Insulin Glargine Both Administered Once Daily				
Karounos, Dennis G	3048106304	\$0.	\$1,000.	\$1,000.
Novo Nordisk Pharmaceuticals Inc A 52 Week Randomized, Controlled, Open Label, Multicenter, Multinational, Parallel, Treat to Target Trial Comparing Efficacy and Safety of SIBA and Insulin Glargine Both Administered Once Daily				
Karounos, Dennis G	3048106304	\$2.	\$0.	\$2.
Novo Nordisk Pharmaceuticals Inc A 52 Week Randomized, Controlled, Open Label, Multicenter, Multinational, Parallel, Treat to Target Trial Comparing Efficacy and Safety of SIBA and Insulin Glargine Both Administered Once Daily				
Karounos, Dennis G	3048106304	\$0.	\$30,512.	\$30,512.
Novo Nordisk Pharmaceuticals Inc A 52 Week Randomized, Controlled, Open Label, Multicenter, Multinational, Parallel, Treat to Target Trial Comparing Efficacy and Safety of SIBA and Insulin Glargine Both Administered Once Daily				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Karounos, Dennis G	3048106971	\$2.	\$0.	\$2.
Novo Nordisk Pharmaceuticals Inc A 26-week, Randomised, Controlled, Open Label, Multicentre, Multinational Three-arm Parallel, Treat-to-Target Trial Comparing Efficacy and Safety of 2 Different Dosing Regiments of SIBA and 1 Dosing Regimen of Insulin				
Kee, Bryan K	3048104993	\$0.	\$9,998.	\$9,998.
Amplimed Corp A Phase 2 Randomized, Double-Blind, Multicenter Trial with Amplimexon plus Gemcitabine versus Gemcitabine plus Placebo in Subjects with Metastatic Chemotherapy Naive Pancreatic Adenocarcinoma (Stage IV)				
Kern, Philip A.	3048105948	\$508,695.	\$0.	\$508,695.
National Institute Diabetes & Digestive & Kidney Regulation of Lipoprotein Lipase in Adipocytes				
Kern, Philip A.	3048106977	\$2.	\$0.	\$2.
GlaxoSmithKline Effects of Fish Oils on Inflammation and Insulin Resistance				
King, Victoria L	3048104393	\$0.	\$366,250.	\$366,250.
National Heart Lung and Blood Institute The role of Prostaglandin E2 in Angiotensin II-induced vascular disease				
Koch, Alvaro		\$2.	\$0.	\$2.
Schering Plough Co Boceprevir and Peginterferon/Ribavirin for the Treatment of Chronic Hepatitis C in Treatment-Naive Subjects: A Comparison of Erythropoietin Use Versus Ribavirin Dose Reduction for the Management of Anemia				
Koch, Alvaro	3048062500	\$0.	\$5,400.	\$5,400.
Integrated Therapeutics Technology Pegylated Interferon Alfa-2b and Ribavirin after Orthotopic Liver Transplantation: Efficacy and Safety in Hepatitis C Recurrence Therapy				
Koch, Alvaro	3048062500	\$0.	\$3,118.	\$3,118.
Integrated Therapeutics Technology Pegylated Interferon Alfa-2b and Ribavirin after Orthotopic Liver Transplantation: Efficacy and Safety in Hepatitis C Recurrence Therapy				
Koch, Alvaro	3048068400	\$0.	\$-30.	\$-30.
Sanofi Aventis US Inc Satavaptan in the Prevention of Ascited Recurrence: A Double-Blind, Randomized, Parallel-Group Comparison of 12 Weeks Treatment with SR121463B at 5 to 10 mg Daily Versus Placebo in Patients with Recurrent Ascited due to Cirrhosis of the Liver				
Koch, Alvaro	3048068400	\$0.	\$30.	\$30.
Sanofi Aventis US Inc Satavaptan in the Prevention of Ascited Recurrence: A Double-Blind, Randomized, Parallel-Group Comparison of 12 Weeks Treatment with SR121463B at 5 to 10 mg Daily Versus Placebo in Patients with Recurrent Ascited due to Cirrhosis of the Liver				
Koch, Alvaro	3048104481	\$0.	\$1,391.	\$1,391.
GlaxoSmithKline Randomized, placebo-controlled, multi-center study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy ENABLE 2				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Koch, Alvaro	3048104481	\$0.	\$1,348.	\$1,348.
GlaxoSmithKline Randomized, placebo-controlled, multi-center study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy ENABLE 2				
Koch, Alvaro	3048104481	\$0.	\$2,394.	\$2,394.
GlaxoSmithKline Randomized, placebo-controlled, multi-center study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy ENABLE 2				
Koch, Alvaro	3048104481	\$0.	\$1,070.	\$1,070.
GlaxoSmithKline Randomized, placebo-controlled, multi-center study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy ENABLE 2				
Koch, Alvaro	3048104481	\$0.	\$1,223.	\$1,223.
GlaxoSmithKline Randomized, placebo-controlled, multi-center study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy ENABLE 2				
Koch, Alvaro	3048104481	\$0.	\$1,412.	\$1,412.
GlaxoSmithKline Randomized, placebo-controlled, multi-center study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy ENABLE 2				
Koch, Alvaro	3048104481	\$0.	\$1,476.	\$1,476.
GlaxoSmithKline Randomized, placebo-controlled, multi-center study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy ENABLE 2				
Koch, Alvaro	3048104481	\$0.	\$1,881.	\$1,881.
GlaxoSmithKline Randomized, placebo-controlled, multi-center study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy ENABLE 2				
Koch, Alvaro	3048104828	\$0.	\$600.	\$600.
Sanofi Aventis US Inc A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Type 2 Diabetic Patients with Non-Alcoholic Steatohepatitis (NASH)				
Koch, Alvaro	3048105298	\$0.	\$8,155.	\$8,155.
Schering Plough Co A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects with Chronic Hepatitis C Genotype 1				
Koch, Alvaro	3048105298	\$0.	\$4,617.	\$4,617.
Schering Plough Co A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects with Chronic Hepatitis C Genotype 1				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Internal Medicine</u>				
Koch, Alvaro	3048105298	\$0.	\$12,695.	\$12,695.
Schering Plough Co A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects with Chronic Hepatitis C Genotype 1				
Koch, Alvaro	3048105298	\$0.	\$7,928.	\$7,928.
Schering Plough Co A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects with Chronic Hepatitis C Genotype 1				
Koch, Alvaro	3048105298	\$0.	\$8,402.	\$8,402.
Schering Plough Co A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects with Chronic Hepatitis C Genotype 1				
Koch, Alvaro	3048105298	\$0.	\$-4,617.	\$-4,617.
Schering Plough Co A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects with Chronic Hepatitis C Genotype 1				
Koch, Alvaro	3048105298	\$0.	\$3,456.	\$3,456.
Schering Plough Co A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects with Chronic Hepatitis C Genotype 1				
Koch, Alvaro	3048105298	\$0.	\$4,617.	\$4,617.
Schering Plough Co A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects with Chronic Hepatitis C Genotype 1				
Koch, Alvaro	3048105298	\$0.	\$5,297.	\$5,297.
Schering Plough Co A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects with Chronic Hepatitis C Genotype 1				
Koch, Alvaro	3048105298	\$0.	\$10,920.	\$10,920.
Schering Plough Co A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects with Chronic Hepatitis C Genotype 1				
Koch, Alvaro	3048105298	\$0.	\$4,469.	\$4,469.
Schering Plough Co A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects with Chronic Hepatitis C Genotype 1				
Koch, Alvaro	3048105298	\$0.	\$5,108.	\$5,108.
Schering Plough Co A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects with Chronic Hepatitis C Genotype 1				
Koch, Alvaro	3048106560	\$2.	\$0.	\$2.
Schering Plough Co A Single-Arm Study to Provide Boceprevir Treatment in Subjects With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin in Previous Schering-Plough Boceprevir Studies				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Li, Zhenyu	3048105848	\$71,500.	\$0.	\$71,500.
American Heart Association The Role of Platelets in Sepsis				
Lohr, Kristine	3048105465	\$25,000.	\$0.	\$25,000.
American College of Rheumatology Fellowship for Lucia Hardi: Rheumatology Fellowship Training Award				
Lohr, Kristine	3048105764	\$0.	\$6,023.	\$6,023.
Pfizer Inc Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of CP-690,550 in Patients with Active Rheumatoid Arthritis on Background Methotrexate				
Lohr, Kristine	3048105764	\$0.	\$4,293.	\$4,293.
Pfizer Inc Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Efficacy and Safety of 2 Doses of CP-690,550 in Patients with Active Rheumatoid Arthritis on Background Methotrexate				
Lohr, Kristine	3048106309	\$2.	\$0.	\$2.
Pfizer Inc A Prospective Observational Study to Evaluate Long-Term Safety and Functional Status of Subjects with Rheumatoid Arthritis Previously Enrolled in Studies of CP-690, 550				
Luo, Jia	3048105463	\$0.	\$251,772.	\$251,772.
National Institute on Alcohol Abuse and Alcoholism GSK-3 beta, a Mediator of Ethanol Neurotoxicity				
Luo, Jia	3048105464	\$0.	\$326,329.	\$326,329.
National Institute on Alcohol Abuse and Alcoholism Alcohol and Breast Cancer				
Luo, Jia	3048105944	\$95,857.	\$0.	\$95,857.
National Institute on Alcohol Abuse and Alcoholism ARRA: Alcohol and Breast Cancer				
Malluche, Hartmut H	3048057000	\$0.	\$15,805.	\$15,805.
Emory University Pyrophosphate in Vascular Calcification of Renal Failure				
Malluche, Hartmut H	3048105910	\$150,878.	\$0.	\$150,878.
Vifor Pharma International Inc Effects of Various Phosphate Binders on Mineral and Bone Metabolism				
Mardini, Houssam Eddin	3048103706	\$0.	\$2,150.	\$2,150.
PRS Clinical Inc Chemoprevention of Colorectal Adenomas				
Massarweh, Suleiman A.	3048104541	\$0.	\$33,145.	\$33,145.
Novartis A Phase II Study of Combined Fulvestrant (Fulvestrant) and RAD001 (Everolimus) in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
McDonagh, Kevin T	3046946800	\$0.	\$1,871.	\$1,871.
Novartis A Randomized Open-label Study of 400 mg Versus 800 mg of Gleevac/Gilvac (imatinab mesylate) in patients with newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) using Molecular Endpoints				
McDonagh, Kevin T	3046952500	\$0.	\$562.	\$562.
Bristol Myers Squibb Company A Randomized Two Arm, Multicenter, Open-Label Phase II Study of BMS-354825 Administered Orally at a Dose of 70 mg Twice Daily or 140 mg Once Daily in Subjects with Chronic Myeloid Leukemia in Accelerated Phae or in Myeloid or Lymphoid				
McDonagh, Kevin T	3046952500	\$0.	\$630.	\$630.
Bristol Myers Squibb Company A Randomized Two Arm, Multicenter, Open-Label Phase II Study of BMS-354825 Administered Orally at a Dose of 70 mg Twice Daily or 140 mg Once Daily in Subjects with Chronic Myeloid Leukemia in Accelerated Phae or in Myeloid or Lymphoid				
McDonagh, Kevin T	3046959100	\$0.	\$871.	\$871.
Bristol Myers Squibb Company A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic				
McDonagh, Kevin T	3046959100	\$0.	\$180.	\$180.
Bristol Myers Squibb Company A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic				
McDonagh, Kevin T	3048050100	\$0.	\$1,280.	\$1,280.
Cephalon Inc A Multicenter Phase III Study to Investigate the Safety and Efficacy of Treanda)Bendamustine HC1) in Patients with Indolent Non-Hodgkin's Lymphoma (NHL) who are Refractory to Rituximab (SDX-105-03)				
McDonagh, Kevin T	3048103824	\$0.	\$2,480.	\$2,480.
Proteolix Inc An Open-Label, Single-Arm, Phase 2 Study of Carfilzomib in Patients with Relapsed Multiple Myeloma				
McDonagh, Kevin T	3048103824	\$0.	\$13,730.	\$13,730.
Proteolix Inc An Open-Label, Single-Arm, Phase 2 Study of Carfilzomib in Patients with Relapsed Multiple Myeloma				
McDonagh, Kevin T	3048103824	\$0.	\$7,650.	\$7,650.
Proteolix Inc An Open-Label, Single-Arm, Phase 2 Study of Carfilzomib in Patients with Relapsed Multiple Myeloma				
McDonagh, Kevin T	3048105888	\$0.	\$4,893.	\$4,893.
Millennium Pharmaceuticals Inc An Open-Label Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients with Advanced Hematological Malignancies				
McDonagh, Kevin T	3048105888	\$2.	\$0.	\$2.
Millennium Pharmaceuticals Inc An Open-Label Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients with Advanced Hematological Malignancies				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
McDonagh, Kevin T	3048105888	\$0.	\$6,523.	\$6,523.
Millennium Pharmaceuticals Inc An Open-Label Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients with Advanced Hematological Malignancies				
Miller, Beth A	3046829900	\$0.	\$476.	\$476.
Genentech Inc An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				
Miller, Beth A	3046829900	\$0.	\$2,366.	\$2,366.
Genentech Inc An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				
Miller, Beth A	3046829900	\$0.	\$3,794.	\$3,794.
Genentech Inc An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				
Miller, Beth A	3046829900	\$0.	\$2,366.	\$2,366.
Genentech Inc An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				
Miller, Beth A	3046829900	\$0.	\$476.	\$476.
Genentech Inc An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				
Miller, Beth A	3046829900	\$0.	\$-189.	\$-189.
Genentech Inc An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				
Miller, Beth A	3046829900	\$0.	\$3,661.	\$3,661.
Genentech Inc An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)				
Miller, Beth A	3048041000	\$0.	\$5,000.	\$5,000.
Genentech Inc A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects with Moderate to Severe Persistent Asthma who are Inadequately Controlled with High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists				
Miller, Beth A	3048041000	\$0.	\$1,100.	\$1,100.
Genentech Inc A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects with Moderate to Severe Persistent Asthma who are Inadequately Controlled with High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists				
Miller, Beth A	3048041000	\$0.	\$3,821.	\$3,821.
Genentech Inc A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects with Moderate to Severe Persistent Asthma who are Inadequately Controlled with High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Miller, Beth A	3048105366	\$0.	\$11,369.	\$11,369.
Quintiles Inc A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase III Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen Based Tablets Once Daily to Adult Patients				
Miller, Beth A	3048105366	\$0.	\$24,245.	\$24,245.
Quintiles Inc A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase III Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen Based Tablets Once Daily to Adult Patients				
Miller, Beth A	3048105366	\$0.	\$6,485.	\$6,485.
Quintiles Inc A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase III Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen Based Tablets Once Daily to Adult Patients				
Miller, Beth A	3048105366	\$0.	\$7,486.	\$7,486.
Quintiles Inc A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase III Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen Based Tablets Once Daily to Adult Patients				
Miller, Beth A	3048106757	\$0.	\$1,242.	\$1,242.
GlaxoSmithKline A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Dose Ranging Study to Determine the Effect of Mepolizumab on Exacerbation Rates in Subjects with Severe Uncontrolled Refractory Asthma.				
Miller, Beth A	3048106757	\$0.	\$498.	\$498.
GlaxoSmithKline A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Dose Ranging Study to Determine the Effect of Mepolizumab on Exacerbation Rates in Subjects with Severe Uncontrolled Refractory Asthma.				
Miller, Beth A	3048106757	\$0.	\$1,285.	\$1,285.
GlaxoSmithKline A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Dose Ranging Study to Determine the Effect of Mepolizumab on Exacerbation Rates in Subjects with Severe Uncontrolled Refractory Asthma.				
Miller, Beth A	3048106757	\$2.	\$0.	\$2.
GlaxoSmithKline A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Dose Ranging Study to Determine the Effect of Mepolizumab on Exacerbation Rates in Subjects with Severe Uncontrolled Refractory Asthma.				
Miller, Beth A	3048106775	\$0.	\$9,068.	\$9,068.
Schering Plough Co A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Long Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adult Subjects with a History of Ragweed Induced				
Miller, Beth A	3048106775	\$2.	\$0.	\$2.
Schering Plough Co A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Long Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adult Subjects with a History of Ragweed Induced				
Miller, Ralph E	3046644900	\$0.	\$1,705.	\$1,705.
Eli Lilly and Company Hypopituitary Control and Complications Study				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Internal Medicine</u>				
Miller, Ralph E	3046644900	\$0.	\$1,023.	\$1,023.
Eli Lilly and Company Hypopituitary Control and Complications Study				
Miller, Ralph E	3046644900	\$0.	\$341.	\$341.
Eli Lilly and Company Hypopituitary Control and Complications Study				
Moliterno, David Jon	3048105654	\$0.	\$740.	\$740.
Duke Clinical Research Institute Randomized, Multi-Center, Double-Blind, Placebo-Controlled Trial of the Effects of Erythropoietin on Infarct Size and Left Ventricular Remodeling in Survivors of Acute Myocardial Infarctions (REVEAL)				
Moliterno, David Jon	3048105654	\$0.	\$6,300.	\$6,300.
Duke Clinical Research Institute Randomized, Multi-Center, Double-Blind, Placebo-Controlled Trial of the Effects of Erythropoietin on Infarct Size and Left Ventricular Remodeling in Survivors of Acute Myocardial Infarctions (REVEAL)				
Moliterno, David Jon	3048105654	\$0.	\$5,780.	\$5,780.
Duke Clinical Research Institute Randomized, Multi-Center, Double-Blind, Placebo-Controlled Trial of the Effects of Erythropoietin on Infarct Size and Left Ventricular Remodeling in Survivors of Acute Myocardial Infarctions (REVEAL)				
Moliterno, David Jon	3048106782	\$0.	\$9,446.	\$9,446.
Columbia University The PARIS Registry: Patterns of Non-Adherence to Anti-platelet Regimens In Stented Patients - An Observational Single Arm Study				
Moliterno, David Jon	3048106782	\$0.	\$3,198.	\$3,198.
Columbia University The PARIS Registry: Patterns of Non-Adherence to Anti-platelet Regimens In Stented Patients - An Observational Single Arm Study				
Moliterno, David Jon	3048106782	\$2.	\$0.	\$2.
Columbia University The PARIS Registry: Patterns of Non-Adherence to Anti-platelet Regimens In Stented Patients - An Observational Single Arm Study				
Morris, Andrew	3048104961	\$0.	\$2,000.	\$2,000.
American Heart Association Great Rivers Affiliate Fellowship for Hongmei Ren: Regulation of Triglyceride Synthesis by Membrane Targetting of Lipin/Type 1 Phosphatidic acid Phosphatase				
Morris, Andrew	3048104961	\$0.	\$43,000.	\$43,000.
American Heart Association Great Rivers Affiliate Fellowship for Hongmei Ren: Regulation of Triglyceride Synthesis by Membrane Targetting of Lipin/Type 1 Phosphatidic acid Phosphatase				
Morris, Andrew	3048105297	\$0.	\$3,391.	\$3,391.
National Institute of General Medical Sciences Role of Lipid Phosphatases in Cholesterol and Triglyceride Synthesis				
Morris, Andrew	3048105297	\$0.	\$282,013.	\$282,013.
National Institute of General Medical Sciences Role of Lipid Phosphatases in Cholesterol and Triglyceride Synthesis				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Morris, Andrew	3048105769	\$23,000.	\$0.	\$23,000.
American Heart Association Great Rivers Affiliate Abdelghaffar Salous Pre-Doc Fellowship: Role of Lipid Phosphatases in Dynamic Regulation of Lipid Metabolism and Signaling in Cardiovasculature				
Mukherjee, Debabrata	3048061600	\$0.	\$1,650.	\$1,650.
Guidant CPI CAPTURE 2 - A Post-Approval Study of the Guidant Carotid Stent Systems and Embolic Protection Systems				
Mukherjee, Debabrata	3048061600	\$0.	\$998.	\$998.
Guidant CPI CAPTURE 2 - A Post-Approval Study of the Guidant Carotid Stent Systems and Embolic Protection Systems				
Mukherjee, Debabrata	3048104415	\$0.	\$8,000.	\$8,000.
Schering Plough Co A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard Care in Subjects with Acute Coronary Syndrome (TRA CER)				
Mukherjee, Debabrata	3048104415	\$0.	\$18,300.	\$18,300.
Schering Plough Co A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard Care in Subjects with Acute Coronary Syndrome (TRA CER)				
Mukherjee, Debabrata	3048104415	\$0.	\$21,500.	\$21,500.
Schering Plough Co A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard Care in Subjects with Acute Coronary Syndrome (TRA CER)				
Mukherjee, Debabrata	3048104415	\$0.	\$1,600.	\$1,600.
Schering Plough Co A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard Care in Subjects with Acute Coronary Syndrome (TRA CER)				
Mukherjee, Debabrata	3048104415	\$0.	\$1,767.	\$1,767.
Schering Plough Co A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard Care in Subjects with Acute Coronary Syndrome (TRA CER)				
Mukherjee, Debabrata	3048104415	\$0.	\$15,700.	\$15,700.
Schering Plough Co A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard Care in Subjects with Acute Coronary Syndrome (TRA CER)				
Mukherjee, Debabrata	3048106689	\$2.	\$0.	\$2.
Abbott Vascular Carotid Stenting for High Surgical Risk Patients; Evaluating Outcomes Through the Collection of Clinical Evidence (CHOICE)				
Nickl, Nicholas J	3048104763	\$0.	\$63.	\$63.
Repligen Corp A Phase III Study to Demonstrate the Efficacy and Safety of RG1068 (Synthetic Human Secretin) Enhanced Magnetic Resonance Cholangiopancreatography (MRCP) in the Evaluation of Subjects with a History of Acute or Acute Recurrent Pancreatitis				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Internal Medicine</u>				
Nickl, Nicholas J	3048104763	\$0.	\$8,959.	\$8,959.
Repligen Corp A Phase III Study to Demonstrate the Efficacy and Safety of RG1068 (Synthetic Human Secretin) Enhanced Magnetic Resonance Cholangiopancreatography (MRCP) in the Evaluation of Subjects with a History of Acute or Acute Recurrent Pancreatitis				
Nickl, Nicholas J	3048104994	\$0.	\$29,918.	\$29,918.
Eurand SPA A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of two doses of Zentase (EUR-1008) in Chronic Pancreatitis (CP) Patients with Exocrine Pancreatic Insufficiency (EPI)				
Nickl, Nicholas J	3048106733	\$0.	\$2,748.	\$2,748.
Sanofi Aventis US Inc Randomized, Double-Blind, Placebo-Controlled Study of the Effect of a Single Injection of SAR164877 REGN475 on Reduction of Pain from Chronic Pancreatitis				
Nickl, Nicholas J	3048106733	\$2.	\$0.	\$2.
Sanofi Aventis US Inc Randomized, Double-Blind, Placebo-Controlled Study of the Effect of a Single Injection of SAR164877 REGN475 on Reduction of Pain from Chronic Pancreatitis				
Panchatcharam, Manikandan	3048105768	\$66,000.	\$0.	\$66,000.
American Heart Association Great Rivers Affiliate Regulation of Smooth Muscle Cells and the Arterial Response to Injury by Lipid Phosphate Phosphatase 3				
Pena, Luis R	3048103663	\$0.	\$4.	\$4.
Solvay Pharmaceuticals A Study to Investigate the Effect of two Doses of CREON on Maldigestion in Patients with Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis				
Pena, Luis R	3048103663	\$0.	\$1,545.	\$1,545.
Solvay Pharmaceuticals A Study to Investigate the Effect of two Doses of CREON on Maldigestion in Patients with Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis				
Rinehart, John J	3048082900	\$0.	\$63.	\$63.
Eli Lilly and Company A Randomized Phase 3 Trial of Alimta (Premetrexed) and Carboplatin versus Etoposide and Carboplatin in Extensive-STage Small Cell Lung Cancer				
Rinehart, John J	3048082900	\$0.	\$8,190.	\$8,190.
Eli Lilly and Company A Randomized Phase 3 Trial of Alimta (Premetrexed) and Carboplatin versus Etoposide and Carboplatin in Extensive-STage Small Cell Lung Cancer				
Rinehart, John J	3048097700	\$0.	\$1,598.	\$1,598.
Pfizer Inc A Randomized Phase II Study of the Efficacy and Safety of Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing as First-Line Therapy for Metastatic Renal Cell Cancer (Renal EFFECT Trail)				
Rinehart, John J	3048097700	\$0.	\$1,443.	\$1,443.
Pfizer Inc A Randomized Phase II Study of the Efficacy and Safety of Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing as First-Line Therapy for Metastatic Renal Cell Cancer (Renal EFFECT Trail)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Rinehart, John J	3048097700	\$0.	\$-2,000.	\$-2,000.
Pfizer Inc A Randomized Phase II Study of the Efficacy and Safety of Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing as Firt-Line Therapy for Metastatic Renal Cell Cancer (Renal EFFECT Trail)				
Rinehart, John J	3048097700	\$0.	\$1,134.	\$1,134.
Pfizer Inc A Randomized Phase II Study of the Efficacy and Safety of Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing as Firt-Line Therapy for Metastatic Renal Cell Cancer (Renal EFFECT Trail)				
Rinehart, John J	3048103857	\$0.	\$264.	\$264.
Genentech Inc A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients with Metastatic Melanoma				
Rinehart, John J	3048103857	\$0.	\$132.	\$132.
Genentech Inc A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients with Metastatic Melanoma				
Rinehart, John J	3048103857	\$0.	\$10,488.	\$10,488.
Genentech Inc A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients with Metastatic Melanoma				
Romond, Edward H	3046177800	\$0.	\$15,410.	\$15,410.
NSABP Foundation NSABP Master Agreement				
Romond, Edward H	3046177800	\$0.	\$1,020.	\$1,020.
NSABP Foundation NSABP Master Agreement				
Romond, Edward H	3046177800	\$0.	\$2,180.	\$2,180.
NSABP Foundation NSABP Master Agreement				
Romond, Edward H	3046177800	\$0.	\$2,200.	\$2,200.
NSABP Foundation NSABP Master Agreement				
Romond, Edward H	3046177800	\$0.	\$10,000.	\$10,000.
NSABP Foundation NSABP Master Agreement				
Romond, Edward H	3046177800	\$0.	\$8,830.	\$8,830.
NSABP Foundation NSABP Master Agreement				
Romond, Edward H	3046177800	\$0.	\$13,050.	\$13,050.
NSABP Foundation NSABP Master Agreement				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Internal Medicine</u>				
Romond, Edward H	3046177800	\$0.	\$8,800.	\$8,800.
NSABP Foundation NSABP Master Agreement				
Romond, Edward H	3046350500	\$0.	\$2,400.	\$2,400.
NSABP Foundation STAR Trial Breast Cancer Prevention Trial (P-2)				
Romond, Edward H	3046350500	\$0.	\$1,800.	\$1,800.
NSABP Foundation STAR Trial Breast Cancer Prevention Trial (P-2)				
Romond, Edward H	3046350500	\$0.	\$5,400.	\$5,400.
NSABP Foundation STAR Trial Breast Cancer Prevention Trial (P-2)				
Romond, Edward H	3046350500	\$0.	\$1,800.	\$1,800.
NSABP Foundation STAR Trial Breast Cancer Prevention Trial (P-2)				
Romond, Edward H	3048105106	\$0.	\$4,200.	\$4,200.
NSABP Foundation NSABP Master Agreement (TIND)				
Romond, Edward H	3048105106	\$0.	\$4,100.	\$4,100.
NSABP Foundation NSABP Master Agreement (TIND)				
Romond, Edward H	3048105106	\$0.	\$4,700.	\$4,700.
NSABP Foundation NSABP Master Agreement (TIND)				
Romond, Edward H	3048105721	\$0.	\$10,998.	\$10,998.
Bristol Myers Squibb Company IXTEND A Randomized Phase 2 Study to Evaluate the Combinations of IXabepilone plus Capecitabine or CapEcitabiNe plus Docetaxel in the Treatment of Metastatic Breast CA 163-131				
Rowland, Randall	3048103818	\$0.	\$600.	\$600.
Southwest Oncology Group The Selenium and Vitamin E Cancer Prevention Trial (Select)				
Rowland, Randall	3048103818	\$0.	\$100.	\$100.
Southwest Oncology Group The Selenium and Vitamin E Cancer Prevention Trial (Select)				
Rowland, Randall	3048103818	\$0.	\$2,895.	\$2,895.
Southwest Oncology Group The Selenium and Vitamin E Cancer Prevention Trial (Select)				
Rowland, Randall	3048103818	\$0.	\$295.	\$295.
Southwest Oncology Group The Selenium and Vitamin E Cancer Prevention Trial (Select)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Internal Medicine</u>				
Rowland, Randall	3048103818	\$0.	\$1,970.	\$1,970.
Southwest Oncology Group The Selenium and Vitamin E Cancer Prevention Trial (Select)				
Rowland, Randall	3048103818	\$0.	\$1,200.	\$1,200.
Southwest Oncology Group The Selenium and Vitamin E Cancer Prevention Trial (Select)				
Rowland, Randall	3048103819	\$0.	\$250.	\$250.
Southwest Oncology Group SWOG UCOP Urologic Cancer Outreach Program				
Rowland, Randall	3048103819	\$0.	\$100.	\$100.
Southwest Oncology Group SWOG UCOP Urologic Cancer Outreach Program				
Rowland, Randall	3048103819	\$0.	\$300.	\$300.
Southwest Oncology Group SWOG UCOP Urologic Cancer Outreach Program				
Rowland, Randall	3048103819	\$0.	\$250.	\$250.
Southwest Oncology Group SWOG UCOP Urologic Cancer Outreach Program				
Rudy, David W	3048106758	\$27,966.	\$0.	\$27,966.
University of Massachusetts RCT for Smoking Cessation in 10 Medical Schools				
Selby, Lisbeth Ann	3048105410	\$0.	\$1,750.	\$1,750.
University of California San Francisco A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women with Inflammatory Bowel Disease Exposed to Immunomodulators and Biologic Therapy				
Smyth, Susan	3048103742	\$0.	\$284,123.	\$284,123.
University of North Carolina Adhesion and Migration in Inflammation				
Smyth, Susan	3048105950	\$108,044.	\$0.	\$108,044.
National Heart Lung and Blood Institute ARRA: Integrin Signaling in Vascular Cells				
Steinhubl, Steven R	3046837600	\$0.	\$250.	\$250.
New Millenium Pharmaceutical Research Institute Evaluating Ischemic and Restenotic Outcomes in the Drug Eluting Stent Era				
Steinhubl, Steven R	3046837600	\$0.	\$750.	\$750.
New Millenium Pharmaceutical Research Institute Evaluating Ischemic and Restenotic Outcomes in the Drug Eluting Stent Era				
Steinhubl, Steven R	3048012900	\$0.	\$1,500.	\$1,500.
Medicines Company CHAMPION-PCI: Cangrelor: A Clinical Trail Comparing Cangrelor to C Lopidogrel in Subjects Who Require Percutaneous Coronary Intervention				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Steinhubl, Steven R	3048103787	\$0.	\$1,785.	\$1,785.
Johnson and Johnson A Propestive, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Even-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose				
Steinhubl, Steven R	3048103787	\$0.	\$590.	\$590.
Johnson and Johnson A Propestive, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Even-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose				
Steinhubl, Steven R	3048103787	\$0.	\$710.	\$710.
Johnson and Johnson A Propestive, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Even-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose				
Steinhubl, Steven R	3048103787	\$0.	\$2,477.	\$2,477.
Johnson and Johnson A Propestive, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Even-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose				
Steinhubl, Steven R	3048103787	\$0.	\$4,138.	\$4,138.
Johnson and Johnson A Propestive, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Even-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose				
Steinhubl, Steven R	3048103787	\$0.	\$2,167.	\$2,167.
Johnson and Johnson A Propestive, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Even-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose				
Steinhubl, Steven R	3048103787	\$0.	\$2,980.	\$2,980.
Johnson and Johnson A Propestive, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Even-Driven, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose				
Supinski, Gerald	3048092400	\$0.	\$355,629.	\$355,629.
National Heart Lung and Blood Institute MAPK/PKR Modulation of Diaphragm Weakness				
Supinski, Gerald	3048106639	\$480,899.	\$0.	\$480,899.
National Heart Lung and Blood Institute ARRA: Evaluation and Treatment of Skeletal Muscle Weakness in Critically Ill Patients				
Tannock, Lisa R	3048105894	\$273,755.	\$0.	\$273,755.
National Heart Lung and Blood Institute ARRA: Angiotensin Induced Proteoglycans in Atherosclerosis				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Internal Medicine</u>				
Tannock, Lisa R	3048106107	\$406,492.	\$0.	\$406,492.
National Heart Lung and Blood Institute ARRA: Role of Serum Amyloid A in Atherosclerosis				
Thornton, Alice C	3048105593	\$0.	\$344,466.	\$344,466.
Health Resources and Services Administration Ryan White Part C Outpatient Early Intervention Services				
Thornton, Alice C	3048105811	\$0.	\$6,000.	\$6,000.
Emory University Kentucky AIDS Education Training Center				
Thornton, Alice C	3048105811	\$165,000.	\$0.	\$165,000.
Emory University Kentucky AIDS Education Training Center				
Thornton, Alice C	3048106029	\$0.	\$113,538.	\$113,538.
KY Cabinet for Health and Family Services Kentucky HIV/AIDS Care Coordinator Program				
Thornton, Alice C	3048106029	\$547,527.	\$0.	\$547,527.
KY Cabinet for Health and Family Services Kentucky HIV/AIDS Care Coordinator Program				
Thornton, Alice C	3048106783	\$350,000.	\$0.	\$350,000.
Health Resources and Services Administration Ryan White Title IV Women, Infants, Children, Youth and Affected Family Members AIDS Healthcare				
Thornton, Alice C	3048106790	\$84,951.	\$0.	\$84,951.
Health Resources and Services Administration Special Projects of National Significance (SPNS) - Capacity Building to Develop Standard Electronic Client Information Data Systems at the Bluegrass Care Clinic				
Van Zant, Gary	3048105418	\$0.	\$319,736.	\$319,736.
National Institute of Child Health and Human Develop Latexin's role in parsing stem cells				
Van Zant, Gary	3048105418	\$0.	\$31,974.	\$31,974.
National Institute of Child Health and Human Develop Latexin's role in parsing stem cells				
Van Zant, Gary	3048106714	\$219,677.	\$0.	\$219,677.
Ellison Medical Foundation Role of the microRNA-290 Gene Cluster in Stem Cell and Organismal Aging				
Van Zant, Gary	3048106975	\$438,780.	\$0.	\$438,780.
National Institute Diabetes & Digestive & Kidney ARRA: Slit2-Mediated Expansion of Primitive Hematopoietic Stem Cell Populations for Transplantation and Hematopoietic Recovery				
Waid, Thomas	3048104654	\$0.	\$8,360.	\$8,360.
Astellas Pharma US Inc A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de novo Kidney Transplant Recipients				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Waid, Thomas	3048104654	\$0.	\$39,975.	\$39,975.
Astellas Pharma US Inc A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de novo Kidney Transplant Recipients				
Waid, Thomas	3048104654	\$0.	\$51,673.	\$51,673.
Astellas Pharma US Inc A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de novo Kidney Transplant Recipients				
Waid, Thomas	3048104654	\$0.	\$6,235.	\$6,235.
Astellas Pharma US Inc A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de novo Kidney Transplant Recipients				
Waid, Thomas	3048104654	\$0.	\$35,104.	\$35,104.
Astellas Pharma US Inc A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de novo Kidney Transplant Recipients				
Waid, Thomas	3048104654	\$0.	\$7,410.	\$7,410.
Astellas Pharma US Inc A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de novo Kidney Transplant Recipients				
Webb, Nancy R	3048106063	\$352,349.	\$0.	\$352,349.
National Institute Diabetes & Digestive & Kidney Group X sPLA2: Regulator of Lipolysis and Glucose Homeostasis				
Ziada, Khaled M	3048066800	\$0.	\$275.	\$275.
Sanofi Aventis US Inc CRESCENDO: EFC5826: Randomized, Multinational, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trail of Rimonabant 20 mg QD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients with Clustering				
Ziada, Khaled M	3048066800	\$0.	\$8,172.	\$8,172.
Sanofi Aventis US Inc CRESCENDO: EFC5826: Randomized, Multinational, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trail of Rimonabant 20 mg QD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients with Clustering				
Ziada, Khaled M	3048066800	\$0.	\$5,535.	\$5,535.
Sanofi Aventis US Inc CRESCENDO: EFC5826: Randomized, Multinational, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trail of Rimonabant 20 mg QD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients with Clustering				
Ziada, Khaled M	3048104460	\$0.	\$9,305.	\$9,305.
Schering Plough Co A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease				
Ziada, Khaled M	3048104460	\$0.	\$25,175.	\$25,175.
Schering Plough Co A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Ziada, Khaled M	3048104460	\$0.	\$1,121.	\$1,121.
Schering Plough Co				
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease				
Ziada, Khaled M	3048104460	\$0.	\$4,500.	\$4,500.
Schering Plough Co				
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease				
Ziada, Khaled M	3048104460	\$0.	\$10,640.	\$10,640.
Schering Plough Co				
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease				
Ziada, Khaled M	3048104460	\$0.	\$10,175.	\$10,175.
Schering Plough Co				
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease				
Ziada, Khaled M	3048104460	\$0.	\$2,453.	\$2,453.
Schering Plough Co				
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease				
Ziada, Khaled M	3048104460	\$0.	\$12,750.	\$12,750.
Schering Plough Co				
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease				
Ziada, Khaled M	3048104460	\$0.	\$4,200.	\$4,200.
Schering Plough Co				
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease				
Ziada, Khaled M	3048104460	\$0.	\$81.	\$81.
Schering Plough Co				
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease				
Ziada, Khaled M	3048104460	\$0.	\$12,925.	\$12,925.
Schering Plough Co				
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease				
Ziada, Khaled M	3048104589	\$0.	\$2,000.	\$2,000.
AstraZeneca Pharmaceuticals				
A 104 Week, Randomized, Double-Blind, Parallel Arm, Multi-Center Phase IIIb Study Comparing the Effects of Treatment with Rosuvastatin 40 mg or Atorvastatin 80 mg on Atherosclerotic Disease Burden As Measured By Intravascular Ultrasound in Patients				
Ziada, Khaled M	3048104589	\$0.	\$9,190.	\$9,190.
AstraZeneca Pharmaceuticals				
A 104 Week, Randomized, Double-Blind, Parallel Arm, Multi-Center Phase IIIb Study Comparing the Effects of Treatment with Rosuvastatin 40 mg or Atorvastatin 80 mg on Atherosclerotic Disease Burden As Measured By Intravascular Ultrasound in Patients				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Internal Medicine				
Ziada, Khaled M	3048104589	\$0.	\$208.	\$208.
AstraZeneca Pharmaceuticals A 104 Week, Randomized, Double-Blind, Parallel Arm, Multi-Center Phase IIIb Study Comparing the Effects of Treatment with Rosuvastatin 40 mg or Atorvastatin 80 mg on Atherosclerotic Disease Burden As Measured By Intravascular Ultrasound in Patients				
Ziada, Khaled M	3048104589	\$0.	\$188.	\$188.
AstraZeneca Pharmaceuticals A 104 Week, Randomized, Double-Blind, Parallel Arm, Multi-Center Phase IIIb Study Comparing the Effects of Treatment with Rosuvastatin 40 mg or Atorvastatin 80 mg on Atherosclerotic Disease Burden As Measured By Intravascular Ultrasound in Patients				
Ziada, Khaled M	3048105414	\$0.	-\$2,000.	-\$2,000.
Abbott Laboratories XIENCE V Everolimus Eluting Coronary Stent System				
Ziada, Khaled M	3048105563	\$0.	\$5,000.	\$5,000.
Portola Pharmaceuticals Inc A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, A Selective and Reversible P2Y12-Receptor Inhibitor vs Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing				
Ziada, Khaled M	3048105563	\$0.	\$3,000.	\$3,000.
Portola Pharmaceuticals Inc A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, A Selective and Reversible P2Y12-Receptor Inhibitor vs Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing				
Ziada, Khaled M	3048105563	\$0.	\$2,000.	\$2,000.
Portola Pharmaceuticals Inc A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, A Selective and Reversible P2Y12-Receptor Inhibitor vs Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing				
Ziada, Khaled M	3048105563	\$0.	\$4,000.	\$4,000.
Portola Pharmaceuticals Inc A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, A Selective and Reversible P2Y12-Receptor Inhibitor vs Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing				
Ziada, Khaled M	3048105563	\$0.	\$2,000.	\$2,000.
Portola Pharmaceuticals Inc A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, A Selective and Reversible P2Y12-Receptor Inhibitor vs Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing				
Ziada, Khaled M	3048105563	\$0.	\$1,000.	\$1,000.
Portola Pharmaceuticals Inc A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, A Selective and Reversible P2Y12-Receptor Inhibitor vs Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing				
Ziada, Khaled M	3048105563	\$0.	-\$2,000.	-\$2,000.
Portola Pharmaceuticals Inc A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, A Selective and Reversible P2Y12-Receptor Inhibitor vs Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing				
Ziada, Khaled M	3048105563	\$0.	\$2,700.	\$2,700.
Portola Pharmaceuticals Inc A Randomized, Double-Blind, Active-Controlled Trial to Evaluate Intravenous and Oral PRT060128, A Selective and Reversible P2Y12-Receptor Inhibitor vs Clopidogrel, as a Novel Antiplatelet Therapy in Patients Undergoing				
Internal Medicine	Totals:	\$8,342,897.	\$5,918,560.	\$14,261,457.

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
<u>Microbiology, Immunology & Molecular Gen</u>				
Bondada, Subbarao	3048105046	\$0.	\$219,750.	\$219,750.
National Institute of Allergy and Infectious Diseases Importance of CD5 for the function of regulatory T cells				
D'Orazio, Sarah	3048106120	\$74,250.	\$0.	\$74,250.
National Institute of Allergy and Infectious Diseases MHC-Ib restricted T cell responses against Listeria monocytogenes				
Garvy, Beth A	3048104324	\$0.	\$366,250.	\$366,250.
National Heart Lung and Blood Institute Role of B cells in host defense against Pneumocystis				
Garvy, Beth A	3048106054	\$217,900.	\$0.	\$217,900.
National Institute of Allergy and Infectious Diseases ARRA: Host defense against influenza virus in the lungs of neonatal mice				
Garvy, Beth A	3048106123	\$334,125.	\$0.	\$334,125.
National Heart Lung and Blood Institute Host Response to P. carinii in Neonatal Mice				
Kaetzel, Charlotte S	3048106573	\$124,889.	\$0.	\$124,889.
National Institute of Allergy and Infectious Diseases ARRA: Novel in vivo models for cell-type specific MyD88 signaling in the intestine				
Perry, Robert D	3048105494	\$0.	\$329,625.	\$329,625.
National Institute of Allergy and Infectious Diseases Yersiniabactin and plague pathogenesis				
Peterson, Martha L	3048105776	\$0.	\$57,739.	\$57,739.
University of Louisville KY IDea Networks of Biomedical Research Excellence				
Peterson, Martha L	3048106506	\$525,000.	\$0.	\$525,000.
National Science Foundation Post-transcriptional control of immunoglobulin expression				
Roszman, Thomas L	3048106799	\$150,000.	\$0.	\$150,000.
KY Lung Cancer Research Fund Inhibition of Lung Cancer Cell Migration/Invasion by Cell Penetrating Peptides				
Sinai, Anthony P	3046975100	\$0.	\$31,398.	\$31,398.
National Institute of Allergy and Infectious Diseases Blockade of Host Apoptosis by Toxoplasma Gondii				
Sinai, Anthony P	3046975100	\$0.	\$310,845.	\$310,845.
National Institute of Allergy and Infectious Diseases Blockade of Host Apoptosis by Toxoplasma Gondii				
Spear, Brett T	3048104385	\$0.	\$294,319.	\$294,319.
National Institute Diabetes & Digestive & Kidney Albumin-AFP Gene Family Regulation in Fetal and Adult Liver				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Microbiology, Immunology & Molecular Gen</u>				
Spear, Brett T	3048106630	\$33,000.	\$0.	\$33,000.
ParaTechs Corp Paratechs Corporation Contract				
Stevenson, Brian	3046983300	\$0.	\$345,384.	\$345,384.
National Institute of Allergy and Infectious Diseases Analysis of Borrelia Burgdorferi Erp Proteins				
Stevenson, Brian	3046983300	\$0.	\$348,872.	\$348,872.
National Institute of Allergy and Infectious Diseases Analysis of Borrelia Burgdorferi Erp Proteins				
Stevenson, Brian	3048104946	\$0.	\$183,125.	\$183,125.
National Institute of Allergy and Infectious Diseases Leptospira interrogans Len adhesins				
Stevenson, Brian	3048106699	\$51,710.	\$0.	\$51,710.
National Institute of Allergy and Infectious Diseases Fellowship Brisette: Role of Borrelia burgdorferi fibronectin-binding proten in Lyme Disease				
Straley, Susan C	3048103204	\$0.	\$507,596.	\$507,596.
National Institute of Allergy and Infectious Diseases YopM and Protective Innate Defenses Against Plague				
Straley, Susan C	3048103204	\$0.	\$49,789.	\$49,789.
National Institute of Allergy and Infectious Diseases YopM and Protective Innate Defenses Against Plague				
Straley, Susan C	3048105907	\$222,750.	\$0.	\$222,750.
National Institute of Allergy and Infectious Diseases ARRA: A novel ternary virulence system in plague				
Suzuki, Yasuhiro	3048105746	\$0.	\$141,984.	\$141,984.
University of Chicago Towards a Vaccine to Prevent Toxoplasmosis				
Suzuki, Yasuhiro	3048105746	\$0.	\$-141,984.	\$-141,984.
University of Chicago Towards a Vaccine to Prevent Toxoplasmosis				
Suzuki, Yasuhiro	3048105794	\$0.	\$-19,144.	\$-19,144.
National Institute of Allergy and Infectious Diseases Elimination of Toxoplasma gondii cysts by T cells				
Suzuki, Yasuhiro	3048105795	\$0.	\$367,031.	\$367,031.
National Institute of Allergy and Infectious Diseases IFN-gamma productin by microglia for prevention of toxoplasmic encephalitis				
Suzuki, Yasuhiro	3048106568	\$127,798.	\$0.	\$127,798.
Stanley Medical Research Institute Determination of serological profiles in anti-toxoplasma gondii antibodies following reactivation of chronica infection with the parasite in the brain and following infection				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
<u>Microbiology, Immunology & Molecular Gen</u>				
Suzuki, Yasuhiro	3048106727	\$141,984.	\$0.	\$141,984.
University of Chicago Towards a Vaccine to Prevent Toxoplasmosis				
Woodward, Jerold G	3048105035	\$0.	\$146,500.	\$146,500.
National Eye Institute To Produce Transgenic Mice Which Express T Cell Receptors Specific for (IRBP)				
Yannelli, John R	3048105252	\$0.	\$182,024.	\$182,024.
National Cancer Institute Cryopreparation of PBMC for Immunotherapy and Immune Assessment Studies				
Microbiology, Immunology & Molecular Gen	Totals:	\$2,003,406.	\$3,721,103.	\$5,724,509.
<u>Family Practice & Community Medicine</u>				
Elder, William G	3048106724	\$221,695.	\$0.	\$221,695.
National Center for Complementary & Alternative Med CAM Referral and Outcomes: Chronic Low Back Pain in Urban and Rural Primary Care				
Joyce, Jennifer M	3048106723	\$190,301.	\$0.	\$190,301.
Health Resources and Services Administration Predoctoral Training in Rural Kentucky				
King, Michael Rhea	3048106763	\$192,280.	\$0.	\$192,280.
Health Resources and Services Administration Engaging Family Medicine Residents in the Chronic Care Model				
Matheny, Samuel C	3048106725	\$315,320.	\$0.	\$315,320.
Health Resources and Services Administration Academic Administrative Units in Primary Care				
Parrish, Sarah A	3048106762	\$6,000.	\$0.	\$6,000.
Good Samaritan Foundation Radiological Imaging and Dental Services for Lexington's Homeless and Uninsured.				
Roeder, Phillip W	3048104606	\$0.	\$3,171.	\$3,171.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
Roeder, Phillip W	3048104606	\$0.	\$47,140.	\$47,140.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
Roeder, Phillip W	3048104606	\$0.	\$49,763.	\$49,763.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
Roeder, Phillip W	3048105725	\$0.	\$17,678.	\$17,678.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
Roeder, Phillip W	3048105725	\$0.	\$71,498.	\$71,498.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Family Practice & Community Medicine				
Roeder, Phillip W	3048105725	\$0.	\$31,226.	\$31,226.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
Roeder, Phillip W	3048105725	\$0.	\$51,804.	\$51,804.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
Roeder, Phillip W	3048105725	\$0.	\$48,967.	\$48,967.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
Roeder, Phillip W	3048105725	\$0.	\$52,313.	\$52,313.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
Roeder, Phillip W	3048105725	\$0.	\$-572,967.	\$-572,967.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
Roeder, Phillip W	3048105725	\$0.	\$625,556.	\$625,556.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
Roeder, Phillip W	3048105725	\$2.	\$0.	\$2.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
Roeder, Phillip W	3048105725	\$0.	\$32,905.	\$32,905.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
Roeder, Phillip W	3048105725	\$0.	\$2,888.	\$2,888.
KY Department of Corrections Department of Corrections Health Care Network Monitor & Coordinator - UK Administration				
Stanley, Michael W		\$679,416.	\$0.	\$679,416.
Health Resources and Services Administration Health Center Cluster (DHHS BPHC Section 330 Community Health Center)				
Stanley, Michael W	3048105674	\$0.	\$650,000.	\$650,000.
Health Resources and Services Administration ARRA: Health Center Cluster New Access Point (DHHS BPHC HRSA Section 330 Community Health Center)				
Stanley, Michael W	3048105706	\$0.	\$28,500.	\$28,500.
Health Resources and Services Administration Health Center Cluster (DHHS BPHC HRSA Section 330 Community Health Center)				
Stanley, Michael W	3048105818	\$0.	\$1,000.	\$1,000.
Health Resources and Services Administration ARRA:Health Center Integrated Services Development				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Family Practice & Community Medicine</u>				
Stanley, Michael W	3048105865	\$470,640.	\$0.	\$470,640.
Health Resources and Services Administration ARRA: Capital Improvement Program: June Buchanan Satellite Site				
Stone, Daria Nicole	3048106427	\$10,000.	\$0.	\$10,000.
Hazard Perry County Community Foundation Oral Health Navigator				
Family Practice & Community Medicine	Totals:	\$2,085,654.	\$1,141,442.	\$3,227,096.
<u>Obstetrics & Gynecology</u>				
Coker, Ann L	3048106424	\$400,000.	\$0.	\$400,000.
Center for Disease Control and Prevention Green Dot across the Bluegrass: Evaluation of primary prevention intervention to reduce sexual violence				
Coker, Ann L	3048106644	\$371,250.	\$0.	\$371,250.
National Center on Minority Health and Health Disparities Does Violence Against Women Result in Disparities in Cancer Care for Women with Breast, Colorectal or Cervical Cancer?				
Curry, Thomas E	3048105482	\$0.	-\$7,918.	-\$7,918.
National Center for Research Resources Center of Biomedical Research Excellence in Women's Health (COBRE)				
Curry, Thomas E	3048106095	\$500,000.	\$0.	\$500,000.
National Institute on Drug Abuse Building Interdisciplinary Research Careers in Women's Health in Kentucky				
Curry, Thomas E	3048106578	\$301,394.	\$0.	\$301,394.
National Institute of Child Health and Human Development The MMP system in human ovulation: localization, regulation, and function				
Hansen, Wendy	3048102149	\$0.	\$263.	\$263.
March of Dimes Birth Defects Foundation Prematurity Prevention Initiative in Kentucky - Healthy Babies are Worth the Wait				
Hansen, Wendy	3048102149	\$0.	\$10,000.	\$10,000.
March of Dimes Birth Defects Foundation Prematurity Prevention Initiative in Kentucky - Healthy Babies are Worth the Wait				
Hansen, Wendy	3048102149	\$0.	\$934.	\$934.
March of Dimes Birth Defects Foundation Prematurity Prevention Initiative in Kentucky - Healthy Babies are Worth the Wait				
Lain, Kristine	3048106416	\$160,000.	\$0.	\$160,000.
American Diabetes Association Inc Cardiometabolic Outcomes Following Pregnancy Complicated by Gestational Diabetes				
Muse, Kenneth N	3046856500	\$0.	\$4,909.	\$4,909.
Xanodyne Pharmaceuticals Inc A Twelve-Month, Open Label, Multicenter Study to Evaluate the Safety of a 1.3 g Oral Dose of a New Modified-Release Tranexamic Acid Formulation Administered Three Times Daily as Needed for up to 5 Days During the				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
<u>Obstetrics & Gynecology</u>				
Muse, Kenneth N	3046898000	\$0.	\$488.	\$488.
TAP Pharmaceuticals Inc A Phase 3, Continuation Study to Evaluate the Long-Term Safety of Asoprisnil in Subjects with Uterine Leiomyomata Incorporating Amendment 1				
Muse, Kenneth N	3048104346	\$0.	\$3,725.	\$3,725.
Bayer Pharmaceuticals A multicenter, double-blind, randomized, placebo-controlled study to determine the lowest effective dose of oral Angeliq for their relief of moderate to severe vasomotor symptoms in postmenopausal women over a treatment period of 12 weeks.				
Muse, Kenneth N	3048104550	\$0.	\$1,882.	\$1,882.
Biosante Pharmaceuticals Inc A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Libigel for the Treatment of Hypoactive Sexual Disorder in Surgically Menopausal Women(testW008)				
Muse, Kenneth N	3048104550	\$0.	\$2,192.	\$2,192.
Biosante Pharmaceuticals Inc A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Libigel for the Treatment of Hypoactive Sexual Disorder in Surgically Menopausal Women(testW008)				
Muse, Kenneth N	3048104551	\$0.	\$3,918.	\$3,918.
Biosante Pharmaceuticals Inc A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Long Term Safety and Efficacy of Libigel for the Treatment of Hypoactive Sexual Desire in Postmenopausal Women(testW007)				
Muse, Kenneth N	3048104551	\$0.	\$718.	\$718.
Biosante Pharmaceuticals Inc A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Long Term Safety and Efficacy of Libigel for the Treatment of Hypoactive Sexual Desire in Postmenopausal Women(testW007)				
Muse, Kenneth N	3048104551	\$0.	\$-119.	\$-119.
Biosante Pharmaceuticals Inc A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Long Term Safety and Efficacy of Libigel for the Treatment of Hypoactive Sexual Desire in Postmenopausal Women(testW007)				
Muse, Kenneth N	3048104551	\$0.	\$1,329.	\$1,329.
Biosante Pharmaceuticals Inc A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Long Term Safety and Efficacy of Libigel for the Treatment of Hypoactive Sexual Desire in Postmenopausal Women(testW007)				
Muse, Kenneth N	3048104551	\$0.	\$119.	\$119.
Biosante Pharmaceuticals Inc A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Long Term Safety and Efficacy of Libigel for the Treatment of Hypoactive Sexual Desire in Postmenopausal Women(testW007)				
Muse, Kenneth N	3048104551	\$0.	\$119.	\$119.
Biosante Pharmaceuticals Inc A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Long Term Safety and Efficacy of Libigel for the Treatment of Hypoactive Sexual Desire in Postmenopausal Women(testW007)				
Muse, Kenneth N	3048105599	\$0.	\$13,419.	\$13,419.
Wyeth Research A Double-blind, randomized, placebo and active-controlled efficacy and safety study of the effects of Bazedoxifene / Conjugated Estrogens combinations on endometrial hyperplasia and prevention of osteoporosis in postmenopausal women				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Obstetrics & Gynecology</u>				
Muse, Kenneth N	3048105599	\$0.	\$17,517.	\$17,517.
Wyeth Research A Double-blind, randomized, placebo and active-controlled efficacy and safety study of the effects of Bazedoxifene / Conjugated Estrogens combinations on endometrial hyperplasia and prevention of osteoporosis in postmenopausal women				
Muse, Kenneth N	3048105599	\$0.	\$3,020.	\$3,020.
Wyeth Research A Double-blind, randomized, placebo and active-controlled efficacy and safety study of the effects of Bazedoxifene / Conjugated Estrogens combinations on endometrial hyperplasia and prevention of osteoporosis in postmenopausal women				
Muse, Kenneth N	3048105599	\$0.	\$4,925.	\$4,925.
Wyeth Research A Double-blind, randomized, placebo and active-controlled efficacy and safety study of the effects of Bazedoxifene / Conjugated Estrogens combinations on endometrial hyperplasia and prevention of osteoporosis in postmenopausal women				
Muse, Kenneth N	3048105599	\$0.	\$7,222.	\$7,222.
Wyeth Research A Double-blind, randomized, placebo and active-controlled efficacy and safety study of the effects of Bazedoxifene / Conjugated Estrogens combinations on endometrial hyperplasia and prevention of osteoporosis in postmenopausal women				
Muse, Kenneth N	3048105599	\$0.	\$1,701.	\$1,701.
Wyeth Research A Double-blind, randomized, placebo and active-controlled efficacy and safety study of the effects of Bazedoxifene / Conjugated Estrogens combinations on endometrial hyperplasia and prevention of osteoporosis in postmenopausal women				
Muse, Kenneth N	3048105676	\$0.	\$3,569.	\$3,569.
Ferring International Pharmascience Center US Inc A Multicenter, randomized, double-dummy, placebo-controlled study to assess the efficacy and safety of three dosage strengths of pulsatile GnRH delivered from iontophoretic patch (Lutrepach) compared to oral treatment				
Muse, Kenneth N	3048105676	\$0.	\$3,411.	\$3,411.
Ferring International Pharmascience Center US Inc A Multicenter, randomized, double-dummy, placebo-controlled study to assess the efficacy and safety of three dosage strengths of pulsatile GnRH delivered from iontophoretic patch (Lutrepach) compared to oral treatment				
Muse, Kenneth N	3048105676	\$0.	\$15,387.	\$15,387.
Ferring International Pharmascience Center US Inc A Multicenter, randomized, double-dummy, placebo-controlled study to assess the efficacy and safety of three dosage strengths of pulsatile GnRH delivered from iontophoretic patch (Lutrepach) compared to oral treatment				
Muse, Kenneth N	3048105676	\$0.	\$6,841.	\$6,841.
Ferring International Pharmascience Center US Inc A Multicenter, randomized, double-dummy, placebo-controlled study to assess the efficacy and safety of three dosage strengths of pulsatile GnRH delivered from iontophoretic patch (Lutrepach) compared to oral treatment				
Muse, Kenneth N	3048105676	\$0.	\$419.	\$419.
Ferring International Pharmascience Center US Inc A Multicenter, randomized, double-dummy, placebo-controlled study to assess the efficacy and safety of three dosage strengths of pulsatile GnRH delivered from iontophoretic patch (Lutrepach) compared to oral treatment				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Obstetrics & Gynecology</u>				
Muse, Kenneth N	3048105676	\$0.	\$8,498.	\$8,498.
Ferring International Pharmascience Center US Inc A Multicenter, randomized, double-dummy, placebo-controlled study to assess the efficacy and safety of three dosage strengths of pulsatile GnRH delivered from iontophoretic patch (Lutrepach) compared to oral treatment				
Muse, Kenneth N	3048106718	\$2.	\$0.	\$2.
AMGen A Randomized Open-Label Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated with Daily or Weekly Bisphosphonates				
Muse, Kenneth N	3048106810	\$0.	\$-1,699.	\$-1,699.
Wyeth Research RNA Expression Analysis of Endometrial Biopsies Comparing Placebo, Bazedoxifene/Conjugated Estrogens and Raloxifene				
Muse, Kenneth N	3048106810	\$2.	\$0.	\$2.
Wyeth Research RNA Expression Analysis of Endometrial Biopsies Comparing Placebo, Bazedoxifene/Conjugated Estrogens and Raloxifene				
Muse, Kenneth N	3048106810	\$0.	\$1,699.	\$1,699.
Wyeth Research RNA Expression Analysis of Endometrial Biopsies Comparing Placebo, Bazedoxifene/Conjugated Estrogens and Raloxifene				
Muse, Kenneth N	3048106965	\$2.	\$0.	\$2.
Wyeth Research Evaluation of Changes in Mammographic Breast Density Associated with Bazedoxifene Acetate/Conjugated Estrogens, Raloxifene and Placebo in Postmenopausal Women: An Ancillary study of Protocol 3115A1-303-WW				
Ueland, Frederick R	3046897300	\$0.	\$-426.	\$-426.
Gynecologic Oncology Group Gynecologic Oncology Group				
Ueland, Frederick R	3046897300	\$0.	\$3,000.	\$3,000.
Gynecologic Oncology Group Gynecologic Oncology Group				
Ueland, Frederick R	3046897300	\$0.	\$36,452.	\$36,452.
Gynecologic Oncology Group Gynecologic Oncology Group				
Ueland, Frederick R	3046897300	\$0.	\$32,495.	\$32,495.
Gynecologic Oncology Group Gynecologic Oncology Group				
Ueland, Frederick R	3046897300	\$0.	\$41,080.	\$41,080.
Gynecologic Oncology Group Gynecologic Oncology Group				
Ueland, Frederick R	3048103872	\$0.	\$378.	\$378.
Genentech Inc A Phase III, Multicenter, Randomized, Blinded, Placebo-Controlled Trial of Carboplatin and Gencitabine Plus Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Obstetrics & Gynecology</u>				
Ueland, Frederick R	3048103872	\$0.	\$8,499.	\$8,499.
Genentech Inc A Phase III, Multicenter, Randomized, Blinded, Placebo-Controlled Trial of Carboplatin and Gencitabine Plus Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovary, Promary Peritoneal, or Fallopian Tube Carcinoma				
Ueland, Frederick R	3048103872	\$0.	\$16,397.	\$16,397.
Genentech Inc A Phase III, Multicenter, Randomized, Blinded, Placebo-Controlled Trial of Carboplatin and Gencitabine Plus Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovary, Promary Peritoneal, or Fallopian Tube Carcinoma				
Ueland, Frederick R	3048105547	\$0.	\$998.	\$998.
ImClone Systems CP12-0711: A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma				
VanNagell, John R	3048105004	\$0.	\$975,000.	\$975,000.
KY Council on Postsecondary Education Ovarian Cancer Screening in Kentucky				
Obstetrics & Gynecology	Totals:	\$1,732,650.	\$1,222,361.	\$2,955,011.
<u>Pathology & Lab Medicine</u>				
Lutz, Charles	3048106550	\$374,803.	\$0.	\$374,803.
National Institute of Allergy and Infectious Diseases ARRA: Molecular Mechanisms Controlling NK Cells Receptor Expression				
Pathology & Lab Medicine	Totals:	\$374,803.	\$0.	\$374,803.
<u>Pediatrics</u>				
Anstead, Michael I	3048103215	\$0.	\$11,070.	\$11,070.
PPD Development Inc Multi-center, multi-national, randomized, placebo-controlled trial of Azithromycin in participants with Cystic Fibrosis 6-18 years old, Culter negative for Pseudomonas aeruginosa				
Anstead, Michael I	3048106571	\$2.	\$0.	\$2.
Vertex Pharmaceuticals Inc A Phase 3, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Pharmacokinetics, Efficacy and Safety of VX-770 in Subjects with Cystic Fibrosis and the G551D Mutation				
Anstead, Michael I	3048106660	\$2.	\$0.	\$2.
Gilead Sciences Inc Expanded Access Program for Aztreonam Lysine for Inhalation in Patients with Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection Who Have Limited Treatment Options and are at Risk for Disease Progression				
Bada, Henrietta S	3048105011	\$0.	\$2,800.	\$2,800.
Yale University Gene Targets for Prevention of Intraventricular Hemorrhage				
Bada, Henrietta S	3048106034	\$0.	\$4,200.	\$4,200.
Yale University Gene Targets for Prevention of Intraventricular Hemorrhage				
Bada, Henrietta S	3048106034	\$18,582.	\$0.	\$18,582.
Yale University Gene Targets for Prevention of Intraventricular Hemorrhage				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Pediatrics				
Bada, Henrietta S	3048106301	\$384,350.	\$0.	\$384,350.
KY Cabinet for Health and Family Services Infant Intensive Care				
Bay, Carolyn A	3048106040	\$180,864.	\$0.	\$180,864.
KY Cabinet for Health and Family Services Genetic Services				
Bricker, J Timothy	3048105980	\$262,000.	\$0.	\$262,000.
KY Cabinet for Health and Family Services Newborn Screening				
Cottrill, Carol M	3048105440	\$0.	\$2,998.	\$2,998.
Merck and Company Inc A Phase III, Randomized, Open-Label, Parallel-Group, Dose Ranging Clinical Trial to Study the Safety and Efficacy of MK-0954/Losartan Potassium in Pediatric Patients with Hypertension				
Greenwood, Martha F	3048104875	\$0.	\$3,300.	\$3,300.
National Childhood Cancer Foundation Children's Oncology Group				
Greenwood, Martha F	3048104875	\$0.	\$6,100.	\$6,100.
National Childhood Cancer Foundation Children's Oncology Group				
Greenwood, Martha F	3048104875	\$0.	\$40.	\$40.
National Childhood Cancer Foundation Children's Oncology Group				
Greenwood, Martha F	3048104875	\$0.	\$21,500.	\$21,500.
National Childhood Cancer Foundation Children's Oncology Group				
Greenwood, Martha F	3048104875	\$0.	\$220.	\$220.
National Childhood Cancer Foundation Children's Oncology Group				
Greenwood, Martha F	3048104875	\$0.	\$14,348.	\$14,348.
National Childhood Cancer Foundation Children's Oncology Group				
Greenwood, Martha F	3048104875	\$0.	\$400.	\$400.
National Childhood Cancer Foundation Children's Oncology Group				
Greenwood, Martha F	3048104875	\$0.	\$6,550.	\$6,550.
National Childhood Cancer Foundation Children's Oncology Group				
Greenwood, Martha F	3048104875	\$0.	\$1,000.	\$1,000.
National Childhood Cancer Foundation Children's Oncology Group				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Pediatrics				
Hayes, Don	3048103855	\$0.	\$2,108.	\$2,108.
Novartis A Randomized, Open-Label, Multicenter, Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Comparec to TOBI in Cystic Fibrosis Subjects				
Hayes, Don	3048103855	\$0.	\$1,822.	\$1,822.
Novartis A Randomized, Open-Label, Multicenter, Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Comparec to TOBI in Cystic Fibrosis Subjects				
Hayes, Don	3048106781	\$5,000.	\$0.	\$5,000.
Chest Foundation University of Kentucky Salvation Army Clinic				
Kanga, Jamshed F	3048087000	\$0.	\$10,300.	\$10,300.
Inspire Pharmaceuticals A Multicenter, Double-Blind, Palcebo Controlled, Randomized, Efficacy and Safety Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Patients with Mild Cystic Fibrosis Lung Disease				
Kanga, Jamshed F	3048105098	\$0.	\$55,958.	\$55,958.
Inspire Pharmaceuticals A Phase 3, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Denufosol Tetrasodium Inhalation Solution in Patients with Cystic Fibrosis Lung Disease and FEV, => 75% but =<110% Predicted				
Kanga, Jamshed F	3048105677	\$0.	\$1,200.	\$1,200.
Seattle Childrens Research Institute The EPIC Observational Study: Effectiveness and Safety of Intermittent Antimicrobial Therapy for the Treatment of New Onset Pseudomonas Aeruginosa (Pa) Airway Infection in Young Patients with Cystic Fibrosis				
Kanga, Jamshed F	3048105677	\$0.	\$840.	\$840.
Seattle Childrens Research Institute The EPIC Observational Study: Effectiveness and Safety of Intermittent Antimicrobial Therapy for the Treatment of New Onset Pseudomonas Aeruginosa (Pa) Airway Infection in Young Patients with Cystic Fibrosis				
Kanga, Jamshed F	3048105677	\$0.	\$475.	\$475.
Seattle Childrens Research Institute The EPIC Observational Study: Effectiveness and Safety of Intermittent Antimicrobial Therapy for the Treatment of New Onset Pseudomonas Aeruginosa (Pa) Airway Infection in Young Patients with Cystic Fibrosis				
Kanga, Jamshed F	3048106035	\$98,830.	\$0.	\$98,830.
Cystic Fibrosis Foundation Cystic Fibrosis Center Program				
Kanga, Jamshed F	3048106519	\$2.	\$0.	\$2.
Inspire Pharmaceuticals Study 08-114: Open-Label Extension of Study 08-110--A Multi-Center Study of Denufosol Tetrasodium Inhalation Solution in Patients with Cystic Fibrosis Lung Disease				
Kanga, Jamshed F	3048106519	\$0.	\$3,465.	\$3,465.
Inspire Pharmaceuticals Study 08-114: Open-Label Extension of Study 08-110--A Multi-Center Study of Denufosol Tetrasodium Inhalation Solution in Patients with Cystic Fibrosis Lung Disease				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Pediatrics</u>				
Kanga, Jamshed F	3048106570	\$2.	\$0.	\$2.
Vertex Pharmaceuticals Inc A Phase 3, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Pharmacokinetics, Efficacy and Safety of VX-770 in Subjects aged 6-11 with Cystic Fibrosis and the G551D Mutation				
Li, Xiangan	3048106683	\$225,227.	\$0.	\$225,227.
National Institute of General Medical Sciences ARRA: Role of SR-BI LPS detoxification				
Liu, Jun	3048106929	\$124,200.	\$0.	\$124,200.
American Diabetes Association Inc ADA Junior Faculty Award: Regulation of Adipose Lipolysis by a Novel Inhibitor				
Maguire, Grace F	3048105978	\$390,592.	\$0.	\$390,592.
KY Cabinet for Health and Family Services Medically Fragile Foster Family Practice FY10				
Moscow, Jeffrey	3048104776	\$0.	\$235.	\$235.
AAIPharma Inc An Open-Label Study to Assess the Pharmacokinetics of Leucovorin in Patients Receiving High Dose Methotrexate, with or without Voraxaze Treatment.				
Moscow, Jeffrey	3048106666	\$162,432.	\$0.	\$162,432.
KY Commission for Children with Special Health Hemophilia Treatment Center				
Moscow, Jeffrey	3048106666	\$0.	\$25,000.	\$25,000.
KY Commission for Children with Special Health Hemophilia Treatment Center				
Moscow, Jeffrey	3048106840	\$9,730.	\$0.	\$9,730.
University of North Carolina Comprehensive Diagnostic and Treatment Center				
Omar, Hatim	3048106097	\$0.	\$75,000.	\$75,000.
KY Cabinet for Health and Family Services Young Parents Program				
Omar, Hatim	3048106097	\$291,296.	\$0.	\$291,296.
KY Cabinet for Health and Family Services Young Parents Program				
Omar, Hatim	3048106316	\$100,849.	\$0.	\$100,849.
Marshall University Research Co West Virginia IDeA Network of Biomedical Research Excellence (WV-INBRE)				
Perman, Jay A	3048105239	\$0.	\$73,250.	\$73,250.
National Institute of Child Health and Human Develop Academic-Community Coalition for a School-Based Obesity Prevention/Treatment Program				
Perman, Jay A	3048105240	\$0.	\$25,000.	\$25,000.
KY Diabetes Research Trust Fund Academic-Community Coalition for a School-Based Obesity Prevention/Treatment Program				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Pediatrics</u>				
Pollack, Susan H	3048106701	\$6,000.	\$0.	\$6,000.
American Academy of Pediatrics Foster Care and Mental Health Systems				
Radulescu, Vlad	3048105260	\$0.	\$2,806.	\$2,806.
Baxter Healthcare Co A Phase I, Randomized, Crossover Study to Compare the Pharmacokinetics and Daefty of rAHF-PFM Reconstituted in 2mL versus 5mL in Previously Treated Severe Hemophilia A Patients				
Radulescu, Vlad	3048105393	\$0.	\$125.	\$125.
Novartis reGISTry				
Radulescu, Vlad	3048106058	\$0.	\$3,225.	\$3,225.
Baxter Healthcare Co Recombinant Von Willebrand Factor/Recombinant Factor VIII (rvWF:rFVIII): A Phase 1 Study Evaluating the Pharmacokinetics, Safety, and Tolerability in Type 3 Von Willebrand Disease				
Radulescu, Vlad	3048106058	\$0.	\$14,825.	\$14,825.
Baxter Healthcare Co Recombinant Von Willebrand Factor/Recombinant Factor VIII (rvWF:rFVIII): A Phase 1 Study Evaluating the Pharmacokinetics, Safety, and Tolerability in Type 3 Von Willebrand Disease				
Radulescu, Vlad	3048106058	\$0.	\$5,355.	\$5,355.
Baxter Healthcare Co Recombinant Von Willebrand Factor/Recombinant Factor VIII (rvWF:rFVIII): A Phase 1 Study Evaluating the Pharmacokinetics, Safety, and Tolerability in Type 3 Von Willebrand Disease				
Radulescu, Vlad	3048106058	\$2.	\$0.	\$2.
Baxter Healthcare Co Recombinant Von Willebrand Factor/Recombinant Factor VIII (rvWF:rFVIII): A Phase 1 Study Evaluating the Pharmacokinetics, Safety, and Tolerability in Type 3 Von Willebrand Disease				
Reynolds, Eric W	3048065500	\$0.	\$108,000.	\$108,000.
National Institute of Child Health and Human Develop Cervical (Neck) Auscultation and Development Outcomes				
Schneider, Douglas	3048106659	\$2.	\$0.	\$2.
AGA Medical Co Closure of Muscular Ventricular Septal Defects with the Amplatzer Muscular VSD Occluder--Post Approval Study (Muscular VPA)				
Schneider, Douglas	3048106659	\$0.	\$800.	\$800.
AGA Medical Co Closure of Muscular Ventricular Septal Defects with the Amplatzer Muscular VSD Occluder--Post Approval Study (Muscular VPA)				
Schneider, Douglas	3048106659	\$0.	\$1,198.	\$1,198.
AGA Medical Co Closure of Muscular Ventricular Septal Defects with the Amplatzer Muscular VSD Occluder--Post Approval Study (Muscular VPA)				
Shashidhar, Harohalli	3048106842	\$2.	\$0.	\$2.
UCB Pharma A Phase 2, Open-Label, Multicenter Study to Assess the Safety and Efficacy of Certolizumab Pegol in Children and Adolescents with Active Crohn's Disease				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Pediatrics</u>				
Smart, Eric J	3046982800	\$0.	\$355,629.	\$355,629.
National Heart Lung and Blood Institute Saturated Fatty Acid and Cardiovascular Disease				
Smart, Eric J	3048048400	\$0.	\$285,783.	\$285,783.
National Institute Diabetes & Digestive & Kidney Protective Effects of Stearic Acid on Gestational and Acquired Diabetes Mellitus				
Smith, Wilburn J	3046897200	\$0.	\$900.	\$900.
Genentech Inc Genentech National Cooperative Growth Study Post Marketing Surveillance Program for Protropin/Somatrem and Nutropin/ Somatropin				
Wallace, Carmel	3048106662	\$333,700.	\$0.	\$333,700.
KY Cabinet for Health and Family Services Pediatric Assessment, Case Management and Training				
Young, Thomas L	3048106036	\$16,000.	\$0.	\$16,000.
Lexington Fayette County Health Department Arlington Elementary School Center				
Young, Thomas L	3048106037	\$8,000.	\$0.	\$8,000.
Lexington Fayette County Health Department Tates Creek Elementary School Center				
Young, Thomas L	3048106038	\$31,200.	\$0.	\$31,200.
Lexington Fayette County Health Department Harrison Elementary School Center				
Young, Thomas L	3048106039	\$16,000.	\$0.	\$16,000.
Lexington Fayette County Health Department William Wells Brown Elementary School Center				
Pediatrics	Totals:	\$2,664,866.	\$1,127,825.	\$3,792,691.
<u>Molecular & Biomedical Pharmacology</u>				
Craven, Rolf J	3048106846	\$150,000.	\$0.	\$150,000.
KY Lung Cancer Research Fund PTEN and Akt regulation by a Novel Pathway in Lung Cancer				
Kaetzel, David M	3048058700	\$0.	\$74,250.	\$74,250.
National Cancer Institute Molecular Mechanisms of Metastasis Suppression by NM23				
Kaetzel, David M	3048058700	\$0.	\$203,946.	\$203,946.
National Cancer Institute Molecular Mechanisms of Metastasis Suppression by NM23				
Landfield, Philip W	3048106412	\$578,719.	\$0.	\$578,719.
National Institute on Aging Hippocampal Electrophysiology and Myelinogenesis in Healthy Cognitive Aging				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Molecular & Biomedical Pharmacology</u>				
Plattner, Rina	3048103677	\$0.	\$268,384.	\$268,384.
National Cancer Institute ABI kinases in growth factor signaling, motility, and invasion.				
Swanson, Hollie	3048042200	\$0.	\$260,130.	\$260,130.
National Institute of Environmental Health Sciences AHR-Protac, a Novel Aryl Hydrocarbon Receptor Antagonist				
Thibault, Olivier	3048106024	\$298,460.	\$0.	\$298,460.
National Institute on Aging Metabolic syndrome and hippocampal Ca ²⁺ dysregulation in aging-related memory decline				
Yang, Xiuwei		\$149,853.	\$0.	\$149,853.
Susan G Komen Breast Cancer Foundation Critical Role of integrin-associated CD151 in Progression of ER-negative mammary tumors				
Molecular & Biomedical Pharmacology	Totals:	\$1,177,032.	\$806,710.	\$1,983,742.
<u>Physiology</u>				
Andrade, Francisco H	3048105205	\$0.	\$412,785.	\$412,785.
National Eye Institute Determinants of Extraocular Muscle Function				
Campbell, Kenneth S	3048105039	\$0.	\$329,625.	\$329,625.
National Heart Lung and Blood Institute Myocardial Stiffness in Diastolic Heart Failure				
Campbell, Kenneth S	3048106702	\$43,000.	\$0.	\$43,000.
American Heart Association Great Rivers Affiliate Fellowship Mitov: Gender Specific mechanisms leading to elevated myocardial stiffness in type 1 diabetes				
Delisle, Brian P.	3048104549	\$0.	\$293,000.	\$293,000.
National Heart Lung and Blood Institute Delayed Rectifier K Channel Biogenesis is Unveiled in Models of Long QT Syndrome				
Delisle, Brian P.	3048105881	\$150,223.	\$0.	\$150,223.
National Heart Lung and Blood Institute ARRA: Delayed Rectifier K Channel Biogenesis is Unveiled in Models of Long QT Syndrome				
Derbenev, Andrei V.	3048105438	\$0.	\$-124,362.	\$-124,362.
National Heart Lung and Blood Institute Regulation of presympathetic RVLM neurons by cannabinoids				
Esser, Karyn A	3048102201	\$0.	\$301,456.	\$301,456.
National Institute Arthritis Musculoskeletal & Skin Intracellular Signaling during Skeletal Muscle Hypertrophy				
Esser, Karyn A	3048104593	\$0.	\$327,389.	\$327,389.
National Institute Arthritis Musculoskeletal & Skin Circadian Rhythms and Skeletal Muscle				
Esser, Karyn A	3048104593	\$0.	\$19,857.	\$19,857.
National Institute Arthritis Musculoskeletal & Skin Circadian Rhythms and Skeletal Muscle				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Physiology				
Esser, Karyn A	3048105059	\$0.	\$-45,000.	\$-45,000.
American Heart Association Great Rivers Affiliate Fellowship Miyazaki: Hypertension, Skeletal Muscle Disease and the Circadian Clock				
Esser, Karyn A	3048105059	\$0.	\$45,000.	\$45,000.
American Heart Association Great Rivers Affiliate Fellowship Miyazaki: Hypertension, Skeletal Muscle Disease and the Circadian Clock				
Esser, Karyn A	3048106557	\$297,000.	\$0.	\$297,000.
National Institute Arthritis Musculoskeletal & Skin ARRA: Intracellular signaling during skeletal muscle hypertrophy				
Esser, Karyn A	3048106558	\$500,000.	\$0.	\$500,000.
National Institute of Environmental Health Sciences ARRA:Clock genes, environmental challenges and cardiopulmonary disease				
Esser, Karyn A	3048106736	\$45,000.	\$0.	\$45,000.
American Heart Association Great Rivers Affiliate Fellowship Miyazaki: Hypertension, Skeletal Muscle Disease and the Circadian Clock				
Estus, George Steven	3048032100	\$0.	\$-137,668.	\$-137,668.
National Institute on Aging LDLR Genetics, Splicing and AD Risk				
Estus, George Steven	3048032100	\$0.	\$137,668.	\$137,668.
National Institute on Aging LDLR Genetics, Splicing and AD Risk				
Estus, George Steven	3048032100	\$0.	\$137,668.	\$137,668.
National Institute on Aging LDLR Genetics, Splicing and AD Risk				
Estus, George Steven	3048106839	\$212,355.	\$0.	\$212,355.
University of Illinois Apolipoprotein E Receptor Biology and Neurodegeneration				
Frazier, Donald T	3048106583	\$379,596.	\$0.	\$379,596.
National Institute of General Medical Sciences Interactive Learning Modules for Writing Grant Proposals				
Frolenkov, Gregory I	3048105300	\$0.	\$296,663.	\$296,663.
National Institute on Deafness & Other Communications Role of Staircase Hair Bundle Morphology in Auditory Mechanotransduction				
Frolenkov, Gregory I	3048105300	\$0.	\$29,666.	\$29,666.
National Institute on Deafness & Other Communications Role of Staircase Hair Bundle Morphology in Auditory Mechanotransduction				
Frolenkov, Gregory I	3048105618	\$0.	\$277,380.	\$277,380.
National Institute on Deafness & Other Communications Regulation of outer hair cell electromotility and noise-induced hearing loss				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Physiology				
Frolenkov, Gregory I	3048105905	\$180,694.	\$0.	\$180,694.
National Institute on Deafness & Other Communications ARRA: Role of Staircase Hair Bundle Morphology in Auditory Mechanotransduction				
Frolenkov, Gregory I	3048106934	\$63,113.	\$0.	\$63,113.
University of Michigan Myosin 15:Genetics, Pathology, and Therapeutic Potential				
Gong, Ming Cui	3048032700	\$0.	\$320,066.	\$320,066.
National Heart Lung and Blood Institute Vascular Smooth Muscle Hyper-Contractility and Hypertension in Type-II-Diabetes				
Gong, Ming Cui	3048106579	\$23,000.	\$0.	\$23,000.
American Heart Association Great Rivers Affiliate Fellowship Calderon: The role calcium-independent phospholipase A2-and microRNA-1 in AngII-induced vascular remodeling and inflammation.				
Gu, Qihai	3048105048	\$0.	\$73,250.	\$73,250.
National Institute of Allergy and Infectious Diseases PAR2, Bronchopulmonary Sensory Nerve and Pathogenesis of Asthma				
Gu, Qihai	3048106567	\$77,000.	\$0.	\$77,000.
American Heart Association Modulation of Acid Sensing in Pulmonary C-Fiber Sensory Nerves by Protease-activated Receptor-2				
High, Karin W.	3048103002	\$0.	\$56,000.	\$56,000.
National Institute of Neurological Disorders & Stroke Neurogenic Amplification of Pancreatitis Pain				
High, Karin W.	3048103002	\$0.	\$-56,000.	\$-56,000.
National Institute of Neurological Disorders & Stroke Neurogenic Amplification of Pancreatitis Pain				
High, Karin W.	3048105906	\$10,443.	\$0.	\$10,443.
National Institute of Neurological Disorders & Stroke ARRA: Neurogenic Amplification of Pancreatitis Pain				
Lee, Lu Yuan	3048106504	\$346,081.	\$0.	\$346,081.
National Heart Lung and Blood Institute ARRA: Role of TRPV1 in Airway Hypersensitivity Induced by Inflammation				
McCarthy, John J	3048103202	\$0.	\$71,785.	\$71,785.
National Institute Arthritis Musculoskeletal & Skin Circadian Regulation of Myod 1 Transcription				
McClintock, Timothy S	3046977300	\$0.	\$326,631.	\$326,631.
National Institute on Deafness & Other Communications Genomics of Olfactory Regeneration				
McClintock, Timothy S	3048032400	\$0.	\$317,567.	\$317,567.
National Institute on Deafness & Other Communications Functional Domains and Expression of Olfactory Receptors				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Physiology				
McClintock, Timothy S	3048105707	\$185,625.	\$0.	\$185,625.
National Institute on Deafness & Other Communications ARRA: Olfactory Support Cells				
McClintock, Timothy S	3048105890	\$153,308.	\$0.	\$153,308.
National Institute on Deafness & Other Communications ARRA: Functional Domains and Expression of Olfactory Receptors				
McClintock, Timothy S	3048105943	\$74,852.	\$0.	\$74,852.
National Institute on Deafness & Other Communications ARRA: Genomics of Olfactory Regeneration				
Nikolova-Karakashian, Mariana	3048106632	\$377,290.	\$0.	\$377,290.
National Institute on Aging Ceramide and acute phase protein elevation during aging				
Randall, David C	3048106797	\$155,949.	\$0.	\$155,949.
National Heart Lung and Blood Institute NRSA T32: Interdisciplinary Cardiovascular Training Program				
Reid, Michael B	3048105851	\$149,823.	\$0.	\$149,823.
National Heart Lung and Blood Institute NRSA T32: Research Training in Muscle Biology of Cardiopulmonary System				
Reid, Michael B	3048106703	\$23,000.	\$0.	\$23,000.
American Heart Association Great Rivers Affiliate Fellowship Gilliam: Intracellular mechanisms of doxorubicin-induced respiratory muscle dysfunction				
Reid, Michael B	3048106704	\$47,000.	\$0.	\$47,000.
American Heart Association Great Rivers Affiliate Fellowship Leonardo Ferreira: Mechanisms of diaphragm weakness caused by sphingomyelinase activation				
Satin, Jonathan	3048105528	\$0.	\$204.	\$204.
National Heart Lung and Blood Institute Fellowship William Lester: L-Type Calcium Entry Triggered Diastolic Sparks				
Smith, Bret N.	3048105496	\$0.	\$316,440.	\$316,440.
National Institute Diabetes & Digestive & Kidney Glucocorticoids and endocannabinoids in vagal complex				
Smith, Bret N.	3048105496	\$0.	\$31,644.	\$31,644.
National Institute Diabetes & Digestive & Kidney Glucocorticoids and endocannabinoids in vagal complex				
Smith, Bret N.	3048106409	\$354,000.	\$0.	\$354,000.
National Institute Diabetes & Digestive & Kidney Neural circuitry in the dorsal vagal complex				
Snyder, Carol T	3048104856	\$0.	\$137,500.	\$137,500.
KY Council on Postsecondary Education Professional Education Preparation Program (PEPP)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Physiology</u>				
Snyder, Carol T	3048104856	\$0.	\$25,500.	\$25,500.
KY Council on Postsecondary Education Professional Education Preparation Program (PEPP)				
Stocker, Sean D	3048105094	\$0.	\$21,000.	\$21,000.
American Heart Association Great Rivers Affiliate Fellowship Bardgett: Neural Mechanisms of Sympathetic Activation During Hyperinsulinemia and Obesity-Induced Hypertension				
Taylor, Bradley Kenneth	3048105490	\$0.	\$123,298.	\$123,298.
National Institute on Drug Abuse Neuropeptidergic Inhibition of Spinal Pain Transmission				
Taylor, Bradley Kenneth	3048105684	\$0.	\$29,237.	\$29,237.
National Institute of Neurological Disorders & Stroke PPAR Inhibition of Spinal Pain Transmission				
Taylor, Bradley Kenneth	3048105684	\$0.	\$292,359.	\$292,359.
National Institute of Neurological Disorders & Stroke PPAR Inhibition of Spinal Pain Transmission				
Taylor, Bradley Kenneth	3048106907	\$26,976.	\$0.	\$26,976.
National Institute of Neurological Disorders & Stroke Fellowship for Solway: Contribution of endogenous NPY signaling to chronic pain				
Wilson, Melinda E	3048105730	\$591,929.	\$0.	\$591,929.
National Science Foundation ARRA: Developmental regulation of estrogen receptor alpha by spigenetic modification				
Physiology	Totals:	\$4,467,257.	\$4,387,608.	\$8,854,865.
<u>Psychiatry</u>				
Brenzel, Allen J	3048106779	\$162,216.	\$0.	\$162,216.
Eastern KY University UTC Title IV-E/Title IV-E Admin Basic Child Abuse and Neglect				
Carvalho, Cletus Savio	3048011800	\$0.	\$-15,719.	\$-15,719.
Bristol Myers Squibb Company A Multicenter, Double-Blind, Study on the Efficacy and Safety of Aripiprazole in Combination				
Carvalho, Cletus Savio	3048011800	\$0.	\$4,410.	\$4,410.
Bristol Myers Squibb Company A Multicenter, Double-Blind, Study on the Efficacy and Safety of Aripiprazole in Combination				
Carvalho, Cletus Savio	3048011800	\$0.	\$12,309.	\$12,309.
Bristol Myers Squibb Company A Multicenter, Double-Blind, Study on the Efficacy and Safety of Aripiprazole in Combination				
Glaser, Paul E	3048103808	\$0.	\$11,738.	\$11,738.
Eli Lilly and Company A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Psychiatry				
Glaser, Paul E	3048103808	\$0.	\$2,150.	\$2,150.
Eli Lilly and Company A Double Blind Study of Atomoxetine Hydrochloride vs. Placebo for the Treatment of ADHA in Young Adults with an Assessment of Associated Functional Outcomes				
Glaser, Paul E	3048105960	\$0.	\$4,742.	\$4,742.
Eli Lilly and Company A Long Term OPen Label Safety Study of Oral Olanzapine in Adolescents with Bipolar I Disporder (Manic or Mixed Episodes) or Schizophrenia				
Glaser, Paul E	3048105960	\$0.	\$63.	\$63.
Eli Lilly and Company A Long Term OPen Label Safety Study of Oral Olanzapine in Adolescents with Bipolar I Disporder (Manic or Mixed Episodes) or Schizophrenia				
Glaser, Paul E	3048105960	\$0.	\$252.	\$252.
Eli Lilly and Company A Long Term OPen Label Safety Study of Oral Olanzapine in Adolescents with Bipolar I Disporder (Manic or Mixed Episodes) or Schizophrenia				
Glaser, Paul E	3048105960	\$0.	\$126.	\$126.
Eli Lilly and Company A Long Term OPen Label Safety Study of Oral Olanzapine in Adolescents with Bipolar I Disporder (Manic or Mixed Episodes) or Schizophrenia				
Glaser, Paul E	3048105960	\$0.	\$-4,468.	\$-4,468.
Eli Lilly and Company A Long Term OPen Label Safety Study of Oral Olanzapine in Adolescents with Bipolar I Disporder (Manic or Mixed Episodes) or Schizophrenia				
Glaser, Paul E	3048105960	\$0.	\$4,468.	\$4,468.
Eli Lilly and Company A Long Term OPen Label Safety Study of Oral Olanzapine in Adolescents with Bipolar I Disporder (Manic or Mixed Episodes) or Schizophrenia				
Glaser, Paul E	3048105960	\$0.	\$4,410.	\$4,410.
Eli Lilly and Company A Long Term OPen Label Safety Study of Oral Olanzapine in Adolescents with Bipolar I Disporder (Manic or Mixed Episodes) or Schizophrenia				
Glaser, Paul E	3048105960	\$2.	\$0.	\$2.
Eli Lilly and Company A Long Term OPen Label Safety Study of Oral Olanzapine in Adolescents with Bipolar I Disporder (Manic or Mixed Episodes) or Schizophrenia				
Glaser, Paul E	3048105961	\$0.	\$3,465.	\$3,465.
Eli Lilly and Company A Double Blind Study Placebo Controlled Studyof Atomoxetine Hydrochloride for the Treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents with ADHD and Comorbid Dyslexia				
Glaser, Paul E	3048105961	\$0.	\$63.	\$63.
Eli Lilly and Company A Double Blind Study Placebo Controlled Studyof Atomoxetine Hydrochloride for the Treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents with ADHD and Comorbid Dyslexia				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Psychiatry				
Glaser, Paul E	3048105961	\$0.	\$2,518.	\$2,518.
Eli Lilly and Company A Double Blind Study Placebo Controlled Studyof Atomoxetine Hydrochloride for the Treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents with ADHD and Comorbid Dyslexia				
Glaser, Paul E	3048105961	\$0.	\$2,650.	\$2,650.
Eli Lilly and Company A Double Blind Study Placebo Controlled Studyof Atomoxetine Hydrochloride for the Treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents with ADHD and Comorbid Dyslexia				
Glaser, Paul E	3048105961	\$0.	\$5,227.	\$5,227.
Eli Lilly and Company A Double Blind Study Placebo Controlled Studyof Atomoxetine Hydrochloride for the Treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents with ADHD and Comorbid Dyslexia				
Glaser, Paul E	3048105961	\$0.	\$4,998.	\$4,998.
Eli Lilly and Company A Double Blind Study Placebo Controlled Studyof Atomoxetine Hydrochloride for the Treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents with ADHD and Comorbid Dyslexia				
Glaser, Paul E	3048105961	\$0.	\$1,761.	\$1,761.
Eli Lilly and Company A Double Blind Study Placebo Controlled Studyof Atomoxetine Hydrochloride for the Treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents with ADHD and Comorbid Dyslexia				
Glaser, Paul E	3048105961	\$0.	\$672.	\$672.
Eli Lilly and Company A Double Blind Study Placebo Controlled Studyof Atomoxetine Hydrochloride for the Treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents with ADHD and Comorbid Dyslexia				
Glaser, Paul E	3048105961	\$0.	\$4,470.	\$4,470.
Eli Lilly and Company A Double Blind Study Placebo Controlled Studyof Atomoxetine Hydrochloride for the Treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents with ADHD and Comorbid Dyslexia				
Glaser, Paul E	3048105961	\$0.	\$1,008.	\$1,008.
Eli Lilly and Company A Double Blind Study Placebo Controlled Studyof Atomoxetine Hydrochloride for the Treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents with ADHD and Comorbid Dyslexia				
Glaser, Paul E	3048105961	\$0.	\$-5.	\$-5.
Eli Lilly and Company A Double Blind Study Placebo Controlled Studyof Atomoxetine Hydrochloride for the Treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents with ADHD and Comorbid Dyslexia				
Glaser, Paul E	3048105961	\$0.	\$68.	\$68.
Eli Lilly and Company A Double Blind Study Placebo Controlled Studyof Atomoxetine Hydrochloride for the Treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents with ADHD and Comorbid Dyslexia				
Glaser, Paul E	3048105961	\$0.	\$-2,650.	\$-2,650.
Eli Lilly and Company A Double Blind Study Placebo Controlled Studyof Atomoxetine Hydrochloride for the Treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents with ADHD and Comorbid Dyslexia				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Psychiatry</u>				
Glaser, Paul E	3048105961	\$2.	\$0.	\$2.
Eli Lilly and Company A Double Blind Study Placebo Controlled Study of Atomoxetine Hydrochloride for the Treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents with ADHD and Comorbid Dyslexia				
Kaak, Hans O	3048106686	\$10,000.	\$0.	\$10,000.
KY Cabinet for Health and Family Services UK CATS Project SJPC: Early Mental Health Training				
Lofwall, Michelle Renee	3048103695	\$0.	\$125.	\$125.
CRS Associates LLC Product Familiarity Interview: Post marketing Surveillance Project for Subutex and Suboxone				
Lofwall, Michelle Renee	3048106091	\$371,250.	\$0.	\$371,250.
National Institute on Drug Abuse Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal				
Martin, Catherine A	3048104416	\$0.	\$1,166.	\$1,166.
Yaupon Therapeutics Inc SBIR: Lobeline Clinical Study in ADHD				
Psychiatry	Totals:	\$543,470.	\$50,017.	\$593,487.
<u>Surgery</u>				
Bernard, Andrew C	3048104408	\$0.	\$3,771.	\$3,771.
AstraZeneca Pharmaceuticals A Placebo-Controlled, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients with Severe Sepsis				
Bernard, Andrew C	3048104408	\$0.	\$11,498.	\$11,498.
AstraZeneca Pharmaceuticals A Placebo-Controlled, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients with Severe Sepsis				
Bernard, Andrew C	3048104408	\$0.	\$10,044.	\$10,044.
AstraZeneca Pharmaceuticals A Placebo-Controlled, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients with Severe Sepsis				
Bernard, Andrew C	3048104408	\$0.	\$4,000.	\$4,000.
AstraZeneca Pharmaceuticals A Placebo-Controlled, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients with Severe Sepsis				
Bernard, Andrew C	3048104408	\$0.	\$17,916.	\$17,916.
AstraZeneca Pharmaceuticals A Placebo-Controlled, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients with Severe Sepsis				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Surgery				
Bernard, Andrew C	3048104408	\$0.	\$-7,362.	\$-7,362.
AstraZeneca Pharmaceuticals A Placebo-Controlled, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients with Severe Sepsis				
Bernard, Andrew C	3048104408	\$0.	\$7,362.	\$7,362.
AstraZeneca Pharmaceuticals A Placebo-Controlled, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients with Severe Sepsis				
Bernard, Andrew C	3048104408	\$0.	\$2,000.	\$2,000.
AstraZeneca Pharmaceuticals A Placebo-Controlled, Double-Blind, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous Infusions of CytoFab (AZD9773) in Patients with Severe Sepsis				
Bernard, Andrew C	3048105127	\$0.	\$4,230.	\$4,230.
Pfizer Inc Prospective Evaluation of Sputum Staphylococcus Aureus Resistance Patterns				
Bonnell, Mark	3048105264	\$0.	\$630.	\$630.
Levitronix LLC Levitronix CentriMag VAS Failure-to-Wean from Cardiopulmonary Bypass Trial				
Chang, Phillip K	3048105310	\$0.	\$4,755.	\$4,755.
Canica Design Inc A Prospective Evaluation of ABRA Abdominal Wall Closure System in Combination with V.A.C. Therapy Compared V.A.C. Therapy Alone in the Management of Open Abdomen				
Chang, Phillip K	3048105762	\$0.	\$5,778.	\$5,778.
Takeda Pharmaceuticals North America Inc Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of TAK-242 vs. Placebo in Subjects with Sepsis Induced Cardiovascular and Respiratory Failure. Protocol No. TAK-242-301				
Chang, Phillip K	3048106626	\$2.	\$0.	\$2.
GlaxoSmithKline A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Anti-Inflammatory Activity, Efficacy, and Safety of Intravenous SB-681323 in Subjects at Risk for Development of Acute Lung Injury or ARDS				
Endean, Eric D	3048106531	\$1,183.	\$0.	\$1,183.
Blue Grass Community Fdtn Jane Keeble Resident Education Fund				
Ferraris, Victor	3048105521	\$0.	\$-3,780.	\$-3,780.
Dyax Corp KALAHARI 1: Kallikrein Antagonist (DX-88 Ecallantide) Effect on Blood Loss Associated w/Heart Surgery Requiring Institution of Bypass, Amendment 2 DX-88/16				
Gedaly, Roberto	3046944500	\$0.	\$20,580.	\$20,580.
Novartis A 24-month, Multicenter, Randomized, Open Label Non-Inferiority Study of Efficacy and Safety Comparing Concentration Controlled Certican in Two Doses (1.5 and 3.0mg/day starting doses) with Reduced Neoral versus 1.44 Myfortic with Standard Dose Neoral				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Surgery</u>				
Gedaly, Roberto	3046944500	\$0.	\$9,016.	\$9,016.
Novartis A 24-month, Multicenter, Randomized, Open Label Non-Inferiority Study of Efficacy and Safety Comparing Concentration Controlled Certican in Two Doses (1.5 and 3.0mg/day starting doses) with Reduced Neoral versus 1.44 Myfortic with Standard Dose Neoral				
Gedaly, Roberto	3046944500	\$0.	\$38,564.	\$38,564.
Novartis A 24-month, Multicenter, Randomized, Open Label Non-Inferiority Study of Efficacy and Safety Comparing Concentration Controlled Certican in Two Doses (1.5 and 3.0mg/day starting doses) with Reduced Neoral versus 1.44 Myfortic with Standard Dose Neoral				
Gedaly, Roberto	3048104407	\$0.	\$1,692.	\$1,692.
Wyeth Pharmaceuticals Inc A Randomized, Placebo Controlled, Double-Blind Comparative Study Evaluating the Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus				
Gedaly, Roberto	3048104407	\$0.	\$7,494.	\$7,494.
Wyeth Pharmaceuticals Inc A Randomized, Placebo Controlled, Double-Blind Comparative Study Evaluating the Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus				
Gedaly, Roberto	3048104407	\$0.	\$18,783.	\$18,783.
Wyeth Pharmaceuticals Inc A Randomized, Placebo Controlled, Double-Blind Comparative Study Evaluating the Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus				
Gedaly, Roberto	3048104532	\$0.	\$2,452.	\$2,452.
Novartis A Facilitated Access Program to Provide Everolimus (RAD) for Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation				
Gedaly, Roberto	3048105361	\$0.	\$30,926.	\$30,926.
Novartis A 24 Month, Multi-Center, Open-Label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Concentration-Controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de novo Liver Transplant Recipients				
Gedaly, Roberto	3048106625	\$0.	\$-2.	\$-2.
Wyeth Pharmaceuticals Inc Planned Transition to Sirolimus-Based Therapy vs. Continued Tacrolimus-Based Therapy in Renal Allograft Recipients				
Gedaly, Roberto	3048106625	\$0.	\$5,205.	\$5,205.
Wyeth Pharmaceuticals Inc Planned Transition to Sirolimus-Based Therapy vs. Continued Tacrolimus-Based Therapy in Renal Allograft Recipients				
Gedaly, Roberto	3048106625	\$2.	\$0.	\$2.
Wyeth Pharmaceuticals Inc Planned Transition to Sirolimus-Based Therapy vs. Continued Tacrolimus-Based Therapy in Renal Allograft Recipients				
Jeon, Hoonbae	3048103203	\$0.	\$806.	\$806.
Albert Einstein College of Medicine Cellcept (Mycophenolate Mofetil, MMF) Maintenance Immunosuppression in Liver Transplant Recipients with Long-Term Follow-up Post-Transplantation for Non Autoimmune				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Surgery				
Jeon, Hoonbae	3048103203	\$0.	\$13,514.	\$13,514.
Albert Einstein College of Medicine Cellcept (Mycophenolate Mofetil, MMF) Maintenance Immunosuppression in Liver Transplant Recipients with Long-Term Follow-up Post-Transplantation for Non Autoimmune				
Johnston, Thomas	3048064300	\$0.	\$795.	\$795.
Bristol Myers Squibb Company Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENEFIT) BMS IM103008				
Johnston, Thomas	3048104315	\$0.	\$-603.	\$-603.
Bristol Myers Squibb Company A Randomized, Open-Label, Multicenter, Parallel-Group Study of Belatacept-Based Corticosteroid-Free Regimens in Renal Transplant				
Johnston, Thomas	3048104407	\$0.	\$1,865.	\$1,865.
Wyeth Pharmaceuticals Inc A Randomized, Placebo Controlled, Double-Blind Comparative Study Evaluating the Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus				
Johnston, Thomas	3048104407	\$0.	\$4,421.	\$4,421.
Wyeth Pharmaceuticals Inc A Randomized, Placebo Controlled, Double-Blind Comparative Study Evaluating the Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus				
Johnston, Thomas	3048104407	\$0.	\$7,362.	\$7,362.
Wyeth Pharmaceuticals Inc A Randomized, Placebo Controlled, Double-Blind Comparative Study Evaluating the Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus				
Johnston, Thomas	3048104532	\$0.	\$3,193.	\$3,193.
Novartis A Facilitated Access Program to Provide Everolimus (RAD) for Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation				
Kearney, Paul A	3046969400	\$0.	\$21,359.	\$21,359.
Pfizer Inc Linezolid in the Treatment of Subjects iwth Nosocomial Pneumonia Proven to be due to Methicillin-Resistant Staphylococcus Aureus				
Kearney, Paul A	3046969400	\$0.	\$3,670.	\$3,670.
Pfizer Inc Linezolid in the Treatment of Subjects iwth Nosocomial Pneumonia Proven to be due to Methicillin-Resistant Staphylococcus Aureus				
Kearney, Paul A	3046969400	\$0.	\$37,291.	\$37,291.
Pfizer Inc Linezolid in the Treatment of Subjects iwth Nosocomial Pneumonia Proven to be due to Methicillin-Resistant Staphylococcus Aureus				
Kearney, Paul A	3048104280	\$0.	\$992.	\$992.
Wyeth Pharmaceuticals Inc A Multicenter, Randomized, Double-Blind, Placebo Controlled, Paralledl-Group Study of Intravenous Methylnaltrexone (MOA-728) for the Treatment of Postoperative Ileus After Ventral Hernia Repair				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Surgery				
Kearney, Paul A	3048104280	\$0.	\$10,699.	\$10,699.
Wyeth Pharmaceuticals Inc A Multicenter, Randomized, Double-Blind, Placebo Controlled, Paralledl-Group Study of Intravenous Methylnaltrexone (MOA-728) for the Treatment of Postoperative Ileus After Ventral Hernia Repair				
Kenady, Daniel E	3046440200	\$0.	\$756.	\$756.
GenVec Inc GV 001.002.An Open-Label, Phase I, Dose-Escalation Study of Tumor Necrosis Factor-alpha (TNFerade Biologic) Gene Therapy with Radiaton for Locally Advanced, Recurrent or Metastatic Solid Tumors				
Kenady, Daniel E	3046440200	\$0.	\$3,213.	\$3,213.
GenVec Inc GV 001.002.An Open-Label, Phase I, Dose-Escalation Study of Tumor Necrosis Factor-alpha (TNFerade Biologic) Gene Therapy with Radiaton for Locally Advanced, Recurrent or Metastatic Solid Tumors				
Kenady, Daniel E	3046440200	\$0.	\$3,150.	\$3,150.
GenVec Inc GV 001.002.An Open-Label, Phase I, Dose-Escalation Study of Tumor Necrosis Factor-alpha (TNFerade Biologic) Gene Therapy with Radiaton for Locally Advanced, Recurrent or Metastatic Solid Tumors				
Kenady, Daniel E	3046561400	\$0.	\$756.	\$756.
GenVec Inc An Open Label Phase 1 Dose-Escalation Study of TNFerade Biologic with Radation Therapy as an Adjunct to Surgery or for Palliation in Soft Tissue Sarcoma of the Extremities				
Kenady, Daniel E	3046561400	\$0.	\$3,213.	\$3,213.
GenVec Inc An Open Label Phase 1 Dose-Escalation Study of TNFerade Biologic with Radation Therapy as an Adjunct to Surgery or for Palliation in Soft Tissue Sarcoma of the Extremities				
Kenady, Daniel E	3046561400	\$0.	\$3,150.	\$3,150.
GenVec Inc An Open Label Phase 1 Dose-Escalation Study of TNFerade Biologic with Radation Therapy as an Adjunct to Surgery or for Palliation in Soft Tissue Sarcoma of the Extremities				
Kenady, Daniel E	3046633200	\$0.	\$327.	\$327.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
Kenady, Daniel E	3046633200	\$0.	\$50.	\$50.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
Kenady, Daniel E	3046633200	\$0.	\$50.	\$50.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				
Kenady, Daniel E	3046633200	\$0.	\$532.	\$532.
GenVec Inc A Randomized, Phase II, Study of TNFerade Biologic with-5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Surgery				
Kenady, Daniel E	3046919900	\$0.	\$630.	\$630.
IRx Therapeutics Inc A Phase 2, Open Label Trial of the Safety and Biological Effect of Pre-Operative Peri-Lymphatic Ultralow Dose of IRX-2 (with Cyclophosphamide, Indomethacin, and Zinc) in Patients with Locally Advanced, Resectable Cancer of the Head and Neck				
McKeown, John W	3046972800	\$0.	\$2,328.	\$2,328.
Isotechnika Inc A Phase IIb, Randomized, Multicenter, Open-Label, Concentration-Controlled, Safety Study of ISA247 and Tacrolimus (Prograf) in De Novo Renal Transplant Patients				
McKeown, John W	3046972800	\$0.	\$630.	\$630.
Isotechnika Inc A Phase IIb, Randomized, Multicenter, Open-Label, Concentration-Controlled, Safety Study of ISA247 and Tacrolimus (Prograf) in De Novo Renal Transplant Patients				
Mullett, Timothy	3048104442	\$0.	\$630.	\$630.
Fresenius Biotech North America Protocol EZ-2053-001: A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-T Lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary				
Mullett, Timothy	3048105640	\$0.	\$1,890.	\$1,890.
Covidien A Prospective Multi-Center Randomized clinical study to Evaluate the PleuraSeal Sealant System as an Adjunct to Standard Closure Techniques for Control of Visceral Pleural Air Leaks Following Elective Pulmonary Resection Via Open Thoracotomy				
Mullett, Timothy	3048105640	\$0.	\$6,928.	\$6,928.
Covidien A Prospective Multi-Center Randomized clinical study to Evaluate the PleuraSeal Sealant System as an Adjunct to Standard Closure Techniques for Control of Visceral Pleural Air Leaks Following Elective Pulmonary Resection Via Open Thoracotomy				
Ramaiah, Chandrashekhar	3048105082	\$0.	\$630.	\$630.
IFlow Corp Multicenter Infection Surveillance Study Following Cardiac Surgical Procedures				
Ramaiah, Chandrashekhar	3048105082	\$0.	\$3,750.	\$3,750.
IFlow Corp Multicenter Infection Surveillance Study Following Cardiac Surgical Procedures				
Ramaiah, Chandrashekhar	3048105082	\$0.	\$-2,000.	\$-2,000.
IFlow Corp Multicenter Infection Surveillance Study Following Cardiac Surgical Procedures				
Ramaiah, Chandrashekhar	3048105082	\$0.	\$2,046.	\$2,046.
IFlow Corp Multicenter Infection Surveillance Study Following Cardiac Surgical Procedures				
Ramaiah, Chandrashekhar	3048105082	\$0.	\$5,750.	\$5,750.
IFlow Corp Multicenter Infection Surveillance Study Following Cardiac Surgical Procedures				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Surgery</u>				
Ramaiah, Chandrashekhar	3048105352	\$0.	\$340.	\$340.
Merck and Company Inc A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity and Safety of a Single Dose of Merck 0657nl Staphylococcus Aureus Vaccine V710 in Adult Patients Scheduled for Cardiothoracic Surgery				
Ramaiah, Chandrashekhar	3048105352	\$0.	\$14,704.	\$14,704.
Merck and Company Inc A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity and Safety of a Single Dose of Merck 0657nl Staphylococcus Aureus Vaccine V710 in Adult Patients Scheduled for Cardiothoracic Surgery				
Ramaiah, Chandrashekhar	3048105352	\$0.	\$21,606.	\$21,606.
Merck and Company Inc A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity and Safety of a Single Dose of Merck 0657nl Staphylococcus Aureus Vaccine V710 in Adult Patients Scheduled for Cardiothoracic Surgery				
Ramaiah, Chandrashekhar	3048105352	\$0.	\$23,054.	\$23,054.
Merck and Company Inc A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity and Safety of a Single Dose of Merck 0657nl Staphylococcus Aureus Vaccine V710 in Adult Patients Scheduled for Cardiothoracic Surgery				
Ramaiah, Chandrashekhar	3048105686	\$0.	\$14,965.	\$14,965.
Cubist Pharmaceuticals Inc A Clinical Outcomes and Safety Trial in Investigate Ecallantide's Effect on Reducing Surgical Blood Loss Volume				
Ramaiah, Chandrashekhar	3048105686	\$0.	\$15,154.	\$15,154.
Cubist Pharmaceuticals Inc A Clinical Outcomes and Safety Trial in Investigate Ecallantide's Effect on Reducing Surgical Blood Loss Volume				
Ramaiah, Chandrashekhar	3048105686	\$0.	\$6,613.	\$6,613.
Cubist Pharmaceuticals Inc A Clinical Outcomes and Safety Trial in Investigate Ecallantide's Effect on Reducing Surgical Blood Loss Volume				
Ramaiah, Chandrashekhar	3048105953	\$0.	\$5,544.	\$5,544.
Schering Co The Effect of Acadesine on Clinically Significant Adverse Cardiovascular and Cerebrovascular Events in High-Risk Subjects Undergoing Coronary Artery Bypass Graft (CABG) Surgery Using Cardiopulmonary Bypass (RED-CABG Trial)				
Ramaiah, Chandrashekhar	3048105953	\$0.	\$13,464.	\$13,464.
Schering Co The Effect of Acadesine on Clinically Significant Adverse Cardiovascular and Cerebrovascular Events in High-Risk Subjects Undergoing Coronary Artery Bypass Graft (CABG) Surgery Using Cardiopulmonary Bypass (RED-CABG Trial)				
Ramaiah, Chandrashekhar	3048105953	\$0.	\$5,355.	\$5,355.
Schering Co The Effect of Acadesine on Clinically Significant Adverse Cardiovascular and Cerebrovascular Events in High-Risk Subjects Undergoing Coronary Artery Bypass Graft (CABG) Surgery Using Cardiopulmonary Bypass (RED-CABG Trial)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Surgery				
Ramaiah, Chandrashekhar	3048105953	\$2.	\$0.	\$2.
Schering Co The Effect of Acadesine on Clinically Significant Adverse Cardiovascular and Cerebrovascular Events in High-Risk Subjects Undergoing Coronary Artery Bypass Graft (CABG) Surgery Using Cardiopulmonary Bypass (RED-CABG Trial)				
Ramaiah, Chandrashekhar	3048106031	\$0.	\$7,861.	\$7,861.
Medicines Company Maintenance of Platelet Inhibition with Cangrelor After Discontinuation of Thienopyridines in Patients Undergoing Surgery: The BRIDGE Study				
Ramaiah, Chandrashekhar	3048106031	\$0.	\$3,146.	\$3,146.
Medicines Company Maintenance of Platelet Inhibition with Cangrelor After Discontinuation of Thienopyridines in Patients Undergoing Surgery: The BRIDGE Study				
Ramaiah, Chandrashekhar	3048106031	\$0.	\$5,353.	\$5,353.
Medicines Company Maintenance of Platelet Inhibition with Cangrelor After Discontinuation of Thienopyridines in Patients Undergoing Surgery: The BRIDGE Study				
Ramaiah, Chandrashekhar	3048106031	\$2.	\$0.	\$2.
Medicines Company Maintenance of Platelet Inhibition with Cangrelor After Discontinuation of Thienopyridines in Patients Undergoing Surgery: The BRIDGE Study				
Ranjan, Dinesh	3046639300	\$0.	\$81,355.	\$81,355.
Wyeth Pharmaceuticals Inc A Randomized, Open-Label, Comparative evaluation of Conversion from Calcineurin Inhibitor Treatment to Sirolimus Treatment vs. Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing Maintenance Therapy				
Ranjan, Dinesh	3048103804	\$0.	\$693.	\$693.
ViroPharma Inc A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir Versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants				
Ranjan, Dinesh	3048103804	\$0.	\$3,906.	\$3,906.
ViroPharma Inc A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir Versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants				
Ranjan, Dinesh	3048103804	\$0.	\$2,912.	\$2,912.
ViroPharma Inc A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir Versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants				
Ranjan, Dinesh	3048103804	\$0.	\$12,019.	\$12,019.
ViroPharma Inc A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir Versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants				
Ranjan, Dinesh	3048103804	\$0.	\$1,701.	\$1,701.
ViroPharma Inc A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir Versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Surgery</u>				
Ranjan, Dinesh	3048103804	\$0.	\$1,533.	\$1,533.
ViroPharma Inc A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir Versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants				
Ranjan, Dinesh	3048105361	\$0.	\$1,100.	\$1,100.
Novartis A 24 Month, Multi-Center, Open-Label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Concentration-Controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de novo Liver Transplant Recipients				
Ranjan, Dinesh	3048105361	\$0.	\$5,353.	\$5,353.
Novartis A 24 Month, Multi-Center, Open-Label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Concentration-Controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de novo Liver Transplant Recipients				
Ranjan, Dinesh	3048105361	\$0.	\$9,138.	\$9,138.
Novartis A 24 Month, Multi-Center, Open-Label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Concentration-Controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de novo Liver Transplant Recipients				
Rinker, Brian	3048106569	\$44,377.	\$0.	\$44,377.
Genzyme Corp An Evaluation of the Relative Adhesion Reduction Efficacy of HA Based Materials in a Flexor Tendon Repair Model				
Rinker, Brian	3048106594	\$0.	\$3,463.	\$3,463.
AxoGen Incorporated A Multicenter, Prospective, Randomized, Comparative Study of Hollow Nerve Conduit and AVANCE Nerve Graft Evaluating Recovery Outcomes of Nerve Repair in the Hand (CHANGE)				
Rinker, Brian	3048106594	\$2.	\$0.	\$2.
AxoGen Incorporated A Multicenter, Prospective, Randomized, Comparative Study of Hollow Nerve Conduit and AVANCE Nerve Graft Evaluating Recovery Outcomes of Nerve Repair in the Hand (CHANGE)				
Rinker, Brian	3048106991	\$2.	\$0.	\$2.
AxoGen Incorporated A Multi-Center Retrospective Study of Advanc TM Nerve Graft Utilization, Evaluations, and Outcomes in Peripheral Nerve Injury Repair (RANGER)				
Roth, John Scott	3048105757	\$0.	\$3,148.	\$3,148.
Minnesota Medical Development Inc MMDI Rebound Hernia Repair Device (HRD)				
Roth, John Scott	3048105759	\$0.	\$2,518.	\$2,518.
Covidien Feasibility Study of the Use of Permacol Surgical Implant in the Closure of Abdominal Wall Defects after Removal of Infected Prosthetic Mesh				
Roth, John Scott	3048105759	\$0.	\$6,551.	\$6,551.
Covidien Feasibility Study of the Use of Permacol Surgical Implant in the Closure of Abdominal Wall Defects after Removal of Infected Prosthetic Mesh				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Surgery</u>				
Roth, John Scott	3048105759	\$0.	\$630.	\$630.
Covidien Feasibility Study of the Use of Permacol Surgical Implant in the Closure of Abdominal Wall Defects after Removal of Infected Prosthetic Mesh				
Roth, John Scott	3048105759	\$0.	\$779.	\$779.
Covidien Feasibility Study of the Use of Permacol Surgical Implant in the Closure of Abdominal Wall Defects after Removal of Infected Prosthetic Mesh				
Roth, John Scott	3048106960	\$5,638.	\$0.	\$5,638.
Davol Inc Speciality Access Products A Prospective, Single Arm, Multi-Center Study of Complex Ventral Hernia Repair Utilizing the AlloMax Surgical Graft with Component Separation				
Saha, Sibü	3048103829	\$0.	\$26,820.	\$26,820.
CVRx Inc Rheos Pivotal Trial				
Saha, Sibü	3048103829	\$0.	\$925.	\$925.
CVRx Inc Rheos Pivotal Trial				
Saha, Sibü	3048103829	\$0.	\$2,152.	\$2,152.
CVRx Inc Rheos Pivotal Trial				
Saha, Sibü	3048103829	\$0.	\$18,334.	\$18,334.
CVRx Inc Rheos Pivotal Trial				
Saha, Sibü	3048103829	\$0.	\$5,000.	\$5,000.
CVRx Inc Rheos Pivotal Trial				
Saha, Sibü	3048103829	\$0.	\$655.	\$655.
CVRx Inc Rheos Pivotal Trial				
Saha, Sibü	3048103829	\$0.	\$8,236.	\$8,236.
CVRx Inc Rheos Pivotal Trial				
Saha, Sibü	3048103829	\$0.	\$916.	\$916.
CVRx Inc Rheos Pivotal Trial				
Saha, Sibü	3048103829	\$0.	\$32,536.	\$32,536.
CVRx Inc Rheos Pivotal Trial				
Saha, Sibü	3048103829	\$0.	\$9,534.	\$9,534.
CVRx Inc Rheos Pivotal Trial				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Surgery</u>				
Saha, Sib	3048103829	\$0.	\$24,858.	\$24,858.
CVRx Inc Rheos Pivotal Trial				
Saha, Sib	3048103829	\$0.	\$16,321.	\$16,321.
CVRx Inc Rheos Pivotal Trial				
Saha, Sib	3048103829	\$0.	\$599.	\$599.
CVRx Inc Rheos Pivotal Trial				
Saha, Sib	3048103829	\$0.	\$16,964.	\$16,964.
CVRx Inc Rheos Pivotal Trial				
Saha, Sib	3048103829	\$0.	\$8,621.	\$8,621.
CVRx Inc Rheos Pivotal Trial				
Saha, Sib	3048103829	\$0.	\$823.	\$823.
CVRx Inc Rheos Pivotal Trial				
Saha, Sib	3048103829	\$0.	\$19,134.	\$19,134.
CVRx Inc Rheos Pivotal Trial				
Saha, Sib	3048104218	\$0.	\$630.	\$630.
Baxter Healthcare Co Clinical Evaluation of Efficacy and Safety of FS VH S/D 500 S-APR for Hemostasis in Subjects Undergoing Vascular Surgery				
Saha, Sib	3048104218	\$0.	\$630.	\$630.
Baxter Healthcare Co Clinical Evaluation of Efficacy and Safety of FS VH S/D 500 S-APR for Hemostasis in Subjects Undergoing Vascular Surgery				
Saha, Sib	3048104218	\$0.	\$5,002.	\$5,002.
Baxter Healthcare Co Clinical Evaluation of Efficacy and Safety of FS VH S/D 500 S-APR for Hemostasis in Subjects Undergoing Vascular Surgery				
Saha, Sib	3048105856	\$0.	\$20,319.	\$20,319.
Baxter Healthcare Co Clinical Evaluation of Efficacy and Safety of FS VH S/D 500 S-APR for Hemostasis in Subjects Undergoing Vascular Surgery				
Saha, Sib	3048105856	\$0.	\$6,613.	\$6,613.
Baxter Healthcare Co Clinical Evaluation of Efficacy and Safety of FS VH S/D 500 S-APR for Hemostasis in Subjects Undergoing Vascular Surgery				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Surgery</u>				
Saha, Sib	3048105856	\$2.	\$0.	\$2.
Baxter Healthcare Co Clinical Evaluation of Efficacy and Safety of FS VH S/D 500 S-APR for Hemostasis in Subjects Undergoing Vascular Surgery				
Saha, Sib	3048106537	\$3,150.	\$0.	\$3,150.
Pacira Pharmaceuticals A Phase 2 Open-Label, parallel Group, Randomized Dose-Finding Study to Assess the Efficacy and safety on Intecostal SKY0402 in Subjects Undergoing Posterolateral Thoracotomy				
Saha, Sib	3048106850	\$2.	\$0.	\$2.
CSL Behring GmbH An Open-Label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX P/N Compared with Plasma for Rapid Reversal of Coagulopathy				
Saito, Hiroshi	3048106554	\$97,196.	\$0.	\$97,196.
National Institute on Aging Vulnerability to sepsis in old age				
Vasconez, Henry	3048105913	\$0.	\$11,847.	\$11,847.
Stemnion Inc A Phase I/II Prospective Randomized, Double-Blind Safety and Dose-determining Efficacy Clinical Trial Comparing ACCS in Four Different Regimens with Standardized Care Using 0.9% NaCl Solution				
Vasconez, Henry	3048105913	\$2.	\$0.	\$2.
Stemnion Inc A Phase I/II Prospective Randomized, Double-Blind Safety and Dose-determining Efficacy Clinical Trial Comparing ACCS in Four Different Regimens with Standardized Care Using 0.9% NaCl Solution				
Waid, Thomas	3048103550	\$0.	\$1,000.	\$1,000.
Astellas Pharma US Inc A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (tacrolimus)/MMF, Modified Release (MR) Tacrolimus/MMF and Neoral (cyclosporine)/MMF in De Nove Kidney Trans Recip.				
Waid, Thomas	3048103550	\$0.	\$630.	\$630.
Astellas Pharma US Inc A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (tacrolimus)/MMF, Modified Release (MR) Tacrolimus/MMF and Neoral (cyclosporine)/MMF in De Nove Kidney Trans Recip.				
Wright, Heather R		\$35,000.	\$0.	\$35,000.
Susan G Komen Foundation Lexington Affiliate Komen Grant Project/Breast Cancer				
Zwischenberger, Joseph	3048105935	\$0.	\$5,000.	\$5,000.
MC3 Inc Arterial Cannula with Permissive Distal Perfusion				
Zwischenberger, Joseph	3048105935	\$0.	\$10,000.	\$10,000.
MC3 Inc Arterial Cannula with Permissive Distal Perfusion				
Zwischenberger, Joseph	3048105935	\$0.	\$-2.	\$-2.
MC3 Inc Arterial Cannula with Permissive Distal Perfusion				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

	New Accounts	Adjustments to Existing Accounts	Total
Medicine			
Surgery			
Zwischenberger, Joseph 3048105935 MC3 Inc Arterial Cannula with Permissive Distal Perfusion	\$0.	\$10,000.	\$10,000.
Zwischenberger, Joseph 3048105935 MC3 Inc Arterial Cannula with Permissive Distal Perfusion	\$2.	\$0.	\$2.
Surgery Totals:	\$186,564.	\$877,380.	\$1,063,944.
Neurology			
Bensalem Owen, Meriem Katre nec 3048104422 Inc Research Inc A Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome	\$0.	\$-5,435.	\$-5,435.
Bensalem Owen, Meriem Katre nec 3048104797 Inc Research Inc Safety and Effectiveness of Open-Label clobazam in Subjects with Lennox-Gastaut Syndrome	\$0.	\$-970.	\$-970.
Bensalem Owen, Meriem Katre nec 3048105553 Quintiles Inc A Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome	\$0.	\$3.	\$3.
Bensalem Owen, Meriem Katre nec 3048105553 Quintiles Inc A Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome	\$0.	\$4,622.	\$4,622.
Bensalem Owen, Meriem Katre nec 3048105553 Quintiles Inc A Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome	\$0.	\$6,775.	\$6,775.
Bensalem Owen, Meriem Katre nec 3048105553 Quintiles Inc A Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome	\$0.	\$1,370.	\$1,370.
Bensalem Owen, Meriem Katre nec 3048105553 Quintiles Inc A Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome	\$0.	\$393.	\$393.
Bensalem Owen, Meriem Katre nec 3048105554 Quintiles Inc Safety and Effectiveness of Open-Label clobazam in Subjects with Lennox-Gastaut Syndrome	\$0.	\$487.	\$487.
Bensalem Owen, Meriem Katre nec 3048105554 Quintiles Inc Safety and Effectiveness of Open-Label clobazam in Subjects with Lennox-Gastaut Syndrome	\$0.	\$6,908.	\$6,908.
Bensalem Owen, Meriem Katre nec 3048105554 Quintiles Inc Safety and Effectiveness of Open-Label clobazam in Subjects with Lennox-Gastaut Syndrome	\$0.	\$4,158.	\$4,158.

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Neurology				
Bensalem Owen, Meriem Katre nec	3048105554	\$0.	\$369.	\$369.
Quintiles Inc Safety and Effectiveness of Open-Label clobazam in Subjects with Lennox-Gastaut Syndrome				
Bensalem Owen, Meriem Katre nec	3048105554	\$0.	\$2,743.	\$2,743.
Quintiles Inc Safety and Effectiveness of Open-Label clobazam in Subjects with Lennox-Gastaut Syndrome				
Bensalem Owen, Meriem Katre nec	3048105554	\$0.	\$196.	\$196.
Quintiles Inc Safety and Effectiveness of Open-Label clobazam in Subjects with Lennox-Gastaut Syndrome				
Bensalem Owen, Meriem Katre nec	3048105554	\$0.	\$970.	\$970.
Quintiles Inc Safety and Effectiveness of Open-Label clobazam in Subjects with Lennox-Gastaut Syndrome				
Berger, Joseph R	3048102204	\$0.	\$1,044.	\$1,044.
UCB Pharma Double-blind Placebo Controlled, Randomized, Parallel-group, Phase II study in subjects with relapsing forms of Multiple Sclerosis to evaluate the effects of two doses of CDP323 over 24 weeks with a rater blind MRI follow up over 12 weeks				
Berger, Joseph R	3048104087	\$0.	\$-522.	\$-522.
PPD Development Inc A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of C105 in Persons with Multiple Sclerosis with Cognitive Impairment				
Berger, Joseph R	3048104087	\$0.	\$522.	\$522.
PPD Development Inc A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of C105 in Persons with Multiple Sclerosis with Cognitive Impairment				
Berger, Joseph R	3048105403	\$0.	\$-4,077.	\$-4,077.
Biogen Research Co A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)				
Berger, Joseph R	3048105911	\$0.	\$2,373.	\$2,373.
Biogen Research Co TYGRIS: TYSABRI Global Observational Program in Safety				
Berger, Joseph R	3048105911	\$2.	\$0.	\$2.
Biogen Research Co TYGRIS: TYSABRI Global Observational Program in Safety				
Berger, Joseph R	3048106780	\$17,688.	\$0.	\$17,688.
Vanderbilt University CNS Viral Dynamics and Cellular Immunity During AIDS				
Cambi, Franca	3048079000	\$0.	\$317,265.	\$317,265.
National Institute of Neurological Disorders & Stroke PLP Alternative Splicing and Oligodendrocyte Differentiation				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Neurology				
Cambi, Franca	3048105501	\$0.	\$25,277.	\$25,277.
National Institute of Neurological Disorders & Stroke Neuroprotection Exploratory Trials in PD (NET-PD)				
Cambi, Franca	3048106613	\$220,213.	\$0.	\$220,213.
National Institute of Neurological Disorders & Stroke ARRA: PLP Alternative splicing and oligodendrocyte differentiation				
Cambi, Franca	3048106948	\$54,206.	\$0.	\$54,206.
National Institute of Neurological Disorders & Stroke Neuroprotection Exploratory Trials in PD (NET-PD)				
Dobbs, Michael R	3048106112	\$2.	\$0.	\$2.
University of North Carolina Carotid Occlusion Surgery Study (COSS)				
Fakhoury, Toufic A	3046747200	\$0.	\$1,493.	\$1,493.
Schwarz BioSciences Inc A Multi Center Double Blind Randomized Placebo Controlled Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg day, 400mg day, 600 mg day) as Adjunctive Therapy in Subjects with Partial Seizures				
Fakhoury, Toufic A	3046747200	\$0.	\$1,250.	\$1,250.
Schwarz BioSciences Inc A Multi Center Double Blind Randomized Placebo Controlled Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg day, 400mg day, 600 mg day) as Adjunctive Therapy in Subjects with Partial Seizures				
Fakhoury, Toufic A	3046843900	\$0.	\$2,987.	\$2,987.
Schwarz BioSciences Inc An Open Label-Extension Trial to Determine Safety and Efficacy of Long Term SPM 927 in Patients with Partial Seizures. SP 756				
Fakhoury, Toufic A	3048103108	\$0.	\$6,045.	\$6,045.
Eisai Medical Research Inc A Double-Blind, Placebo-Controlled, Parallel-Group, Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Seizures				
Fakhoury, Toufic A	3048103108	\$0.	\$270.	\$270.
Eisai Medical Research Inc A Double-Blind, Placebo-Controlled, Parallel-Group, Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Seizures				
Fakhoury, Toufic A	3048103891	\$0.	\$6,498.	\$6,498.
Pharmaceutical Research Associates A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Ganaxolone as Add-On Therapy in Adult Subjects with Epilepsy Consisting of Uncontrolled Partial-Onset Seizures				
Fakhoury, Toufic A	3048103891	\$0.	\$2,193.	\$2,193.
Pharmaceutical Research Associates A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Ganaxolone as Add-On Therapy in Adult Subjects with Epilepsy Consisting of Uncontrolled Partial-Onset Seizures				
Fakhoury, Toufic A	3048103891	\$0.	\$27,879.	\$27,879.
Pharmaceutical Research Associates A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Ganaxolone as Add-On Therapy in Adult Subjects with Epilepsy Consisting of Uncontrolled Partial-Onset Seizures				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Neurology</u>				
Fakhoury, Toufic A	3048104048	\$0.	\$4,468.	\$4,468.
Eisai Medical Research Inc An Open Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Onset Seizures				
Fakhoury, Toufic A	3048104396	\$0.	\$2,759.	\$2,759.
Pfizer Inc A Double-Blind, Multicenter Efficacy Safety Study of Pregabalin (Lyrica) as a Monotherapy in Patients with partial Seziures				
Fakhoury, Toufic A	3048104396	\$0.	\$2,438.	\$2,438.
Pfizer Inc A Double-Blind, Multicenter Efficacy Safety Study of Pregabalin (Lyrica) as a Monotherapy in Patients with partial Seziures				
Fakhoury, Toufic A	3048104396	\$0.	\$3,175.	\$3,175.
Pfizer Inc A Double-Blind, Multicenter Efficacy Safety Study of Pregabalin (Lyrica) as a Monotherapy in Patients with partial Seziures				
Fakhoury, Toufic A	3048104396	\$0.	\$7,435.	\$7,435.
Pfizer Inc A Double-Blind, Multicenter Efficacy Safety Study of Pregabalin (Lyrica) as a Monotherapy in Patients with partial Seziures				
Fakhoury, Toufic A	3048104396	\$0.	\$806.	\$806.
Pfizer Inc A Double-Blind, Multicenter Efficacy Safety Study of Pregabalin (Lyrica) as a Monotherapy in Patients with partial Seziures				
Fakhoury, Toufic A	3048104396	\$0.	\$3,799.	\$3,799.
Pfizer Inc A Double-Blind, Multicenter Efficacy Safety Study of Pregabalin (Lyrica) as a Monotherapy in Patients with partial Seziures				
Fakhoury, Toufic A	3048104396	\$0.	\$4,108.	\$4,108.
Pfizer Inc A Double-Blind, Multicenter Efficacy Safety Study of Pregabalin (Lyrica) as a Monotherapy in Patients with partial Seziures				
Fakhoury, Toufic A	3048104533	\$0.	\$1,117.	\$1,117.
Marinus Pharmaceuticals Inc An Open-Label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Ganaxolone as Add-on Therapy in Adult Patients with Epilepsy Consisting of Uncontrolled Partial-Onset Seizures				
Fakhoury, Toufic A	3048104596	\$0.	\$5,306.	\$5,306.
UCB Pharma An Open-Label, Multicenter, Follow-up Trial to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose Up to a Maximum of 150 mg/day in Subjects Aged 16 years or Older Suffering from Epilepsy				
Fakhoury, Toufic A	3048104596	\$0.	\$2,994.	\$2,994.
UCB Pharma An Open-Label, Multicenter, Follow-up Trial to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose Up to a Maximum of 150 mg/day in Subjects Aged 16 years or Older Suffering from Epilepsy				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Neurology				
Fakhoury, Toufic A	3048104596	\$0.	\$3,404.	\$3,404.
UCB Pharma An Open-Label, Multicenter, Follow-up Trial to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose Up to a Maximum of 150 mg/day in Subjects Aged 16 years or Older Suffering from Epilepsy				
Fakhoury, Toufic A	3048105126	\$0.	\$793.	\$793.
Pfizer Inc An Open Label Multicenter Extension Study to Determine Long Term Safety and Efficacy of Pregabalin (Lyrica) as Monotherapy in Patients with Partial Seizures				
Fakhoury, Toufic A	3048105126	\$0.	\$1,361.	\$1,361.
Pfizer Inc An Open Label Multicenter Extension Study to Determine Long Term Safety and Efficacy of Pregabalin (Lyrica) as Monotherapy in Patients with Partial Seizures				
Fakhoury, Toufic A	3048105126	\$0.	\$2,192.	\$2,192.
Pfizer Inc An Open Label Multicenter Extension Study to Determine Long Term Safety and Efficacy of Pregabalin (Lyrica) as Monotherapy in Patients with Partial Seizures				
Fakhoury, Toufic A	3048105126	\$0.	\$576.	\$576.
Pfizer Inc An Open Label Multicenter Extension Study to Determine Long Term Safety and Efficacy of Pregabalin (Lyrica) as Monotherapy in Patients with Partial Seizures				
Fakhoury, Toufic A	3048105126	\$0.	\$3,729.	\$3,729.
Pfizer Inc An Open Label Multicenter Extension Study to Determine Long Term Safety and Efficacy of Pregabalin (Lyrica) as Monotherapy in Patients with Partial Seizures				
Fakhoury, Toufic A	3048105381	\$0.	\$3,148.	\$3,148.
PPD Development Inc An International, Double-Blind, Randomized, Multi-Center, Parallel Group, Historical-Control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (16 to 75 years old) With Partial Onset Seizures With or Without				
Fakhoury, Toufic A	3048105382	\$0.	\$2,500.	\$2,500.
PPD Development Inc An Open-Label, Multinational, Multicenter, Follow-Up Study to Evaluate the Long-Term Safety and Efficacy of Brivaracetam, Used at a Flexible Dose up to a Maximum of 150 mg/day, in Subjects aged 16 years or older suffering from Epilepsy				
Fakhoury, Toufic A	3048105453	\$0.	\$5,147.	\$5,147.
Eisai Medical Research Inc A Double-blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial Seizures				
Fakhoury, Toufic A	3048105760	\$0.	\$3,569.	\$3,569.
Eisai Medical Research Inc An Open-label Extension Phase of the Double-blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007(perampanel)Given as Adjunctive Therapy in Subjects with Refractory Partial Seizures				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Neurology				
Houff, Sidney A	3048103412	\$0.	\$818.	\$818.
Serono Laboratories Inc A Randomized, Multicenter, Two-arm, Open Label, 12 Week Phase IIIB Study to Evaluate the Tolerability of Rebif (IFN Beta-LA) and Betaseron (IFN Beta-1B) in IFN-Naive Subjects with Relapsing Remitting Multiple Sclerosis; Followed by a Single-Arm 24				
Houff, Sidney A	3048103412	\$0.	\$292.	\$292.
Serono Laboratories Inc A Randomized, Multicenter, Two-arm, Open Label, 12 Week Phase IIIB Study to Evaluate the Tolerability of Rebif (IFN Beta-LA) and Betaseron (IFN Beta-1B) in IFN-Naive Subjects with Relapsing Remitting Multiple Sclerosis; Followed by a Single-Arm 24				
Houff, Sidney A	3048103412	\$0.	\$678.	\$678.
Serono Laboratories Inc A Randomized, Multicenter, Two-arm, Open Label, 12 Week Phase IIIB Study to Evaluate the Tolerability of Rebif (IFN Beta-LA) and Betaseron (IFN Beta-1B) in IFN-Naive Subjects with Relapsing Remitting Multiple Sclerosis; Followed by a Single-Arm 24				
Houff, Sidney A	3048103412	\$0.	\$1,153.	\$1,153.
Serono Laboratories Inc A Randomized, Multicenter, Two-arm, Open Label, 12 Week Phase IIIB Study to Evaluate the Tolerability of Rebif (IFN Beta-LA) and Betaseron (IFN Beta-1B) in IFN-Naive Subjects with Relapsing Remitting Multiple Sclerosis; Followed by a Single-Arm 24				
Houff, Sidney A	3048104530	\$0.	\$292.	\$292.
Genzyme Corp A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif) in Treatment-Naive Patients with Relapsing Multiple Sclerosis				
Houff, Sidney A	3048104530	\$0.	\$630.	\$630.
Genzyme Corp A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif) in Treatment-Naive Patients with Relapsing Multiple Sclerosis				
Kasarskis, Edward J	3048105231	\$0.	\$6,500.	\$6,500.
Kendle International A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients				
Kasarskis, Edward J	3048105777	\$0.	\$12,664.	\$12,664.
Massachusetts General Hospital Ceftriaxone in ALS - Kentucky Subcontract				
Kasarskis, Edward J	3048106861	\$2.	\$0.	\$2.
Columbia University Multicenter ALS Cohort Study of Oxidative Stress and Disease Progression				
Pettigrew, Luther C	3046450600	\$0.	\$-2,520.	\$-2,520.
Mayo Foundation Siblings with Ischemic Stroke (SWISS)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Neurology				
Pettigrew, Luther C	3046749700	\$0.	\$8,700.	\$8,700.
AGA Medical Co Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment (RESPECT Trial)				
Pettigrew, Luther C	3046749700	\$0.	\$1,000.	\$1,000.
AGA Medical Co Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment (RESPECT Trial)				
Pettigrew, Luther C	3048038100	\$0.	\$11,720.	\$11,720.
Miami University Albumin in Stroke (ALIAS) Trial				
Pettigrew, Luther C	3048103735	\$0.	\$400.	\$400.
Columbia University Warfarin vs. Aspirin in Reduced Cardiac Ejection Fraction (WARCEF).				
Pettigrew, Luther C	3048103735	\$0.	\$4,860.	\$4,860.
Columbia University Warfarin vs. Aspirin in Reduced Cardiac Ejection Fraction (WARCEF).				
Pettigrew, Luther C	3048103735	\$0.	\$798.	\$798.
Columbia University Warfarin vs. Aspirin in Reduced Cardiac Ejection Fraction (WARCEF).				
Pettigrew, Luther C	3048105979	\$110,035.	\$0.	\$110,035.
Medical College of Georgia Minocycline to Improve Neurologic Outcomes				
Pettigrew, Luther C	3048106111	\$0.	\$398.	\$398.
Mayo Clinic Siblings with Ischemic Stroke (SWISS)				
Pettigrew, Luther C	3048106111	\$2.	\$0.	\$2.
Mayo Clinic Siblings with Ischemic Stroke (SWISS)				
Pettigrew, Luther C	3048106976	\$2.	\$0.	\$2.
University of British Columbia Secondary Prevention of Small Subcortical Strokes (SPS3)				
Slevin, John T	3048105543	\$0.	\$3,601.	\$3,601.
University of Rochester A Randomized Double-Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Three Doses of Aplindore MR (1,3 and 6 mg Twice Daily) in Patients with Early Parkinson Disease (Aplindore-211)				
Slevin, John T	3048105620	\$0.	\$2,504.	\$2,504.
Quintiles Inc Open -label, 6-12 months Safety and Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson's Disease and Severe Motor-Fluctuations, Protocol# S187.3.004				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Neurology				
Slevin, John T	3048105620	\$0.	\$863.	\$863.
Quintiles Inc Open -label, 6-12 months Safety and Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson's Disease and Severe Motor-Fluctuations, Protocol# S187.3.004				
Slevin, John T	3048105620	\$0.	\$1,000.	\$1,000.
Quintiles Inc Open -label, 6-12 months Safety and Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson's Disease and Severe Motor-Fluctuations, Protocol# S187.3.004				
Slevin, John T	3048105620	\$0.	\$15,000.	\$15,000.
Quintiles Inc Open -label, 6-12 months Safety and Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson's Disease and Severe Motor-Fluctuations, Protocol# S187.3.004				
Slevin, John T	3048105620	\$0.	\$10,949.	\$10,949.
Quintiles Inc Open -label, 6-12 months Safety and Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson's Disease and Severe Motor-Fluctuations, Protocol# S187.3.004				
Slevin, John T	3048106716	\$36,752.	\$0.	\$36,752.
American Parkinsons Disease Association Parkinson Disease Infomation and Referral Center				
Slevin, John T	3048106766	\$2.	\$0.	\$2.
Quintiles Inc A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments with Parkinson Medicinal Products, who Continue to				
Smith, Charles D	3048106677	\$0.	\$59,998.	\$59,998.
Genzyme Corp Cognitive, Motor and Driving Performance in Euthryoid and Hypothyroid States				
Smith, Charles D	3048106677	\$2.	\$0.	\$2.
Genzyme Corp Cognitive, Motor and Driving Performance in Euthryoid and Hypothyroid States				
Tucker, Tarvez	3048104872	\$0.	\$1,034.	\$1,034.
Merck and Company Inc A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled, Crossover Study to Evaluate the Safety and Efficacy of MK-0974 iin Treatment of Acute Migraine in Patients with Stable Vascular Disease				
Tucker, Tarvez	3048104872	\$0.	\$811.	\$811.
Merck and Company Inc A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled, Crossover Study to Evaluate the Safety and Efficacy of MK-0974 iin Treatment of Acute Migraine in Patients with Stable Vascular Disease				
Tucker, Tarvez	3048104872	\$0.	\$5,363.	\$5,363.
Merck and Company Inc A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled, Crossover Study to Evaluate the Safety and Efficacy of MK-0974 iin Treatment of Acute Migraine in Patients with Stable Vascular Disease				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Neurology</u>				
Vaishnav, Anand G	3046746400	\$0.	\$12,000.	\$12,000.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
Vaishnav, Anand G	3046746400	\$0.	\$17,600.	\$17,600.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
Vaishnav, Anand G	3046746400	\$0.	\$4,870.	\$4,870.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
Vaishnav, Anand G	3046746400	\$0.	\$9,270.	\$9,270.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
Vaishnav, Anand G	3046746400	\$0.	\$4,800.	\$4,800.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
Vaishnav, Anand G	3046746400	\$0.	\$16,000.	\$16,000.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
Vaishnav, Anand G	3046746400	\$0.	\$12,990.	\$12,990.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
Vaishnav, Anand G	3046746400	\$0.	\$26,900.	\$26,900.
University of Texas Health Science Center at Sa Secondary Prevention of Small Subcortical Strokes (SPS3)				
Neurology	Totals:	\$438,908.	\$731,846.	\$1,170,754.
<u>Surgery - Neurosurgery</u>				
Eum, Sung Yong	3048105864	\$77,000.	\$0.	\$77,000.
American Heart Association Lipid Rafts-Mediated Signaling Mechanism in Polychlorinated Biphenyl-Induced Brain Inflammation				
Tibbs, Phillip A	3048082800	\$0.	\$14,309.	\$14,309.
DePuy Spine SLIM-Loc Plating fusion vs. DISCOVER Artificial Disc				
Tibbs, Phillip A	3048082800	\$0.	\$-79.	\$-79.
DePuy Spine SLIM-Loc Plating fusion vs. DISCOVER Artificial Disc				
Tibbs, Phillip A	3048104419	\$0.	\$1,444.	\$1,444.
Kyphon Inc Treatment of Lumbar Spinal Stenosis with X-Stop IPD in Moderately Symptomatic Patients to Assess the Long-Term Safety and Performance of X-Stop Interspinous Decompression System				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Surgery - Neurosurgery</u>				
Tibbs, Phillip A	3048104419	\$0.	\$3,264.	\$3,264.
Kyphon Inc Treatment of Lumbar Spinal Stenosis with X-Stop IPD in Moderately Symptomatic Patients to Assess the Long-Term Safety and Performance of X-Stop Interspinous Decompression System				
Tibbs, Phillip A	3048104419	\$0.	\$693.	\$693.
Kyphon Inc Treatment of Lumbar Spinal Stenosis with X-Stop IPD in Moderately Symptomatic Patients to Assess the Long-Term Safety and Performance of X-Stop Interspinous Decompression System				
Tibbs, Phillip A	3048104419	\$0.	\$1,180.	\$1,180.
Kyphon Inc Treatment of Lumbar Spinal Stenosis with X-Stop IPD in Moderately Symptomatic Patients to Assess the Long-Term Safety and Performance of X-Stop Interspinous Decompression System				
Toberek, Michal	3046928600	\$0.	\$265,301.	\$265,301.
National Institute of Neurological Disorders & Stroke Tat-Mediated Brain Endothelial Cell Dysfunction				
Toberek, Michal	3048105020	\$0.	\$347,938.	\$347,938.
National Institute of Mental Health Implications of Caveolae in Tat Signaling and Integrity of Brain Endothelium				
Toberek, Michal	3048105922	\$43,000.	\$0.	\$43,000.
American Heart Association Great Rivers Affiliate Fellowship for Wen Huang: Novel Mechanisms of PPAR-mediated Protection Against HIV-1 Mediated Disruption of Endothelial Interguity				
Toberek, Michal	3048105923	\$43,000.	\$0.	\$43,000.
American Heart Association Great Rivers Affiliate Fellowship for Lei Chen: Novel Mechanisms for Nanoparticle-Induced Cerebrovascular Toxicity in an Experimental Stroke Model				
Toberek, Michal	3048106930	\$359,125.	\$0.	\$359,125.
National Institute on Drug Abuse Exercise as a Novel Strategy to Target Methamphetamine-Induced Cerebrovascular Toxicity				
Young, Alfred B	3048105520	\$0.	\$630.	\$630.
Adnexus Tolerability and Efficacy of CT-322 (Angiocept) Monotherapy and Combination with Irinotecan in Patients with Recurrent Glioblastoma Multiforme CT-322.002				
Young, Alfred B	3048105604	\$0.	\$15,998.	\$15,998.
Solvay Pharmaceuticals A Randomized, Double Blind, Placebo-Controlled Dose Escalation Study to Investigate the Safety and Pharmacokinetics after Single and Multiple Doses of SLV334 in Sequential Cohorts of Patients with Moderate and Severe Traumatic				
Young, Alfred B	3048106857	\$0.	\$5,498.	\$5,498.
Baxter Healthcare Co An Exploratory Phase 2 Study Evaluating the Efficacy and Safety of Fibrin Sealant, Vapor Heated, Solvent/Detergent Treated (FS VH S/D) 500 S-APR for the Sealing of Dura Defect Sutures in Posterior Fossa Surgery				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Surgery - Neurosurgery</u>				
Young, Alfred B	3048106857	\$2.	\$0.	\$2.
Baxter Healthcare Co An Exploratory Phase 2 Study Evaluating the Efficacy and Safety of Fibrin Sealant, Vapor Heated, Solvent/Detergent Treated (FS VH S/D) 500 S-APR for the Sealing of Dura Defect Sutures in Posterior Fossa Surgery				
Yurek, David M	3048105997	\$239,125.	\$0.	\$239,125.
National Institute of Neurological Disorders & Stroke Targeted DNA Nanoparticles in Brain				
Surgery - Neurosurgery	Totals:	\$761,252.	\$656,176.	\$1,417,428.
<u>Ophthalmology</u>				
Ambati, Jayakrishna	3048102202	\$0.	\$37,500.	\$37,500.
Burroughs Wellcome Fund Target-Independent Suppression of Angiogenesis by siRNAs				
Ambati, Jayakrishna	3048102202	\$0.	\$37,500.	\$37,500.
Burroughs Wellcome Fund Target-Independent Suppression of Angiogenesis by siRNAs				
Ambati, Jayakrishna	3048103629	\$0.	\$361,879.	\$361,879.
National Eye Institute Pro- and Anti-Angiogenic Effect of Vascular Endothelial Growth Factor-A				
Ambati, Jayakrishna	3048104229	\$0.	\$23,604.	\$23,604.
Taigen Biotechnology Co Ltd Taigen Antagonist: Prevention and Regression of Laser-Induced Choroidal Neovascularization.				
Ambati, Jayakrishna	3048104491	\$0.	\$431,640.	\$431,640.
National Eye Institute Intrinsic Anti-Angiogenic Activity of siRNA				
Ambati, Jayakrishna	3048105306	\$0.	\$71,830.	\$71,830.
Doris Duke Charitable Foundation Short non-Interfering RNAs as Novel Therapies for Age Related Macular Degeneration				
Ambati, Jayakrishna	3048106022	\$222,750.	\$0.	\$222,750.
National Eye Institute Novel TLR3 inhibitors for geographic atrophy of age-related macular degeneration				
Ambati, Jayakrishna	3048106636	\$500,000.	\$0.	\$500,000.
National Eye Institute ARRA: CCR3: A molecular maker for neovascular AMD				
Baffi, Judit Zsuzsanna	3048106912	\$100,000.	\$0.	\$100,000.
International Retinal Research Foundation CCR3 as an Early Detection Target in Age Related Macular Degeneration				
Blackburn, Peter	3046948500	\$0.	\$59,782.	\$59,782.
Control Delivery Systems Inc A Randomized, Double-Masked, Parallel Group, Multi-Center Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 pg/day and				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Ophthalmology</u>				
Deokule, Sunil	3048106688	\$1,007.	\$0.	\$1,007.
Alcon Laboratories Inc A Study of the Safety and IOP Lowering Efficacy of Anectortave Acetate in Patients with Open-Angle Glaucoma				
Fannon, Michael	3048088600	\$0.	\$330,960.	\$330,960.
National Heart Lung and Blood Institute Computer Modeling of Perlecan as a Vascular Regulator				
Mohan, Royce	3048103665	\$0.	\$366,250.	\$366,250.
National Eye Institute Molecular Targets of Corneal Antiangiogenesis				
Mohan, Royce	3048104877	\$0.	\$295,574.	\$295,574.
National Cancer Institute Novel Modular Vascular Patterning Assay for HTS				
Pearson, Paul A	3048050700	\$0.	\$2,854.	\$2,854.
University of Wisconsin Standard Care Versus Corticosteriod for Retinal Vein Occlusion(SCORE) Study				
Pearson, Paul A	3048050700	\$0.	\$5,670.	\$5,670.
University of Wisconsin Standard Care Versus Corticosteriod for Retinal Vein Occlusion(SCORE) Study				
Pearson, Paul A	3048086000	\$0.	\$-2,000.	\$-2,000.
Eli Lilly and Company A Phase 2b, Randomized, Parallel-group, Placebo-controlled, Double masked Study				
Pearson, Paul A	3048105483	\$0.	\$100,000.	\$100,000.
Research to Prevent Blindness Research To Prevent Blindness Unrestricted Grant				
Pearson, Paul A	3048105619	\$0.	\$7,002.	\$7,002.
Thrombogenics A Randomized, Placebo Controlled, Double-Masked, Multicenter of Microplamin Intavitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion				
Pearson, Paul A	3048105619	\$0.	\$1,800.	\$1,800.
Thrombogenics A Randomized, Placebo Controlled, Double-Masked, Multicenter of Microplamin Intavitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion				
Pearson, Paul A	3048105619	\$0.	\$16,211.	\$16,211.
Thrombogenics A Randomized, Placebo Controlled, Double-Masked, Multicenter of Microplamin Intavitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion				
Pearson, Paul A	3048105619	\$0.	\$16,474.	\$16,474.
Thrombogenics A Randomized, Placebo Controlled, Double-Masked, Multicenter of Microplamin Intavitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Ophthalmology</u>				
Pearson, Paul A	3048106678	\$0.	\$17,642.	\$17,642.
Alimera Sciences Incorporated A Randomized, Double-Masked, Pilot Study of the Safety and Efficacy of 0.5 ug/day and .02 ug/day Iluvien (Fluocinolone Acetonide Intravitreal Insert) 0.19mg in Subjects with Macular Edema Secondary to Retinal Vein Occlusion				
Pearson, Paul A	3048106678	\$2.	\$0.	\$2.
Alimera Sciences Incorporated A Randomized, Double-Masked, Pilot Study of the Safety and Efficacy of 0.5 ug/day and .02 ug/day Iluvien (Fluocinolone Acetonide Intravitreal Insert) 0.19mg in Subjects with Macular Edema Secondary to Retinal Vein Occlusion				
Raisler, Brian J	3048081400	\$0.	\$50,000.	\$50,000.
Research to Prevent Blindness The Role of Cellular Immunity in Neovascular Ischemic Retinopathies				
Ophthalmology	Totals:	\$823,759.	\$2,232,172.	\$3,055,931.
<u>Orthopaedic Surgery</u>				
Giordani, Mauro	3048105937	\$0.	\$4,507.	\$4,507.
McMaster University Trial to Evaluate UltraSound in the Treatment of Tibial Fractures (TRUST)				
Giordani, Mauro	3048105937	\$2.	\$0.	\$2.
McMaster University Trial to Evaluate UltraSound in the Treatment of Tibial Fractures (TRUST)				
Lattermann, Christian	3048105458	\$0.	\$4,093.	\$4,093.
Advanced Technologies and Regenerative Medicine A multicenter, Randomized, Pivotal Study to Evaluate the Safety and Efficacy of the Cartilage Autograft Implantation				
Lattermann, Christian	3048106990	\$2.	\$0.	\$2.
Biomet Inc A Feasibility Study to Determine the Up-Regulation of Anti-Inflammatory Cytokines in Whole Blood from Patients with Osteoarthritis				
Orthopaedic Surgery	Totals:	\$4.	\$8,600.	\$8,604.
<u>Radiation Medicine</u>				
Kudrimoti, Mahesh	3046880600	\$0.	\$273.	\$273.
AMGen A Phase 3 Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction of Oral Mucositis in Subjects with Advanced Head and Neck Cancer Receiving Radiotherapy				
Kudrimoti, Mahesh	3048044300	\$0.	\$5,660.	\$5,660.
TRIAD Burden of Illness Inc Risk and Outcomes of Mucositis in Subjects Being Treated for Breast, Colorectal, Head and Neck, Non-small Cell Lung or Ovarian Cancers				
Kudrimoti, Mahesh	3048105244	\$0.	\$2,449.	\$2,449.
AMGen A Phase 2 Randomized Trial of Chemoradiation with or without Panitumumab in Subjects with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Medicine				
Radiation Medicine				
Kudrimoti, Mahesh	3048105244	\$0.	\$1,478.	\$1,478.
AMGen A Phase 2 Randomized Trial of Chemoradiation with or without Panitumumab in Subjects with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck				
Kudrimoti, Mahesh	3048105244	\$0.	\$16,983.	\$16,983.
AMGen A Phase 2 Randomized Trial of Chemoradiation with or without Panitumumab in Subjects with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck				
McGarry, Ronald	3046594300	\$0.	\$-500.	\$-500.
American College of Radiology Support of Ongoing Activities with the American College of Radiology				
McGarry, Ronald	3046594300	\$0.	\$-3,000.	\$-3,000.
American College of Radiology Support of Ongoing Activities with the American College of Radiology				
McGarry, Ronald	3048105548	\$0.	\$2,800.	\$2,800.
American College of Radiology Radiation Therapy Oncology Group: Master Agreement				
McGarry, Ronald	3048105548	\$0.	\$2,650.	\$2,650.
American College of Radiology Radiation Therapy Oncology Group: Master Agreement				
McGarry, Ronald	3048105548	\$0.	\$10,000.	\$10,000.
American College of Radiology Radiation Therapy Oncology Group: Master Agreement				
McGarry, Ronald	3048105548	\$0.	\$5,000.	\$5,000.
American College of Radiology Radiation Therapy Oncology Group: Master Agreement				
McGarry, Ronald	3048105548	\$0.	\$15,500.	\$15,500.
American College of Radiology Radiation Therapy Oncology Group: Master Agreement				
Randall, Marcus	3048106761	\$8,800.	\$0.	\$8,800.
Gynecologic Oncology Group Chair or Co-Chair of the Gynecologic Oncology Group				
Randall, Marcus	3048107012	\$8,800.	\$0.	\$8,800.
Gynecologic Oncology Group Chair or Co-Chair of the Corpus Committee Gynecologic Oncology Group				
Rangnekar, Vivek M	3046936200	\$0.	\$246,909.	\$246,909.
National Cancer Institute Regulation of Cell Survival and Tumor Progression by AKT				
Rangnekar, Vivek M	3048106661	\$318,752.	\$0.	\$318,752.
National Cancer Institute ARRA: Mechanism of Apoptosis and Inhibition of Tumor Progression and Metastasis by Par-4				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Medicine</u>				
<u>Radiation Medicine</u>				
Sellitti, Marguerite	3046859800	\$0.	\$870.	\$870.
American Cancer Society Transportation Grant- Satellites				
Sellitti, Marguerite	3046859800	\$0.	\$870.	\$870.
American Cancer Society Transportation Grant- Satellites				
Sellitti, Marguerite	3046859800	\$0.	\$870.	\$870.
American Cancer Society Transportation Grant- Satellites				
St Clair, William H	3048103792	\$0.	\$250,538.	\$250,538.
National Cancer Institute Redox Modulation Of Prostate Cancer				
Radiation Medicine	Totals:	\$336,352.	\$559,350.	\$895,702.
<u>Physical Medicine and Rehabilitation</u>				
Adams, Lumy Sawaki	3048104591	\$0.	\$252,000.	\$252,000.
National Institute of Child Health and Human Develop Sensory-driven Motor Recovery in Poorly Recovered Subacute Stroke Patients				
Adams, Lumy Sawaki	3048106657	\$118,967.	\$0.	\$118,967.
National Institute of Child Health and Human Develop ARRA: Sensory driven motor recovery in poorly recovered subacute stroke patients				
Springer, Joe E	3048104366	\$0.	\$98,588.	\$98,588.
KY Spinal Cord and Head Injury Research Trust Therapeutic Potential of NEU2000, A Dual Acting Pharmacological Agent in the Treatment of Acute Spinal Cord Injury				
Springer, Joe E	3048105780	\$122,544.	\$0.	\$122,544.
Craig H Neilsen Foundation Targeting Mitochondrial Function in Traumatic Spinal Cord Injury				
Springer, Joe E	3048106844	\$491,655.	\$0.	\$491,655.
National Institute of Neurological Disorders & Stroke NIM811 for the Treatment of Acute Spinal Cord Injury				
Physical Medicine and Rehabilitation	Totals:	\$733,166.	\$350,588.	\$1,083,754.
	Medicine Totals:	\$61,471,907.	\$44,456,908.	\$105,928,815.
<u>Pharmacy</u>				
<u>Pharmacy</u>				
Stinchcomb, Audra L	3048103101	\$0.	\$280,002.	\$280,002.
National Institute on Drug Abuse Naltrexone Prodrugs for transdermal Delivery				
Pharmacy	Totals:	\$0.	\$280,002.	\$280,002.
<u>Pharmaceutical Tech</u>				
Al-Ghananeem, Abeer	3048103825	\$0.	\$88,091.	\$88,091.
US Worldmeds LLC Formulation Development of Intravenous and Oral Dosage Forms				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Pharmacy				
Pharmaceutical Tech				
Anderson, Bradley D	3048105301	\$0.	\$60,000.	\$60,000.
Boehringer Ingelheim Optimizing Oral Absorption of Poorly Water Soluble Drug Candidates: Mechanisms and Predictive Models for the Selection of Excipients to Maintain Supersaturation by Inhibiting Nucleation and Crystallization				
Bae, Younsoo	3048106808	\$150,000.	\$0.	\$150,000.
KY Lung Cancer Research Fund Mixed Polymer Nanoassemblies for Tunable Combination Drug Delivery to Lung Cancer Tumors				
Bummer, Paul M	3048103769	\$0.	\$290,101.	\$290,101.
National Cancer Institute Development of Dosage Forms and Delivery Systems for Anti-Tumor Agents				
Crooks, Peter A	3046581000	\$0.	\$111,871.	\$111,871.
US Worldmeds LLC KSTC R & D Voucher: Product development and formulation				
Crooks, Peter A	3048106529	\$0.	\$83,225.	\$83,225.
Cornell University A Novel Thiadiazolidine-Dione Targets Human Leukemia Stem Cells				
Crooks, Peter A	3048106529	\$15,860.	\$0.	\$15,860.
Cornell University A Novel Thiadiazolidine-Dione Targets Human Leukemia Stem Cells				
Crooks, Peter A	3048106992	\$98,444.	\$0.	\$98,444.
Vanderbilt University Development of Small Molecule Radiation Sensitizers				
Dwoskin, Linda P	3046930400	\$0.	\$572,644.	\$572,644.
National Institute on Drug Abuse Development of Novel Therapies for Methamphetamine Abuse				
Dwoskin, Linda P	3048106407	\$174,300.	\$0.	\$174,300.
Boston University Cognitive Aspects of Addiction-Related Behavior				
Dwoskin, Linda P	3048106708	\$1,027,710.	\$0.	\$1,027,710.
National Institute on Drug Abuse ARRA: Development of Novel Therapies or Methamphetamine Abuse Supplement				
Graf, Gregory Allen	3048106008	\$23,000.	\$0.	\$23,000.
American Heart Association Great Rivers Affiliate Fellowship for Liu: The Role of D2 in the Metabolism of Atypical Fatty Acids in Adipose Tissue				
Graf, Gregory Allen	3048106509	\$340,056.	\$0.	\$340,056.
National Institute Diabetes & Digestive & Kidney Regulation of the ABCG5 ABCG8 Sterol Transporter				
Kim, Kyung Bo	3048104666	\$0.	\$27,835.	\$27,835.
Baylor University Medical Center To Degrade or Not To Degrade: Targeting the Androgen Receptor in AR Deendent Prostate Cancer				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Pharmacy				
Pharmaceutical Tech				
Kim, Kyung Bo	3048105969	\$6,000.	\$0.	\$6,000.
American Foundation for Pharmaceutical Ed Fellowship for Wehenkel: AFPE Predoctoral Fellowship				
Lee, Woojin	3048106078	\$44,046.	\$0.	\$44,046.
Washington University Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction				
Lee, Woojin	3048106832	\$150,000.	\$0.	\$150,000.
KY Lung Cancer Research Fund Immunoproteasome in Lung Cancer				
Nixon, Kimberly	3048104311	\$0.	\$375,419.	\$375,419.
National Institute on Alcohol Abuse and Alcoholism Ethanol Alteration of the Neurogenic Niche				
Nixon, Kimberly	3048105792	\$0.	\$7,425.	\$7,425.
National Institute on Alcohol Abuse and Alcoholism ARRA: Ethanol Alteration of the Neurogenic Niche				
Pauly, Jim	3048106083	\$281,780.	\$0.	\$281,780.
National Institute of Child Health and Human Develop The Combination of Cyclosporin and Choline Optimizes Outcomes in Focal and Diffuse Rat Models of TBI				
Porter, Todd D	3048106032	\$181,406.	\$0.	\$181,406.
National Center for Complementary & Alternative Med Inhibition of Cholesterol Synthesis by Green and Black Tea				
Stinchcomb, Audra L	3048105827	\$0.	\$204.	\$204.
National Institute on Drug Abuse NRSA Fellowship for Swadley: Transdermal Delivery of Hydroxyphenylarachidonylamides				
Stinchcomb, Audra L	3048105827	\$30,524.	\$0.	\$30,524.
National Institute on Drug Abuse NRSA Fellowship for Swadley: Transdermal Delivery of Hydroxyphenylarachidonylamides				
Van Lanen, Steven	3048105216	\$0.	\$10,000.	\$10,000.
Daiichi Pharmaceutical Corp Biosynthesis of Nucleoside Antibiotics				
Van Lanen, Steven	3048106514	\$80,000.	\$0.	\$80,000.
KY Science and Technology Co Inc KSEF R&D Excellence: Nucleoside Antibiotics Targeting Bacterial Translocase I				
Yokel, Robert A	3048104222	\$0.	\$500,000.	\$500,000.
Environmental Protection Agency Safety/Toxicity Assessment of Ceria (A Model engineered NP) to the Brain				
Zhan, Chang-Guo	3048046400	\$0.	\$41,418.	\$41,418.
University of Michigan Development of Esterases for the Treatment of Cocaine Overdose and Abuse				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Pharmacy</u>				
<u>Pharmaceutical Tech</u>				
Zhan, Chang-Guo	3048046900	\$0.	\$348,516.	\$348,516.
National Institute on Drug Abuse Redesign of Butyrylcholinesterase for Cocaine Metabolism				
Zhan, Chang-Guo	3048104655	\$0.	\$13,943.	\$13,943.
MITRE Corporation Enzyme Analysis and Design				
Zhan, Chang-Guo	3048104655	\$0.	\$29,065.	\$29,065.
MITRE Corporation Enzyme Analysis and Design				
Zhan, Chang-Guo	3048105116	\$0.	\$489,970.	\$489,970.
National Institute on Drug Abuse High-Activity Mutants of Cocaine Esterase for Treatment of Drug Addiction				
Zhan, Chang-Guo	3048106838	\$208,662.	\$0.	\$208,662.
West Virginia University ARRA: Phosphodiesterase-2 and Mood Disorders: Target Validation and Drug Discovery				
Zhan, Chang-Guo	3048106916	\$50,000.	\$0.	\$50,000.
Columbia University Novel PDE5 Inhibitors as a Therapeutic Tool Against Alzheimer's Disease				
Zheng, Guangrong	3048105479	\$0.	\$181,294.	\$181,294.
National Institute on Drug Abuse Development of Antagonists for M5 Muscarinic Acetylcholine Receptor				
Pharmaceutical Tech	Totals:	\$2,861,788.	\$3,231,021.	\$6,092,809.
<u>Pharmacy Practice & Science</u>				
Talbert, Jeffery C	3048105430	\$0.	\$76,242.	\$76,242.
Urban Institute Effects of Medicaid Reform on Access to Care, Program Sustainability, and Administrative Efficiency in Idaho and KY				
Talbert, Jeffery C	3048105859	\$250,000.	\$0.	\$250,000.
KY Cabinet for Health and Family Services Medicaid Utilization Study				
Talbert, Jeffery C	3048105945	\$905,686.	\$0.	\$905,686.
Department for Mental Health Mental Retardation Service Research and Information Systems Management for KY Department for Mental Health/Mental Retardation				
Talbert, Jeffery C	3048106652	\$1,700,468.	\$0.	\$1,700,468.
KY Cabinet for Health and Family Services Money Follows the Person (MFP) 2009-2010 Medicaid Utilization Study				
Pharmacy Practice & Science	Totals:	\$2,856,154.	\$76,242.	\$2,932,396.
	Pharmacy Totals:	\$5,717,942.	\$3,587,265.	\$9,305,207.

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Health Sciences</u>				
<u>Rehabilitation Sciences</u>				
Butterfield, Timothy	3048106574	\$61,694.	\$0.	\$61,694.
Ohio State University Massage Therapy in Eccentric Exercise Induced Muscle Weakness and Inflammation				
Butterfield, Timothy	3048106833	\$934.	\$0.	\$934.
NATA Research & Education Foundation The Role of Fiber Dynamics in Strain-Induced Muscle Damage				
Butterfield, Timothy	3048106834	\$984.	\$0.	\$984.
NATA Research & Education Foundation Effects of Massage on Lymphangiogenesis and Inflammation				
Capilouto, Gilson J	3048104021	\$0.	\$104,467.	\$104,467.
Arizona State University Discourse Processing in Healthy Aging				
Dupont-Versteegden, Esther	3048049900	\$0.	\$277,005.	\$277,005.
National Institute on Aging Integrated Study of Musculoskeletal Loss and Restoration				
Effgen, Susan K	3048105863	\$171,989.	\$0.	\$171,989.
Department of Education PREPaRE: Preparing Related Services Personnel for Rural Employment				
English, Robert A	3048105836	\$0.	\$480.	\$480.
Massachusetts General Hospital Validation of a New Device to Measure Neuromuscular Disease Progression: Part B: Developing a Normal Data Bank and Comparison to Self Reported Activity				
English, Robert A	3048105836	\$0.	\$1,078.	\$1,078.
Massachusetts General Hospital Validation of a New Device to Measure Neuromuscular Disease Progression: Part B: Developing a Normal Data Bank and Comparison to Self Reported Activity				
English, Robert A	3048105836	\$2.	\$0.	\$2.
Massachusetts General Hospital Validation of a New Device to Measure Neuromuscular Disease Progression: Part B: Developing a Normal Data Bank and Comparison to Self Reported Activity				
English, Robert A	3048105836	\$0.	\$2,520.	\$2,520.
Massachusetts General Hospital Validation of a New Device to Measure Neuromuscular Disease Progression: Part B: Developing a Normal Data Bank and Comparison to Self Reported Activity				
Uhl, Timothy	3048106711	\$3,507.	\$0.	\$3,507.
Oxford Physical Therapy Centers Development and implementation of clinical outcome database for physical therapists				
Rehabilitation Sciences	Totals:	\$239,110.	\$385,550.	\$624,660.
<u>Administrative Services</u>				
Peterson, Charlotte A.	3048049700	\$0.	\$260,888.	\$260,888.
National Institute on Aging Changes in Myogenic Progenitor Potential with Age				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Health Sciences</u>				
<u>Administrative Services</u>				
Peterson, Charlotte A.	3048106027	\$148,500.	\$0.	\$148,500.
National Institute on Aging Defining the role of satellite cells in muscle maintenance throughout the lifespan using genetic labeling				
Peterson, Charlotte A.	3048106518	\$174,618.	\$0.	\$174,618.
National Institute on Aging ARRA: Contribution of Altered Muscle Hemodynamics to Fatigability in Older Persons with and without Fibromyalgia				
Administrative Services	Totals:	\$323,118.	\$260,888.	\$584,006.
<u>Clinical Sciences</u>				
Bruckner, Geza G	3048104972	\$0.	\$25,000.	\$25,000.
KY Diabetes Research Trust Fund Developing Health Sciences Students to Be Health Navigators for Diabetes Prevention and Care				
Chendil, Damodaran	3048106970	\$161,494.	\$0.	\$161,494.
National Cancer Institute Targeting Signaling to Prevent Colon Cancer				
Ko, Chemyong	3046997400	\$0.	\$229,100.	\$229,100.
National Institute of Child Health and Human Develop Endothelin-2 in Ovarian Follicle Rupture				
Ko, Chemyong	3048106908	\$156,316.	\$0.	\$156,316.
RNL Bio Company Limited Steroid Outcome of Adipocyte Stem Cell Injection				
Mao, Catherine	3048106548	\$152,211.	\$0.	\$152,211.
National Institute on Aging ARRA: Role of Matrix Metalloproteinase-1 in Endothelial Cell Senescence				
Powdrill, Samuel G	3048106501	\$0.	\$55,467.	\$55,467.
Health Resources and Services Administration Targeted Training for Physician Assistant Students Caring for At Risk Populations in Kentucky				
Powdrill, Samuel G	3048106501	\$65,114.	\$0.	\$65,114.
Health Resources and Services Administration Targeted Training for Physician Assistant Students Caring for At Risk Populations in Kentucky				
Clinical Sciences	Totals:	\$535,135.	\$309,567.	\$844,702.
	Health Sciences Totals:	\$1,097,363.	\$956,005.	\$2,053,368.
<u>Public Health</u>				
<u>Public Health Leadership Institute</u>				
Scutchfield, F Douglas	3048106413	\$142,500.	\$0.	\$142,500.
KY Cabinet for Health and Family Services Kentucky Public Health Leadership Institute				
Public Health Leadership Institute	Totals:	\$142,500.	\$0.	\$142,500.
<u>Preventive Med & Environmental Health</u>				
Albuquerque, Samantha	3048106516	\$67,910.	\$0.	\$67,910.
KY Department for Public Health Heart Disease and Stroke Prevention Program (Epidemiologist Services)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Public Health</u>				
<u>Preventive Med & Environmental Health</u>				
Allweiss, Pamela H	3048107013	\$152,797.	\$0.	\$152,797.
Center for Disease Control and Prevention IPA for Centers for Disease Control and Prevention				
Figgs, Larry W	3048085600	\$0.	\$31,500.	\$31,500.
Lexington Fayette County Health Department Manager, Evironmental Health and Protection				
Preventive Med & Environmental Health	Totals:	\$220,707.	\$31,500.	\$252,207.
<u>Health Behavior</u>				
Cecil, James C	3048106066	\$223,387.	\$0.	\$223,387.
KY Department for Public Health MCH Institute				
Crosby, Richard	3048012800	\$0.	\$610,410.	\$610,410.
National Institute of Allergy and Infectious Diseases Do Condoms Protect from Non-Viral Sexually Transmitted Infections?				
Swanson, Mark	3048106750	\$2,654.	\$0.	\$2,654.
Foundation for a Healthy KY The Value of Peer Specialists in Primary Health Care				
Health Behavior	Totals:	\$226,041.	\$610,410.	\$836,451.
<u>Health Services Management</u>				
Costich, Julia F	3048105628	\$0.	\$19,621.	\$19,621.
KY Cabinet for Health and Family Services Harmonizing State Privacy Law Collaborative Project				
Health Services Management	Totals:	\$0.	\$19,621.	\$19,621.
<u>Epidemiology</u>				
Browning, Steven	3048104983	\$0.	\$31,440.	\$31,440.
St Elizabeth Medical Center Evaluation of Northern Kentucky Womens Cardiovascular Assessment, Risk Reduction and Care Collaborative				
Hopenhayn, Claudia	3048105972	\$60,000.	\$0.	\$60,000.
Foundation for a Healthy KY County-Level Analysis of Behavioral Risk Factor Surveillance System Data				
Robl, Joyce M	3048105838	\$55,700.	\$0.	\$55,700.
KY Department for Public Health UK Birth Surveillance Registry FY10				
Epidemiology	Totals:	\$115,700.	\$31,440.	\$147,140.
<u>Gerontology</u>				
Teaster, Pamela B	3048106914	\$23,150.	\$0.	\$23,150.
National Committee Prevention of Elder Abuse Empowering Elder Abuse Organizations through Local, State and National Efforts				
Gerontology	Totals:	\$23,150.	\$0.	\$23,150.

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Public Health</u>				
<u>Center for Prevention Research</u>				
Clayton, R R	3048106649	\$75,000.	\$0.	\$75,000.
Robert Wood Johnson Foundation Strategic Advisor and Consultant for RWJF Alumni Network				
Jones, Jeffery A	3048105974	\$83,723.	\$0.	\$83,723.
Foundation for a Healthy KY 2009-2010 Coordinated School Health Initiative				
Center for Prevention Research	Totals:	\$158,723.	\$0.	\$158,723.
<u>KY Injury Prevention & Research Center</u>				
Bunn, Terry L	3048105871	\$268,150.	\$0.	\$268,150.
National Institute of Occupational Safety and Health Kentucky Occupational Safety and Health Surveillance				
Costich, Julia F	3048104743	\$0.	\$-20,000.	\$-20,000.
KY Department for Public Health KIPRC Consumer Product Safety Commission				
Costich, Julia F	3048105812	\$0.	\$8,800.	\$8,800.
KY Department for Public Health State Injury Prevention Program				
Costich, Julia F	3048105812	\$311,688.	\$0.	\$311,688.
KY Department for Public Health State Injury Prevention Program				
Costich, Julia F	3048105854	\$46,000.	\$0.	\$46,000.
KY Department for Public Health Consumer Product Safety Commission 2009-2010				
Costich, Julia F	3048105992	\$127,358.	\$0.	\$127,358.
Center for Disease Control and Prevention Public Health Injury Surveillance and Prevention Program				
McCool, Robert H	3048106030	\$143,470.	\$0.	\$143,470.
Center for Disease Control and Prevention Kentucky Residential Fire Injury Prevention Project				
McCool, Robert H	3048106818	\$113,983.	\$0.	\$113,983.
Federal Emergency Management Agency Assistance to Firefighters Grant Program: US Fire Administration Smoke Alarm Installation and Fire Education (USFA SAIFE)				
Pollack, Susan H	3048106067	\$112,600.	\$0.	\$112,600.
KY Department for Public Health Pediatric and Adolescent Injury Prevention Program/CFR				
Singleton, Michael	3048106837	\$55,763.	\$0.	\$55,763.
KY Transportation Cabinet Kentucky Crash Outcome Data Evaluation System (CODES)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Public Health</u>				
<u>KY Injury Prevention & Research Center</u>				
Walsh, Sabrina L	3048106306	\$219,561.	\$0.	\$219,561.
Center for Disease Control and Prevention Kentucky Violent Death Reporting System				
Walsh, Sabrina L	3048106999	\$17,821.	\$0.	\$17,821.
Ace Info Solutions Incorporated Elder Maltreatment Surveillance Pilot Project				
KY Injury Prevention & Research Center	Totals:	\$1,416,394.	\$-11,200.	\$1,405,194.
<u>Southeast Cntr for Ag Health & Injury Pr</u>				
McKnight, Robert H	3048105180	\$0.	\$6,247.	\$6,247.
National Institute of Occupational Safety and Health Southeast Center for Agricultural Health and Injury Prevention				
McKnight, Robert H	3048105800	\$60,148.	\$0.	\$60,148.
Center for Disease Control and Prevention Agricultural Safety and Health Training for Public Health Graduate Students				
McKnight, Robert H	3048105995	\$63,346.	\$0.	\$63,346.
KY Department for Medicaid Services Department of Medicaid Services KCHIP Migrant Outreach Project				
McKnight, Robert H	3048106680	\$0.	\$49,035.	\$49,035.
National Institute of Occupational Safety and Health Southeast Center for Agricultural Health and Injury Prevention				
McKnight, Robert H	3048106680	\$819,286.	\$0.	\$819,286.
National Institute of Occupational Safety and Health Southeast Center for Agricultural Health and Injury Prevention				
Southeast Cntr for Ag Health & Injury Pr	Totals:	\$942,780.	\$55,282.	\$998,062.
<u>Council on Aging</u>				
Johnson, Helen A	3048106651	\$369,077.	\$0.	\$369,077.
Health Resources and Services Administration OVAR/GEC Interdisciplinary Care				
Johnson, Helen A	3048106682	\$183,447.	\$0.	\$183,447.
KY Department for Public Health UK KDPH Emergency Preparedness for Aging				
Council on Aging	Totals:	\$552,524.	\$0.	\$552,524.
<u>Center for Public Health Syst & Svcs Res</u>				
Dearinger, Angela Tackett	3048105692	\$0.	\$39,648.	\$39,648.
KY Public Health Association Kentucky Public Health Research Network (KPHReN)				
Dearinger, Angela Tackett	3048106650	\$24,999.	\$0.	\$24,999.
University of Arkansas An Evaluation of the Public Health Response to the Pandemic Outbreak of Novel Influenze H1N1				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Public Health</u>				
<u>Center for Public Health Syst & Svcs Res</u>				
Jones, Jeffery A	3048105889	\$195,411.	\$0.	\$195,411.
Robert Wood Johnson Foundation PHSSR (Public Health Systems & Services Research) Data Integration				
Lamberth, Cynthia	3048106910	\$149,859.	\$0.	\$149,859.
Robert Wood Johnson Foundation Public Health Data Integration Survey System-Managing an Internet Survey Firm's Selection & Performance & Combining Resulting Datasets from 3 Public Health Membership Organization Surveys				
Scutchfield, F Douglas	3048106759	\$12,500.	\$0.	\$12,500.
National Library of Medicine Increasing the Availability & Promoting the use of Public Health Systems & Services Research Resources				
Scutchfield, F Douglas	3048106809	\$160,000.	\$0.	\$160,000.
Public Health Foundation Center of Excellence for Public Health Workforce Research & Policy				
Scutchfield, F Douglas	3048106979	\$17,552.	\$0.	\$17,552.
Ohio State University Buckeye Bluegrass Regional Leadership Academy				
Center for Public Health Syst & Svcs Res	Totals:	\$560,321.	\$39,648.	\$599,969.
<u>Kentucky Rural Cancer Prevention Center</u>				
Crosby, Richard	3048106773	\$790,000.	\$0.	\$790,000.
National Center for Chronic Disease Prevention & Health Promotion The Rural Cancer Prevention Center: Category 1 Proposal				
Kentucky Rural Cancer Prevention Center	Totals:	\$790,000.	\$0.	\$790,000.
<u>Assoc Dean for Research</u>				
Hill, Raymond E	3048106911	\$41,509.	\$0.	\$41,509.
University of Arizona Certificate in MCH Public Health				
Assoc Dean for Research	Totals:	\$41,509.	\$0.	\$41,509.
<u>Dean</u>				
Wyatt, Stephen W	3048106843	\$150,000.	\$0.	\$150,000.
Cancer Prevention and Research Institute of Texas Prevention Review Council Chairman				
Dean	Totals:	\$150,000.	\$0.	\$150,000.
	Public Health Totals:	\$5,340,349.	\$776,701.	\$6,117,050.
<u>Assoc Provost Undergrad Educati</u>				
<u>Undergraduate Studies</u>				
Tannenbaum, Robert S	3046842100	\$0.	\$467,377.	\$467,377.
National Science Foundation Recruiting, Retaining, and Graduating University of Kentucky Appalachian and Minority Science, Technology, Engineering, and Mathematics Majors \ (UK AMSTEMM)				
Undergraduate Studies	Totals:	\$0.	\$467,377.	\$467,377.

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Assoc Provost Undergrad Educati</u>				
<u>Teaching & Academic Support Ctr</u>				
Cunningham, Kathryn	3048106201	\$848.	\$0.	\$848.
Louisiana Campus Compact Service-Learning Train the Trainer Institute Travel Grant				
Teaching & Academic Support Ctr	Totals:	\$848.	\$0.	\$848.
Assoc Provost Undergrad Education Totals:		\$848.	\$467,377.	\$468,225.
<u>Agriculture</u>				
<u>International Programs</u>				
Reed, Michael R	3046900500	\$0.	\$12,100.	\$12,100.
Foreign Agricultural Service Technical Assistance to the Extension System in Serbia				
Reed, Michael R	3048106419	\$13,393.	\$0.	\$13,393.
Foreign Agricultural Service Borlaug International Science Program for Central America on Postharvest Technology				
International Programs	Totals:	\$13,393.	\$12,100.	\$25,493.
<u>Assoc Dean Research/Director AES</u>				
Cox, Nancy Marguerite	3048087900	\$0.	\$30,000.	\$30,000.
Agricultural Research Service ARS/SCA Cooperative Agreement				
Cox, Nancy Marguerite	3048104749	\$0.	\$819,795.	\$819,795.
Agricultural Research Service Improving Sustainability of Forage-Based Production				
Cox, Nancy Marguerite	3048106539	\$0.	\$8,250.	\$8,250.
Agricultural Research Service Acquisition of Goods and Services for USDA Offices in Ag North - 2009-2010				
Cox, Nancy Marguerite	3048106539	\$29,825.	\$0.	\$29,825.
Agricultural Research Service Acquisition of Goods and Services for USDA Offices in Ag North - 2009-2010				
Cox, Nancy Marguerite	3048106770	\$5,000.	\$0.	\$5,000.
KY Department of Agriculture Local Food Systems Initiative				
Assoc Dean Research/Director AES	Totals:	\$34,825.	\$858,045.	\$892,870.
<u>Center for the Environment</u>				
Hanley, Carol D	3048106060	\$21,250.	\$0.	\$21,250.
KY Department of Education Kentucky Green and Healthy Schools				
Center for the Environment	Totals:	\$21,250.	\$0.	\$21,250.
<u>Agr Economics</u>				
Halich, Gregory S.	3048106420	\$43,381.	\$0.	\$43,381.
Texas A&M University Transitioning to a Forage-Finished Beef Enterprise in the Upper South				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Agr Economics</u>				
Hu, Wuyang	3048106621	\$196,865.	\$0.	\$196,865.
Environmental Protection Agency Assessment of a Market-Based Water Quality Trading System for Kentucky River Watersheds				
Katchova, Ani L.	3048106755	\$62,654.	\$0.	\$62,654.
Rural Development Local Sourcing as a Differentiation and Recruitment Strategy for Food Consumer Cooperatives				
Meyer, Alphonse L	3048105988	\$20,000.	\$0.	\$20,000.
University of Georgia Kentucky 2009 SARE Model State Plan - Program Assistant				
Meyer, Alphonse L	3048106020	\$10,000.	\$0.	\$10,000.
University of Georgia Kentucky 2009 SARE Model State Plan - Training				
Meyer, Alphonse L	3048106116	\$52,911.	\$0.	\$52,911.
University of Georgia Supporting and Enhancing the Role of SARE in Extension and Other Land Grant University Programs in the South				
Meyer, Alphonse L	3048106421	\$38,648.	\$0.	\$38,648.
Texas A&M University Kentucky Annie's Project and Beyond: Risk Management Education for Farm Women				
Meyer, Alphonse L	3048106618	\$0.	\$7,350.	\$7,350.
Cooperative State Research Education and Extension A Common Field: A Whole Farm Management Education Program for Beginning Farmers				
Meyer, Alphonse L	3048106618	\$742,533.	\$0.	\$742,533.
Cooperative State Research Education and Extension A Common Field: A Whole Farm Management Education Program for Beginning Farmers				
Meyer, Alphonse L	3048106729	\$41,034.	\$0.	\$41,034.
Texas A&M University Kentucky Agriculture in Transition: Ensuring Sustainability, Security, and Profitability				
Skees, Jerry R	3048106972	\$39,706.	\$0.	\$39,706.
GlobalAgRisk Inc Innovation in Catastrophic Weather Insurance to Improve the Livelihoods of Rural Households				
Snell, William M	3048106769	\$12,500.	\$0.	\$12,500.
University of Tennessee Coordination with Center for Tobacco Grower Research				
Walters, Cory Gene	3048106735	\$11,157.	\$0.	\$11,157.
Texas A&M University Integrating ACRE and Crop Insurance: A Comprehensive Risk Management Strategy				
Woods, Timothy A	3048105994	\$30,000.	\$0.	\$30,000.
University of Illinois Building Commerical Readiness of, and Market Access for, Small and Mid- Sized Farmers through MarketMaker				
Agr Economics	Totals:	\$1,301,389.	\$7,350.	\$1,308,739.

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Biosystems & Ag Eng</u>				
Colliver, Donald G	3048104859	\$0.	\$25,000.	\$25,000.
National Renewable Energy Laboratory Solar Decathlon - 2009				
Colliver, Donald G	3048106800	\$50,000.	\$0.	\$50,000.
University of Louisville Optimal Energy Usage Control for Residential Solar Photovoltaic Systems (Smart PV Houses)				
Fehr, Robert L	3048105858	\$0.	\$30,000.	\$30,000.
KY Energy and Environment Cabinet Energy - A Cooperative Extension Program for Kentucky's Building Systems Energy Needs 2009-2010				
Fehr, Robert L	3048105858	\$98,000.	\$0.	\$98,000.
KY Energy and Environment Cabinet Energy - A Cooperative Extension Program for Kentucky's Building Systems Energy Needs 2009-2010				
Fehr, Robert L	3048106545	\$126,198.	\$0.	\$126,198.
KY Cabinet for Health and Family Services Radon-Cooperative Extension Radon and Indoor Air Quality Education				
Higgins, Stephen F	3048106827	\$454,343.	\$0.	\$454,343.
KY Energy and Environment Cabinet Cane Run and Royal Spring Watershed Based Plan Implementation Project				
McNeill, S G	3048106747	\$6,006.	\$0.	\$6,006.
Foreign Agricultural Service TDY Nigeria:Commodity Storage and Handling Assessment Mission				
McNeill, S G	3048106955	\$30,470.	\$0.	\$30,470.
Foreign Agricultural Service Nigeria:Commodity Storage-Technical Assistance				
Montross, Michael D	3048106534	\$370,000.	\$0.	\$370,000.
Agricultural Research Service Laboratory and Field Data for Establishing New Grain Packing Factors				
Payne, Frederick A	3048105108	\$0.	\$90,040.	\$90,040.
National Institute for Hometown Security Technology Optimization of a Milk Transport Security System				
Shearer, Scott A	3048106535	\$25,748.	\$0.	\$25,748.
John Deere Dubuque Works of Deere and Company Harvested Crop Sensing Suite: Obj 1 and 2				
Stombaugh, Timothy S	3048106530	\$439,107.	\$0.	\$439,107.
Cooperative State Research Education and Extension Precision Agriculture: Precision Resource Management - Phase V				
Stombaugh, Timothy S	3048106533	\$37,563.	\$0.	\$37,563.
Department of Education Food and Energy Production: Internationalized Agricultural and Engineering Programs				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Biosystems & Ag Eng</u>				
Warner, Richard C	3048106742	\$94,123.	\$0.	\$94,123.
Natural Resources Conservation Service Soil Moisture-Based Automatic Pulse Irrigation System for Water Conservation				
Warner, Richard C	3048106822	\$94,123.	\$0.	\$94,123.
Natural Resources Conservation Service Soil Moisture-Based Automatic Pulse Irrigation System for Water Conservation				
Wilhoit, John H	3048105870	\$25,000.	\$0.	\$25,000.
Burley Tobacco Growers Cooperative Association Inc Evaluation of Pallet Rack Systems as an Economical Option for Tobacco Curing Capacity Expansion				
Workman, Stephen R	3048105389	\$0.	\$-20,000.	\$-20,000.
Texas A&M University 2008 Southern Regional Water Resource Project				
Biosystems & Ag Eng	Totals:	\$1,850,681.	\$125,040.	\$1,975,721.
<u>Plant & Soil Sciences</u>				
Bertsch, Paul M	3048105332	\$0.	\$110,000.	\$110,000.
Duke University Center for the Environmental Implications of Nanotechnology (CEIN)				
Bruening, William P	3048106601	\$6,000.	\$0.	\$6,000.
KY Small Grain Growers Association Performance of Small Grain Varieties in Kentucky				
Chappell, Joseph	3048103869	\$0.	\$176,478.	\$176,478.
National Science Foundation Unraveling the Catalytic Specificity of Terpene Hydroxylases and Engineering Sesquiterpene Hydroxylation into Plants				
Chappell, Joseph	3048106580	\$3,027,575.	\$0.	\$3,027,575.
National Institute of General Medical Sciences ARRA: Advancing Drug Development in Medicinal Plants using Transcriptomics and Metabolomics				
Hildebrand, David F	3048105189	\$0.	\$90,000.	\$90,000.
Consortium for Plant Biotechnology Research Inc Oilseeds as a Renewable Source of Epoxy Fatty Acids				
Hildebrand, David F	3048105380	\$0.	\$59,910.	\$59,910.
United Soybean Board Further Development of Soybeans with Higher Levels of Improved Oil and Enhanced Fungal Resistance				
Hildebrand, David F	3048106615	\$5,000.	\$0.	\$5,000.
KY Small Grain Growers Association Evaluation of Early Flowering Chia (Salvia hispanica) Lines as a New Small Grain Crop for Kentucky				
Hildebrand, David F	3048106813	\$10,000.	\$0.	\$10,000.
Ashland Inc Renewable Lubricant Production				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Plant & Soil Sciences</u>				
Karathanasis, Anastasios D	3048104924	\$0.	\$5,000.	\$5,000.
KY Health Services Cabinet Soil Morphology Training for On-Site Sewage Disposal Systems				
Karathanasis, Anastasios D	3048106093	\$30,000.	\$0.	\$30,000.
KY Cabinet for Health and Family Services Soil Morphology Training for On-Site Sewage Disposal Systems				
Lee, Brad Davis	3048105666	\$0.	\$43,307.	\$43,307.
Texas A&M University 2008 Southern Regional Water Resource Project				
Lee, Chad D	3048105104	\$0.	\$75,630.	\$75,630.
Iowa State University Agronomic Limitations of Soybean Yield and Seed Quality in U.S.				
Lee, Chad D	3048105104	\$0.	\$-75,630.	\$-75,630.
Iowa State University Agronomic Limitations of Soybean Yield and Seed Quality in U.S.				
Lee, Chad D	3048105876	\$4,000.	\$0.	\$4,000.
United Sorghum Checkoff Program A Regional Grain Sorghum Management Guide for Mid-South States				
Lee, Chad D	3048106616	\$14,000.	\$0.	\$14,000.
KY Small Grain Growers Association Wheat Response to Old Corn Rows: Phase 2				
Lee, Chad D	3048106619	\$0.	\$3,000.	\$3,000.
KY Small Grain Growers Association Wheat Yield in 15-inch Rows, Year 2				
Lee, Chad D	3048106619	\$6,000.	\$0.	\$6,000.
KY Small Grain Growers Association Wheat Yield in 15-inch Rows, Year 2				
Lee, Chad D	3048106825	\$79,871.	\$0.	\$79,871.
National Institute of Food and Agriculture Grain Farming without Subsidies - Sabbatical to Argentina				
Martin, James R	3048106624	\$6,000.	\$0.	\$6,000.
KY Small Grain Growers Association Managing Giant Ragweed and Marestalk in Wheat				
McCulley, Rebecca L	3048104653	\$0.	\$56,676.	\$56,676.
Duke University Effects of Warming and Altered Precipitation Regime on Managed Grassland Structure and Function				
McCulley, Rebecca L	3048105142	\$0.	\$50,419.	\$50,419.
National Science Foundation Collaborative Research: Decomposition in Drylands: Soil Erosion and UV Interactions				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Plant & Soil Sciences</u>				
McNear, David H	3048106920	\$1,500.	\$0.	\$1,500.
KY Council on Postsecondary Education Speciation and Spatial Distribution of Cr, Cu, and As in Bulk and Rhizosphere Soils Adjacent to CCA Treated Fences throughout the Landscape				
Miller, Robert D	3048106950	\$1,000,000.	\$0.	\$1,000,000.
RJ Reynolds Tobacco Co Tobacco Breeding and Cultural Practices Agreement				
Miller, Robert D	3048106988	\$975,000.	\$0.	\$975,000.
Philip Morris International Management SA Burley Tobacco Breeding and Genetics				
Murdock, Lloyd W	3048106604	\$5,000.	\$0.	\$5,000.
KY Small Grain Growers Association Improving Nitrogen Application Technology under Kentucky Conditions				
Perry, Sharyn E	3048105879	\$300,000.	\$0.	\$300,000.
National Science Foundation ARRA: Transcriptional Regulatory Networks Controlling Higher Plant Embryogenesis				
Perry, Sharyn E	3048106777	\$74,284.	\$0.	\$74,284.
United Soybean Board Enhancement of Soybean Somatic Embryo Development to Improve Regeneration and Transformation Efficiency (Year 1 of 2)				
Perry, Sharyn E	3048106998	\$74,284.	\$0.	\$74,284.
United Soybean Board Enhancement of Soybean Somatic Embryo Development to Improve Regeneration and Transformation Efficiency (Year 1 of 2)				
Pfeiffer, T W	3048104613	\$0.	\$32,000.	\$32,000.
South Dakota State University Regional Biomass Feedstock Partnership - Herbaceous Bioenergy Crop Field Trials				
Slack, Charles H	3048105661	\$0.	\$800.	\$800.
Monsanto Co Service Order No. 6 Dicamba-Tolerant Soybean: Weed Control				
Slack, Charles H	3048105675	\$0.	\$160.	\$160.
Monsanto Co Formulation Testing of Encapsulated Acetochlor in Soybeans - Service Order No. 8				
Slack, Charles H	3048105679	\$0.	\$640.	\$640.
Monsanto Co Encapsulated Acetochlor in Soybeans EUP Academic - Service Order No. 7				
Slack, Charles H	3048106105	\$9,000.	\$0.	\$9,000.
Pioneer Hi Bred International Inc Optimum® GAT® Corn University				
Slack, Charles H	3048106106	\$5,700.	\$0.	\$5,700.
Pioneer Hi Bred International Inc GAT Corn/Soy - PRE No-Till				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Plant & Soil Sciences</u>				
Smalle, Jan A H	3048106005	\$400,000.	\$0.	\$400,000.
National Science Foundation ARRA: Molecular Genetic Analysis of a Novel Feedback Inhibition Mechanism in the Cytokinin Response Pathway				
Van Sanford, D A	3048030900	\$0.	\$149,316.	\$149,316.
Agricultural Research Service US Wheat & Barley Scab Initiative's Networking and Facilitation Office and Website				
Van Sanford, D A	3048105647	\$0.	\$56,359.	\$56,359.
Agricultural Research Service Accelerating the Development of FHB-Resistant Soft Red Winter Wheat Varieties				
Van Sanford, D A	3048105647	\$0.	\$1,350.	\$1,350.
Agricultural Research Service Accelerating the Development of FHB-Resistant Soft Red Winter Wheat Varieties				
Van Sanford, D A	3048106599	\$45,188.	\$0.	\$45,188.
KY Small Grain Growers Association Soft Red Winter Wheat Breeding and Variety Development in Kentucky				
Wendroth, Ole Otto	3048106603	\$6,000.	\$0.	\$6,000.
KY Small Grain Growers Association Winter Wheat Development, Grain Yield and Soil Water and Nitrogen Dynamics in a Farmer's Field in Western Kentucky				
Williams, David W	3048104694	\$0.	\$17,000.	\$17,000.
South Dakota State University Regional Biomass Feedstock Partnership				
Witt, William W	3046705900	\$0.	\$178,099.	\$178,099.
KY Transportation Cabinet Management of Troublesome Weeds in Highway Rights of Way				
Yuan, Ling	3048106957	\$12,642.	\$0.	\$12,642.
Department of Energy ARRA: Department of Energy Merit Review				
Zhu, Hongyan	3048106081	\$150,000.	\$0.	\$150,000.
Department of Agriculture Defense versus Symbiosis: Host Genetic Control of Nodulation Specificity in Soybean				
Plant & Soil Sciences	Totals:	\$6,247,044.	\$1,030,514.	\$7,277,558.
<u>Animal and Food Sciences</u>				
Amaral-Phillips, Donna M	3048104479	\$0.	\$15,000.	\$15,000.
University of Nebraska DAIReXNET: A National Dairy Information and Communications Resource				
Bullock, Kevin D	3048106696	\$47,500.	\$0.	\$47,500.
Cornell University National Beef Cattle Evaluation Consortium				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Animal and Food Sciences</u>				
Burris, Walter R	3046556200	\$0.	\$151,750.	\$151,750.
KY Cattleman's Association Master Cattlemen Program				
Cantor, Austin H	3048104339	\$0.	\$28,620.	\$28,620.
Alltech Biotechnology Inc Student Sponsorship Agreement for Lizza Macalintal				
Harmon, David L	3046522900	\$0.	\$-112,406.	\$-112,406.
Hills Pet Nutrition Inc Nutrient Utilization in the Dog				
Harmon, David L	3048104079	\$0.	\$30,000.	\$30,000.
Alltech Biotechnology Inc Student Sponsorship Agreement - Holder				
Hennig, B	3048105614	\$0.	\$34,998.	\$34,998.
National Institute of Environmental Health Sciences Nutrition and Superfund Chemical Toxicity				
Hennig, B	3048105977	\$0.	\$43.	\$43.
National Institute of Environmental Health Sciences ARRA: Nutrition and Superfund Chemical Toxicity Summer Supplement				
Hennig, B	3048105977	\$153,067.	\$0.	\$153,067.
National Institute of Environmental Health Sciences ARRA: Nutrition and Superfund Chemical Toxicity Summer Supplement				
Hennig, B	3048106513	\$221,038.	\$0.	\$221,038.
National Institute of Environmental Health Sciences ARRA: Nutrition and Superfund Chemical Toxicity Administrative Supplement				
Lawrence, Laurie M	3048104078	\$0.	\$30,000.	\$30,000.
Alltech Biotechnology Inc Sponsored Student Stipend - Brummer				
Lawrence, Laurie M	3048106541	\$29,554.	\$0.	\$29,554.
Prairie Oat Growers Association Past, Present and Future: The Nutritional Value of Oats in Horse Feeds				
McLeod, Kyle R	3048089100	\$0.	\$-84,230.	\$-84,230.
Hills Pet Nutrition Inc Essential Amino Acid and Fatty Acid Studies in Cats				
Newman, Melissa C	3048105947	\$1,333,929.	\$0.	\$1,333,929.
National Institute for Hometown Security The Use of Natural Antimicrobials to Mitigate Biological Threat Agents in High Risk Foods				
Pescatore, Anthony J	3048105347	\$0.	\$32,400.	\$32,400.
Alltech Biotechnology Inc Student Sponsorship Agreement for Anthony Quant				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Animal and Food Sciences</u>				
Rentfrow, Gregg K		\$263,654.	\$0.	\$263,654.
KY Governor's Office of Agricultural Policy Food Production Research and Development for Kentucky's Small Food Processors				
Urschel, Kristine L	3048106994	\$108,000.	\$0.	\$108,000.
Morris Animal Foundation Protein metabolism in old horses: effects of inflammation and glucocorticoid excess				
Animal and Food Sciences	Totals:	\$2,156,742.	\$126,175.	\$2,282,917.
<u>Entomology</u>				
Bessin, Ricardo T	3048106103	\$90,354.	\$0.	\$90,354.
Environmental Protection Agency Reducing Organophosphate Insecticide Use in Kentucky Apple Orchards				
Bessin, Ricardo T	3048106544	\$7,500.	\$0.	\$7,500.
Monsanto Co Evaluation of fall armyworm and corn earworm efficacy of SmartStax corn hybrids and related biotech stacks				
Dobson, Stephen Leonard	3048035600	\$0.	\$310,665.	\$310,665.
National Institute of Allergy and Infectious Diseases Eradication of a Primary Filariasis Vector Population at an Endemic Field Site				
Dobson, Stephen Leonard	3048104232	\$0.	\$15,828.	\$15,828.
Bill and Melinda Gates Foundation Supplemental Vector Intervention Required to Eliminate Lymphatic Filariasis in the South Pacific				
Harwood, James Douglas	3048105717	\$40,000.	\$0.	\$40,000.
Washington State Potato Commission Washington State Potato Commission: Who's Eating Who? Molecular Detection of Predator Diets in Washington Potatoes				
Harwood, James Douglas	3048106855	\$349,130.	\$0.	\$349,130.
Washington State University Area-Wide Management of Potato Pests (AMPP) in the Pacific Northwest				
Johnson, Douglas W	3048106013	\$108,169.	\$0.	\$108,169.
Cooperative State Research Education and Extension An Integrated Pest Management Program for Kentucky				
Obyrcki, John J	3048105461	\$0.	\$127,619.	\$127,619.
Animal and Plant Health Inspection Service Cooperative Agricultural Pest Survey				
Obyrcki, John J	3048105575	\$0.	\$5,742.	\$5,742.
Department of Agriculture Biological Control of the Hemlock Woolly Adelgid				
Obyrcki, John J	3048105662	\$0.	\$33,701.	\$33,701.
Animal and Plant Health Inspection Service Light Brown Apple Moth (LBAM) National Survey				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Entomology</u>				
Obrycki, John J	3048106734	\$10,000.	\$0.	\$10,000.
KY Energy and Environment Cabinet Hemlock Woolly Adelgid Sampling Surveys				
Obrycki, John J	3048106806	\$223,933.	\$0.	\$223,933.
Animal and Plant Health Inspection Service Cooperative Agricultural Pest Survey: Gypsy Moth				
Obrycki, John J	3048106902	\$0.	\$35,437.	\$35,437.
Animal and Plant Health Inspection Service Light Brown Apple Moth (LBAM) National Survey				
Obrycki, John J	3048106902	\$11,813.	\$0.	\$11,813.
Animal and Plant Health Inspection Service Light Brown Apple Moth (LBAM) National Survey				
Obrycki, John J	3048107007	\$177,164.	\$0.	\$177,164.
Animal and Plant Health Inspection Service Emerald Ash Borer Survey and Outreach in Kentucky				
Palli, Subba R	3046862500	\$0.	\$19,343.	\$19,343.
National Institute of General Medical Sciences Molecular Analysis of Juvenile Hormone Action				
Palli, Subba R	3048106792	\$10,000.	\$0.	\$10,000.
Cooperative State Research Education and Extension Insect Molecular Physiology: Basic Science to Applications				
Palli, Subba R	3048106860	\$208,500.	\$0.	\$208,500.
National Institute of General Medical Sciences Molecular Analysis of Juvenile Hormone Action				
Potter, Daniel A	3048105072	\$0.	\$26,530.	\$26,530.
Dow AgroSciences Evaluation of Transgenic Turfgrasses for Resistance to Root-Feeding White Grubs				
Rieske-Kinney, Lynne K	3048106562	\$6,574.	\$0.	\$6,574.
Northern Nut Growers Association Interactions between the Asian Chestnut gall wasp and potential natural enemies				
White, Jennifer A	3048105842	\$0.	\$-49,658.	\$-49,658.
KY Science and Technology Co Inc KSEF R&D Excellence: Molecular Characterization of the Microbial Community of Invasive Arthropods				
White, Jennifer A	3048105842	\$99,341.	\$0.	\$99,341.
KY Science and Technology Co Inc KSEF R&D Excellence: Molecular Characterization of the Microbial Community of Invasive Arthropods				
White, Jennifer A	3048106712	\$46,148.	\$0.	\$46,148.
University of Minnesota Ecological Ramifications of Defensive Symbiosis in an Invasive Aphid Pest				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Entomology</u>				
Zhou, Xuguo	3048105426	\$0.	\$52,230.	\$52,230.
KY Science and Technology Co Inc Kentucky Commercialization Fund: Integration of Double Stranded RNA into Baiting System: A Novel Genetic Control Strategy for Termites				
Entomology	Totals:	\$1,388,626.	\$577,437.	\$1,966,063.
<u>Forestry</u>				
Arthur, Mary A	3048105924	\$10,000.	\$0.	\$10,000.
Forest Service Challenge Cost Share: Prescribed Fire Research in the Daniel Boone National Forest				
Barton, Christopher D	3048105939	\$14,000.	\$0.	\$14,000.
Forest Service Long-Term Effects of Forestry Best Management Practices on Hydrology, Water Chemistry and Woody Debris in Three Appalachian Headwater Catchments				
Barton, Christopher D	3048106581	\$8,000.	\$0.	\$8,000.
KY Nature Preserves Commission Characterization of Headwater Seeps in the Frances Palk State Nature Preserve				
Barton, Christopher D	3048106931	\$56,024.	\$0.	\$56,024.
University of Georgia ARRA: Stream System Field Condition Assessment - Phase II				
Cox, John J	3048106303	\$30,000.	\$0.	\$30,000.
KY Department of Fish and Wildlife The Common Raven in Cliff Habitat: Detection and Occupancy				
Cox, John J	3048106722	\$107,000.	\$0.	\$107,000.
KY Department of Fish and Wildlife Dispersal & Population Expansion of the Black Bear in Eastern Kentucky				
Lacki, Michael J	3048105719	\$51,305.	\$0.	\$51,305.
KY Department of Fish and Wildlife Roosting and Foraging Behavior of Rafinesque's Big-Eared Bat near the Northern Limits of the Species Range				
Lacki, Michael J	3048106726	\$13,897.	\$0.	\$13,897.
KY Department of Fish and Wildlife Status, Distribution, and Reproductive Characteristics of River Otters in Kentucky				
Lhotka, Laura R	3048105963	\$10,500.	\$0.	\$10,500.
Auburn University Fostering Environmental Stewardship of the Gulf of Mexico: A Trans-Boundary Network of Water Education and Monitoring for Animal Producers, Classrooms and Community Volunteers				
Stringer, Jeffrey W	3048105908	\$7,500.	\$0.	\$7,500.
Forest Service Silvicultural Prescriptions for Degraded Hardwood Stands				
Stringer, Jeffrey W	3048105909	\$294,000.	\$0.	\$294,000.
KY Energy and Environment Cabinet Economic Impact of Fire on Forest Product Values in the Appalachian Regions of Kentucky and Tennessee				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Forestry</u>				
Stringer, Jeffrey W	3048106576	\$30,000.	\$0.	\$30,000.
KY Energy and Environment Cabinet Kentucky Woodland Magazine - Degraded Stand Revitalization and Small Woodland Management Issue				
Stringer, Jeffrey W	3048106740	\$15,000.	\$0.	\$15,000.
KY Department of Fish and Wildlife Forest Management Assistance on State Wildlife Management Areas and Private Lands Technical Assistance				
Stringer, Jeffrey W	3048106996	\$67,631.	\$0.	\$67,631.
Forest Service Long-Lived Wood Products: Carbon and Competitive Advantages for Hardwood Mills				
Forestry	Totals:	\$714,857.	\$0.	\$714,857.
<u>Family & Consumer Sciences</u>				
Ashurst, Kerri Lynn	3048105210	\$0.	\$100,000.	\$100,000.
Kansas State University Kentucky Operation: Military Kids				
Stephenson, Laura F	3048105012	\$0.	\$4,000.	\$4,000.
Auburn University Kentucky Healthy Homes and Communities				
Family & Consumer Sciences	Totals:	\$0.	\$104,000.	\$104,000.
<u>Horticulture</u>				
Archbold, Douglas D	3048106909	\$1,633.	\$0.	\$1,633.
Cornell University Viticulture Consortium East				
DeBolt, Seth	3048106049	\$300,000.	\$0.	\$300,000.
National Science Foundation From small molecule to gene: using chemical genetics to understand cell wall sensing and advance molecular resources				
Downie, A Bruce	3048106713	\$0.	\$6,000.	\$6,000.
National Science Foundation Collaborative Research: An F-box protein targeting PIF1 and PIF3				
Downie, A Bruce	3048106713	\$153,310.	\$0.	\$153,310.
National Science Foundation Collaborative Research: An F-box protein targeting PIF1 and PIF3				
Durham, Richard E	3048104490	\$0.	\$15,000.	\$15,000.
University of Nebraska eXtension Consumer Horticulture Certified Cop Leadership Funds 2008				
Houtz, Robert L	3046893300	\$0.	\$-2.	\$-2.
Energy Research Mechanism and Significance of Post-Translational Modifications in the Large Subunit of Ribulose Biphosphate Carboxylase/Oxygenase				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Horticulture</u>				
Houtz, Robert L	3046893300	\$0.	\$-14,663.	\$-14,663.
Energy Research Mechanism and Significance of Post-Translational Modifications in the Large Subunit of Ribulose Biphosphate Carboxylase/Oxygenase				
Ingram, Dewayne L	3046999200	\$0.	\$-3,897.	\$-3,897.
Department of Agriculture New Crop Opportunities, KY, Phase VII				
Ingram, Dewayne L	3046999200	\$0.	\$2,346.	\$2,346.
Department of Agriculture New Crop Opportunities, KY, Phase VII				
Ingram, Dewayne L	3048079200	\$0.	\$-838,000.	\$-838,000.
KY Horticulture Council Kentucky Horticulture Council, Grant 4				
Ingram, Dewayne L	3048079200	\$0.	\$682,334.	\$682,334.
KY Horticulture Council Kentucky Horticulture Council, Grant 4				
Ingram, Dewayne L	3048079200	\$0.	\$9,776.	\$9,776.
KY Horticulture Council Kentucky Horticulture Council, Grant 4				
Ingram, Dewayne L	3048106021	\$489,451.	\$0.	\$489,451.
Cooperative State Research Education and Extension New Crop Opportunities, Phase X				
Ingram, Dewayne L	3048106793	\$0.	\$-10,000.	\$-10,000.
KY Horticulture Council Kentucky Horticulture Council, Grant 4 - FY10				
Ingram, Dewayne L	3048106793	\$0.	\$9,000.	\$9,000.
KY Horticulture Council Kentucky Horticulture Council, Grant 4 - FY10				
Ingram, Dewayne L	3048106793	\$838,000.	\$0.	\$838,000.
KY Horticulture Council Kentucky Horticulture Council, Grant 4 - FY10				
Williams, Mark A	3048106741	\$276,448.	\$0.	\$276,448.
Iowa State University Sustainable Systems for Cucurbit Crops on Organic Farms				
Horticulture	Totals:	\$2,058,842.	\$-142,106.	\$1,916,736.
<u>Plant Pathology</u>				
Ghabrial, Said A	3048106033	\$36,380.	\$0.	\$36,380.
University of Illinois Construction of a DNA-Based Virus Induced Gene Silencing Tools for Functional Genomics of Soybeans				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Plant Pathology</u>				
Ghabrial, Said A	3048106995	\$52,333.	\$0.	\$52,333.
University of Illinois Multiple Disease Resistant Soybeans: Gene Discovery and Transfer of Disease Resistance into Soybean				
Goodin, Michael M	3048104575	\$0.	\$150,000.	\$150,000.
National Science Foundation A Host Protein Interaction and Localization Map for a Plant				
Hershman, Donald E	3048104661	\$0.	\$11,223.	\$11,223.
North Carolina State University ipmPIPE 2008: University of Kentucky Component				
Kachroo, Aardra P	3048104449	\$0.	\$130,617.	\$130,617.
United Soybean Board Enhancing Soybean Yield by Manipulating the Expression of Seed Trait-Determining Genes				
Kachroo, Pradeep	3048104688	\$0.	\$12,000.	\$12,000.
National Science Foundation Glycerol Metabolism and Its Role in Biotrophy Versus Necrotrophy in an Arabidopsis/Fungal Hemibiotroph Model System				
Schardl, Christopher L	3048105841	\$98,663.	\$0.	\$98,663.
KY Science and Technology Co Inc KSEF R&D Excellence: Development and deployment of a non-toxic endophyte in tall fescue for forage				
Schardl, Christopher L	3048106721	\$421,394.	\$0.	\$421,394.
Cooperative State Research Education and Extension Advanced Genetic Technologies, KY				
Seebold, Kenneth W	3048104757	\$0.	\$6,000.	\$6,000.
North Carolina State University Expanding ipmPIPE for Cucurbit Downy Mildew Forecasting				
Seebold, Kenneth W	3048106094	\$80,000.	\$0.	\$80,000.
KY Science and Technology Co Inc KSEF R&D Excellence: Investigating the Role of the Cuticle in Resistance to Foliar Plant Pathogens				
Seebold, Kenneth W	3048106730	\$10,000.	\$0.	\$10,000.
University of Florida Managing Phytophthora capsici on Pepper and Summer Squash with Combinations of Bioten and Conventional Fungicides				
Vincelli, Paul	3048104024	\$0.	\$39,000.	\$39,000.
University of Florida Southern Region Plant Diagnostic Network, IPM PIPE 2007, KY Component				
Plant Pathology	Totals:	\$698,770.	\$348,840.	\$1,047,610.
<u>Community & Leadership Devel</u>				
Clore, Danielle T	3048106694	\$250,000.	\$0.	\$250,000.
Administration for Children and Families ARRA: Building the Capacity of Kentucky's Nonprofit Organizations				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Community & Leadership Devel</u>				
Hustedde, Ronald J	3048106525	\$200,000.	\$0.	\$200,000.
Appalachian Regional Commission Youth E-Discovery Challenge				
Jones, Kenneth R	3048106968	\$10,000.	\$0.	\$10,000.
University of Arizona CYFAR Sustainable Community Projects Common Measures Study				
Nah, Seungahn	3048105038	\$0.	\$5,000.	\$5,000.
American University The Kentucky Citizen Media Project: The Lexington Commons (via New Voices)				
Community & Leadership Devel	Totals:	\$460,000.	\$5,000.	\$465,000.
<u>Veterinary Science</u>				
Bailey, Ernest F	3048105938	\$28,125.	\$0.	\$28,125.
University of Minnesota Phase 3: Continuation of SNP Gene Mapping Projects				
Chambers, Thomas M	3048105193	\$0.	\$32,503.	\$32,503.
Science Applications International Co Testing Methods for Influenza Infection in Equine Models				
Chambers, Thomas M	3048105726	\$0.	\$5,977.	\$5,977.
Intervet Inc Does Vaccination of Very Young Foals with FluAvert in the Presence of Maternal Antibodies Protect them from Infection?				
Chambers, Thomas M	3048106302	\$50,730.	\$0.	\$50,730.
Science Applications International Co Testing Methods for Influenza Infection in Equine Models (Pilot #2)				
Horohov, David W	3048106836	\$200,000.	\$0.	\$200,000.
National Institute of Food and Agriculture The Effect of Age on Equine Dendritic Cell Interactions with Rhodococcus Equi				
Howe, Daniel K	3048106631	\$500,000.	\$0.	\$500,000.
Cooperative State Research Education and Extension Genome Sequence for the Apicomplexan Sarcocystis Neurona				
Issel, Charles J	3046978700	\$0.	\$-153,485.	\$-153,485.
IDEXX Laboratories Inc Equine Infectious Anemia Diagnostics				
Lear, Teri L	3048106853	\$35,839.	\$0.	\$35,839.
Indiana State University Behavioral Genomics of the White-throated Sparrow				
MacLeod, James N		\$100,000.	\$0.	\$100,000.
Morris Animal Foundation Orthopaedic Pathology and Genetic Associations in Cervical Stenotic Myelopathy				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Veterinary Science</u>				
MacLeod, James N	3048105919	\$33,333.	\$0.	\$33,333.
University of Minnesota Genes and Genetic Mechanisms Modulating Maturation and Repair of Articular Cartilage and Responses to Intra-Articular Glucocorticoid Therapy				
Troedsson, Mats H.T.	3048106104	\$40,000.	\$0.	\$40,000.
Morris Animal Foundation Morris Animal Foundation (MAF) Pfizer Animal Health (PAH) Veterinary Fellowship				
Veterinary Science	Totals:	\$988,027.	-\$115,005.	\$873,022.
<u>Regulatory Services</u>				
Thom, William O	3048104801	\$0.	\$34,131.	\$34,131.
Food and Drug Administration Medicated Feed Mill & BSE Rule Inspections				
Regulatory Services	Totals:	\$0.	\$34,131.	\$34,131.
<u>Livestock Diag Disease Center</u>				
Carter, Craig N	3048105173	\$0.	\$32,718.	\$32,718.
Texas A&M University R Equi Phneumonia: Airborne Exposure and Foal Immunity / Rhodococcus Equi Airborne Environmental Study				
Carter, Craig N	3048105878	\$400,000.	\$0.	\$400,000.
KY Department of Agriculture Diagnostic Laboratory Services for Farmers and Agribusinesses				
Carter, Craig N	3048106082	\$27,477.	\$0.	\$27,477.
Foreign Agricultural Service TDY to Afghanistan on OIE Disease Reporting				
Carter, Craig N	3048106590	\$254,514.	\$0.	\$254,514.
Cooperative State Research Education and Extension Regional Animal Health Data Warehousing and Data Mining System				
Carter, Craig N	3048106617	\$22,800.	\$0.	\$22,800.
KY Department of Agriculture Bovine Spongiform Encephalopathy Testing and Related Services				
Carter, Craig N	3048106620	\$5,000.	\$0.	\$5,000.
KY Department of Fish and Wildlife KY Fish and Wildlife Diagnostic Services 2010				
Livestock Diag Disease Center	Totals:	\$709,791.	\$32,718.	\$742,509.
<u>Area Extension Field Programs</u>				
Stamper, Charles E	3048107006	\$36,480.	\$0.	\$36,480.
EQT Foundation Enhancing the Marketing Skills for East Kentucky Artisans				
Area Extension Field Programs	Totals:	\$36,480.	\$0.	\$36,480.
<u>Family & Consumer Sciences</u>				
Stephenson, Laura F	3048105941	\$90,890.	\$0.	\$90,890.
University of Tennessee Investor Education for College Students				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Family & Consumer Sciences</u>				
Stephenson, Laura F	3048106582	\$10,000.	\$0.	\$10,000.
KY Department of Agriculture Kentucky Proud Healthy Habits				
Vail, Ann	3048106000	\$566,400.	\$0.	\$566,400.
Cooperative State Research Education and Extension Health Education Leadership, KY				
Vail, Ann	3048106542	\$0.	\$1,040,731.	\$1,040,731.
KY Cabinet for Health and Family Services Supplemental Nutrition Assistance Program-Education (SNAP-Ed)				
Vail, Ann	3048106542	\$442,686.	\$0.	\$442,686.
KY Cabinet for Health and Family Services Supplemental Nutrition Assistance Program-Education (SNAP-Ed)				
Family & Consumer Sciences	Totals:	\$1,109,976.	\$1,040,731.	\$2,150,707.
<u>e-Extension</u>				
Griffin, Ashley S	3048104498	\$0.	\$15,000.	\$15,000.
University of Nebraska HorseQuest Community of Practice				
Griffin, Ashley S	3048106801	\$38,750.	\$0.	\$38,750.
Michigan State University The Development, Evaluation and Implementation of an Online Safety Course for Youth Working on Equine Facilities				
Wood, Craig H	3046887200	\$0.	\$161,668.	\$161,668.
University of Nebraska ECOP/CSREES E-eXtension-Supplement				
Wood, Craig H	3046887200	\$0.	\$25,740.	\$25,740.
University of Nebraska ECOP/CSREES E-eXtension-Supplement				
Wood, Craig H	3048104096	\$0.	\$337,894.	\$337,894.
University of Nebraska The Transformation of Cooperative Extension				
e-Extension	Totals:	\$38,750.	\$540,302.	\$579,052.
<u>Agr Programs</u>				
Hancock, John N	3048106069	\$6,000.	\$0.	\$6,000.
University of Tennessee AgrAbility UT-KY Agreement				
Husband, Andrea L	3048106528	\$90,000.	\$0.	\$90,000.
Cooperative State Research Education and Extension Enhancing the EDEN Strengthening Community Agrosecurity Planning (S-CAP) Project				
Husband, Andrea L	3048106917	\$101,000.	\$0.	\$101,000.
Purdue University The EDEN Strengthening Community Agrosecurity Planning (S-CAP) Train-the-Trainer Project: Phase 2				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Agr Programs</u>				
Palmer, Gary K	3048106746	\$54,000.	\$0.	\$54,000.
KY Energy and Environment Cabinet University of Kentucky Cooperative Extension Service Liaison				
Yeargan, Ricky N	3048072700	\$0.	\$-47,000.	\$-47,000.
Purdue University Development of an Animal Emergency/Biosecurity Management Course				
Yeargan, Ricky N	3048072700	\$0.	\$70,000.	\$70,000.
Purdue University Development of an Animal Emergency/Biosecurity Management Course				
Agr Programs	Totals:	\$251,000.	\$23,000.	\$274,000.
<u>Nutrition and Food Science</u>				
Forsythe, Hazel W	3048104395	\$0.	\$30,114.	\$30,114.
Lexington Fayette Urban County Government Bluegrass/Aspendale HOPE VI Revitalization				
Kurzynske, Janet S	3048105665	\$0.	\$170,000.	\$170,000.
Cooperative State Research Education and Extension Children, Youth, and Families Education and Research Network - Program Component				
Kurzynske, Janet S	3048106543	\$700,000.	\$0.	\$700,000.
Cooperative State Research Education and Extension Children, Youth, and Families at Risk Capacity Building Program				
Tietyen, Janet L	3048106812	\$5,000.	\$0.	\$5,000.
Foundation for a Healthy KY Survey of Kentucky Food Consumers' Knowledge and Attitudes on Calories in Quick Serve Menu Items				
Nutrition and Food Science	Totals:	\$705,000.	\$200,114.	\$905,114.
<u>Family Studies</u>				
Johnson, Cheryl Ann	3048105861	\$10,000.	\$0.	\$10,000.
KY Department of Education Teacher Educators' Professional Development Grant - FY10				
Werner-Wilson, Ronald J.	3048106641	\$60,867.	\$0.	\$60,867.
KY Cabinet for Health and Family Services Healthy Marriage Child Support Community Demonstration Project				
Family Studies	Totals:	\$70,867.	\$0.	\$70,867.
<u>Merchandising, Apparel & Textiles</u>				
Easter, Elizabeth P	3046898300	\$0.	\$38,785.	\$38,785.
National Association of Institutional Linen Management Quality Control Laboratory For NAILM				
Merchandising, Apparel & Textiles	Totals:	\$0.	\$38,785.	\$38,785.
<u>Ky Tobacco Research & Dev Center</u>				
Littleton, John M	3048104656	\$0.	\$181,968.	\$181,968.
Naprogenix STTR: Hypericum Extracts as Potential Anti-Relapse Medications in Alcoholism				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Agriculture</u>				
<u>Ky Tobacco Research & Dev Center</u>				
Littleton, John M	3048104657	\$0.	\$127,853.	\$127,853.
Naprogenix STTR: Transgenic Plant Cells as a Source of Hepatoprotective Drugs				
Littleton, John M	3048105602	\$0.	\$42,160.	\$42,160.
Naprogenix Potential Anti-Relapse Drugs: A Plant Genomics Approach				
Ky Tobacco Research & Dev Center	Totals:	\$0.	\$351,981.	\$351,981.
	Agriculture Totals:	\$20,856,310.	\$5,199,152.	\$26,055,462.
<u>Minority Affairs</u>				
<u>Minority Affairs</u>				
Thomas, Toni	3048105087	\$0.	\$69,769.	\$69,769.
KY Council on Postsecondary Education Governor's Minority Student College Preparation Program				
Minority Affairs	Totals:	\$0.	\$69,769.	\$69,769.
<u>Student Support Services</u>				
Wims, Lydia E	3046933700	\$0.	\$304,857.	\$304,857.
Department of Education Student Support Services				
Student Support Services	Totals:	\$0.	\$304,857.	\$304,857.
	Minority Affairs Totals:	\$0.	\$374,626.	\$374,626.
<u>Student Affairs</u>				
<u>VIP Center</u>				
Edwards, Dorothy Jo		\$47,006.	\$0.	\$47,006.
KY Justice Cabinet ARRA: VIP Center Specialized Victim Advocate				
VIP Center	Totals:	\$47,006.	\$0.	\$47,006.
	Student Affairs Totals:	\$47,006.	\$0.	\$47,006.
<u>Library Administration</u>				
<u>Library Administration</u>				
Boyd, Douglas A.	3048106108	\$900.	\$0.	\$900.
KY Historical Society Kentucky Legislature Oral History Project				
Boyd, Douglas A.	3048106515	\$3,500.	\$0.	\$3,500.
KY Historical Society Kentucky Writers Oral History Project				
Greider, Antoinette	3048090900	\$0.	\$112,714.	\$112,714.
Lexmark International Inc Lexmark International, Inc. Information Center				
Molinaro, Mary H	3046894500	\$0.	\$5,222.	\$5,222.
National Endowment for the Humanities National Digital Newspaper Program Phase One: The Kentucky Test Bed, or KNP Redux				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Library Administration</u>				
<u>Library Administration</u>				
Molinaro, Mary H	3046894500	\$0.	\$393,081.	\$393,081.
National Endowment for the Humanities National Digital Newspaper Program Phase One: The Kentucky Test Bed, or KNP Redux				
Library Administration	Totals:	\$4,400.	\$511,017.	\$515,417.
<u>Medical Center Library</u>				
Stith, Janet B	3046555600	\$0.	\$9,362.	\$9,362.
Frontier School Midwifery Family Nursing Consulting Agreement UKCMC Library & Frontier School Midwifery and Family Nursing				
Medical Center Library	Totals:	\$0.	\$9,362.	\$9,362.
	Library Administration Totals:	\$4,400.	\$520,379.	\$524,779.
<u>Office of the Provost</u>				
<u>Office of the Provost</u>				
Hollingsworth, Randolph	3048105873	\$55,000.	\$0.	\$55,000.
Suder Foundation The Suder Foundation Program Model/Center Development Planning Grant				
Office of the Provost	Totals:	\$55,000.	\$0.	\$55,000.
<u>Art Museum</u>				
Walsh-Piper, Kathleen A	3048105971	\$50,000.	\$0.	\$50,000.
National Endowment for the Arts ARRA: The Arts and the American Recovery and Reinvestment Act of 2009, Public Law 111-5				
Walsh-Piper, Kathleen A	3048106520	\$7,200.	\$0.	\$7,200.
Lexarts Community Outreach Grant				
Art Museum	Totals:	\$57,200.	\$0.	\$57,200.
<u>Partnership Inst. for Math and Science</u>				
Eakin, Paul M	3048106536	\$56,000.	\$0.	\$56,000.
Northern KY University Kentucky Center for Mathematics Regional Coordinator / Mathematics Outreach Specialists				
Eakin, Paul M	3048106987	\$49,980.	\$0.	\$49,980.
Northern KY University Kentucky Early Mathematics Testing Program / KYOTE				
Yopp, John H	3048106654	\$24,000.	\$0.	\$24,000.
AT&T Foundation AT&T Foundation Bardstown PEP Implementation				
Yopp, John H	3048106961	\$499,794.	\$0.	\$499,794.
Toyota Foundation Partnership Enhancement Model for P-16 Mathematics and Science Education				
Yopp, John H	3048106963	\$10,000.	\$0.	\$10,000.
Virginia Polytechnic Institute and State University Evaluate - E (Examining VALUe Added in Trasatlantic Exchanges in Engineering)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Office of the Provost</u>				
<u>Partnership Inst. for Math and Science</u>				
Zeidler-Watters, Kimberly Jean	3048105139	\$0.	\$160,000.	\$160,000.
KY Department of Education Math and Science Leadership Network				
Zeidler-Watters, Kimberly Jean	3048106007	\$200,000.	\$0.	\$200,000.
KY Department of Education Developing Algebraic Thinking (YR 3) - Learning Targets, Asessments and Intervention for K-5				
Zeidler-Watters, Kimberly Jean	3048106009	\$200,000.	\$0.	\$200,000.
KY Department of Education Partnering to Progress (YR 3) - Learning in Physical Science K-5				
Zeidler-Watters, Kimberly Jean	3048106606	\$195,000.	\$0.	\$195,000.
KY Department of Education Making Algebraic Connections (MAC) - UK MAC Math Partnership Year 1				
Zeidler-Watters, Kimberly Jean	3048106607	\$195,000.	\$0.	\$195,000.
KY Department of Education Learning in Physical Science (LeaPs) - UK Leaps Science Partnership Year 1				
Partnership Inst. for Math and Science	Totals:	\$1,429,774.	\$160,000.	\$1,589,774.
<u>International Affairs</u>				
Bettez, David J	3048106308	\$70,000.	\$0.	\$70,000.
German American Fulbright 2009 German Fulbright Diversity Institute				
Herron, Shana L	3048104969	\$0.	\$41,000.	\$41,000.
Freeman Foundation National Consortium for Teaching About Asia - Year XI and XII				
Herron, Shana L	3048105305	\$0.	\$150,000.	\$150,000.
Freeman Foundation Undergraduate Asian Studies Program				
Herron, Shana L	3048106605	\$4,510.	\$0.	\$4,510.
Japan Foundation Matsuri in Kentucky				
International Affairs	Totals:	\$74,510.	\$191,000.	\$265,510.
	Office of the Provost Totals:	\$1,616,484.	\$351,000.	\$1,967,484.
<u>Arts & Sciences</u>				
<u>Anthropology</u>				
Ahler, Steven R	3048103305	\$0.	\$69,922.	\$69,922.
KY Transportation Cabinet Phase I Archaeological Survey - Anthropology Prime Account				
Ahler, Steven R	3048103305	\$0.	\$3,599.	\$3,599.
KY Transportation Cabinet Phase I Archaeological Survey - Anthropology Prime Account				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Arts & Sciences</u>				
<u>Anthropology</u>				
Ahler, Steven R	3048103305	\$0.	\$12,599.	\$12,599.
KY Transportation Cabinet Phase I Archaeological Survey - Anthropology Prime Account				
Ahler, Steven R	3048105831	\$62,221.	\$0.	\$62,221.
CDP Engineers Inc Phase III Data Record Excavations at 15ED111 in Estill County, Kentucky				
Ahler, Steven R	3048105832	\$29,018.	\$0.	\$29,018.
Geotech Engineering & Testing Inc Phase I Archaeological Survey, Purchase Area Regional Industrial Authority (PRP) Industrial Park, Graves County, Kentucky				
Ahler, Steven R	3048105833	\$10,760.	\$0.	\$10,760.
KY Department for Facilities Management Phase I Archaeological Survey and Phase II Testing for Sewer Line Changes, Green River State Park				
Ahler, Steven R	3048105834	\$4,893.	\$0.	\$4,893.
Owingsville Bath County Parks and Recreation Commiss Archaeological Survey for Park Improvements, Bath County, Kentucky				
Ahler, Steven R	3048105835	\$6,887.	\$0.	\$6,887.
Edmonson County Water District Archeological Survey for Water District Improvements, Edmonson County, Kentucky, Job WX21061028				
Ahler, Steven R	3048105837	\$8,101.	\$0.	\$8,101.
University of Louisville A Proposal to Perform a Phase 1 Archaeological Survey of a Proposed Stream Restoration Project in Oldham County, KY				
Ahler, Steven R	3048106025	\$2,475.	\$0.	\$2,475.
KY Heritage Council Hacker Branch and Fish Creek Boat Ramps, Owsley County, Kentucky Grant #sY10-09-AGN-401				
Ahler, Steven R	3048106709	\$3,833.	\$0.	\$3,833.
KY Finance and Administration Cabinet ARRA: Archaeological Survey of a Water Line Extension at the Bluegrass Station Facility, Fayette County, Kentucky				
Ahler, Steven R	3048106710	\$5,854.	\$0.	\$5,854.
KY Finance and Administration Cabinet ARRA: Archaeological Survey for Force Main and New Wastewater Treatment Plant at Pennyriple Forest State Resort Park, Christian County, Kentucky				
Ahler, Steven R	3048106720	\$2,999.	\$0.	\$2,999.
KY Finance and Administration Cabinet ARRA: Archaeological Survey for Sewer Line Changes General Burnside Island State Park, Pulaski County, KY				
Ahler, Steven R	3048106802	\$11,403.	\$0.	\$11,403.
Northern KY University Archaeological Survey of Cultural Resources in Grant County, Ky (Reb Stacey Property)				
Ahler, Steven R	3048106826	\$39,999.	\$0.	\$39,999.
Forest Service ARRA: Fitchburg Furnace Stabalization Agreement 10-PA-11084419-006				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Arts & Sciences</u>				
<u>Anthropology</u>				
Ahler, Steven R	3048106851	\$10,831.	\$0.	\$10,831.
University of Louisville Design, Construction, and Monitoring of the Harrison Fork Watershed Project in Nelson County, Kentucky				
Ahler, Steven R	3048106854	\$5,484.	\$0.	\$5,484.
KY State University Phase I Archaeological Survey of 315 Old Maryland Avenue and an Adjacent Lot on the Kentucky State University Campus in Franklin County, Kentucky				
Ahler, Steven R	3048106982	\$3,600.	\$0.	\$3,600.
KY Heritage Council Archaeological Survey For Proposed Boat Ramp At Sledd Creek On Kentucky Lake, Marshall County, Kentucky				
Cliggett, Lisa C	3048106772	\$0.	\$4,856.	\$4,856.
National Science Foundation Fellowship for Karen Rignall: Doctoral Disseration Research: Expanding cultivation, land, and livelihood transformations in southern Morocco				
Cliggett, Lisa C	3048106772	\$750.	\$0.	\$750.
National Science Foundation Fellowship for Karen Rignall: Doctoral Disseration Research: Expanding cultivation, land, and livelihood transformations in southern Morocco				
Crothers, George M	3048106028	\$8,000.	\$0.	\$8,000.
Western KY University Cave Spring Cavern Educational Reserve, Warren County, Kentucky				
Koch, Erin	3048106743	\$52,250.	\$0.	\$52,250.
National Council for Eurasian and East European Resear Humanitarianism as Politics: Internally Displaced Persons, Health, and Citizenship in the Republic of Georgia				
Ramberg, Lucinda E.	3048106546	\$62,400.	\$0.	\$62,400.
Harvard University A Question of Theogamy: Kinmaking Between Goals and Humans				
Udvardy, Monica L	3048105897	\$14,918.	\$0.	\$14,918.
National Science Foundation Fellowship: The Effects of the Migration on Gender Norms and Relations: The Post-Repatriation Experience in Bor, South Sudan				
Anthropology	Totals:	\$346,676.	\$90,976.	\$437,652.
<u>Ky Archaeological Survey</u>				
McBride, Kim A	3048106974	\$5,000.	\$0.	\$5,000.
Summers County Historic Landmark Commission Continue Frontier Forts Project				
Pollack, David	3048106586	\$12,000.	\$0.	\$12,000.
KY Nature Preserves Commission Archaeolgical Survey of HLCF Tracts at Various State Nature Preserves and Natural Area-Three Ponds Hills, and R&S Salvage				
Pollack, David	3048106635	\$40,000.	\$0.	\$40,000.
National Park Service Archaeological Investigation of New River Gorge National River Lowlands in Summers and Raleigh Counties, West Virginia				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Arts & Sciences</u>				
<u>Ky Archaeological Survey</u>				
Stottman, Michael Jay	3048106110	\$49,740.	\$0.	\$49,740.
Riverside the Farnsley Moremen Landing Farnsley-Moremen Landing, Building Blocks of History Education Program 2009-2010				
Stottman, Michael Jay	3048106597	\$17,500.	\$0.	\$17,500.
JPJ Main Street LLC Archaeological Mitigation of Lewis Pottery Site, 418 East Main Street, Louisville, Kentucky				
Ky Archaeological Survey	Totals:	\$124,240.	\$0.	\$124,240.
<u>Chemistry</u>				
Anthony, John Edward	3046842200	\$0.	\$107,000.	\$107,000.
US Office of Naval Research Photovoltaic Devices from Self-Assembled Organic Semiconductors				
Anthony, John Edward	3048104433	\$0.	\$115,000.	\$115,000.
National Science Foundation A Exploration of Higher Acenes				
Anthony, John Edward	3048104433	\$0.	\$19,398.	\$19,398.
National Science Foundation A Exploration of Higher Acenes				
Anthony, John Edward	3048105188	\$0.	\$108,640.	\$108,640.
Pennsylvania State University TiO2 Nanotube Array-Organic Semiconductor Heterojunction Solar Cells for Efficient, Low Cost, Large Area Scalable Energy Conversion				
Atwood, David A	3046933600	\$0.	\$44,996.	\$44,996.
Merloc LLC Chemical Solutions to Metal Waste Problems				
Atwood, David A	3046933600	\$0.	\$21,936.	\$21,936.
Merloc LLC Chemical Solutions to Metal Waste Problems				
Atwood, David A	3046933600	\$0.	\$10,000.	\$10,000.
Merloc LLC Chemical Solutions to Metal Waste Problems				
Atwood, David A	3048106623	\$20,160.	\$0.	\$20,160.
US Army Research Office Syposium at American Chemical Society Meeting, Washington DC, Aug. 19-20, 2009: "Sensing and Destroying Chemical Warfare Agents and Pesticides"				
Bachas, Leonidas G	3048105598	\$0.	\$200,777.	\$200,777.
Western KY University Versatile Biosensing Platform for Monitoring Bone Markers for Space Medicine				
Bachas, Leonidas G	3048106841	\$47,836.	\$0.	\$47,836.
Western KY University Versatile Biosensing Platform for Monitoring Bone Markers for Space Medicine (State Match)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Arts & Sciences				
Chemistry				
Butterfield, David A	3048104686	\$0.	\$118,441.	\$118,441.
St Louis University Oxidative Dysfunction of Lrp at the Blood-Brain Barrier in Alzheimer's Disease				
Clouthier, Dennis J	3048104912	\$0.	\$62,450.	\$62,450.
National Science Foundation Laser Spectroscopy of Main Group Reactive Intermediates				
Daunert, Sylvia	3048104224	\$0.	\$96,431.	\$96,431.
University of California Irvine C-MEMS/C-NEMS for Miniature Biofuels Cells				
Daunert, Sylvia	3048105588	\$0.	\$302,022.	\$302,022.
National Institute of General Medical Sciences Modified Photoproteins as Labels and Molecular Switches in Bioanalysis				
Daunert, Sylvia	3048106084	\$4,622.	\$0.	\$4,622.
iGlyko Inc Preparation of Glucose Precognition Peptides				
Knecht, Marc R.	3048104966	\$0.	\$25,000.	\$25,000.
Petroleum Research Fund Biomimetic Synthesis of Heterogeneous Catalysts				
Miller, Anne-Frances	3048105958	\$276,829.	\$0.	\$276,829.
National Institute of General Medical Sciences ARRA: Enzyme Mis-Metallation, Consequences and Opportunities				
Wei, Yinan	3048106609	\$26,971.	\$0.	\$26,971.
Western KY University Fellowship for Ferrell: Toward the In-flight Detection of Pathogenic Microbes During Space Travel				
Yang, Dong-Sheng	3048106015	\$0.	\$50,000.	\$50,000.
KY Science and Technology Co Inc KSEF R&D Excellence: High Resolution Pulsed-Field-Ionization Ion Spectroscopy of Transition-Metal-Oxide Clusters				
Yang, Dong-Sheng	3048106015	\$50,000.	\$0.	\$50,000.
KY Science and Technology Co Inc KSEF R&D Excellence: High Resolution Pulsed-Field-Ionization Ion Spectroscopy of Transition-Metal-Oxide Clusters				
Yang, Dong-Sheng	3048106715	\$100,000.	\$0.	\$100,000.
American Chemical Society American Chemical Society Petroleum Research Fund: Spectroscopy and Structures of Transition Metal Oxide Clusters				
Yates, S W	3048107018	\$245,000.	\$0.	\$245,000.
Idaho State University Advanced Elastic/Inelastic Nuclear Data Development Project				
Chemistry	Totals:	\$771,418.	\$1,282,091.	\$2,053,509.

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Arts & Sciences				
Geography				
Phillips, Jonathan D		\$26,905.	\$0.	\$26,905.
Forest Service				
Impacts of off-highway vehicles in the Ouachita National Forest				
Schein, Richard H	3048106051	\$1,400.	\$0.	\$1,400.
KY Oral History Commission				
Entrepreneurship in the Arts: Understanding the Craft Industry in Eastern Kentucky				
Zook, Matthew A	3048106086	\$14,102.	\$0.	\$14,102.
ZookNIC Inc				
Investigating the Space of Google Maps				
Geography	Totals:	\$42,407.	\$0.	\$42,407.
Geology				
Moecher, David P	3048105337	\$0.	\$33,729.	\$33,729.
National Science Foundation				
Upgrade of the University of Kentucky ARL SEMQ Electron Probe Microanalyzer				
Romanek, Christopher Scott	3048106628	\$55,920.	\$0.	\$55,920.
University of Georgia				
Cavity Ring Down Spectroscopy: Proof of Concept for Environmental Analysis and Monitoring of Process Systems of Defense Programs at DOE's Savannah River Site				
Romanek, Christopher Scott	3048106629	\$19,903.	\$0.	\$19,903.
University of Georgia				
Survey of Environmental Monitoring Techniques for Application to Defense Program Analysis and Monitoring Needs				
Romanek, Christopher Scott	3048106675	\$11,865.	\$0.	\$11,865.
National Science Foundation				
Collaborative Research: Holocene Shell Accumulation from the Southeast Brazilian Bight: Multi-Centennial Dynamics of Oceanographic, Environmental, and Ecological Changes				
Romanek, Christopher Scott	3048106786	\$0.	\$103,775.	\$103,775.
University of Wisconsin				
Inorganic and Organic ligand-promoted carbonate nucleation				
Romanek, Christopher Scott	3048106786	\$28,922.	\$0.	\$28,922.
University of Wisconsin				
Inorganic and Organic ligand-promoted carbonate nucleation				
Woolery, Edward W	3048106401	\$45,896.	\$0.	\$45,896.
US Geological Survey				
2009 National Earthquake Hazards Reduction Program: Ground Motion Site Effects in the Wabash Valley Region from the 18 April 2008 Mt Carmel Illinois Earthquake and Aftershocks				
Woolery, Edward W	3048106584	\$59,484.	\$0.	\$59,484.
US Geological Survey				
Collaborative Research Between the University of Kentucky and the University of Memphis: High-Resolution P- and S-Waves Velocity Structure of the Post-Paleozoic Sediments in the Upper Mississippi Embayment: 2009 Earthquake Hazards Reduction Program				
Geology	Totals:	\$221,990.	\$137,504.	\$359,494.

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Arts & Sciences</u>				
<u>Mathematics</u>				
Eakin, Paul M	3046635800	\$0.	\$-82,000.	\$-82,000.
National Science Foundation Appalachian Mathematics and Science Partnership				
Eakin, Paul M	3046635800	\$0.	\$300,000.	\$300,000.
National Science Foundation Appalachian Mathematics and Science Partnership				
Ehrenborg, Richard	3048105846	\$156,625.	\$0.	\$156,625.
National Science Foundation ARRA: Bruhut and balanced graphs, manifolds, partitions, and affine permutations				
Gluesing-Lueerssen, Heide	3048106526	\$183,418.	\$0.	\$183,418.
National Science Foundation Weight Enumeration for Convolutional Codes				
Lee, C W	3046540100	\$0.	\$47,700.	\$47,700.
University of Tennessee Appalachian Collaborative Center for Learning, Assessment, and Instruction in Mathematics (ACCLAIM)				
Lee, C W	3048105223	\$0.	\$152,406.	\$152,406.
University of Louisville Geometry Assessments for Secondary Teachers (GAST)				
Lewis, J L	3048106017	\$55,637.	\$0.	\$55,637.
National Science Foundation Applications of Boundary Harnack Inequities for p Harmonic Functions to Problems in Harmonic Analysis, PDE, and Function Theory				
Nagel, Uwe R	3048105523	\$0.	\$41,209.	\$41,209.
National Security Agency Hilbert Functions and Betti Numbers				
Readdy, Margaret	3048106959	\$7,633.	\$0.	\$7,633.
National Science Foundation Combinatorics 2010: Advances, Trends & Speculations (CATS 2010 Workshop)				
Shen, Zhongwei	3048106547	\$63,322.	\$0.	\$63,322.
National Science Foundation Harmonic Analysis and Elliptic Homogenization Problems				
Wang, Chong	3048106052	\$42,732.	\$0.	\$42,732.
University of Minnesota IMA New Directions Research Professorship				
Mathematics	Totals:	\$509,367.	\$459,315.	\$968,682.
<u>Physics and Astronomy</u>				
Cao, Gang	3048105753	\$0.	\$120,000.	\$120,000.
National Science Foundation Novel Phenomena in Single-Crystal Oxides				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Arts & Sciences				
Physics and Astronomy				
Cavagnero, Michael J	3048106121	\$300,000.	\$0.	\$300,000.
National Science Foundation ARRA: Universal Quantum Few-Body Codes for Research and Education				
Crawford, Christopher B.	3048106026	\$300,000.	\$0.	\$300,000.
National Science Foundation Fundamental Symmetry Tests Using Low Energy Neutrons				
Das, Sumit Ranjan	3048106016	\$173,200.	\$0.	\$173,200.
National Science Foundation Research String Theory and Gauge Theory				
Eides, Michael	3048104663	\$0.	\$60,001.	\$60,001.
National Science Foundation Theory of Light Hydrogenlike Bound States: High Order Corrections to Lamb Shift, Hyperfine Splitting, and g-Factors				
Eides, Michael	3048104663	\$0.	\$35,998.	\$35,998.
National Science Foundation Theory of Light Hydrogenlike Bound States: High Order Corrections to Lamb Shift, Hyperfine Splitting, and g-Factors				
Elitzur, Moshe	3048106563	\$159,671.	\$0.	\$159,671.
National Science Foundation ARRA: Collaborative Proposal: Resolved Mid-IR Observations & Modeling of AGN and their Hosts				
Elitzur, Moshe	3048106858	\$0.	\$34,896.	\$34,896.
National Aeronautics and Space Administration IR Emission and the Viewing Angle of AGN				
Elitzur, Moshe	3048106858	\$34,896.	\$0.	\$34,896.
National Aeronautics and Space Administration IR Emission and the Viewing Angle of AGN				
Fatemi, Renee H.	3048106502	\$479,875.	\$0.	\$479,875.
National Science Foundation ARRA: Fundamental Studies of the Nucleon Spin in QCD				
Ferland, Gary	3048104595	\$0.	\$125,505.	\$125,505.
National Aeronautics and Space Administration Unraveling the Message of the Light; Spectral Diagnostics of AGN, Starbursts, and Star-forming Regions				
Ferland, Gary	3048106610	\$156,571.	\$0.	\$156,571.
National Science Foundation Numerical Simulations of Non-Equilibrium Plasmas and their Spectra-extensions to the Molecular Environs of AGN & Starburst Galaxies				
Gardner, Susan V	3046921600	\$0.	\$-12,600.	\$-12,600.
Department of Energy Tests of Fundamental Symmetries				
Gardner, Susan V	3046921600	\$0.	\$100,000.	\$100,000.
Department of Energy Tests of Fundamental Symmetries				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Arts & Sciences				
Physics and Astronomy				
Gorringer, Tim P	3048106425	\$587,955.	\$0.	\$587,955.
National Science Foundation ARRA: Studies of fundamental constants, interactions and symmetries via low-energy, high precision muon experiments				
Korsch, Wolfgang	3046251300	\$0.	\$170,000.	\$170,000.
Energy Research Studies of Hadronic Structure Using Electromagnetic Probes				
Korsch, Wolfgang	3048106633	\$10,600.	\$0.	\$10,600.
Thomas Jefferson National Accelerator Facility Fellowship Allada: JSA/JLab Graduate Fellowship				
Kovash, Michael A	3048106738	\$22,275.	\$0.	\$22,275.
Department of Energy Measurements of Low Energy Neutrons from Neutron-Induced Fission				
Kovash, Michael A	3048106803	\$102,604.	\$0.	\$102,604.
University of Michigan Large-Area Detectors for Low Energy Fission Neutrons				
Lebeau, Raymond P	3048106101	\$0.	\$73,103.	\$73,103.
National Aeronautics and Space Administration Development and Application of Computational Simulations for Observed Persistent and Time-Varying Phenomena in the Atmospheres of the Ice Giants				
Liu, Kehfei	3046169100	\$0.	\$24,823.	\$24,823.
Energy Research Research in Theoretical Nuclear Physics				
Martin, Nicholas L	3048106019	\$120,000.	\$0.	\$120,000.
National Science Foundation Out of scattering plane (e,2e) and laser assisted electron impact autoionization studies of helium				
Murthy, Ganpathy	3048104379	\$0.	\$100,000.	\$100,000.
National Science Foundation Mesoscopic Quantum Critical Regimes and Disorder-Driven Deconfinement				
Plaster, Bradley R.	3048105057	\$0.	\$79,800.	\$79,800.
Department of Energy Fundamental Electroweak and Hadronic Physics Studies of the Neutron				
Shapere, Alfred D	3048105987	\$7,500.	\$0.	\$7,500.
Department of Energy Travel Funding for Quantum Theory and Symmetries 6 (Nuclear): An International Symposium on Cross-Disciplinary Trends in Theoretical Physics				
Shlosman, Isaac	3048105711	\$0.	\$156,874.	\$156,874.
National Science Foundation Evolution of Inner Halos: Disk Growth and First Generation of Galactic Bars				
Shlosman, Isaac	3048106695	\$25,000.	\$0.	\$25,000.
Western KY University Galaxy Formation: Growing Disks in Dark Matter Halos				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Arts & Sciences</u>				
<u>Physics and Astronomy</u>				
Strachan, Douglas R.	3048106684	\$6,000.	\$0.	\$6,000.
University of Pennsylvania REU Supplemental Request to Graphene- and Metal-Based Atomically Precise Nanoelectronics (DMR-0805136)				
Strachan, Douglas R.	3048106685	\$0.	\$70,384.	\$70,384.
University of Pennsylvania Graphene-and-Metal-Based Atomically Precise Nanoelectronics				
Strachan, Douglas R.	3048106685	\$71,189.	\$0.	\$71,189.
University of Pennsylvania Graphene-and-Metal-Based Atomically Precise Nanoelectronics				
Troland, Thomas H	3048106512	\$299,312.	\$0.	\$299,312.
National Science Foundation ARRA: Observations of Magnetic Fields in Molecular Clouds - Exploring Two Key Issues				
Physics and Astronomy	Totals:	\$2,856,648.	\$1,138,784.	\$3,995,432.
<u>Psychology</u>				
Akins, Chana	3048106852	\$181,406.	\$0.	\$181,406.
National Institute on Drug Abuse Enhancement of Sexual Motivation				
Bardo, Michael T	3046741300	\$0.	\$40,912.	\$40,912.
National Institute on Drug Abuse Novelty, Dopamine and Response to Amphetamine				
Bardo, Michael T	3048105936	\$369,377.	\$0.	\$369,377.
National Institute on Drug Abuse Novelty, Dopamine and Response to Amphetamine				
Bardo, Michael T	3048105952	\$0.	\$39,883.	\$39,883.
National Institute on Drug Abuse CDART-Center for Drug Abuse Research Translation				
Bardo, Michael T	3048105952	\$1,478,270.	\$0.	\$1,478,270.
National Institute on Drug Abuse CDART-Center for Drug Abuse Research Translation				
Barron, Susan	3048106538	\$208,617.	\$0.	\$208,617.
National Institute on Alcohol Abuse and Alcoholism ARRA: In Vitro and in Vivo Models for Ethanol Withdrawl and Antepartum Hypoxia				
Butler, Tracy	3048106053	\$30,396.	\$0.	\$30,396.
National Institute on Alcohol Abuse and Alcoholism NRSA Fellowship for Tracy Butler: Adenosine Receptors and Ethanol Withdrawl				
Carlson, Charles R	3048106001	\$56,000.	\$0.	\$56,000.
Eastern State Hospital Eastern State Hospital Student Affiliation Program				
DeWall, Nathan J.	3048106862	\$82,927.	\$0.	\$82,927.
University of Miami Does Religious Cognition Promote Self Control? A Program of Experimental Research				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Arts & Sciences				
Psychology				
Fillmore, Mark	3048052100	\$0.	\$-44,348.	\$-44,348.
National Institute on Alcohol Abuse and Alcoholism Mechanisms Of Alcohol Tolerance And Priming In Humans				
Fillmore, Mark	3048052100	\$0.	\$192,040.	\$192,040.
National Institute on Alcohol Abuse and Alcoholism Mechanisms Of Alcohol Tolerance And Priming In Humans				
Fillmore, Mark	3048106627	\$314,309.	\$0.	\$314,309.
National Institute on Alcohol Abuse and Alcoholism Alcohol Tolerance and Behavioral Disinhibition in Humans				
Fillmore, Mark	3048106719	\$30,443.	\$0.	\$30,443.
National Institute on Alcohol Abuse and Alcoholism Fellowship for Jessica Weafer: Alcohol Sensitivity and Abuse Potential in ADHD				
Kearns, Christia Spears	3048105903	\$149,858.	\$0.	\$149,858.
Foundation for Child Development Academic Engagement of Ethnic Minority Children				
Prendergast, Mark A	3048106540	\$0.	\$15,516.	\$15,516.
National Institute on Alcohol Abuse and Alcoholism Hippocampal neurotoxicity induced by ethanol withdrawal				
Prendergast, Mark A	3048106540	\$352,688.	\$0.	\$352,688.
National Institute on Alcohol Abuse and Alcoholism Hippocampal neurotoxicity induced by ethanol withdrawal				
Segerstrom, Suzanne	3048019200	\$0.	\$328,924.	\$328,924.
National Institute on Aging Repetitive Thought, Stress and Immunity in Older Adults				
Smith, Gregory T	3048104634	\$0.	\$55,255.	\$55,255.
National Institute on Alcohol Abuse and Alcoholism Developmental Transitions and Risk for Alcohol Use				
Smith, Gregory T	3048105899	\$18,849.	\$0.	\$18,849.
National Institute on Alcohol Abuse and Alcoholism ARRA: Developmental Transitions and Risk for Alcohol Use				
Zentall, Thomas R	3048106014	\$214,311.	\$0.	\$214,311.
National Institute of Child Health and Human Develop ARRA: Effect of Prior Event on Reward Value				
Psychology	Totals:	\$3,487,451.	\$628,182.	\$4,115,633.
Statistics				
Zhou, Mai	3048106993	\$16,574.	\$0.	\$16,574.
Childrens Hospital Medical Center Empirical Likelihood Bayes Analysis of Quantile Regression Model				
Statistics	Totals:	\$16,574.	\$0.	\$16,574.

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Arts & Sciences</u>				
<u>Sociology</u>				
Oser, Carrie	3048103624	\$0.	\$147,860.	\$147,860.
National Institute on Drug Abuse Rural Drug Abuse Treatment: Organizations, Counselors, and Client Outcomes				
Oser, Carrie	3048104523	\$0.	\$579,622.	\$579,622.
National Institute on Drug Abuse African American Female Drug Users: HIV, Health Disparities, & Criminality				
Sociology	Totals:	\$0.	\$727,482.	\$727,482.
<u>Biological Sciences</u>				
Cassone, Vincent	3048105121	\$0.	\$203,054.	\$203,054.
Texas A&M Research Foundation Coordination of Circadian Physiology in Diverse Organism: Project 4: Pacemaker Properties of the Avian Pineal				
Harrison, Douglas Allan	3048105901	\$0.	\$398,515.	\$398,515.
National Science Foundation ARRA: Role of Unpaired3 in Janus kinase signaling				
Harrison, Douglas Allan	3048105901	\$1,485.	\$0.	\$1,485.
National Science Foundation ARRA: Role of Unpaired3 in Janus kinase signaling				
Voss, Stephen Randal	3048106043	\$0.	\$-11,880.	\$-11,880.
National Center for Research Resources ARRA: Genome Resources for Model Amphibians				
Voss, Stephen Randal	3048106043	\$581,875.	\$0.	\$581,875.
National Center for Research Resources ARRA: Genome Resources for Model Amphibians				
Voss, Stephen Randal	3048106778	\$601,962.	\$0.	\$601,962.
Tulane University Signaling Network Interactions Controlling Mouse and Salamander Limb Regeneration				
Voss, Stephen Randal	3048106816	\$0.	\$-74,249.	\$-74,249.
University of Florida ARRA: Validation of a Novel Genetic Model for Neural Regeneration				
Voss, Stephen Randal	3048106816	\$371,249.	\$0.	\$371,249.
University of Florida ARRA: Validation of a Novel Genetic Model for Neural Regeneration				
Weisrock, David W.	3048106969	\$204,726.	\$0.	\$204,726.
National Science Foundation Genome level resolution of species boundaries and phylogeny of the north american tiger salamander radiation				
Westneat, David F	3048034800	\$0.	\$6,000.	\$6,000.
National Science Foundation Development of Signaler and Receiver Phenotypes				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Arts & Sciences</u>				
<u>Biological Sciences</u>				
Westneat, David F	3048105874	\$2,125.	\$0.	\$2,125.
American Ornithologists Union A genetic basis of individual variation in parental care in wild birds				
Biological Sciences	Totals:	\$1,763,422.	\$521,440.	\$2,284,862.
<u>English</u>				
Kalliney, Peter J.	3048106745	\$50,400.	\$0.	\$50,400.
National Endowment for the Humanities Institutions of the Transatlantic World, 1930-1970				
English	Totals:	\$50,400.	\$0.	\$50,400.
<u>Modern & Classical Languages</u>				
Slymaker, Douglas N	3048106978	\$77,177.	\$0.	\$77,177.
Japan Foundation Building a Japan Studies Concentration at the University of Kentucky				
Modern & Classical Languages	Totals:	\$77,177.	\$0.	\$77,177.
<u>Philosophy</u>				
Breazeale, James D	3048105902	\$50,400.	\$0.	\$50,400.
National Endowment for the Humanities Fichte's Path from Kant to the Wissenschaftsehre, Zurich Writings (1793-1794)				
Philosophy	Totals:	\$50,400.	\$0.	\$50,400.
	Arts & Sciences Totals:	\$10,318,170.	\$4,985,774.	\$15,303,944.
<u>Business & Economics</u>				
<u>Management</u>				
Dineen, Brian R	3048106310	\$75,390.	\$0.	\$75,390.
Society for Human Resource Management Resume Fraud: Investigations of the Antecedents and Consequences of Fabrication, Embellishment, and Omission				
Holbein, Gordon F	3048106588	\$29,663.	\$0.	\$29,663.
KY Economic Development Cab Business Plan Competition 2009-10				
Management	Totals:	\$105,053.	\$0.	\$105,053.
<u>B&E Poverty Center</u>				
Ziliak, James P	3048106739	\$424,958.	\$0.	\$424,958.
Assistant Secretary for Planning and Evaluation University of Kentucky Center for Poverty Research				
B&E Poverty Center	Totals:	\$424,958.	\$0.	\$424,958.
<u>Center for Entrepreneurship</u>				
Naugle, Lottie Becky	3046356600	\$0.	\$60,000.	\$60,000.
Small Business Administration OnGoing SBDC PROGRAM INCOME ACCOUNT				
Center for Entrepreneurship	Totals:	\$0.	\$60,000.	\$60,000.
	Business & Economics Totals:	\$530,011.	\$60,000.	\$590,011.

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Education</u>				
<u>Educational Leadership Studies</u>				
Bjork, Lars	3048106737	\$2,500.	\$0.	\$2,500.
KY Department of Education KILTn District Partnership				
Jackson, Jim	3048105850	\$61,506.	\$0.	\$61,506.
KY Department of Education CEO Superintendent Network				
Educational Leadership Studies	Totals:	\$64,006.	\$0.	\$64,006.
<u>Curriculum & Instruction</u>				
Smith, Douglas C	3048105779	\$4,000.	\$0.	\$4,000.
KY Department of Education UK Perkins 09-10				
Swan, Kathleen O	3048106817	\$14,800.	\$0.	\$14,800.
Kazanjian Economics Foundation Econocast: The production, consumption and distribution of economic pod casts for the K-12 classrooms				
Curriculum & Instruction	Totals:	\$18,800.	\$0.	\$18,800.
<u>Educational & Counseling Psych</u>				
Ruble, Lisa A.	3048106307	\$499,986.	\$0.	\$499,986.
National Institute of Mental Health ARRA: Randomized Study of Training in Autism				
Educational & Counseling Psych	Totals:	\$499,986.	\$0.	\$499,986.
<u>Kinesiology and Health Promoti</u>				
Abel, Mark Glendon	3048106679	\$19,820.	\$0.	\$19,820.
KY Community & Technical College System/University of Effects of Strength Training on the Health, Fitness, and Performance of Firefighters-Physical Training Program at Richmond Fire Department				
Shapiro, Robert	3048106004	\$50,000.	\$0.	\$50,000.
Western KY University Biomedical and Cardiovascular Responses of Healthy Men and Women to Standing, Walking and Running in Simulated Lunar, Mars and Earth Gravitational Environments				
Kinesiology and Health Promoti	Totals:	\$69,820.	\$0.	\$69,820.
<u>Educational Policy Studies & Evaluation</u>				
Carey, K W	3048105893	\$36,000.	\$0.	\$36,000.
KY Council on Postsecondary Education Development and Implementation of the Statewide Assessment of College Level Learning				
Educational Policy Studies & Evaluation	Totals:	\$36,000.	\$0.	\$36,000.
<u>Special Ed & Rehab Counseling</u>				
Bausch, Margaret	3046935500	\$0.	\$99,996.	\$99,996.
Department of Education Kentucky Assistive and Rehabilitation Technology Training (KARTT)				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Education				
Special Ed & Rehab Counseling				
Bottge, Brian A	3048105823	\$2,330,164.	\$0.	\$2,330,164.
Department of Education Special Education-Research and Innovation to Improve Services and Results for Children with Disabilities- NCSEER-CASL G3 Evaluating the Efficacy of Enhanced Anchored Instruction for Middle School Students with Learning Disabilities in Math				
Crystal, Ralph M	3046933100	\$0.	\$198,665.	\$198,665.
Department of Education University of Kentucky Accelerated Distance Education Program in Rehabilitation Counseling				
Grisham-Brown, Jennifer L	3048105720	\$250,000.	\$0.	\$250,000.
KY Department of Education Kids Now Evaluation				
Grisham-Brown, Jennifer L	3048106041	\$235,000.	\$0.	\$235,000.
KY Department of Education Deaf-Blind Project Supplemental Grant				
Grisham-Brown, Jennifer L	3048106647	\$165,145.	\$0.	\$165,145.
KY Department of Education UK / Kentucky Deaf-Blind Project Main Grant				
Jung, Lee Ann	3048105918	\$198,748.	\$0.	\$198,748.
Department of Education Combined Priority for Personnel Development - Increasing the Number, Competence, and Resources of Early Interventions in Areas of Shortage through Distance Learning: INCREAS-DL				
Jung, Lee Ann	3048105970	\$90,381.	\$0.	\$90,381.
KY Health Services Cabinet UK First Steps Part C Coordinator 09-10				
McCormick, Katherine	3048106311	\$238,514.	\$0.	\$238,514.
KY Cabinet for Health and Family Services University of Kentucky First Step Technical Assistance Team				
Rogers, Jackie	3048106044	\$199,999.	\$0.	\$199,999.
Department of Education National Master's Rehabilitation Initiative with an Emphasis on Job Placement for Persons with Severe Disabilities in Rural Areas				
Sampers, Jackie L	3048106561	\$0.	\$7,358.	\$7,358.
KY Cabinet for Health and Family Services SJPB FS Primary Evaluation				
Sampers, Jackie L	3048106561	\$78,975.	\$0.	\$78,975.
KY Cabinet for Health and Family Services SJPB FS Primary Evaluation				
Schuster, John W	3048104791	\$0.	\$200,000.	\$200,000.
Special Education and Rehabilitative Services Special Education Leadership Program in Applied Behavior Analysis (SELABA) in Distance Teacher Preparation				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Education</u>				
<u>Special Ed & Rehab Counseling</u>				
Slaton, Deborah B	3048105766	\$115,085.	\$0.	\$115,085.
KY Department of Education 2009-2010 Reading First Coach				
Special Ed & Rehab Counseling	Totals:	\$3,902,011.	\$506,019.	\$4,408,030.
<u>Collaborative Center for Literacy Develo</u>				
Cantrell, Susan Chambers		\$500,287.	\$0.	\$500,287.
Danville Schools Striving Readers Grant 1				
Cantrell, Susan Chambers	3048106089	\$50,086.	\$0.	\$50,086.
KY Department of Education Kentucky Reading First Evaluation Project				
Cantrell, Susan Chambers	3048106924	\$291,481.	\$0.	\$291,481.
KY Department of Education Striving Reader Grant 2				
Smith, Felicia C	3048105968	\$200,000.	\$0.	\$200,000.
KY Department of Education Adolescent Literacy Project 09-10				
Smith, Felicia C	3048106056	\$538,121.	\$0.	\$538,121.
KY Council on Postsecondary Education Kentucky Adult Education Literacy Institute-KAELI 09-10				
Collaborative Center for Literacy Develo	Totals:	\$1,579,975.	\$0.	\$1,579,975.
	Education Totals:	\$6,170,598.	\$506,019.	\$6,676,617.
<u>Engineering</u>				
<u>Visualization Center</u>				
Bailey, Stephen P	3048106062	\$145,171.	\$0.	\$145,171.
KY Office of Energy Policy Documentary Examining the Significance of Coal in Kentucky's Past, Present and Future				
Donohue, Kevin D	3048106532	\$69,999.	\$0.	\$69,999.
Federal Bureau of Investigation Statistical Array Geometries for Real-Time Covert Surveillance with Parallel Computer Implementations				
Seales, William B	3048106698	\$82,523.	\$0.	\$82,523.
National Science Foundation III: Small:FoLIO-Framework for Longitudinal Image-based Organization				
Walcott, Bruce L	3048043800	\$0.	\$1,572,001.	\$1,572,001.
US Army Large Rapidly Deployable Immersive Visualization for Training and Simulation in Urban Terrains				
Walcott, Bruce L	3048043800	\$0.	\$418,705.	\$418,705.
US Army Large Rapidly Deployable Immersive Visualization for Training and Simulation in Urban Terrains				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Engineering				
Visualization Center				
Yang, Ruigang	3048106612	\$1,013,906.	\$0.	\$1,013,906.
National Science Foundation MRI: Development of Versatile Mobile Range Scanning System-Enabling Large-scale High-density 3D Data Acquisition for Cross-Disciplinary Research				
Yang, Ruigang	3048106668	\$299,991.	\$0.	\$299,991.
VSee Lab Inc STTR: Rapidly Deployable Display with Continuous Self-Correction				
Yang, Ruigang	3048106798	\$0.	\$25,000.	\$25,000.
Lockheed Active and Passive Sensing Fusion for High-Quality 3D Reconstruction				
Yang, Ruigang	3048106798	\$25,000.	\$0.	\$25,000.
Lockheed Active and Passive Sensing Fusion for High-Quality 3D Reconstruction				
Visualization Center	Totals:	\$1,636,590.	\$2,015,706.	\$3,652,296.
Computer Science				
Calvert, Kenneth L	3048106511	\$100,000.	\$0.	\$100,000.
National Science Foundation Net SE: Medium: Collaborative Research; Towards Human-Network Interaction (HNI) for the Home				
Griffioen, James N	3048105220	\$0.	\$132,870.	\$132,870.
BBN Technologies Instrumentation Tools for a GENI Prototype				
Griffioen, James N	3048106821	\$258,761.	\$0.	\$258,761.
BBN Technologies ARRA: A ShadowBox-based Protogeni Instrumentation and Measurement Infrastructure				
Klapper, Andrew M	3048105921	\$308,309.	\$0.	\$308,309.
National Science Foundation CIF: Small: Primitives for Cryptography and Communication				
Liu, Jinze	3048106073	\$0.	\$62,432.	\$62,432.
National Science Foundation ARRA: Exon Splice Pattern Characterization of the Whole mRNA Transcriptome				
Liu, Jinze	3048106073	\$1,027,384.	\$0.	\$1,027,384.
National Science Foundation ARRA: Exon Splice Pattern Characterization of the Whole mRNA Transcriptome				
Seales, William B	3048047200	\$0.	\$118,000.	\$118,000.
National Science Foundation EDUCE: Enhanced Digital Unwrapping for Conservation and Exploration				
Truszczynski, Miroslaw	3048106422	\$384,999.	\$0.	\$384,999.
National Science Foundation RI: Small: Qualitative Preferences: Merging Paradigms, Extending the Language, Reasoning about Incomplete Outcomes				
Computer Science	Totals:	\$2,079,453.	\$313,302.	\$2,392,755.

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Engineering</u>				
<u>Kentucky Transportation Center</u>				
Agent, Kenneth R	3048106751	\$60,000.	\$0.	\$60,000.
KY Transportation Cabinet Identification and Analysis of Crash Locations RS-10-01				
Agent, Kenneth R	3048106752	\$80,450.	\$0.	\$80,450.
KY Transportation Cabinet Safety Belt and Child Restraint Usage Surveys OP-10-04				
Agent, Kenneth R	3048106753	\$20,000.	\$0.	\$20,000.
KY Transportation Cabinet Attitudes and Awareness Survey PT-10-45				
Anderson, Patsy P	3048105573	\$0.	\$46,107.	\$46,107.
KY Transportation Cabinet FHWA/LTAP Technology Transfer Assistance to Local Agencies				
Anderson, Patsy P	3048106820	\$140,000.	\$0.	\$140,000.
KY Transportation Cabinet FHWA/LTAP Technology Transfer Assistance to Local Agencies				
Chen, Mei	3048106549	\$30,000.	\$0.	\$30,000.
KY Transportation Cabinet Travel Time Based Congestion Measures for Freeway Corridors - Stage 2 Planning Study No 18				
Crabtree, Joseph D	3048106591	\$49,000.	\$0.	\$49,000.
Department of Transportation FMCSA Wireless Roadside Inspection Testing and Evaluation				
Crabtree, Joseph D	3048106901	\$35,545.	\$0.	\$35,545.
Battelle Memorial Institute Truck Identification Sensor System for Virtual Weigh Stations and Smart Roadside				
Crabtree, Joseph D	3048106915	\$157,816.	\$0.	\$157,816.
KY Transportation Cabinet Assessment of the Kentucky Dept of Vehicle Regulations Fee and Tax Structure, Research Study-Federal No. 29				
Crabtree, Joseph D	3048106927	\$59,772.	\$0.	\$59,772.
KY Transportation Cabinet Support for Kentucky's Dept. of Vehicle Regulation in Preparation for Startup of Customer Service Center -- Research Study-State No 14				
Green, Eric R	3048106754	\$50,000.	\$0.	\$50,000.
KY Transportation Cabinet Locating Traffic Crashes K9-10-07				
Grossardt, Theodore H	3046337100	\$0.	\$100,000.	\$100,000.
KY Transportation Cabinet Information Technology Technical Assistance Project -- Federal Aid Research Task No. 88				
Grossardt, Theodore H	3048104480	\$0.	\$35,595.	\$35,595.
University of Tennessee Southeastern Transportation Center Transportation Systems Management Program				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Engineering				
<u>Kentucky Transportation Center</u>				
Hartman, Donald G	3048105816	\$260,000.	\$0.	\$260,000.
KY Transportation Cabinet Kentucky Cooperative Transportation Research Program KCTRP 10-30 (Part III)				
Hartman, Donald G	3048105817	\$0.	\$-22,350.	\$-22,350.
KY Transportation Cabinet Kentucky Cooperative Transportation Research Program Part II KCTRP 10-30				
Hartman, Donald G	3048105817	\$0.	\$9,100.	\$9,100.
KY Transportation Cabinet Kentucky Cooperative Transportation Research Program Part II KCTRP 10-30				
Hartman, Donald G	3048105817	\$0.	\$-50,000.	\$-50,000.
KY Transportation Cabinet Kentucky Cooperative Transportation Research Program Part II KCTRP 10-30				
Hartman, Donald G	3048105817	\$0.	\$50,000.	\$50,000.
KY Transportation Cabinet Kentucky Cooperative Transportation Research Program Part II KCTRP 10-30				
Hartman, Donald G	3048105817	\$2,756,740.	\$0.	\$2,756,740.
KY Transportation Cabinet Kentucky Cooperative Transportation Research Program Part II KCTRP 10-30				
Hopwood, Theodore	3046719700	\$0.	\$20,000.	\$20,000.
KY Transportation Cabinet Taping and Minute Preparation for Pre-Bid and Pre-Construction Meetings to Support Maintenance Painting Operations for FY 2004--Kentucky Highway Investigative Task No. 46				
Hopwood, Theodore	3048104617	\$0.	\$156,576.	\$156,576.
Northwestern University Continuation of the Midwest Bridge Working Group - Phase XIII				
Hopwood, Theodore	3048105976	\$0.	\$5,824.	\$5,824.
KY Transportation Cabinet Investigation of Stay Cables on the US 231 Natcher Bridge over the Ohio River Near Owensboro, Kentucky Highway Investigative Task No. 66				
Hopwood, Theodore	3048105976	\$24,176.	\$0.	\$24,176.
KY Transportation Cabinet Investigation of Stay Cables on the US 231 Natcher Bridge over the Ohio River Near Owensboro, Kentucky Highway Investigative Task No. 66				
Hunsucker, David Q	3046553100	\$0.	\$42,000.	\$42,000.
NORPASS Inc NORPASS Program Support				
Rister, Bradley W	3048105477	\$0.	\$8,000.	\$8,000.
KY Transportation Cabinet I-65 Jefferson County (128-132) In-Situ Pavment Evaluation, Federal Aid Research Task No. 177				
Kentucky Transportation Center	Totals:	\$3,723,499.	\$400,852.	\$4,124,351.

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Engineering				
<u>OISTL/Engineering Distance Learning</u>				
Lu, Y. Charles	3048105981	\$45,000.	\$0.	\$45,000.
Western KY University Characterization and Modeling of High Temperature PolymerMatrix Composites(HTPMCs) for Aerospace				
Lu, Y. Charles	3048106602	\$27,000.	\$0.	\$27,000.
Western KY University KSGC Fellowship for Fulcher: Mechanical Characterization of Shape Memory Polymers for Reconfigurable Aerospace Structures				
OISTL/Engineering Distance Learning	Totals:	\$72,000.	\$0.	\$72,000.
<u>Chemical and Materials Engin.</u>				
Anderson, Kimberly Ward	3048103842	\$0.	\$3,240.	\$3,240.
National Science Foundation IGERT: Building Leadership Through a Program on Engineered Bioactive Interfaces and Devices				
Balk, Thomas John	3048060700	\$0.	\$5,000.	\$5,000.
American Iron and Steel Institute Developing Ferrous Matallurgy Course Material For An Updated Materials Engineering Curriculum at the University Of Kentucky				
Balk, Thomas John	3048105263	\$0.	\$80,000.	\$80,000.
National Science Foundation CAREER: Understanding Nanoscale Deformation by Characterizing the Mechanical Behavior of Nanoporus Noble Metals				
Balk, Thomas John	3048105973	\$299,917.	\$0.	\$299,917.
National Science Foundation GOALI: Understanding the Microstructural Evolution and High-Temperature Behavior of Osmium-Ruthenium Coatings for Dispenser Cathodes				
Beck, Matthew J.	3048106823	\$23,800.	\$0.	\$23,800.
Sandia National Laboratories Time Dependent Density Functional Theory Calculations of Electron Dynamics in Nanoscale Systems				
Cheng, Yang-Tse	3048105346	\$0.	\$675.	\$675.
General Motors Research Strategies for Mitigating Stress-Induced Damages to Lithium Ion Battery Electrodes				
Cheng, Yang-Tse	3048106731	\$56,074.	\$0.	\$56,074.
Michigan State University High Authority Two-Way Surface Form Memory				
Dziubla, Thomas D	3048106522	\$110,358.	\$0.	\$110,358.
National Institute of Dental Research ARRA: Enhanced Oral Tissue Repair via Self Assembled Polymer Multi-layer Barriers for the Delivery of Antioxidants				
Dziubla, Thomas D	3048106555	\$568,502.	\$0.	\$568,502.
US Office of Naval Research DEPSCOR: Development of a Targeted Antioxidant Polymers for the Prevention of Combat Trauma Related lachemia/Reperfusion				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Engineering				
<u>Chemical and Materials Engin.</u>				
Dziubla, Thomas D	3048106674	\$100,000.	\$0.	\$100,000.
KY Science and Technology Co Inc EPSCOR: Development of a Targeted Antioxident Polymers for the Prevention of Combat Trauma Related lachemia/Reperfusion: Cost Share Account				
Grulke, Eric A	3048103802	\$0.	\$50,000.	\$50,000.
Department of Energy DOE EPSCoR: Nanoscale Materials and Architecture for Energy Conversion				
Grulke, Eric A	3048103802	\$0.	\$700,000.	\$700,000.
Department of Energy DOE EPSCoR: Nanoscale Materials and Architecture for Energy Conversion				
Grulke, Eric A	3048103803	\$0.	\$250,000.	\$250,000.
KY Council on Postsecondary Education State DOE EPSCoR Match: Nanoscale Materials and Architecture for Energy Conversion				
Grulke, Eric A	3048103803	\$0.	\$-250,000.	\$-250,000.
KY Council on Postsecondary Education State DOE EPSCoR Match: Nanoscale Materials and Architecture for Energy Conversion				
Grulke, Eric A	3048103803	\$0.	\$250,000.	\$250,000.
KY Council on Postsecondary Education State DOE EPSCoR Match: Nanoscale Materials and Architecture for Energy Conversion				
Grulke, Eric A	3048106937	\$45,260.	\$0.	\$45,260.
Optical Dynamics Co ARRA: Scale-up of Green Nanoscience Pathway for Optically Transparent Nanocomposites.				
Hinds, Bruce J	3048057100	\$0.	\$293,060.	\$293,060.
National Institute on Drug Abuse Gated Carbon Nanotube Membrane Transdermal Drug Delivery				
Hinds, Bruce J	3048106986	\$25,519.	\$0.	\$25,519.
US Army Raman spectrometer enabling SWCNT membrane synthesis for water purification applications				
Knutson, Barbara	3048104976	\$0.	\$83,044.	\$83,044.
KY Office of Energy Policy Separation and Recovery of High-value Pentose Derivatives from Cellulosic Biomass using Mol+				
Ray, Asit K	3048106418	\$270,810.	\$0.	\$270,810.
National Institute of Occupational Safety and Health Effect of Droplet Size, Charge and Presence of Surfactants on Coal Dust Capture				
Zhai, Tongguang	3048103774	\$0.	\$60,000.	\$60,000.
National Science Foundation CAREER: Quantitative Understanding of the Effects of Micro and Macro-Texture on Fatigue Crack Initiation and Early Growth in High Performance Alloys				
Chemical and Materials Engin.	Totals:	\$1,500,240.	\$1,525,019.	\$3,025,259.

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Engineering</u>				
<u>CFFLS</u>				
Huffman, Gerald P	3046900100	\$0.	\$912,000.	\$912,000.
Department of Energy Development of Novel Technologies for the Production and Storage of Hydrogen from Coal Using C1 Chemistry				
Huffman, Gerald P	3048103876	\$0.	\$1,441,500.	\$1,441,500.
US Army Production of Military Fuels by C1 Chemistry				
CFFLS	Totals:	\$0.	\$2,353,500.	\$2,353,500.
<u>Civil Engineering</u>				
Bryson, Lindsey Sebastian	3048106906	\$0.	\$-230,465.	\$-230,465.
National Institute for Hometown Security Assessment and Mitagation of Waterside Attacks on Dams				
Bryson, Lindsey Sebastian	3048106906	\$1,393,734.	\$0.	\$1,393,734.
National Institute for Hometown Security Assessment and Mitagation of Waterside Attacks on Dams				
Davis, Douglas	3048106958	\$75,000.	\$0.	\$75,000.
Metal Building Manufacturers Association Sheer Strength of Web-Tapered I-Shape Members				
Goodrum, Paul	3048106811	\$19,000.	\$0.	\$19,000.
National Center for Construction Education and Research Research Support on the Contractors Workforce Development Assessment Survey (FU-NDED)				
Harik, Issam E		\$75,000.	\$0.	\$75,000.
KY Science and Technology Co Inc COMMFUND: High Performance Materials for Structural Repair				
Harik, Issam E	3048106900	\$75,000.	\$0.	\$75,000.
KY Science and Technology Co Inc COMMFUND:High Performance Materials for Structural Repair				
Harik, Issam E	3048106939	\$130,000.	\$0.	\$130,000.
National Institute for Hometown Security Development of New Materials/Coatings for Application in the Trnasportation Sector				
Wigginton, Andrew J	3048106003	\$222,000.	\$0.	\$222,000.
KY Department of Environmental Protection Assessment of Ecological Conditions Compared to Environmental Sampling at the Paducah Gaseous Diffusion Plant With a Reassessment of Previous Analysis				
Civil Engineering	Totals:	\$1,989,734.	\$-230,465.	\$1,759,269.
<u>Mining Engineering</u>				
Honaker, Rick	3048106551	\$2,741,955.	\$0.	\$2,741,955.
Department of Energy Center for Advanced Separation Technology (KY)				
Lusk, Braden Trex	3048106505	\$200,000.	\$0.	\$200,000.
Department of the Interior Field Testing and Analysis of Blasts Utilizing Short Delays with Electronic Detonators				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Engineering				
Mining Engineering				
Sweigard, Richard J	3046748200	\$0.	\$90,787.	\$90,787.
Partnership for Energy and Environment Re Ukrainian Mine Safety Project				
Tao, Dongping	3046957100	\$0.	\$-67,253.	\$-67,253.
Florida Institute of Phosphate Research Pilot-Scale Testing and Demonstration of Picobubble Enhanced Flotation of Phosphate for Increased Recovery and Reduced Reagent Consumption				
Tao, Dongping	3048105940	\$67,253.	\$0.	\$67,253.
Florida Institute of Phosphate Research Pilot-Scale Testing and Demonstration of Picobubble Enhanced Flotation of Phosphate for Increase Recovery and Reduced Reagent Consumption				
Tao, Dongping	3048106905	\$241,978.	\$0.	\$241,978.
Illinois Clean Coal Institute Cavacation Picobubble Enhanced Flotation Process for More Efficient Fine Coal Recovery				
Wala, Andrzej M	3048106118	\$249,498.	\$0.	\$249,498.
Center for Disease Control and Prevention Advancing Critical Health & Safety Aspects of Mine Ventilation Through Technical Development and Training				
Mining Engineering	Totals:	\$3,500,684.	\$23,534.	\$3,524,218.
Electrical and Computer Engineering				
Adams, Robert J	3046777800	\$0.	\$22,000.	\$22,000.
US Office of Naval Research Efficient Iterative and Direct Solvers for Electromagnetic Simulations				
Adams, Robert J	3046777800	\$0.	\$116,894.	\$116,894.
US Office of Naval Research Efficient Iterative and Direct Solvers for Electromagnetic Simulations				
Adams, Robert J	3046777800	\$0.	\$105,292.	\$105,292.
US Office of Naval Research Efficient Iterative and Direct Solvers for Electromagnetic Simulations				
Gedney, Stephen D	3048105132	\$0.	\$1.	\$1.
ERC Inc DGFETD/MSCAT Enhancement				
Hannemann, Regina	3048105996	\$300,000.	\$0.	\$300,000.
National Science Foundation ARRA: REU Site in Electrical & Computer Engineering at The University of Kentucky				
Hastings, Jeffrey T	3048104534	\$0.	\$77,053.	\$77,053.
National Science Foundation CAREER: Reference Compensation for Localized Surface-Plasmon Resonance Sensors				
Hastings, Jeffrey T	3048104543	\$0.	\$6,000.	\$6,000.
National Science Foundation Tip Directed-Assembly of Nanoparticles via Surface Plasmon Excitation				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Engineering				
Electrical and Computer Engineering				
Hastings, Jeffrey T	3048106400	\$0.	\$150,000.	\$150,000.
Defense Advanced Research Projects Agency Nanoscale Electron Beam Induced Processing using Liquid Reactants				
Hastings, Jeffrey T	3048106400	\$150,000.	\$0.	\$150,000.
Defense Advanced Research Projects Agency Nanoscale Electron Beam Induced Processing using Liquid Reactants				
Holloway, Lawrence E	3048106079	\$85,000.	\$0.	\$85,000.
Adaptive Intelligent Systems LLC SBIR Phase 2: A Modified GMAW System for Distortion Reduction and Travel Speed Increase through Separate Heat Input and Deposition Rate Control				
Lau, Daniel L	3048082200	\$0.	\$-1,472.	\$-1,472.
M2 Technologies Inc Anti-Sniper Infrared Targeting Systems (ASITS) Phase IIIa				
Lau, Daniel L	3048082200	\$0.	\$31,668.	\$31,668.
M2 Technologies Inc Anti-Sniper Infrared Targeting Systems (ASITS) Phase IIIa				
Li, Jingshan	3048106087	\$220,000.	\$0.	\$220,000.
National Science Foundation EAGER: Improvability Theory for Hospital Emergency Department: A System-Theoretic Method to Reduce Crowding				
Li, Jingshan	3048106985	\$400,000.	\$0.	\$400,000.
National Science Foundation CAREER: Robust Production Systems: Theory and Applications				
Lu, Caicheng	3048106973	\$6,000.	\$0.	\$6,000.
National Science Foundation 2009 IEEE AP-S International Symposium, Student Travel Grants and Student Paper Competition Award				
Lumpp, James E	3048106002	\$0.	\$-30,527.	\$-30,527.
KY Science and Technology Co Inc Kentucky Space Satellite Development				
Lumpp, James E	3048106002	\$0.	\$140,293.	\$140,293.
KY Science and Technology Co Inc Kentucky Space Satellite Development				
Lumpp, James E	3048106002	\$181,712.	\$0.	\$181,712.
KY Science and Technology Co Inc Kentucky Space Satellite Development				
Lumpp, James E	3048106667	\$25,000.	\$0.	\$25,000.
Western KY University CubeSats as Secondary Payloads on NASA Sounding Rockets				
Lumpp, Janet K	3048105269	\$0.	\$17,814.	\$17,814.
Western KY University KSGC Fellowship: Integrated Structural-Electrical Composite Spacecraft Graduate Fellowship				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Engineering</u>				
<u>Electrical and Computer Engineering</u>				
Lumpp, Janet K	3048105755	\$1,000.	\$0.	\$1,000.
Puget Sound Center For Teaching Learning and Technol MISS Electricity				
Lumpp, Janet K	3048105957	\$30,000.	\$0.	\$30,000.
KY Science and Technology Co Inc Spacecraft Design On-Line Course Development				
Lumpp, Janet K	3048106789	\$25,000.	\$0.	\$25,000.
Western KY University High Altitude Balloon Launch Teacher Workshop				
Singh, Vijay	3048106815	\$181,528.	\$0.	\$181,528.
University of Louisville Nanostructured Device Designs for Enhancing the Performance of Thin Film Cd'Te/CdS and CIS/CdS Solar Cell Devices				
Electrical and Computer Engineering	Totals:	\$1,605,240.	\$635,016.	\$2,240,256.
<u>UK Center for Manufacturing</u>				
Holloway, Lawrence E	3048104587	\$0.	\$28,242.	\$28,242.
Adaptive Intelligent Systems LLC Sensor Torch Based Adaptive Intelligent Control for Circumferential Welding of Pipes: SBIR Phase II				
Holloway, Lawrence E	3048104587	\$0.	\$20,000.	\$20,000.
Adaptive Intelligent Systems LLC Sensor Torch Based Adaptive Intelligent Control for Circumferential Welding of Pipes: SBIR Phase II				
Jawahir, Ibrahim S	3048106933	\$85,550.	\$0.	\$85,550.
AB Sandvik Coromant Optimization of Deep Groove Machining Process				
Jawahir, Ibrahim S	3048106936	\$525,325.	\$0.	\$525,325.
National Institute of Standards & Technology ARRA: Development of Metrics, Metrology and a Framework for Product-Process Ontology for Interoperability in Model-Based Sustainable Manufacturing				
Kalika, Douglass S	3048105735	\$101,841.	\$0.	\$101,841.
University of Texas at Austin Characterization of Thermally-Modified Polyimides for Use in Pervaporations and Gas Separations				
Walcott, Bruce L	3048106664	\$3,000.	\$0.	\$3,000.
KY Department of Education 2009 Student Technology Leadership Program (STLP) Showcase				
Zhang, Yuming	3048106064	\$400,000.	\$0.	\$400,000.
National Science Foundation ARRA: Machine-Human Cooperative Control of Welding Process				
UK Center for Manufacturing	Totals:	\$1,115,716.	\$48,242.	\$1,163,958.

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
Engineering				
<u>Mechanical Engineering</u>				
Herrin, David W	3048106055	\$45,000.	\$0.	\$45,000.
National Science Foundation US Egypt Cooperative Research: Simulation of Diesel Particulate Filters in Exhaust Systems				
Karaca, Haluk E.	3048106585	\$7,500.	\$0.	\$7,500.
Western KY University Fellowship/Shulte: Novel Shape Memory Composites for Space Applications				
Karaca, Haluk E.	3048106707	\$25,000.	\$0.	\$25,000.
Western KY University Characterization of the Shape Memory Properties of NiTiHfCu Alloys				
Smith, Suzanne W	3048105471	\$0.	\$43,674.	\$43,674.
NextGen Aeronautics SUAVE Phase II: Materials, Modeling and Integrated Environment Testing				
Smith, Suzanne W	3048105581	\$0.	\$121,263.	\$121,263.
US Equestrian Federation Improving Equestrian Jump Safety				
Smith, Suzanne W	3048105840	\$17,000.	\$0.	\$17,000.
National Space Grant Foundation The Role of Design Optimization in Systems Engineering				
Smith, Suzanne W	3048106524	\$17,138.	\$0.	\$17,138.
Western KY University Fellowship for Gilliam: Nonlinear Support Systems for Future Space Applications				
Smith, Suzanne W	3048106764	\$31,998.	\$0.	\$31,998.
University of Louisville Pitch-Plunge Apparatus for Wind-Tunnel Testing of Bio-Inspired UAV's				
Smith, Suzanne W	3048106981	\$12,500.	\$0.	\$12,500.
NextGen Aeronautics Innovative Ground Habitat for Lunar Operations Outpost (IGLOO) Phase I				
Mechanical Engineering	Totals:	\$156,136.	\$164,937.	\$321,073.
<u>IR4TD</u>				
Li, Tianxiang	3048106983	\$149,558.	\$0.	\$149,558.
Revstone Industries LLC Improving Performance of Revstone's Aluminum Melting Furnace				
Salazar, Abraham J	3048106984	\$149,984.	\$0.	\$149,984.
Revstone Industries LLC Plastic Pallet Study and Improvement				
IR4TD	Totals:	\$299,542.	\$0.	\$299,542.
	Engineering Totals:	\$17,678,834.	\$7,249,643.	\$24,928,477.

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Communication & Information Studies</u>				
<u>School of Journalism</u>				
Barnes, Beth	3048105222	\$0.	\$11,090.	\$11,090.
American International Health Alliance Partnering with ZAMCOM to train Zambian Journalists in coverage of HIV/AIDS.				
School of Journalism	Totals:	\$0.	\$11,090.	\$11,090.
<u>Communication</u>				
Cohen, Elisia	3048106614	\$14,656.	\$0.	\$14,656.
Washington University Communication-based Strategies to Eliminate Cancer Disparities				
Helme, Donald W	3048106692	\$12,884.	\$0.	\$12,884.
Davidson College ARRA: Implementation and Dissemination of Tobacco Cessation Strategies in Free Clinics				
Helme, Donald W	3048106784	\$20,557.	\$0.	\$20,557.
University of New Mexico ARRA: Web-Based Substance Abuse and STD/HIV Prevention				
Palmgreen, Philip C	3046965300	\$0.	\$32,832.	\$32,832.
National Institute of Mental Health Targeting Mass Media Campaigns for HIV, STD and Pregnancy Prevention				
Sellnow, Timothy L	3048104430	\$0.	\$82,375.	\$82,375.
University of Minnesota National Center for Food Protection and Defense: Robust Case Study Analysis of Media				
Communication	Totals:	\$48,097.	\$115,207.	\$163,304.
<u>School of Library & Information Science</u>				
Huber, Jeffrey Todd	3048106693	\$7,300.	\$0.	\$7,300.
KY Department for Libraries and Archives KDLA LSTA KY Guide Program				
Kim, Sujin	3048105786	\$9,945.	\$0.	\$9,945.
Medical Library Association A Study of Microscopic Image Description Through Captions Published in Academic Biomedical Journals				
School of Library & Information Science	Totals:	\$17,245.	\$0.	\$17,245.
Communication & Information Studies Totals:		\$65,342.	\$126,297.	\$191,639.
<u>Design</u>				
<u>Design</u>				
Carpenter, Clyde R	3046816600	\$0.	\$10,575.	\$10,575.
KY Transportation Cabinet Interns for Cultural Historic Assessment of Highway Projects				
Design	Totals:	\$0.	\$10,575.	\$10,575.
Design Totals:		\$0.	\$10,575.	\$10,575.

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Social Work</u>				
<u>Social Work</u>				
Badger, Karen	3048106552	\$15,000.	\$0.	\$15,000.
Phoenix Society for Burn Survivors Station nightclub fire needs assessment.				
Cerel, Julie A	3048105272	\$0.	\$18,000.	\$18,000.
Department for Mental Health Mental Retardation Service Suicide Prevention for Youth - SPYCE Project Evaluation				
Cerel, Julie A	3048106077	\$37,893.	\$0.	\$37,893.
Department for Mental Health Mental Retardation Service Suicide Prevention for Youth - SPYCE Project Evaluation				
Cerel, Julie A	3048106830	\$99,996.	\$0.	\$99,996.
Substance Abuse & Mental Health Services Administr University of Kentucky KEEP: University of Kentucky Increasing Networks for Campus Awareness to Suicide				
Cook-Craig, Patricia G	3048106012	\$59,650.	\$0.	\$59,650.
KY Association of Sexual Assault Programs EMPOWER Project				
Gillen, Martie L	3048106100	\$235,681.	\$0.	\$235,681.
KY Cabinet for Health and Family Services Post Secondary - Successful Transitions Program & Comprehensive Family Services				
Godlaski, Theodore M	3048106787	\$43,453.	\$0.	\$43,453.
Catholic Social Services of the Diocese of Scranton Services in Supportive Housing				
Hall, Jennifer G		\$900,000.	\$0.	\$900,000.
Administration for Children and Families National Quality Improvement Center on the Privatization of Child Welfare Services				
Hall, Jennifer G	3048106317	\$124,434.	\$0.	\$124,434.
KY Cabinet for Health and Family Services KY Diligent Recruitment of Families for Children in the Foster Care System - Project MATCH				
Rompf, Elizabeth L	3048105930	\$8,428.	\$0.	\$8,428.
Eastern KY University Public Child Welfare Certification Program				
Segress, Melissa Jh	3048105925	\$364,343.	\$0.	\$364,343.
Eastern KY University Training Resource Center: Adoption Support Programs				
Segress, Melissa Jh	3048105926	\$211,163.	\$0.	\$211,163.
Eastern KY University Training Resource Center: Resource Parent Training Program				
Segress, Melissa Jh	3048105927	\$5,210.	\$0.	\$5,210.
Eastern KY University Training Resource Center: Cultural Diversity				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Social Work</u>				
<u>Social Work</u>				
Segress, Melissa Jh	3048105931	\$117,466.	\$0.	\$117,466.
Eastern KY University Training Resource Center: Medically Fragile Program				
Segress, Melissa Jh	3048105932	\$357,608.	\$0.	\$357,608.
Eastern KY University Training Resource Center: Resource Parent Mentor Program/Retention				
Segress, Melissa Jh	3048105933	\$317,003.	\$0.	\$317,003.
Eastern KY University Training Resource Center: Office of Technology & Outcome Support				
Segress, Melissa Jh	3048105934	\$75,000.	\$0.	\$75,000.
Eastern KY University Training Resource Center: Evidence Based Child Welfare Network				
Segress, Melissa Jh	3048106099	\$0.	\$-4,565.	\$-4,565.
KY Cabinet for Health and Family Services Citizens Review Panel				
Segress, Melissa Jh	3048106099	\$83,401.	\$0.	\$83,401.
KY Cabinet for Health and Family Services Citizens Review Panel				
Segress, Melissa Jh	3048106402	\$40,000.	\$0.	\$40,000.
KY Administrative Office of the Courts Fayette County Model Court Evaluation				
Sprang, Mary	3048105651	\$0.	\$2.	\$2.
University of Louisville Pandemic Planning and Preparedness Program				
Sprang, Mary	3048105928	\$54,000.	\$0.	\$54,000.
Eastern KY University Training Resource Center: Adoption Support Programs				
Sprang, Mary	3048106592	\$400,000.	\$0.	\$400,000.
Substance Abuse & Mental Health Services Administr Child and Adolescent Trauma Treatment Institute				
Tindall, Michele Staton	3048105363	\$0.	\$91,800.	\$91,800.
Chrysalis Inc Chrysalis House PPW-2 Evaluation				
Tindall, Michele Staton	3048106046	\$216,930.	\$0.	\$216,930.
National Institute on Alcohol Abuse and Alcoholism Re-Entry Alcohol Services for Rural Offenders				
Weeks, Pamela L	3048105929	\$0.	\$4,520.	\$4,520.
Eastern KY University Training Resource Center: Credit for Learning Program				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Social Work</u>				
<u>Social Work</u>				
Weeks, Pamela L	3048105929	\$437,415.	\$0.	\$437,415.
Eastern KY University Training Resource Center: Credit for Learning Program				
Social Work	Totals:	\$4,204,074.	\$109,757.	\$4,313,831.
<u>Cntr for Stdy of Violence Against Childr</u>				
Clark, James J	3048105984	\$658,000.	\$0.	\$658,000.
KY Cabinet for Health and Family Services Comprehensive Assessment and Training Services Project-Title V				
Sprang, Mary	3048105983	\$200,000.	\$0.	\$200,000.
KY Cabinet for Health and Family Services Comprehensive Assessment and Training Services Project -IV-B				
Cntr for Stdy of Violence Against Childr	Totals:	\$858,000.	\$0.	\$858,000.
	Social Work Totals:	\$5,062,074.	\$109,757.	\$5,171,831.
<u>Graduate School</u>				
<u>Martin School of Public Policy</u>				
Berger, Philip K	3048106829	\$145,530.	\$0.	\$145,530.
University of Cincinnati Worker Health and Safety Cooperative Agreement				
Cowen, Joshua M.	3048105718	\$34,243.	\$0.	\$34,243.
University of Arkansas Milwaukee Longitudinal Eductional Growth Study				
Jennings, Edward T	3048104847	\$0.	\$93,437.	\$93,437.
KY Department of Military Affairs Hazard Mitigation Grants Program FY 2009 and 2010				
Jennings, Edward T	3048105230	\$0.	\$105,430.	\$105,430.
KY Council on Developmental Disabilities Policy Analysis for the Kentucky Council on Developmental Disabilitites				
Jennings, Edward T	3048106732	\$105,900.	\$0.	\$105,900.
KY Department of Military Affairs Hazard Mitigation Grants Program FY 2009 and 2010				
Toma, E F		\$0.	\$-2,500.	\$-2,500.
KY Council on Postsecondary Education Martin School Graduate Student 2008				
Toma, E F	3048105577	\$0.	\$498,541.	\$498,541.
National Science Foundation Research, Evaluation, and Technical Assistance: Student Outcome Effects of the Appalachian Math and Science Partnership				
Toma, E F	3048105951	\$279,100.	\$0.	\$279,100.
Spencer Foundation Teaching Careers in Rural Schools				

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Graduate School</u>				
<u>Martin School of Public Policy</u>				
Toma, E F	3048106771	\$12,770.	\$0.	\$12,770.
KY Education Professional Standards Board P-20 Data Warehouse				
Martin School of Public Policy	Totals:	\$577,543.	\$694,908.	\$1,272,451.
<u>Graduate School Dean</u>				
Blackwell, J L	3048104269	\$0.	\$40,500.	\$40,500.
National Science Foundation National Science Foundation Graduate Fellowship Program				
Graduate School Dean	Totals:	\$0.	\$40,500.	\$40,500.
<u>Center for Biomedical Engineering</u>				
Bruce, Eugene N	3048105587	\$0.	\$58,824.	\$58,824.
National Institute on Aging Dynamics of Sleep Fragmentation in the Elderly				
Knapp, Charles F	3048104489	\$0.	\$242,481.	\$242,481.
Western KY University NASA EPSCoR: Efficacy of Countermeasures to Cardiovascular Deconditioning in Men and Women During Simulated Moon Explorations				
Knapp, Charles F	3048106700	\$125,000.	\$0.	\$125,000.
Western KY University 2nd Year, State Match: Efficacy of Countermeasures to Cardiovascular Deconditioning in Men and Women during simulated moon explorations				
Knapp, Charles F	3048106926	\$75,000.	\$0.	\$75,000.
Western KY University NASA/EPSCOR: State Match for Year 3 to NASA Grant #NNX07AT58A Research Area I - WKURF 516204--Efficacy of Countermeasures to Cardiovascular Deconditioning in Men and Women During Simulated Moon Exploration				
Puleo, David A	3048105785	\$849,000.	\$0.	\$849,000.
US Army Medical Research and Materiel Command Tissue Repair and Regeneration Following Orthopedic and Craniofacial Trauma				
Shin, Hainsworth Y	3048105954	\$66,000.	\$0.	\$66,000.
American Heart Association Great Rivers Affiliate Modulation of Leukocyte Mechanotransduction of Fluid Shear Stress by the Cell Membrane				
Sunderam, Sridhar	3048106804	\$62,012.	\$0.	\$62,012.
National Institute of Neurological Disorders & Stroke ARRA: Towards a Behavioral Index of Seizure Susceptibility				
Yu, Guoqiang	3048105915	\$65,941.	\$0.	\$65,941.
American Heart Association Great Rivers Affiliate A Portable Optical Flow-Oximeter for Assessment of Cerebral Hemodynamics and Metabolism During Obstructive Sleep Apnea				
Center for Biomedical Engineering	Totals:	\$1,242,953.	\$301,305.	\$1,544,258.
	Graduate School Totals:	\$1,820,496.	\$1,036,713.	\$2,857,209.

Sponsored Project Awards Received Through UKRF Fiscal Year 2010 as of 3/31/2010

		New Accounts	Adjustments to Existing Accounts	Total
<u>Fine Arts</u>				
<u>Center for the Arts Service Ctr</u>				
Grice, Michael	3048106805	\$7,000.	\$0.	\$7,000.
Association of Performing Arts Presenters				
Creative Pathways: The Arts of Listening (Proposal Planning)				
Center for the Arts Service Ctr		Totals: \$7,000.	\$0.	\$7,000.
		Fine Arts Totals: \$7,000.	\$0.	\$7,000.
		University Totals: \$191,864,300.	\$81,721,987.	\$273,586,287.